UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
(Mark One)
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF
1934
OR
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2024
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to .
OR
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
Commission file number: 001-38283
InflaRx N.V.
(Exact name of Registrant as specified in its charter)
The Netherlands
(Jurisdiction of incorporation or organization)
Winzerlaer Str. 2
07745 Jena, Germany
+49 (3641) 508 180
(Address of principal executive offices)
Dr. Thomas Taapken,
Chief Financial Officer
Tel: +49 (3641) 508 180
Winzerlaer Str. 2, 07745 Jena, Germany
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Copies to:
Sophia Hudson
Kirkland & Ellis LLP
601 Lexington Avenue
New York, NY 10022
Phone: +1 (212) 446-4750
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Ordinary Shares, nominal value €0.12
per share
IFRX
The Nasdaq Stock Market LLC
Securities registered or to be registered pursuant to Section 12(g) of the Act:
None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
None
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period
covered by the annual report.
The number of outstanding ordinary shares as of December 31, 2024 was 59,351,710.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes No
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934.
Yes No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes No
Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit such files).
Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an
emerging growth company. See definition of “large accelerated filer”, “accelerated filer,” and “emerging growth company” in
Rule 12b-2 of the Exchange Act.
Large Accelerated Filer Accelerated Filer Non-accelerated Filer
Emerging growth company
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards† provided pursuant to Section 13(a) of the Exchange Act.
†
The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards
Board to its Accounting Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the
effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b))
by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the
registrant included in the filing reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-
based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
§240.10D-1(b).
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP
International Financial Reporting Standards as issued by the International Accounting Standards Board
Other
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow.
Item 17 Item 18
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act).
Yes No
InflaRx N.V.
TABLE OF CONTENTS
Page
FORWARD-LOOKING-STATEMENTS
iv
ENFORCEMENT OF JUDGMENTS
vi
PART I
1
ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
1
A. Directors and senior management
1
B. Advisers
1
C. Auditors
1
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
1
A. Offer statistics
1
B. Method and expected timetable
1
ITEM 3. KEY INFORMATION
2
A. [Reserved]
2
B. Capitalization and indebtedness
2
C. Reasons for the offer and use of proceeds
2
D. Risk factors
2
ITEM 4. INFORMATION ON THE COMPANY
57
A. History and development of the company
57
B. Business overview
58
C. Organizational structure
91
D. Property, plant and equipment
91
ITEM 4A. UNRESOLVED STAFF COMMENTS
92
ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS
92
A. Operating results
92
B. Financial operations overview
93
C. Liquidity and capital resources
97
D. Research and development, patents and licenses, etc.
100
E. Trend information
100
F. Critical accounting estimates
100
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
101
A. Directors and senior management
101
B. Compensation
103
C. Board practices
107
D. Employees
110
i
E. Share ownership
110
F. Disclosure of a registrant’s action to recover erroneously awarded compensation
110
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
110
A. Major shareholders
110
B. Related party transactions
114
ITEM 8. FINANCIAL INFORMATION
115
A. Consolidated statements and other financial information
115
B. Significant changes
115
ITEM 9. THE OFFER AND LISTING
116
A. Offering and listing details
116
B. Plan of distribution
116
C. Markets
116
D. Selling shareholders
116
E. Dilution
116
F. Expenses of the issue
116
ITEM 10. ADDITIONAL INFORMATION
117
A. Share capital
117
B. Memorandum and articles of association
117
C. Material contracts
117
D. Exchange controls
117
E. Taxation
117
ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
139
ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
139
A. Debt securities
139
B. Warrants and rights
139
C. Other securities
139
D. American Depositary Shares
139
PART II
140
ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
140
A. Defaults
140
B. Arrears and delinquencies
140
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
140
A. Material modifications to instruments
140
B. Material modifications to rights
140
C. Withdrawal or substitution of assets
140
ii
D. Change in trustees or paying agents
140
E. Use of proceeds
140
ITEM 15. CONTROLS AND PROCEDURES
141
A. Disclosure controls and procedures
141
B. Management’s annual report on internal control over financial reporting
141
C. Attestation report of the registered public accounting firm
141
D. Changes in internal control over financial reporting
141
ITEM 16. RESERVED
141
ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT
141
ITEM 16B. CODE OF ETHICS
141
ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
142
A. Audit fees
142
B. Audit-related fees
142
C. Tax fees
142
D. All other fees
142
E. Audit Committee’s pre-approval policies and procedures
142
F. Audit work performed by other than principal accountant if greater than 50%
142
ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
142
ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
142
ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT
142
ITEM 16G. CORPORATE GOVERNANCE
142
ITEM 16H. MINE SAFETY DISCLOSURE
143
ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
143
ITEM 16J. INSIDER TRADING POLICIES
143
ITEM 16K. CYBERSECURITY RISK MANAGEMENT AND STRATEGY
143
PART III
144
ITEM 17. FINANCIAL STATEMENTS
144
ITEM 18. FINANCIAL STATEMENTS
144
ITEM 19. EXHIBITS
144
Index to Consolidated Financial Statements
F-1
iii
Unless otherwise indicated or the context otherwise requires, all references in this Annual Report on Form 20-F, or this
Annual Report, to “InflaRx N.V.,” “InflaRx,” the “Company,” “we,” “our,” “ours,” “us” or similar terms refer to InflaRx N.V.
and its subsidiaries.
Presentation of financial statements
We report in Euros under International Financial Reporting Standards, or IFRS, as issued by the International Accounting
Standards Board, or the IASB. We made rounding adjustments to some of the figures included in this Annual Report.
Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded
them.
In this Annual Report, unless otherwise indicated, translations from U.S. dollars to Euros (and vice versa) relating to
payments made on or before December 31, 2024 were made at the rate in effect at the time of the relevant payment.
The terms “$” or “dollar” refer to U.S. dollars, and the terms “€” or “Euro” refer to the currency introduced at the start of the
third stage of European economic and monetary union pursuant to the treaty establishing the European Community, as amended.
Industry and other data
We obtained the industry, statistical and market data in this Annual Report from our own internal estimates and research as
well as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data
used in this Annual Report involves a number of assumptions and limitations. While we believe that the information from these
industry publications, surveys and studies is reliable, the industry in which we operate is subject to a high degree of uncertainty
and risk due to a variety of important factors, including those described in the section titled “ITEM 3. KEY INFORMATION —
D. Risk factors.” These and other factors could cause results to differ materially from those expressed in the estimates made by the
independent parties and by us.
Trademarks
InflaRx®, GOHIBIC® and Vilwaysi® are our trademarks. The trademarks, trade names and service marks appearing in this
Annual Report are property of their respective owners. Solely for convenience, the trademarks and trade names in this Annual
Report are referred to without the symbols ® and ™, but such references should not be construed as any indication that their
respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
FORWARD-LOOKING STATEMENTS
This Annual Report contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you
can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other
similar expressions intended to identify statements about the future. These statements speak only as of the date of this Annual
Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied
by the forward-looking statements. We based these forward-looking statements largely on our current expectations and projections
about future events and financial trends that we believe may affect our business, financial condition and results of operations.
These forward-looking statements include, without limitation, statements about the following:
our ability to successfully secure distribution channels and commercialize GOHIBIC (vilobelimab) as a treatment for
COVID-19 patients and the receptiveness of our ability to positively influence treatment recommendations by U.S. and
●
European hospitals, guideline bodies and other third-party organizations;
●
our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement
for, estimated returns and return accruals for, and clinical utility of GOHIBIC (vilobelimab) in its approved or authorized
indication or for vilobelimab and any other product candidates, under the Emergency Use Authorization, or EUA, market
authorization, or Market Authorization, and in the future if approved for commercial use in the United States, Europe or
elsewhere;
iv
●
our ability to successfully implement The InflaRx Commitment Program, the success of our future clinical trials for
vilobelimab’s treatment of other debilitating or life-threatening inflammatory indications, including acute respiratory
distress syndrome, or ARDS, pyoderma gangrenosum, or PG, and any other product candidates, including INF904, and
whether such clinical results will reflect results seen in previously conducted pre-clinical studies and clinical trials;
●
the timing, progress and results of preclinical studies and clinical trials of vilobelimab, INF904 and any other product
candidates, including for the development of vilobelimab in several indications, including to obtain full approval of
GOHIBIC (vilobelimab) for COVID-19 and other virally induced ARDS, to treat PG, hidradenitis suppurativa, or HS,
and chronic spontaneous urticaria, or CSU, and statements regarding the timing of initiation and completion of studies or
trials and related preparatory work, the period during which the results of the trials will become available, the costs of
such trials and our research and development programs generally;
●
our interactions with and the receptiveness and approval by regulators regarding the results of clinical trials and potential
regulatory approval or authorization pathways, including our biologics license application submission, or BLA, for
GOHIBIC (vilobelimab);
●
the timing and outcome of any discussions or submission of filings for regulatory approval or authorization of
vilobelimab, INF904 or any other product candidate, and the timing of and our ability to obtain and maintain full
regulatory approval, the EUA and/or Market Authorization of vilobelimab or GOHIBIC (vilobelimab) for any indication;
●
our ability to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat
complement-mediated autoimmune and inflammatory diseases;
●
our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, INF904 and any other
product candidates, and the scope of such protection;
●
whether the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or EMA, or any
comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of
our clinical trials, including any proposed primary or secondary endpoints for such trials;
●
the success of our future clinical trials for vilobelimab, INF904 and any other product candidates and whether such
clinical results will reflect results seen in previously conducted preclinical studies and clinical trials;
●
our expectations regarding the size of the patient populations for, the market opportunity for, the medical need for and
clinical utility of vilobelimab, INF904 or any other product candidates, if approved or authorized for commercial use;
●
our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and
processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our
existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future
clinical trials and for commercial supply of vilobelimab and for the finished product GOHIBIC (vilobelimab) in the U.S.
and Europe;
●
our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain
additional financing;
●
our expectations regarding the scope of any approved indication for vilobelimab;
●
our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if,
approved or authorized, any commercial sales;
●
if any of our product candidates obtain regulatory approval or authorization, our ability to comply with and satisfy
ongoing drug regulatory obligations and continued regulatory overview;
v
●
our ability to comply with enacted and future legislation in seeking marketing approval or authorization and
commercialization;
●
our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional
qualified personnel;
●
our competitive position and the development of and projections relating to our competitors in the development of C5a
and C5aR inhibitors and other therapeutic products being developed in similar medical conditions in which vilobelimab,
INF904 or any other of our product candidates is being developed or our industry; and
●
other risk factors discussed herein under “Risk Factors” or incorporated herein by reference.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or
quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of
future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual
results could differ materially from those projected in the forward-looking statements. You should refer to the “ITEM 3. KEY
INFORMATION: — D. Risk factors.” section of this Annual Report for a discussion of important factors that may cause our
actual results to differ materially from those expressed or implied by our forward-looking statements. Moreover, we operate in an
evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to
predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in
this Annual Report will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or
otherwise. You should, however, review the factors and risks and other information we describe in the reports we will file from
time to time with the U.S. Securities and Exchange Commission, or the SEC, after the date of this Annual Report.
ENFORCEMENT OF JUDGMENTS
We are a public company with limited liability (naamloze vennootschap) incorporated under the laws of the Netherlands and
our headquarters is located in Germany. Substantially all of our assets are located outside the United States. The majority of our
executive officers and directors reside outside the United States. As a result, it may not be possible for investors to effect service
of process within the United States upon such persons or to enforce against them or us in U.S. courts, including judgments
predicated upon the civil liability provisions of the federal securities laws of the United States.
The United States and the Netherlands currently do not have a treaty providing for the reciprocal recognition and enforcement
of judgments, other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by
a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or
enforceable in the Netherlands. In order to obtain a judgment which is enforceable in the Netherlands, the party in whose favor a
final and conclusive judgment of the U.S. court has been rendered will be required to file its claim with a court of competent
jurisdiction in the Netherlands.
This court will have discretion to attach such weight to the judgment rendered by the relevant U.S. court as it deems
appropriate. Under current practice, the courts of the Netherlands may be expected to render a judgment in accordance with the
judgment of the relevant foreign court, provided that such judgment (i) is a final judgment and has been rendered by a court which
has established its jurisdiction vis-à-vis the relevant Dutch companies or Dutch company, as the case may be, on the basis of
internationally accepted grounds of jurisdiction, (ii) has not been rendered in violation with the principles of proper procedure
(behoorlijke rechtspleging), (iii) is not contrary to the public policy of the Netherlands, and (iv) is not incompatible with (a) a
prior judgment of a Dutch court rendered in a dispute between the same parties, or (b) a prior judgment of a foreign court rendered
in a dispute between the same parties, concerning the same subject matter and based on the same cause of action, provided that
such prior judgment is recognizable in the Netherlands. Dutch courts may deny the recognition and enforcement of punitive
damages or other awards. Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize
damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of
judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Civil Procedure Code. If no leave
to enforce is granted, claimants must litigate the claim again before a Dutch competent court.
vi
Dutch civil procedure differs substantially from U.S. civil procedure in a number of respects. Insofar as the production of
evidence is concerned, U.S. law and the laws of several other jurisdictions based on common law provide for pre-trial discovery, a
process by which parties to the proceedings may prior to trial compel the production of documents by adverse or third parties and
the deposition of witnesses. Evidence obtained in this manner may be decisive in the outcome of any proceeding. No such pre-trial
discovery process exists under Dutch law.
The United States and Germany currently do not have a treaty providing for the reciprocal recognition and enforcement of
judgments, in civil and commercial matters. Consequently, a final judgment for payment or declaratory judgments given by a
court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or
enforceable in Germany. German courts may deny the recognition and enforcement of a judgment rendered by a U.S. court if they
consider the U.S. court not to be competent or the decision to be in violation of German public policy principles. For example,
judgments awarding punitive damages are generally not enforceable in Germany. A German court may reduce the amount of
damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or
damages.
In addition, actions brought in a German court against us, our directors, our senior management and the experts named herein
to enforce liabilities based on U.S. federal securities laws may be subject to certain restrictions. In particular, German courts
generally do not award punitive damages. Litigation in Germany is also subject to rules of procedure that differ from U.S. rules,
including with respect to the taking and admissibility of evidence, the conduct of the proceedings and the allocation of costs.
German procedural law does not provide for pre-trial discovery of documents, nor does Germany support pre-trial discovery of
documents under the 1970 Hague Evidence Convention. Proceedings in Germany would have to be conducted in the German
language and all documents submitted to the court would, in principle, have to be translated into German. For these reasons, it
may be difficult for a U.S. investor to bring an original action in a German court predicated upon the civil liability provisions of
U.S. federal securities laws against us, our directors, our senior management and the experts named in this Annual Report.
vii
PART I
ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
A.
Directors and senior management
Not applicable.
B.
Advisers
Not applicable.
C.
Auditors
Not applicable
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
A.
Offer statistics
Not applicable.
B.
Method and expected timetable
Not applicable.
-1-
ITEM 3. KEY INFORMATION
A.
[Reserved]
B.
Capitalization and indebtedness
Not applicable.
C.
Reasons for the offer and use of proceeds
Not applicable.
D.
Risk factors
You should carefully consider the risks and uncertainties described below and the other information in this Annual Report
before making an investment in our ordinary shares. Our business, financial condition or results of operations could be materially
and adversely affected if any of these risks occurs, and as a result, the market price of our ordinary shares could decline, and you
could lose all or part of your investment. This Annual Report also contains forward-looking statements that involve risks and
uncertainties. See “Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated
in these forward-looking statements as a result of certain factors.
Risk factor summary
The following is a summary of the principal risks that could adversely affect our business, operations and financial results.
This summary does not address all of the risks that we face. For a more complete discussion of the material risks facing our
business, see further below.
Risks related to our financial position and need for additional capital
●
Risk of never achieving or maintaining profitability and of investors losing their entire investment
●
Risk related to not obtaining additional funding and risk of delay, reduction or elimination of product discovery and
development programs or commercialization efforts
●
Risks related to limited operating history and history of commercializing pharmaceutical products
●
Risk related to grants funded by the German federal government
Risks related to the discovery, development, manufacturing and commercialization of our product candidates
●
Risk related to the discovery, development and commercialization of our product candidates
●
Risk related to our dependence on the success of our product candidates, including our lead product candidate,
vilobelimab
●
Risk related to regulatory oversight over GOHIBIC (vilobelimab) for which we received the EUA in the United States
and market authorization in Europe, which may lead to a withdrawal or revocation of the granted EUA or market
authorization
●
Risk related to possible occurrence of clinical failure at any stage of clinical development
●
Risk of failing to maintain compliance with FDA requirements and/or remain in alignment with FDA feedback, which
may prevent or delay the development, marketing or manufacturing of vilobelimab for the treatment of critically ill
COVID-19 patients and, potentially, of vilobelimab in ulcerative PG
●
Risk of incurring additional significant expenses in connection with ongoing regulatory obligations and continued
regulatory review of GOHIBIC (vilobelimab) and any other product candidates for which we receive or have received
approval, including the EUA in the U.S. and market authorization in Europe
-2-
●
Risk of incurring additional costs or experience delays in completing, or ultimately being unable to complete, the
development and commercialization of product candidates, if clinical trials of our product candidates fail to satisfactorily
demonstrate safety and efficacy to the FDA and other regulators
●
Risk if our product candidates cause or are perceived to cause undesirable side effects or have other properties that could
delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant
negative consequences following marketing approval, if any
Risks related to our dependence on third parties
●
Risk of reliance on third parties to conduct our clinical trials
●
Risk of dependence on third-party manufacturers and suppliers and maintaining key manufacturing relationships
●
Risk related to the process of manufacturing biologics, such as vilobelimab, that is extremely susceptible to product loss
●
Risk regarding the manufacturing process due to product risk and quality controls
●
Risk that, if our third-party manufacturers are unable to increase the scale of their production of our product candidates
and increase their product yield, our manufacturing costs may increase and product commercialization may be delayed
●
Risk that, if we are unable to establish collaborations on commercially reasonable terms, we may have to alter our
development and commercialization plans
Risks related to our intellectual property
●
Risks related to our dependence on our ability to obtain, maintain, protect, defend and enforce patent, trade secret and
other intellectual property protection
●
Risks related to our patents covering our proprietary anti-C5a and anti C5aR technologies that may be subject to
challenge, narrowing, circumvention and invalidation by third parties
●
Risks related to uncertainty that we were the first to make the anti-C5a and anti-C5aR technologies claimed in our patents
or patent applications or that we were the first to file for patent protection
●
Risks related to patent application process and obtaining patents for which we have applied
Risks related to employee matters and managing growth
●
Risk of having a limited number of employees to manage and operate our business
●
Risk of depending heavily on certain of our executive officers and directors
●
Risk of disruption to our business as a result of managing growth in business operations and number of personnel
●
Risk of liability to our business by improper activities of our employees and third-party contractors
Risks related to our ordinary shares and our status as a public company
●
Risks related to the trading price of our ordinary shares, that has been and may in the future be highly volatile
●
Risk associated with being a foreign private issuer and not being subject to U.S. proxy rules, following home country
governance practices rather than the Nasdaq listing requirements
●
Risk related to us not anticipating paying any cash dividends on our share capital in the foreseeable future.
-3-
General risk factors
●
Risk of business impact resulting out of financial markets, changes to political and regulatory policies and economic
conditions generally
●
Risk of legal, regulatory or market measures to address environmental objectives
●
Risks of dilution to shareholders through raising capital, risk of restriction and/or relinquishment to rights to technologies
and product candidates
●
Risk of facing substantial competition
●
Risk of product liability lawsuits
●
Risks of damage and disruption to our business through cyber-attacks and failure of telecommunication and information
technology equipment
Risks related to our financial position and need for additional capital
We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable
future; we may never achieve or maintain profitability and investors may lose their entire investment
We incurred net losses of €46.1 million, €42.7 million and €29.5 million for the years ended December 31, 2024, 2023 and
2022, respectively. In addition, our accumulated deficit as of December 31, 2024 was €332.2 million.
We expect our net losses to increase as we advance vilobelimab and other product candidates into additional clinical trials, as
well as larger and later-stage clinical trials. Further, we expect our net losses to increase as we advance the implementation of
commercialization of GOHIBIC (vilobelimab) in the United States under the EUA and in the European Union under the
marketing authorization while investing in start-up commercialization and marketing activities. To date, we have not
commercialized any products other than for GOHIBIC (vilobelimab) for the treatment of severe COVID-19 or generated any
meaningful revenues from the sale of products other than limited initial sales of GOHIBIC (vilobelimab) and absent the
realization of sufficient revenues from product sales, we may never attain profitability. We have devoted substantially all of our
financial resources and efforts to research and development, including preclinical studies, clinical trials and manufacturing
development. Our net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash
flows have had, and will continue to have, an adverse effect on our shareholders’ equity and working capital.
We anticipate that our expenses might increase if and as we:
●
continue to develop and conduct clinical trials with respect to our lead product candidate, vilobelimab;
●
continue research, preclinical and clinical development efforts for any future product candidates, including IFX002 and
INF904;
●
actively seek to identify additional research programs and additional product candidates;
●
seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any;
●
establish sales, marketing, distribution and other commercial infrastructure now and in the future to commercialize
various products for which we may obtain marketing authorization or approval, if any;
●
require the scale-up and validation of the manufacturing process and the manufacturing of larger quantities of product
candidates for clinical development and, potentially, commercialization;
●
collaborate with strategic partners to optimize the manufacturing process for vilobelimab, IFX002, INF904 and other
pipeline products;
●
maintain, expand and protect our intellectual property portfolio;
-4-
●
hire and retain additional personnel, such as commercial, marketing, clinical, quality control and scientific personnel; and
●
add operational, financial and management information systems and personnel, including personnel to support our
product development as well as commercialization and help us comply with our obligations as a public company.
Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate
significant revenue unless and until we are, or any future collaborator is, able to obtain marketing authorization or approval for,
and successfully commercialize, one or more of our product candidates. Successful commercialization will require achievement of
key milestones, including completing clinical trials of vilobelimab and any other product candidates, obtaining marketing
authorization or approval for these product candidates, manufacturing, marketing and selling those products for which we, or any
of our future collaborators, may obtain marketing authorization or approval, satisfying any post-marketing requirements and
obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks
associated with these activities, we are unable to accurately predict the timing and amount of revenues, and if or when we might
achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future
collaborators do, we may never generate revenue that is large enough for us to achieve profitability. Even if we do achieve
profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.
We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to
a variety of factors, many of which are beyond our control. In order to succeed, we will need to transition from a company with a
research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen
expenses, difficulties, complications and delays, and may not be successful in such a transition.
Our failure to become and remain profitable could depress the market price of our ordinary shares and could impair our
ability to raise capital, pay dividends, expand our business, diversify our product offerings or continue our operations. If we
continue to suffer losses as we have in the past, investors may not receive any return on their investment and may lose their entire
investment.
We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay,
reduce or discontinue our product discovery and development programs or commercialization efforts
Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming,
expensive and uncertain process that takes years to complete. For example, for the years ended December 31, 2024 and December
31, 2023, we used €48.6 million and €37.8 million, respectively, in net cash for our operating activities, most of which were
related to research and development activities. We expect our expenses to increase in connection with our ongoing activities,
particularly as we initiate new clinical trials of, initiate new research and preclinical development efforts for, establish robust
manufacturing processes for, establish comprehensive commercialization and marketing processes and seek marketing
authorization or approval for, our current product candidates or any future product candidates, including those that we may
acquire. In particular, we will incur significant expenses as we conduct our planned clinical trial program and initiate new research
and preclinical development efforts. In addition, after obtaining the EUA and market authorization for GOHIBIC (vilobelimab) in
the United States and Europe, respectively and if we obtain marketing approval for any of our product candidates, we may incur
significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such
sales, marketing, manufacturing and distribution are not the responsibility of a future collaborator. Furthermore, we expect to
incur significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive
terms, we may be forced to delay, reduce or eliminate our research and development programs or any future commercialization
efforts.
We plan to use our cash on hand primarily to fund our planned clinical trial programs, to initiate new research and preclinical
development efforts, to establish commercial scale manufacturing processes and for working capital and other general corporate
purposes. We will be required to expend significant funds in order to advance the development of vilobelimab in later stages of
clinical development, as well as other product candidates we may seek to develop, including IFX002 and INF904. We are also
evaluating vilobelimab for a number of additional indications. Any future development activities for our pipeline product
candidates will depend heavily on the clinical as well as commercialization and marketing success of vilobelimab in any
indication.
-5-
Our existing cash and cash equivalents will not be sufficient to fund all the efforts that we plan to undertake or to fund the
completion of development of any of our product candidates. Accordingly, we will be required to obtain further funding through
public or private equity offerings, debt financings, royalty-based financings, collaborations and licensing arrangements or other
sources. Currently, we do not have any committed external source of funds. Adequate additional financing may not be available to
us on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts and on terms acceptable to us, we
may have to significantly delay, scale back or discontinue the development or commercialization of vilobelimab or any of our
other product candidates or potentially discontinue operations altogether. Our failure to raise capital as and when needed could
have a negative impact on our financial condition and our ability to pursue our business strategy.
We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses
and capital expenditure requirements under our current business plan for at least the next 18 months. Changing circumstances,
some of which may be beyond our control, could cause us to consume capital significantly faster than we anticipate, and we may
need to seek additional funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend
on many factors, including:
●
the scope, progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, our
current and future product candidates, particularly for vilobelimab;
●
the number of future product candidates and indications that we pursue and their development requirements;
●
the outcome, timing and costs of seeking regulatory approvals;
●
the costs of preparation for and implementation of commercialization and commercialization activities for any of our
product candidates that receive marketing authorization approval to the extent such costs are not the responsibility of any
future collaborators, including the costs and timing of establishing product sales, marketing, distribution and commercial-
scale manufacturing capabilities;
●
the effect of competing technological and market developments;
●
subject to receipt of marketing authorization or approval, revenue, if any, received from commercial sales of our current
and future product candidates;
●
our ability to enter into, and the terms and timing of, any collaborations, licensing or other arrangements;
●
our headcount growth and associated costs as we expand our research, development, manufacturing, regulatory and
commercial activities;
●
the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property
rights including enforcing and defending intellectual property related claims; and
●
the costs of operating as a public company.
We have a limited operating history and history of commercializing pharmaceutical products, which may make it difficult to
evaluate the prospects for our future viability
We commenced operations in 2008. Our operations to date have been limited to establishing our Company, raising capital,
developing our proprietary anti-C5a and anti-C5aR technologies, identifying and testing potential product candidates and
conducting clinical trials of our lead product candidate, vilobelimab and establishing a commercial scale manufacturing process
for vilobelimab. In April 2023, we received the EUA for GOHIBIC (vilobelimab) for the treatment of certain critically ill COVID-
19 patients by the FDA. In January 2025, we received market authorization for GOHIBIC (vilobelimab) for use und exceptional
circumstances by the European Commission following a positive opinion from the Committee for Medicinal Products for Human
Use, or CHMP, recommending the marketing authorization. We have just started to arrange for third parties to manufacture and
distribute our product at small commercial scale on our behalf. However, we have not yet demonstrated an ability to obtain full
marketing approvals or conduct sales and marketing activities at large scale as necessary for successful product
commercialization. Also, we are still in early stages of clinical development with our other product candidates. Accordingly, you
should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in
the early stages of development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make
about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of
successfully developing and commercializing pharmaceutical products.
-6-
We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving
our business objectives. We will eventually need to transition from a company with a predominant development focus to a
company capable of supporting commercial activities. We may not be successful in such a transition.
We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year
to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any
quarterly or annual periods as indications of future operating performance.
We may be subject to risks in relation to financial grants received by the German federal government, which may result in the
partial repayment of such grants
The research allowance act (Forschungszulagengesetz, or FZulG) in Germany is a law designed to promote research and
development, or R&D, activities within companies by offering them tax incentives. Specifically, it allows businesses to claim a
tax credit for eligible R&D expenditures. The tax authorities verify whether the company’s R&D activities meet the criteria for the
tax credit, and whether the expenses were appropriately documented. If the eligibility requirements are met, the determined
research allowance (Forschungszulage) is offset against the tax liability of the eligible company or - if the research allowance
exceeds this tax liability - paid out. The research allowance according to the research allowance act is funded by the German
government, specifically through the Federal Ministry of Education and Research, or BMBF, and managed by the research
allowance office (Forschungszulagenstelle) within the federal central tax office (Bundeszentralamt für Steuern, or BZSt).
In 2024, upon qualifying for an allowance under the German Research Allowance Act, we recognized €5.1 million in income
relating to expenses, eligible for reimbursement, which were incurred in the years 2020 to 2024. We are able to claim amounts
only for activities that have not previously been subject to grants and subsidies by the German or European governments and all of
their grant awarding agencies. The grant allowance period will end in 2027, and we might become subject to future audits by
financial oversight authorities of the German federal government.
Outside of the research allowance under the FZulG, the clinical Phase 3 study of vilobelimab in critically ill COVID-19
patients and certain manufacturing development related activities of our product candidate vilobelimab were partly funded by the
German federal government through a grant awarded to us in October 2021. The grant was structured as a reimbursement of 80%
of certain pre-specified expenses related to the clinical development and manufacturing of vilobelimab. The grant period ended on
June 30, 2023, as planned. In total, throughout the duration of the grant period and up to the date hereof, we received a total
amount of €33.3 million. We might be subject to future audits by financial oversight authorities of the German federal government
or European regulatory bodies and a failure to pass these audits in case the authorities identify non-adherence to all grant
conditions could potentially lead to a retroactive revocation of parts of the funds awarded by the grant.
In addition, the German federal government has, in the case of a special public interest, a non-exclusive and transferable right
to use intellectual property generated as part of the funded work. Contracts with third parties relating to the exploitation of the
results of the funded work must be disclosed to the agency managing the grant on behalf of the German federal government and
any such contracts with parties outside of the European Union require the prior consent of the German federal government to the
extent they deviate from a commercial exploitation plan previously approved by the German federal government. Additionally, we
may be required to grant third parties licenses to use such results under certain conditions. In certain scenarios, including if we
come under the decisive influence of foreign investors, the funded results are exclusively or predominantly used outside Germany
without the prior consent of the German federal government or if we are in breach of our obligations under the grant, the grant
funding, including funding already received, can be revoked.
-7-
Exchange rate fluctuations may materially affect our results of operations and financial condition
Potential future expense and revenue may be incurred or derived from outside the European Union, particularly the United
States. As a result, our business and our share price may be affected by fluctuations in foreign exchange rates between the euro
and other currencies, particularly the U.S. dollar, which may also have a significant impact on our reported results of operations
and cash flows from period to period. We currently do not have any exchange rate hedging arrangements in place.
We may face the risk of substantial write-downs of inventory due to the excess or obsolescence of our inventory relating to
GOHIBIC (vilobelimab) due to expiration prior to sale or unsuitability for alternative use
Excess purchase of raw materials and production of products or the commitments to purchase or produce such items may
result in high inventory levels that might not be commercially viable and could lead to the necessity to partially or fully write-
down these items. Excess and obsolescence risks for our inventory could arise from factors such as shelf-life expiration,
overstocking, or events like supply chain disruptions, manufacturing mistakes, raw material flaws which can result in errors,
wastage, or delays and more. Whether such obsolescence risks materialize, ultimately depends on market demand/penetration and
medical need for our products, regulatory factors such as approvals or approval withdrawals by regulatory agencies in the
territories in which we intend to commercialize our product, the competitive landscape of the markets in which we operate,
including the development of comparable products by our competitors as well as our ability to command prices at which we can
be competitive and our own plans regarding alternative use of unfinished or finished products in our inventory for alternative
purposes, such as clinical trials in additional indications. Furthermore, changes in currency exchange rates can impact the cost of
imported goods and affect inventory valuations. In valuing our inventory, we make assumptions regarding these factors and
update these assumptions when applicable.
1.
Risks related to the discovery, development, manufacturing and commercialization of our product candidates
We are at a clinical development stage in our development efforts, our approach of targeting C5a or C5aR inhibition is novel
and we may not be able to successfully develop and commercialize any product candidates
Vilobelimab is a novel therapeutic antibody and its potential therapeutic benefit is unproven, and C5a or C5aR inhibition to
treat complement-mediated autoimmune and inflammatory diseases has only been partly validated. We have not yet succeeded
and may never succeed in demonstrating efficacy and safety for vilobelimab in pivotal clinical trials or in obtaining marketing
approval thereafter for severe COVID-19 or any other indication. The aforementioned continues to be true, although GOHIBIC
(vilobelimab) has been granted the EUA by the FDA for the treatment of coronavirus disease 19, or COVID-19, in hospitalized
adults when initiated within 48 hours of receiving invasive mechanical ventilation, or IMV, or extracorporeal membrane
oxygenation, or ECMO; and has been granted marketing authorization by the European Commission, or EC, under exceptional
circumstances for GOHIBIC (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced ARDS, who are
receiving systemic corticosteroids as part of standard of care and IMV (with or without ECMO). If we are unsuccessful in our
development efforts, we may not be able to advance the development of our product candidates, commercialize products, raise
capital, expand our business, or continue our operations.
-8-
We depend on the success of our product candidates, including our lead product candidate, vilobelimab, and if we are unable
to obtain approval for and commercialize our product candidates for one or more indications in a timely manner, our business will
be materially harmed
Our success depends on our ability to timely complete clinical trials and obtain marketing authorization or approval for, and
then successfully commercialize, our product candidates, including our lead product candidate, vilobelimab, for one or more
indications. Our product candidates will require additional clinical development, preclinical and manufacturing development
activities, marketing approval from government regulators, commercial manufacturing, substantial investment, and significant
marketing efforts before we generate any revenue from product sales. We are not permitted to market or promote any product
candidates in a jurisdiction before receiving marketing authorization or approval from the relevant regulatory authority, including
the FDA for marketing in the United States and EMA for marketing in Europe, and we may never receive such marketing
approvals or marketing authorizations beyond the EUA and market authorization for GOHIBIC (vilobelimab) granted by the FDA
in April 2023 and the EC in January 2025, respectively. The success of our product candidates will depend on numerous factors,
including:
●
raising additional funds, or entering into collaborations, necessary to complete the clinical development of and to
commercialize of our product candidates;
●
successful and timely completion of our ongoing clinical trials;
●
initiation of successful patient enrollment and completion of additional clinical trials on a timely basis;
●
efficacy, safety and tolerability profiles that are satisfactory to the FDA, EMA or any comparable foreign regulatory
authority for marketing approval;
●
timely receipt of marketing authorizations or approvals for our product candidates from applicable regulatory authorities;
●
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
●
the maintenance of existing, or the establishment of new, supply arrangements with third-party drug product suppliers
and manufacturers;
●
the maintenance of existing, or the establishment of new, scaled production arrangements with third-party manufacturers
to obtain finished products that are appropriately packaged for sale;
●
obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, in the United States and
elsewhere;
●
protection of our rights in our intellectual property portfolio, including our licensed intellectual property;
●
successful launch of commercial sales following any marketing authorization or approval;
●
a continued acceptable safety profile following any marketing authorization or approval;
●
commercial acceptance by patients, the medical community and third-party payors;
●
inclusion of approved or, such as GOHIBIC (vilobelimab), authorized products in guidelines by medical bodies,
including but not limited to National Institute of Health, or NIH, guidelines;
●
inclusion of approved or, such as GOHIBIC (vilobelimab), authorized products on hospitals formulary; and
●
our ability to compete with other therapies.
-9-
Additionally, we cannot be sure that we can obtain necessary regulatory authorizations or approvals on a timely basis, if at all,
for any of the products we are developing or manufacturing or that we can maintain necessary regulatory authorizations or
approvals for our existing products, and all of the following could have a material adverse effect on our business:
●
significant delays in obtaining or failing to obtain required authorizations approvals;
●
loss of, or changes to, previously obtained authorizations or approvals;
●
failure to comply with existing or future regulatory requirements; and
●
changes to manufacturing processes or manufacturing process standards following authorization or approval, or changing
interpretations of these factors.
Many of such factors remain outside of our control, and if we are unable to achieve one or more of the objectives set forth
above, our business will be materially harmed.
GOHIBIC (vilobelimab) for which we received the EUA is subject to continuing regulatory oversight, which might lead to a
withdrawal or revocation of the granted EUA, if the FDA considers the underlying requirements or conditions for the EUA not to
be given anymore. We may incur significant losses including loss of reputation, if the EUA for GOHIBIC (vilobelimab) is
withdrawn or revoked by the FDA
GOHIBIC (vilobelimab) for which we received the EUA for the treatment of COVID-19 in certain hospitalized adult patients,
pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3) is subject to continuing
regulatory oversight, including the determination and verification of underlying requirements such as a public health emergency,
or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the
health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. The granted EUA
will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of drugs and
biological products during the COVID-19 pandemic is terminated under Section 564(b)(2) of the Act or the EUA is revoked under
Section 564(g) of the Act. If the conditions or requirements for granting the EUA cease to be apparent in the future, or if reported
drug safety events lead to a new situation in determining the overall pharmacovigilance of vilobelimab, the FDA may suspend,
withdraw or revoke the granted EUA. Any of these events could have a material adverse effect on our business, financial
condition, results of operations and prospects.
-10-
Clinical failure may occur at any stage of clinical development, and the results of our clinical trials may not support our
proposed indications for our product candidates
Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot
be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. Moreover,
success in clinical trials in a particular indication does not ensure that a product candidate will be successful in other indications,
even for the same underlying disease. A number of companies in the pharmaceutical industry, including biotechnology
companies, have suffered significant setbacks in clinical trials, even after promising results in earlier preclinical studies or clinical
trials or successful later-stage trials in other related indications, including in the context of controlling complement activation
through C5 and C5a or C5aR inhibition. For example, while others in our industry have attempted to develop C5a-specific
antibodies, there is no approved therapy inhibiting C5a. These setbacks have been caused by, among other things, preclinical
findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously
unreported adverse events as well as lack of efficacy and patient benefit as reported by clinical trial investigators. In particular,
development of antibodies that target C5a rather than C5 to control complement activation is comparatively novel, and there is no
approved therapy specifically targeting C5a. As a result, inhibition of C5a rather than C5, which blocks signaling to the two
receptors C5aR and C5L2, may have unforeseen consequences or negative results that may lead to clinical failure or withdrawal in
later stages of our product candidate development. Product candidates in later stages of clinical trials may fail to show the desired
safety and efficacy traits despite having progressed through preclinical and initial clinical trials for a variety of reasons, including
differences in patient populations, changes in trial protocols and complexities of larger, multi-center trials among others. We may
fail to complete clinical trials and/or to meet predetermined endpoints in the clinical trials, which may cause us to abandon a
product candidate or an indication and may delay development of any other product candidates. Any delay in, or termination of,
our clinical trials will delay the submission of the Biologics License Application, or BLA, the New Drug Application, or NDA to
the FDA, the Marketing Authorization Application, or MAA to the EMA or other similar applications with other relevant foreign
regulatory authorities and, ultimately, our ability to commercialize any of our product candidates and generate revenue.
Failure to maintain compliance with FDA requirements and/or remain in alignment with FDA feedback may prevent or delay
the development, marketing or manufacturing of vilobelimab for the treatment of critically ill COVID-19 patients or patients with
SARS-CoV-2-induced ARDS and, potentially, of vilobelimab in ulcerative PG
Our manufacturing and laboratory facilities are periodically subject to inspection by the FDA and other governmental
agencies to ensure they meet production and quality requirements. Operations at these facilities could be interrupted or halted if
the FDA or another governmental agency deems the findings of such inspections unsatisfactory. Further, failure to comply with
FDA or other regulatory requirements regarding the development, marketing, promotion, manufacturing and distribution of
vilobelimab could result in fines, unanticipated compliance expenditures, recall or seizures of our products, total or partial
suspension of production or distribution, restrictions on labeling and promotion, termination of ongoing research, disqualification
of data for submission to regulatory authorities, enforcement actions, injunctions and criminal prosecution. If we do not meet
applicable regulatory or quality standards, our products may be subject to recall, and under certain circumstances, we may be
required to notify applicable regulatory authorities about a recall.
-11-
GOHIBIC (vilobelimab) and any other product candidates for which we receive approval or the EUA are subject to
continuing regulatory oversight, and we will be subject to ongoing regulatory obligations and continued regulatory review, which
may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements
GOHIBIC (vilobelimab) and any other product candidates for which we received or might receive approval or the EUA are
subject to continuing regulatory oversight, including the review of promotional materials and additional safety information, and
the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product or
impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Advertising and
promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable
federal and state laws. In other countries, advertising and promotional material may be subject to similar rules. If we fail to
comply with applicable regulatory requirements following authorization or approval of any of our product candidates, a regulatory
agency may:
●
issue a warning letter asserting that we are in violation of the law;
●
seek an injunction or impose civil or criminal penalties or monetary fines;
●
suspend or withdraw the granted EUA or regulatory approval or revoke a license;
●
suspend any ongoing clinical studies;
●
seize product; or
●
refuse to allow us to enter into supply contracts, including government contracts.
Any government investigation of alleged violations of law could require us to expend significant time and resources in
response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to
commercialize any authorized or approved products and generate revenues.
Any of these events could prevent us from achieving or maintaining market acceptance of any products we may identify and
develop and could have a material adverse effect on our business, financial condition, results of operations and prospects.
If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other
regulators, we, or any future collaborators, may incur additional costs or experience delays in completing, or ultimately be unable
to complete, the development and commercialization of these product candidates
We, and any future collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the
United States without obtaining marketing approval or an EUA from the FDA. Foreign regulatory authorities, such as the EMA,
impose similar requirements in their respective markets as well. We, and any future collaborators, must complete extensive
preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we
will be able to obtain these approvals.
The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of product
development. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be
detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design,
measurements, conduct or analysis of our clinical trials. In addition, many of our product candidates are in early stages of
development or clinical testing. As a result, it may be years before any of our product candidates receives regulatory approval, if
at all, and additional clinical trials may fail to demonstrate safety, efficacy or tolerability for our targeted indications.
-12-
Any inability to successfully complete preclinical and clinical development could result in additional costs to us or any future
collaborators and impair our ability to generate revenue from product sales, regulatory and commercialization milestones and
royalties. Moreover, if we or any future collaborators are required to conduct additional clinical trials or other testing of our
product candidates beyond the trials and testing that we or they contemplate, if we or they are unable to successfully complete
clinical trials of our product candidates or other testing or the results of these trials or tests are unfavorable, uncertain or are only
modestly favorable, or there are unacceptable safety concerns associated with our product candidates, we or any future
collaborators may:
●
incur additional unplanned costs, including costs relating to additional required clinical trials or preclinical testing;
●
be delayed in obtaining marketing approval for vilobelimab or any of our other product candidates;
●
not obtain marketing approval at all or the withdrawal or revocation of the EUA by the FDA or the European marketing
authorization by responsible European regulatory authorities;
●
obtain approval for indications or patient populations that are not as broad as intended or desired;
●
obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings,
including boxed warnings;
●
be subject to additional post-marketing testing or other requirements; or
●
be required to remove the product from the market after obtaining marketing approval or the EUA.
Our failure to successfully complete clinical trials of our product candidates and to demonstrate the efficacy and safety
necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business.
Our product candidates may cause or be perceived to cause undesirable side effects or have other properties that could delay
or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative
consequences following marketing approval, if any
Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt
clinical trials and could result in a more restrictive label or the delay, denial or withdrawal of regulatory approval by the FDA or
comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and
prevalence of side effects or unexpected characteristics. In addition, many of the patients that we enrolled in our clinical trials of
vilobelimab suffer from serious pre-existing disorders. While such disorders may lead to serious adverse events, or SAEs, during
trial periods that may be found to be unrelated to vilobelimab, such events may create a negative safety perception and adversely
impact market acceptance of vilobelimab following any approval.
If unacceptable side effects arise in the development of our product candidates, we, the FDA or comparable foreign regulatory
authorities, the Institutional Review Boards, or IRBs, or independent ethics committees at the institutions in which our studies are
conducted or elsewhere, or the Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials or the FDA
or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for
any or all targeted indications. Side effects, whether treatment-related or not, could also affect patient recruitment or the ability of
enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be
appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product
candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product
candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in
patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.
-13-
Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter
into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent
positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify
undesirable side effects. If, following approval of a product candidate, we, or others, discover that the product is less effective than
previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events
could occur:
●
regulatory authorities may withdraw their authorization or approval of the product or seize the product;
●
we, or any future collaborators, may need to recall the product, or be required to change the way the product is
administered or conduct additional clinical trials;
●
additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;
●
we may be subject to fines, injunctions or the imposition of civil or criminal penalties;
●
regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a
contraindication;
●
we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously
unidentified side effects for distribution to patients;
●
we, or any future collaborators, may be required to implement a REMS that imposes distribution and use restrictions or to
conduct post-market studies or clinical trials;
●
we, or any future collaborators, could be sued and held liable for harm caused to patients;
●
the product may become less competitive; and
●
our reputation may suffer.
Any of these events could harm our business and operations and could negatively impact our share price.
Our most advanced product candidates are either chimeric or humanized antibody proteins that could cause an immune
response in patients, resulting in the creation of harmful or neutralizing antibodies against these therapeutic proteins
In addition to the safety, efficacy, manufacturing and regulatory hurdles faced by our product candidates, the administration
of proteins such as monoclonal antibodies that are chimeric or humanized, including our product candidates vilobelimab and
IFX002, respectively, can cause an immune response, resulting in the creation of antibodies against the therapeutic protein. These
anti-drug antibodies, or ADAs, can have no effect or can neutralize the effectiveness of the protein or require that higher doses be
used to obtain a therapeutic effect. Whether ADAs will be created and how they react can often not be predicted from preclinical
or even clinical studies, and their detection or appearance is often delayed. As a result, neutralizing antibodies may be detected at
a later date or upon longer exposure of patients with our product candidates, such as following more chronic administration in
longer lasting clinical trials. In some cases, detection of such neutralizing antibodies can even occur after pivotal clinical trials
have been completed. Therefore, there can be no assurance that neutralizing antibodies will not be detected in future clinical trials
or at a later date upon longer exposure (including after commercialization). If ADAs reduce or neutralize the effectiveness of our
product candidates, the continued clinical development or receipt of marketing approval for any of our product candidates could
be delayed or prevented and, even if any of our product candidates is approved, their commercial success could be limited, any of
which would impair our ability to generate revenue and continue operations. Low levels of ADAs were detected in previously
completed clinical studies.
Even if we complete the necessary preclinical studies and clinical trials for vilobelimab and any other product candidates, the
marketing approval process including the EUA and European marketing authorization process is expensive, time consuming and
uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our
product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain
marketing authorization or approval to commercialize a product candidate
The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are
subject to extensive regulation by the FDA and comparable foreign regulatory authorities. We, and any future collaborators, are
not permitted to market our product candidates in the United States or in other countries until we, or they, receive approval of a
BLA or the EUA from the FDA or marketing approval from applicable regulatory authorities in other countries. Our product
candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not
submitted an application for or received marketing approval for any product candidate in the United States or in any other
jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals,
including FDA approval of a BLA or EUA. Further, there is no prior history of regulatory approval for product candidates
targeting C5a inhibition.
-14-
The process of obtaining marketing authorizations or approvals, both in the United States and elsewhere is lengthy, expensive
and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors,
including the type, complexity and novelty of the product candidates involved. Securing marketing approval, including the EUA,
requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each
therapeutic indication to establish the product candidate’s safety and efficacy. Securing marketing approval, including the EUA,
also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities
by, the regulatory authorities. The FDA or other regulatory authorities may determine that our product candidates are not safe and
effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude
our obtaining marketing approval or prevent or limit commercial use. In addition, approval policies, regulations, or the type and
amount of clinical data necessary to gain approval may change during the course of a drug candidate’s clinical development and
may vary among jurisdictions. Any marketing approval, including the EUA, we ultimately obtain may be limited or subject to
restrictions or post-approval commitments that render the approved product not commercially viable. For example, the EUA for
the GOHIBIC (vilobelimab) has been granted for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours
of receiving IMV or ECMO. In addition, the EC has granted marketing authorization under exceptional circumstances for
GOHIBIC (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced ARDS who are receiving systemic
corticosteroids as part of standard of care and receiving IMV (with or without ECMO). The FDA, EMA or any comparable
foreign regulatory authorities may delay, limit or deny approval of vilobelimab for many reasons, including:
●
we may not be able to demonstrate that vilobelimab is safe and effective as a treatment for our targeted indications,
excluding GOHIBIC (vilobelimab) in certain applications for the treatment of COVID-19 in hospitalized adults, to the
satisfaction of the FDA, the EMA or certain comparable foreign regulatory agencies;
●
the FDA, EMA or comparable foreign regulatory authorities may require additional activities, clinical trials or non-
clinical studies of vilobelimab in addition to those already performed or planned, either before approval or as a post-
approval commitment, which would increase our costs and prolong our development time for vilobelimab;
●
the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA, EMA or
comparable foreign regulatory authorities to obtain marketing approval;
●
the FDA, EMA or comparable foreign regulatory authorities may disagree with the number, design, size, conduct or
implementation of our clinical trials, including designated clinical endpoints;
●
the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full
population for which we seek approval;
●
the contract research organizations, or CROs, that we retain to conduct clinical trials may take actions outside of our
control that materially adversely impact our clinical trials;
●
the FDA, EMA or comparable foreign regulatory authorities may not find the data from preclinical studies and clinical
trials sufficient to demonstrate that the clinical and other benefits of vilobelimab and any other product candidates
outweigh its safety risks;
●
the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical
studies and clinical trials;
●
the FDA, EMA or comparable foreign regulatory authorities may not accept data generated at clinical trial sites,
including for non-compliance with cGCP;
●
if our BLA, when submitted, is reviewed by an advisory committee, the FDA may have difficulties scheduling an
advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our
application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical
trials, limitations on approved labeling or distribution and use restrictions;
-15-
●
the FDA, EMA or comparable foreign regulatory authorities may require development of a risk evaluation and mitigation
strategy, or REMS, as a condition of approval;
●
the FDA, EMA or comparable foreign regulatory authorities may identify deficiencies in the manufacturing processes or
facilities of our third-party manufacturers, including non-compliance with current Good Manufacturing Practices, or
cGMP; or
●
the FDA, EMA or comparable foreign regulatory authorities may change their respective approval policies or adopt new
regulations.
Of the large number of drugs in development in the biopharmaceutical industry, only a small percentage result in the
submission of a BLA to the FDA and even fewer are approved for commercialization. Furthermore, even if we do receive
regulatory approval to market vilobelimab, any such approval may be subject to limitations on the indicated uses or patient
populations for which we may market the product. Accordingly, even if we are able to obtain the requisite financing to continue to
fund our development programs, we cannot assure you that vilobelimab and/or any other product candidates will be successfully
developed or commercialized.
Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time
and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of
these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a
principal investigator, potentially including because of a financial relationship with us, has a conflict of interest that has affected
interpretation of the study. The FDA or other regulatory authorities may therefore question the integrity of the data generated at
the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in
approval, or rejection, of our marketing applications by the FDA or other regulatory authorities, as the case may be, and may
ultimately lead to the denial of marketing authorization or approval of one or more of our product candidates.
Any delay in obtaining or failure to obtain required approvals could negatively impact our ability or that of any future
collaborators to generate revenue from the particular product candidate, which likely would result in significant harm to our
financial position and adversely impact our share price.
We depend on enrollment of patients in our clinical studies for our product candidates. If we encounter difficulties enrolling
patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
We will also be required to identify and enroll a sufficient number of patients with PG, and potentially other indications, for
our planned or ongoing clinical trial of vilobelimab in these indications. Some of these are rare disease indications or indication
with a relatively small patient population. Trial participant enrollment could be limited in future trials given that many potential
participants may be ineligible because they are already undergoing treatment with approved medications or are participating in
other clinical trials.
Patient enrollment is affected by other factors, including:
●
severity of the disease under investigation;
●
design of the clinical trial protocol;
●
size and nature of the patient population;
●
eligibility criteria for the trial in question;
●
perceived risks and benefits of the product candidate under trial;
●
perceived safety and tolerability of the product candidate;
●
proximity and availability of clinical trial sites for prospective patients;
●
availability of competing therapies and clinical trials;
●
clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available
therapies, including standard-of-care and any new drugs that may be approved for the indications we are investigating;
-16-
●
efforts to facilitate timely enrollment in clinical trials;
●
patient referral practices of physicians; and
●
our ability to monitor patients adequately during and after treatment.
Further, there are only a limited number of specialist physicians who treat patients with these diseases and major clinical
centers are concentrated in a few geographic regions. We also may encounter difficulties in identifying and enrolling such patients
with a stage of disease appropriate for our ongoing or future clinical trials. In addition, the process of finding and diagnosing
patients may prove costly. Our inability to enroll a sufficient number of patients for any of our clinical trials, if any, would result
in significant delays or may require us to abandon one or more clinical trials.
Previously, we experienced slower recruitment than anticipated in the clinical trials of vilobelimab in severe COVID 19, PG
and cSCC, because of other compounds in clinical development for the same patient population, low disease prevalence,
difficulties in diagnosis or due to restrictions at clinical trial sites in light of the COVID-19 pandemic. Further delays in the
completion of any clinical trials will increase our costs, slow down our product candidate development and delay or potentially
jeopardize our ability to commence marketing and generate revenue. In addition, we may not be able to initiate or continue
clinical trials required by the FDA, EMA or other foreign regulatory agencies for vilobelimab or any of our other product
candidates that we pursue if we are unable to locate and enroll a sufficient number of eligible patients to participate in these
clinical trials.
Even if one of our product candidates receives marketing approval, including the EUA, it may fail to achieve the degree of
market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial
success, in which case we may not generate significant revenues or become profitable
Even if our other product candidates are approved by the appropriate regulatory authorities for marketing and sale or receives
the EUA, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in
the medical community. As a general proposition, physicians are often reluctant to switch their patients from existing therapies
even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to
existing therapies and do not want to switch therapies unless their physicians recommend doing so or they are required to do so
due to lack of reimbursement for existing therapies. Further, we may face a lack of acceptance by the physician community of the
efficacy of targeting C5a to inhibit terminal complement activation compared to targeting C5, which is well established in clinical
practice (such as eculizumab). In addition, vilobelimab may not be accepted by physicians or patients if we cannot demonstrate, or
if vilobelimab is perceived as not having, strong duration of effect, including compared to existing treatments. The duration of
effect of vilobelimab has only been studied prospectively for durations less than the expected duration of any pivotal Phase 3
clinical trials. It is possible that the effects seen in shorter term clinical trials will not be replicated at later time points or in larger
clinical trials. Further, even if we are able to demonstrate our product candidates’ safety and efficacy to the FDA and other
regulators, safety concerns in the medical community may hinder market acceptance.
Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require
significant resources, including management time and financial resources, and may not be successful. If any of our product
candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and
we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will
depend on a number of factors, including:
●
the efficacy and safety of the product;
●
the potential advantages of the product compared to competitive therapies, notwithstanding success in meeting or
exceeding clinical trial endpoints;
●
the prevalence and severity of any side effects;
●
whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;
●
our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;
-17-
●
the product’s convenience and ease of administration compared to alternative treatments;
●
the willingness of the target patient population to try, and of physicians to prescribe, the product;
●
limitations or warnings, including distribution or use restrictions contained in the product’s approved labeling;
●
the strength of sales, marketing and distribution support;
●
changes in the standard of care for the targeted indications for the product; and
●
availability and amount of coverage and reimbursement from government payors, managed care plans and other third-
party payors.
The failure of any of our product candidates, if authorized or approved, to find market acceptance would harm our business
and could require us to seek additional financing.
Even if we, or any future collaborators, are able to commercialize any product candidate that we, or they, develop, the product
may become subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, any of which
could harm our business
Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part
of the costs associated with their treatment. Therefore, our ability, and the ability of any future collaborators, to commercialize any
of our product candidates will depend in part on the extent to which coverage and reimbursement for these products and related
treatments will be available from third-party payors including government health administration authorities and public or private
health coverage insurers. Third-party payors decide which medications they will cover and establish reimbursement levels. We
cannot be certain that reimbursement will be available for vilobelimab or any of our product candidates. Also, we cannot be
certain that less fulsome reimbursement policies will not reduce the demand for, or the price we can charge for, our products, if
approved. The insurance coverage and reimbursement status of newly approved products for orphan diseases is particularly
uncertain and failure to obtain or maintain adequate coverage and reimbursement for vilobelimab or any other product candidates
could limit our ability to generate revenue.
If coverage and reimbursement are not available, or reimbursement is available only to limited levels, we, or any future
collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved
reimbursement amount may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient
to realize a sufficient return on our or their investments. In the United States, no uniform policy of coverage and reimbursement
for products exists among third-party payors and coverage and reimbursement for products can differ significantly from payor to
payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide
scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate
reimbursement will be applied consistently or obtained in the first instance.
There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing
approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require
approval of the sales price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing
or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to
continuing governmental control even after initial approval is granted. As a result, we, or any future collaborators, might obtain
marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of
the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of
the product in that country. Adverse pricing limitations may hinder our ability or the ability of any future collaborators to recoup
our or their investment in one or more product candidates, even if our product candidates obtain marketing approval.
The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government
authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for
particular medications, which could affect our ability or that of any future collaborators to sell our product candidates profitably.
These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our
customers, or those of any future collaborators, or may not be sufficient to allow our products, if any, to be marketed on a
competitive basis. Cost-control initiatives or other policy measures by government authorities could cause us, or any future
collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product
revenues. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide coverage
or adequate reimbursement, our prospects for revenue and profitability will suffer.
-18-
There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more
limited than the indications for which the drug is authorized or approved by the FDA or comparable foreign regulatory authorities.
Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs,
including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example,
according to the use of the product and the clinical setting in which it is used. Reimbursement rates may also be based on
reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services.
In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of
new technologies and are challenging the prices charged. We cannot be sure that reimbursement coverage will be available for any
product candidate that we, or any future collaborator, commercialize and, if available, that the reimbursement rates will be
adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws
that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An
inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our
product candidates for which we, or any future collaborator, obtain marketing authorization or approval could significantly harm
our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.
If we are unable to develop our sales, marketing and distribution capability on our own or through collaborations with
marketing partners, we will not be successful in commercializing our product candidates
We have limited marketing, sales or distribution capabilities and experience within our organization. If any of our product
candidates is authorized or approved, we either have to establish a sales and marketing organization with technical expertise and
supporting distribution capabilities to commercialize any such candidate, or to outsource this function to a third party. These
activities were initiated in 2023 regarding the FDA’s EUA for GOHIBIC (vilobelimab) in the United States. Either of these
options would be expensive and time consuming. Some or all of these costs may be incurred in advance of any approval of our
product candidates, including our lead candidate vilobelimab. In addition, we may not be able to hire a sales force in the United
States, Europe or other target market that is sufficient in size or has adequate expertise in the medical markets that we intend to
target. To address these challenges with GOHIBIC (vilobelimab) in Europe, we are pursuing options with regard to product
distribution through a commercial partner. These risks may be particularly pronounced due to our focus on severe COVID-19, as
well as additional focus on PG, each of which are disease areas with relatively small patient populations. Any failure or delay in
the development of our or third parties’ internal sales, marketing and distribution capabilities would adversely impact the
commercialization of vilobelimab and other future product candidates.
With respect to our existing and future product candidates, we may choose to collaborate with third parties that have direct
sales forces and established distribution systems (such as we are planning with GOHIBIC (vilobelimab) in the European Union),
either to augment or to serve as an alternative to our own sales force and distribution systems. Our product revenue may be lower
than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part
upon the efforts of these third parties, which may not be successful and are generally not within our control. If we are unable to
enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any authorized or
approved products. If we are not successful in commercializing any authorized or approved products, our future product revenue
will suffer and we may incur significant additional losses.
We may be subject to risks in relation to shelf-life expiration of drug product for GOHIBIC (vilobelimab), including but not
limited to substantial write-offs in the balance sheet
Our finished drug product for GOHIBIC (vilobelimab) for use of commercial purposes and/or clinical trials is subject to
limited shelf-life periods. If we fail to use such finished drug product for the intended use prior to its shelf-life expiration, such
drug product will have to be destroyed accordingly, which might cause additional and substantial costs and expense as well as
which might lead to substantial write-offs of destroyed drug product.
-19-
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product
candidates or indications that may be more profitable or for which there is a greater likelihood of success
We have limited financial and managerial resources, and therefore we intend to focus on developing product candidates for
specific indications that we identify as most likely to succeed, in terms of both their potential for marketing authorization,
approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for
other indications that may prove to have greater commercial potential.
Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market
opportunities. Our spending on current and future research and development programs and product candidates for specific
indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential
or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through
collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain
sole development and commercialization rights to the product candidate.
Clinical development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or
experience delays in completing, or ultimately be unable to complete, the development and commercialization of vilobelimab or
any other product candidate we may develop
The risk of failure for vilobelimab and any other product candidates we may develop such as INF904 is high. It is impossible
to predict when or if vilobelimab will prove to be effective and safe in humans or will receive full regulatory approval for the
treatment of severe COVID-19 in the U.S., for a PG indication, or other indications. Additionally, before regulatory authorities
grant marketing approval or an EUA for vilobelimab, for any future indications, or any future product candidate that we seek to
develop, we will be required to complete our ongoing extensive clinical trials to demonstrate safety and efficacy in humans.
Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to
outcome. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many
companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless
failed to obtain marketing approval of their drugs.
We may experience numerous unforeseen events during or as a result of the regulatory authorization and/or approval process
that could delay or prevent our ability to receive marketing approval or an EUA from regulators or commercialize vilobelimab or
any future product candidate, including:
●
regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct
a clinical trial at a prospective trial site;
●
clinical trials of our product candidates may produce negative or inconclusive results, including failure to demonstrate
statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon
drug development programs;
●
our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our
investigators, regulators, ethics committees or institutional review boards to suspend or terminate the trials;
●
our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in
a timely manner, or at all;
●
regulators, ethics committees or institutional review boards may require that we or our investigators suspend or terminate
clinical development for various reasons, including noncompliance with regulatory requirements or a finding that the
participants are being exposed to unacceptable health risks; and
●
regulators or institutional review boards my not authorize us or our investigators to commence a clinical trial or conduct a
clinical trail at a prospective trail site.
-20-
We could also encounter delays if a clinical trial is suspended or terminated by us, by an overseeing ethics committee, by the
institutional review boards of the institutions in which such trials are being conducted, by the data safety monitoring board for
such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a
number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical
protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the
imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug,
changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we
experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of
our product candidates will be harmed, and our ability to generate drug revenues from any of these product candidates will be
delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate
development and approval process and jeopardize our ability to commence drug sales and generate revenues. Any of these
occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or
lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval.
Our product development costs will further increase if we experience delays in testing or marketing approvals. Significant
clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product
candidates or allow our competitors to bring drugs to market before we do and impair our ability to successfully commercialize
our product candidates. We are evaluating applications for orphan drug or breakthrough therapy designation for vilobelimab in
various indications, but we may be unable to obtain any such designation or to maintain the benefits associated with orphan drug
status, including market exclusivity, even if that designation is granted
We are evaluating applications for orphan drug or breakthrough therapy designation for vilobelimab in some indications, and
we may seek orphan drug designation for other preclinical product candidates in our pipeline or that we may develop. In the
United States and other countries, orphan drug designation entitles a party to financial incentives such as opportunities for grant
funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA or other foreign regulatory agency grants
orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan
drug designation does not convey any advantage in, or shorten the duration of, the FDA review and approval process.
Breakthrough therapy designation is a process designed to expedite the development and review of drugs that are intended to treat
a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over
available therapy on a clinically significant endpoint. Breakthrough therapy designation may make us eligible for intensive
guidance by the FDA on an efficient drug development program and organizational commitment involving senior FDA managers,
among others. Although we are evaluating applications for orphan drug or breakthrough therapy designation in some indications,
there can be no assurance that we will obtain such designations. Moreover, obtaining orphan drug or breakthrough therapy
designation for one indication does not mean we will be able to obtain such designation for another indication.
If a product that has orphan drug designation from the FDA subsequently receives the first FDA approval for a particular
active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means
that the FDA may not approve any other applications, including a BLA, to market the same drug for the same indication for seven
years, except in limited circumstances such as if the FDA finds that the holder of the orphan drug exclusivity has not shown that it
can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for
which the drug was designated. Similarly, the FDA can subsequently approve a drug with the same active moiety for the same
condition during the exclusivity period if the FDA concludes that the later drug is clinically superior, meaning the later drug is
safer, more effective, or makes a major contribution to patient care. Even if we were to obtain orphan drug designation for
vilobelimab from the FDA, we may not be the first to obtain marketing approval for any particular orphan indication due to the
uncertainties associated with developing pharmaceutical products, and thus approval of vilobelimab could be blocked for seven
years if another company obtains approval and orphan drug exclusivity for the same drug and same condition before us. If we do
obtain exclusive marketing rights in the United States, they may be limited if we seek approval for an indication broader than the
orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective
or if we are unable to assure sufficient quantities of the product to meet the needs of the relevant patients. Further, exclusivity may
not effectively protect the product from competition because different drugs with different active moieties can be approved for the
same condition, the same drugs can be approved for different indications and might then be used off-label in our approved
indication, and different drugs for the same condition may already be approved and commercially available.
-21-
Even if we obtain FDA approval or as we have received market authorization in Europe for vilobelimab or any of our other
product candidates, we may never obtain authorization or approval to commercialize our products outside of the United States
In order to market any approved products outside of the United States, we must establish and comply with numerous and
varying regulatory requirements of other countries regarding clinical trial design, safety and efficacy. If approved by the relevant
governmental authorities, we expect to market vilobelimab for the treatment of COVID-19 and other indications in Europe and
jurisdictions outside the United States, in part due to the relatively larger patient population that exists in Europe as compared to
that in the United States. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries,
and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval
procedures vary among countries and can involve additional product testing and validation and additional administrative review
periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require
additional preclinical studies or clinical trials, which would be costly and time consuming and could delay or prevent introduction
of vilobelimab or any of our other product candidates in those countries.
In addition, we expect to be subject to a variety of risks related to operating in other countries if we obtain the necessary
approvals, including:
●
differing regulatory requirements in countries outside the United States;
●
the potential for so-called parallel importing (i.e., when a local seller, faced with high or higher local prices, opts to
import goods from a foreign market (with low or lower prices) rather than buying them locally);
●
unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
●
economic weakness, including inflation, or political instability in particular foreign economies and markets;
●
foreign reimbursement, pricing and insurance regimes;
●
compliance with tax, employment, immigration and labor laws for employees living or traveling outside the United
States;
●
foreign taxes, including withholding of payroll taxes;
●
foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country;
●
difficulties staffing and managing foreign operations;
●
workforce uncertainty in countries where labor unrest is more common than in the United States;
●
potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;
●
challenges enforcing our contractual and intellectual property rights, especially in countries that do not protect
intellectual property rights to the same extent as in the United States;
●
production shortages resulting from any events affecting raw material supply or manufacturing capabilities as well as
supply chain disruptions outside the United States; and
●
business interruptions, including as a result of geopolitical uncertainty and instability (including related to the Russia-
Ukraine conflict, Hamas-Israel conflict and tensions between China and Taiwan).
If we or our partners fail to comply with regulatory requirements or to obtain and maintain required approvals, our target
market will be reduced, including if we are unable to market vilobelimab in Europe or elsewhere, and our ability to realize the full
market potential of our product candidates will be harmed.
-22-
We are subject to extensive government regulation and the failure to comply with these regulations may have a material
adverse effect on our operations and business
Both before and after approval of any product, we and our suppliers, contract manufacturers and clinical investigators are
subject to extensive regulation by governmental authorities in the United States and other countries, covering, among other things,
testing, manufacturing, quality control, clinical trials, post-marketing studies, labeling, advertising, promotion, distribution, import
and export, governmental pricing, price reporting and rebate requirements. Failure to comply with applicable requirements could
result in one or more of the following actions: warning letters; unanticipated expenditures; delays in approval or refusal to approve
a product candidate; product recall or seizure; interruption of manufacturing or clinical trials; operating or marketing restrictions;
injunctions; criminal prosecution and civil or criminal penalties including fines and other monetary penalties; adverse publicity;
and disruptions to our business. Further, government investigations into potential violations of these laws would require us to
expend considerable resources and face adverse publicity and the potential disruption of our business even if we are ultimately
found not to have committed a violation.
Obtaining FDA, EMA or other regulatory agency authorization or approval of our product candidates requires substantial
time, effort and financial resources and may be subject to both expected and unforeseen delays, and there can be no assurance that
any approval will be granted on any of our product candidates on a timely basis, if at all. The FDA, EMA or other regulatory
agencies may decide that our data are insufficient for authorization or approval of our product candidates and require additional
preclinical, clinical or other studies or additional work related to chemistry, manufacturing and controls, or CMC. If we are
required to conduct additional trials or to conduct other testing of our product candidates beyond that which we contemplate for
regulatory approval, if we are unable to complete successfully our clinical trials or other testing or if the results of these and other
trials or tests fail to demonstrate efficacy or raise safety concerns, we may face substantial additional expenses, be delayed in
obtaining marketing approval for our product candidates or may never obtain marketing approval.
We are also required to comply with extensive governmental regulatory requirements after a product has received marketing
authorization or approval. Governing regulatory authorities may require post-marketing studies that may negatively impact the
commercial viability of a product. Once on the market, a product may become associated with previously undetected adverse
effects and/or may develop manufacturing difficulties. As a result of any of these or other problems, a product’s regulatory
approval could be withdrawn, which could harm our business and operating results.
Our current and future relationships with third-party payors, health care professionals and customers in the United States and
elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment
transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to
significant penalties
Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the
recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future
arrangements with health care professionals, third-party payors and customers may expose us to broadly applicable fraud and
abuse and other healthcare laws and regulations, including the federal Anti-Kickback Statute and the federal civil False Claims
Act, that may constrain the business or financial arrangements and relationships through which we conduct clinical research, sell,
market and distribute any drugs for which we obtain marketing approval. In addition, we may be subject to transparency laws and
patient privacy regulation in the United States and other jurisdictions in which we conduct our business. The applicable federal,
state and foreign healthcare laws and regulations that may affect our ability to operate include the following:
the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and
willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or
reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or
service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. A
●
person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a
violation. Further, several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an
arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback
Statute has been violated. Moreover, the government may assert that a claim including items or services resulting from a
violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims
Act;
-23-
●
federal civil and criminal false claims laws, including the federal civil False Claims Act (that can be enforced through
civil whistleblower or qui tam actions), and the civil monetary penalties law, which impose criminal and civil penalties
against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including
the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to
avoid, decrease or conceal an obligation to pay money to the federal government;
●
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil
liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false
statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to
have actual knowledge of the statute or specific intent to violate it to have committed a violation;
●
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans,
and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually
identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and
transmission of individually identifiable health information;
●
the Physician Payments Sunshine Act, created under Section 6002 of Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act, or collectively the Affordable Care Act, and its
implementing regulations, which requires specified manufacturers of drugs, devices, biologics and medical supplies for
which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific
exceptions, to report annually to the Centers for Medicare & Medicaid Services, or CMS, information related to
payments or other “transfers of value” made to physicians, which is defined to include doctors, dentists, optometrists,
podiatrists and chiropractors, and teaching hospitals and applicable manufacturers to report annually to CMS ownership
and investment interests held by physicians and their immediate family members by the 90th day of each calendar year.
All such reported information is publicly available; and
●
analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply
with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign
laws that require drug manufacturers to report information related to payments and other transfers of value to physicians
and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security
of health information in certain circumstances, many of which differ from each other in significant ways and often are
not preempted by HIPAA, thus complicating compliance efforts.
Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and
regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices,
including our relationships with physicians and other healthcare providers, some of whom may recommend, purchase or prescribe
vilobelimab, if approved, may not comply with current or future statutes, regulations or case law involving applicable fraud and
abuse or other healthcare laws and regulations.
If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us,
we may be subject to significant civil, criminal and administrative penalties, including damages, fines, disgorgement, individual
imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional
reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve
allegations of non-compliance with these laws and the curtailment or restructuring of our operations, which could have a material
adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do
business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions,
including exclusions from participation in government healthcare programs, which could also materially affect our business.
-24-
Enacted and future legislation may increase the difficulty and cost for us to obtain marketing authorization or approval of and
commercialize vilobelimab and affect the prices we may obtain
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of vilobelimab, restrict or
regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing
authorization or approval.
Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in
healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United
States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major
legislative initiatives such as the Affordable Care Act in 2010, a sweeping law intended to broaden access to health insurance,
reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency
requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose
additional health policy reforms. In the coming years, additional legislative and regulatory changes could be made to
governmental health programs that could significantly impact pharmaceutical companies and the success of our drug candidate.
In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These
changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year effective April 1, 2013 and, due to
subsequent legislative amendments to the statute, will stay in effect through 2025, unless additional congressional action is taken.
The American Taxpayer Relief Act of 2012, further reduced, among other things, Medicare payments to several providers, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These
laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on
customers for our drugs, if approved, and, accordingly, our financial operations.
Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments
from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being
able to generate revenue, attain profitability, or commercialize our drugs.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional
activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations,
guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of vilobelimab, if any,
may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent
marketing approval, as well as subject us to more stringent drug labeling and post-marketing testing and other requirements.
Even if we, or any future collaborators, obtain marketing approvals for our product candidates, the terms of approvals and
ongoing regulation of our products may limit how we manufacture and market our products, which could impair our ability to
generate revenue
Once marketing approval or an EUA has been granted, an approved product and its manufacturer and marketer are subject to
ongoing review and extensive regulations. We, and any future collaborators, must therefore comply with requirements concerning
advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional
communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be
consistent with the information in the product’s approved labeling. Thus, we and any future collaborators will not be able to
promote any products we develop for indications or uses for which they are not approved.
In addition, manufacturers of authorized and approved products and those manufacturers’ facilities are required to comply
with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs,
which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records
and documentation and reporting requirements. We, our contract manufacturers, any future collaborators and their contract
manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.
-25-
Accordingly, assuming we, or any future collaborators, receive marketing approval for one or more of our product candidates,
we, and any future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all
areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.
The manufacturing and distribution of GOHIBIC (vilobelimab) is subject to a number of risks that could harm our reputation,
business, financial condition and operating results.
The manufacturing processes of GOHIBIC (vilobelimab) is complex. We may encounter manufacturing difficulties, including
difficulties related to product storage and shelf-life. Such difficulties could result from the complexities of manufacturing product
batches at a larger scale, equipment failure, availability of excipients and other product components/ingredients (including related
to choice and quality of raw materials), analytical testing technology and product instability. Specifically, insufficient product
stability or shelf-life of GOHIBIC (vilobelimab) or its components could materially limit or delay our or our collaborators’ ability
to distribute and commercialize GOHIBIC (vilobelimab) at the current price or at all. Further, if GOHIBIC (vilobelimab) becomes
subject to a product recall, including as the result of manufacturing errors, design/labeling defects or other deficiencies, our
reputation would be adversely affected.
GOHIBIC (vilobelimab) is a “cold-chain product” that must be shipped and stored at cold temperatures. We could lose supply
of GOHIBIC (vilobelimab) due to distribution difficulties, including generally related supply chain management (e.g., shelf-life
expiration) and specifically related to shipping and storing GOHBIC (vilobelimab) at cold temperatures. If so, we could incur
additional manufacturing costs in order to supply required quantities to U.S. hospitals under the EUA.
Any such manufacturing and distribution difficulties may harm our reputation, business, financial condition and operating
results.
Governments, including those outside the United States, tend to impose strict price controls, which may adversely affect our
revenues, if any
In many countries, such as countries of the European Union, the pricing of prescription pharmaceuticals is subject to varying
price control mechanisms, often as part of national health systems. Other countries allow companies to fix their own prices for
medical products but monitor and control company profits. Pricing negotiations with governmental authorities can take
considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some
countries, we, or any future collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our
product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is
set at unsatisfactory levels, our business could be harmed. Additional price controls or other changes in pricing regulation could
restrict the amount that we are able to charge for our product candidates, and we believe the increasing emphasis on cost-
containment initiatives in the European Union has and will continue to put pressure on the pricing and usage of our product
candidates. As a result, given the relatively smaller target markets for severe COVID-19 and PG, any reduced reimbursement for
such product candidates may be insufficient for us to generate commercially reasonable revenue and profits and would adversely
affect our financial condition and results of operations.
Any of our product candidates for which we, or any future collaborators, have obtained an EUA, marketing authorization or
intend to obtain market approval in the future could be subject to post-marketing restrictions or withdrawal from the market and
we, or any future collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements
or if we, or they, experience unanticipated problems with our products following approval or the EUA
Any of our product candidates for which we, or any future collaborators, obtain marketing approval or the EUA, as well as
the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such
product, among other things, will be subject to ongoing requirements of and review by the FDA, the EMA and other regulatory
authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and
listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of
records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing
approval or the EUA of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which
the product may be marketed or to the conditions of approval, including the requirement to implement a REMS.
-26-
The FDA, the EMA and other regulatory authorities may also impose requirements for costly post-marketing studies or
clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the
Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are
manufactured, marketed and distributed only for the authorized or approved indications and in accordance with the provisions of
the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use and if
we, or any future collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for
only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation
of the FDCA and other statutes relating to the promotion and advertising of prescription drugs may lead to investigations or
allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws, including the
False Claims Act.
In addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers
or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:
●
restrictions on the manufacturing of such products;
●
restrictions on the labeling or marketing of such products;
●
restrictions on product distribution or use;
●
requirements to conduct post-marketing studies or clinical trials;
●
warning letters or untitled letters;
●
withdrawal of the products from the market;
●
refusal to approve pending applications or supplements to approved applications that we submit;
●
recall of products;
●
restrictions on coverage by third-party payors;
●
fines, restitution or disgorgement of profits or revenues;
●
suspension or withdrawal of marketing approvals, including the EUA;
●
refusal to permit the import or export of products;
●
product seizure; or
●
injunctions or the imposition of civil or criminal penalties.
Our ability to successfully commercialize and generate revenue from sales of GOHIBIC (vilobelimab) is subject to a number
of risks that could harm our business, financial condition and operating results
Our ability to successfully commercialize GOHIBIC (vilobelimab) is subject to a number of risks that could impact our
business, financial condition and operating results. Specifically, our ability to generate revenue from sales of GOHIBIC
(vilobelimab) is uncertain, including due to the market opportunity for, and interest and perception in, GOHIBIC (vilobelimab). In
particular, given fluctuations in the number of patients developing severe symptoms from COVID-19 infections, the size of the
addressable patient population and, thus, the market opportunity for GOHIBIC (vilobelimab) is uncertain and may shrink over
time. In addition, since GOHIBIC (vilobelimab) has been granted an EUA by the FDA, but not a full FDA approval, sales of
GOHIBIC (vilobelimab) depend on whether healthcare providers at U.S. hospitals are interested in and receptive to providing
GOHIBIC (vilobelimab) as a treatment for COVID-19. Specifically, if GOHIBIC (vilobelimab) is not included in the treatment
guidelines issued by medical institutions and other third-party medical/healthcare organizations, such as the NIH or others, or if
such institutions and organizations do not recommend GOHIBIC (vilobelimab), hospitals may not be willing to make GOHIBIC
(vilobelimab) available for treatment of patients. Ultimately, if we are unable to successfully commercialize and generate revenue
from sales of GOHIBIC (vilobelimab), our business, financial condition and operating results could be adversely affected.
-27-
2.
Risks related to our dependence on third parties
We rely on third parties to conduct our clinical trials. If they do not perform satisfactorily, our business could be harmed
We do not independently conduct clinical trials of any of our product candidates. We rely on third parties, such as CROs,
clinical data management organizations, third-party consultants, medical institutions and clinical investigators, to conduct these
clinical trials and expect to rely on these third-parties to conduct clinical trials of any other product candidate that we develop.
Any of these third parties may terminate their engagements with us under certain circumstances. We may not be able to enter into
alternative arrangements or do so on commercially reasonable terms. In addition, there is a natural transition period when a new
CRO begins work. As a result, delays would likely occur, which could negatively impact our ability to meet our expected clinical
development timelines and harm our business, financial condition and prospects.
Further, although our reliance on these third parties for clinical development activities limits our control over these activities,
we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and
regulatory requirements and scientific standards. For example, notwithstanding the obligations of a CRO for a trial of one of our
product candidates, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general
investigational plan and protocols for the trial. Moreover, the FDA, the EMA and potentially other regulatory agencies of different
countries require us to comply with requirements, commonly referred to as current Good Clinical Practices, or cGCP, for
conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate
and that the rights, integrity and confidentiality of trial participants are protected. The FDA and regulatory agencies inside the
European Union and other regulatory agencies enforce these cGCP regulations through periodic inspections of trial sponsors,
principal investigators, clinical trial sites and IRBs. If we or our third-party contractors fail to comply with applicable cGCP
regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other regulatory agencies
may require us to perform additional clinical trials before approving our product candidates, which would delay the marketing
approval process. We cannot be certain that, upon inspection, the FDA or other regulatory agencies will determine that any of our
clinical trials comply with cGCP. We are also required to register clinical trials and post the results of completed clinical trials on
a government-sponsored database, such as ClinicalTrials.gov in the United States, within certain timeframes. The same
requirement applies to clinical trials outside the United States, such as EudraCT.ema.europa.eu in Europe. Failure to do so can
result in fines, adverse publicity and civil and criminal sanctions.
Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available
to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources
to our ongoing development programs. These contractors may also have relationships with other commercial entities, including
our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede
their ability to devote appropriate time to our clinical programs. If these third parties, including clinical investigators, do not
successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory
requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our
product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our
product candidates. In such an event, our financial results and the commercial prospects for any product candidates that we seek to
develop could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed.
Our reliance on foreign third-party manufacturers and suppliers increases our risk of obtaining adequate, timely and cost-
effective product candidates and products
Foreign manufacturing is subject to a number of risks, including political and economic disruptions, the imposition of tariffs,
quotas and other import or export controls, changes in governmental policies and geopolitical uncertainty and instability, which
have created market volatility. In particular, we rely on third-party manufacturer located in China and elsewhere for supply of
vilobelimab. We outsource all manufacturing of our product candidates and products to third parties while conducting certain
quality control tests in-house. The supply chain and manufacturing in China may, also as a result of the global political situation,
significantly impact our operations.
-28-
We engage a third-party manufacturer located in China for the clinical and commercial supply of the final drug product
formulation of vilobelimab. There is no assurance that we would be able to timely secure needed alternative supply arrangements
on satisfactory terms, or at all, if needed. Our reliance on our manufacturer and our failure to secure alternative supply
arrangements as needed could have a material adverse effect on our ability to complete the development of our product candidates
or, to commercialize them, if approved. There may be difficulties in scaling up to commercial quantities or optimization of
processes and formulation of vilobelimab and the costs of manufacturing could be prohibitive.
Even if we were able to establish and maintain arrangements with other third-party manufacturers, reliance on third-party
manufacturers generally entails additional risks beyond our control, including:
●
reliance on third parties for manufacturing process development, regulatory compliance and quality assurance;
●
reliance on third parties for storage and safeguarding of substantially all inventory;
●
costs and validation of new equipment and facilities required for additional scale-up or optimization of processes;
●
failure to comply with cGMP and similar foreign standards;
●
limitations on supply availability resulting from capacity and scheduling constraints of third parties;
●
lack of qualified backup suppliers for those components that are purchased from a sole or single source supplier;
●
closures and restrictions on critical facilities resulting from public health crises;
●
the ability to freely import clinical trial and marketing material manufactured at our third-party manufacturer in China
into the countries in which the clinical trials are being conducted or product potentially to be sold;
●
the possible breach of manufacturing agreements by third parties because of factors beyond our control; and
●
the possible termination or non-renewal of the manufacturing agreements by the third party, at a time that is costly or
inconvenient to us, and our ability to obtain alternative supply.
If we do not maintain our key manufacturing relationships, we may fail to find replacement manufacturers or develop our
own manufacturing capabilities, which could delay or impair our ability to obtain regulatory approval for our products. If we do
find replacement manufacturers, we may not be able to enter into agreements with them on terms and conditions favorable to us
and there could be a substantial delay before new facilities could be qualified and registered with the FDA and other foreign
regulatory authorities. In addition, a change of the manufacturing facility contains inherent risks and is generally viewed as a
major change in the manufacturing process such that comparability studies have to be conducted to assure comparability between
the before established manufacturing process and the newly established manufacturing process potentially causing delays in the
drug product supply or, in case of a non-comparability of the manufactured drug product, warrant further additional pre-clinical
and or clinical studies with such non-comparable drug product which may also be imposed by any regulatory agency upon review
of the comparability data. Any of the foregoing could have a material adverse effect on our business, financial condition, results of
operations and prospects.
The process of manufacturing biologics, such as vilobelimab, is extremely susceptible to product loss
The process of manufacturing our products is complex, highly regulated and subject to several other risks. The process of
manufacturing biologics, such as vilobelimab, is extremely susceptible to product loss due to contamination, equipment failure or
improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product
characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes
could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations
are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such
manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.
Further, our product candidates that have been produced and are stored for later use may degrade, become contaminated or suffer
other quality defects, which may cause the affected product candidates to no longer be suitable for their intended use in clinical
trials or other development activities. If the defective product candidates cannot be replaced in a timely fashion, we may incur
significant delays in our development programs that could adversely affect the value of such product candidates and, thus,
adversely affect our business, financial condition, results of operations and prospects.
-29-
Our manufacturing process is subject to quality control risks and related regulatory requirements
We participate in the manufacturing process with crucial quality control testing within our own laboratories, and we hold the
manufacturer license for, and therefore oversee, the overall manufacturing process, and we are responsible for ensuring that this
part of our business also operates according to cGMP standards. Additionally, we hold an importing license. We therefore employ
key personnel within the manufacturing process, such as a head of quality assurance, a head of manufacturing and a qualified
person.
Thus, our laboratories and our quality control system and related documentation and personnel, are also subject to frequent
governmental inspections to assure adherence to cGMP guidelines and to maintain our manufacturing and importing license.
Related to these activities, there are risks which could negatively impact our ability to meet our expected clinical development
timelines and harm our business, financial condition and prospects, including:
●
a loss of key personnel within the manufacturing activities could result in significant delays in the manufacturing and
release testing of our drug candidate and replacement of such personnel could be time consuming and be associated with
additional costs for us;
●
mistakes or misconduct within the release testing could result in false results which could result in both, the wrongfully
rejection of a manufactured drug product from being released or the wrongfully acceptance of a dysfunctional drug
product, causing data and trial results achieved with such drug product being false and potentially wrongly interpreted;
and
●
an inadequate cGMP compliance could result in a potential temporary or permanent loss of the manufacturing or
importing license resulting from an inspection of regulatory agencies.
Our third-party manufacturers, or we, may not be able to comply with the cGMP regulatory requirements applicable to
vilobelimab and biologics, including applicable provisions of the FDA’s drug cGMP regulations, device cGMP requirements
embodied in the Quality System Regulation, or QSR, or similar regulatory requirements outside the United States. Our failure, or
the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us,
including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary
recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of
our product candidates. In addition, our third-party manufacturers and suppliers and we are subject to FDA and other local
regulatory authority inspection from time to time. Failure by our third-party manufacturers and suppliers or us to pass such
inspections and otherwise satisfactorily complete the FDA approval regimen with respect to our product candidate may result in
regulatory actions such as the issuance of FDA Form 483 notices of observations, warning letters or injunctions or the loss of
operating licenses.
In addition, we and our third-party manufacturers and suppliers are subject to numerous environmental, health and safety laws
and regulations, including those governing the handling, use, storage, treatment and disposal of waste products, and failure to
comply with such laws and regulations could result in significant costs associated with civil or criminal fines and penalties for
such third parties. Based on the severity of the regulatory action, our clinical or commercial supply of drug and packaging and
other services could be interrupted or limited, which could have a material adverse effect on our business, including our clinical
research activities and our ability to develop our product candidates and market our products following approval, if any.
-30-
If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product
candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture the product may increase and
commercialization may be delayed
In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization
of vilobelimab or any of our other product candidates in our pipeline or that we may develop, our third-party manufacturers will
be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product.
The transition to larger scale production could prove difficult or costly. Further, any claims in our manufacturing process as a
result of scaling up or optimization of the manufacturing, supply and fill process may result in the need to obtain regulatory
approvals. If our third-party manufacturers are not able to optimize manufacturing process to increase the product yield for our
product candidates or are unable to produce increased amounts of our product candidates while maintaining the quality of the
product, then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to
generate profits. Difficulty in achieving commercial scale-up production or production optimization or the need for additional
regulatory approvals as a result could have a material adverse impact on our business and results of operations.
We expect to seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we
may have to alter our development and commercialization plans
We expect to seek one or more collaborators for the development and commercialization of one or more of our product
candidates. Likely collaborators may include large and mid-size pharmaceutical companies, regional and national pharmaceutical
companies and biotechnology companies. In addition, if we obtain marketing authorization or approval for product candidates
from foreign regulatory authorities, we may enter into strategic relationships with international biotechnology or pharmaceutical
companies for the commercialization of such product candidates outside of the United States.
We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a
collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and
conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may
include the potential differentiation of our product candidate from competing product candidates, design or results of clinical
trials, the likelihood of approval by the FDA, the EMA or comparable foreign regulatory authorities and the regulatory pathway
for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering
the product to patients and the potential of competing products. The collaborator may also consider alternative product candidates
or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more
attractive than the one with us for our product candidate. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable
terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to
market and generate product revenue.
Collaborations are complex and time-consuming to negotiate and document. Further, there have been a significant number of
recent business combinations among large pharmaceutical companies that may have resulted in a reduced number of potential
future collaborators. Any collaboration agreements that we enter into in the future may contain restrictions on our ability to enter
into potential collaborations or to otherwise develop specified product candidates. We may not be able to negotiate collaborations
on a timely basis, on acceptable terms, or at all.
If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to
collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential
commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense.
If we enter into collaborations with third parties for the development and commercialization of our product candidates, our
prospects with respect to those product candidates will depend in significant part on the success of those collaborations
We expect to maintain existing collaborations and enter into additional collaborations for the development and
commercialization of certain of our product candidates and in certain geographies. We may have limited control over the amount
and timing of resources that our collaborators will dedicate to the development or commercialization of our product candidates.
Our ability to generate revenues from these arrangements will depend on any future collaborators’ abilities to successfully perform
the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research
or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the
agreed upon terms.
-31-
Collaborations involving our product candidates pose a number of risks, including the following:
●
collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations;
●
collaborators may not perform their obligations as expected;
●
collaborators may not pursue development and commercialization of our product candidates or may elect not to continue
or renew development or commercialization programs, based on clinical trial results, changes in the collaborators’
strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing
priorities;
●
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or
abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for
clinical testing;
●
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
our product candidates;
●
a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the
marketing and distribution of such product or products;
●
disagreements with collaborators, including disagreements over proprietary rights, including trade secrets and other
intellectual property, contract interpretation, or the preferred course of research and development might cause delays or
termination of the research, development or commercialization of product candidates, might lead to additional
responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would
be time-consuming and expensive;
●
collaborators may not properly prosecute, maintain, defend or enforce our intellectual property rights or may use our
proprietary information or other intellectual property in such a way as to invite litigation that could jeopardize or
invalidate our intellectual property or expose us to potential litigation;
●
collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may
expose us to litigation and potential liability;
●
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable product candidates; and
●
collaboration agreements may not lead to development or commercialization of product candidates in the most efficient
manner or at all. If any future collaborator of ours is involved in a business combination, it could decide to delay,
diminish or terminate the development or commercialization of any product candidate licensed to it by us.
Changes in funding or disruptions at the FDA and other governmental agencies caused by funding shortages or global health
concerns could hinder their ability to perform normal business functions on which the operation of our business may rely, which
could negatively impact our business
The ability of the FDA to review and clear or approve new product candidates and products can be affected by a variety of
factors, including:
●
government budget and funding levels, and statutory, regulatory and policy changes;
●
the FDA’s ability to hire and retain key personnel and accept the payment of user fees; and
●
federal government shutdowns and other events that may otherwise affect the FDA’s ability to perform routine functions.
-32-
Average review times at the agency have fluctuated in recent years as a result.
Further, if a prolonged government shutdown occurs, or if global health concerns continue to prevent or delay the FDA or
other regulatory authorities from conducting, at all or in a timely manner, their regular inspections, reviews or other regulatory
activities, the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions could be
significantly impacted, which could have a material adverse effect on our business.
3.
Risks related to our intellectual property
Our success depends on our ability to obtain, maintain, protect, defend and enforce patent, trade secret and other intellectual
property protection
Our success depends on our ability to obtain, maintain, protect, defend and enforce patent, trade secret and other intellectual
property protection in the United States and other countries with respect to vilobelimab and other proprietary product candidates.
If we do not adequately protect, maintain, defend and enforce our intellectual property rights, competitors may be able to erode,
negate or preempt any competitive advantage we may have, which could adversely affect our business and ability to achieve
profitability. To seek to protect our proprietary position, we file patent applications in the United States and in certain other
countries related to our novel product candidates and their potential use in different medical indications that are important to our
business. The patent application and approval process is expensive and time-consuming and we may not be able to file and
prosecute all necessary or desirable patent applications and obtain and maintain issued patents at a reasonable cost or in a timely
manner.
If the scope of the patent protection we obtain is not sufficiently broad, we may not be able to prevent others from developing
and commercializing technology and products similar or identical to ours. The degree of patent protection we require to
successfully compete in the market may be unavailable or severely limited in some cases and may not adequately protect our
rights or permit us to gain or keep any competitive advantage. Although we enter into non-disclosure and confidentiality
agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our
employees, contractors, prospective business collaborators, clinical investigators and other third parties, any of these parties could
breach the agreements and disclose such output before a patent application is filed, which could jeopardize our ability to seek and
obtain patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries,
and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in
some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or
pending patent applications, or that we were the first to file for patent protection of such inventions.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and
factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity,
enforceability, and commercial value of our patent rights may be uncertain. Our pending and future patent applications may not
result in patents being issued which protect our technology or product candidates or which effectively prevent others from
commercializing competitive technologies and product candidates. In addition, the coverage claimed in a patent application can be
significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our patent applications
issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other
third parties from competing with us, or otherwise provide us with any competitive advantage. For example, there can be no
assurance that our issued patents contain and pending patent applications will contain, when granted, claims of sufficient breadth
to cover all antibodies alleged to be a biosimilar of our product candidates. Furthermore, there can be no assurance that our issued
patents will not be challenged at the United States Patent and Trademark Office, or USPTO, or foreign patent offices or in court
proceedings, and if any such challenge were successful, the scope of our issued patent claims could be limited so as to not cover
antibodies alleged to be a biosimilar of our product candidates. In addition, changes in either the patent laws or interpretation of
the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent
protection. In addition, the laws of other countries may not protect our rights to the same extent or in the same manner as the laws
of the United States. For example, patent laws in various jurisdictions, including significant commercial markets, such as Europe,
restrict the patentability of methods of treatment of the human body more than patent laws in the United States.
-33-
Some of our future patents and patent applications and other intellectual property may be co-owned with third parties. If we
are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patents or patent applications or other
intellectual property, such co-owners may be able to license their rights to other third parties, including our competitors, and our
competitors could market competing products and technology. In addition, we would need the cooperation of any such co-owners
of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore,
we, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of
development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss
potential opportunities to strengthen our patent position. Any of the foregoing could have a material adverse effect on our
business, financial condition, results of operations and prospects.
Our patents covering our proprietary anti-C5a and anti C5aR technologies may be subject to challenge, narrowing,
circumvention and invalidation by third parties
Any of our patents may be challenged, narrowed, circumvented, or invalidated by third parties. The issuance of a patent is not
conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent
offices in the United States and elsewhere. We may be subject to a third-party pre-issuance submission of prior art to the USPTO
or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review, or interference
proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission,
proceeding or litigation could reduce the scope of, enforceability or invalidate, our patent rights, allow third parties to
commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to
manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in
interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as
oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such challenges may
result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the
duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost
and require significant time from our scientists and management, even if the eventual outcome is favorable to us.
In addition, our competitors and other third parties may be able to circumvent our patents by developing similar or alternative
technologies or products in a non-infringing manner. For example, a third party may develop a competitive therapy that provides
benefits similar to vilobelimab or other product candidates but that uses a technology that falls outside the scope of our patent
protection. Our competitors may also seek approval to market generic versions of any approved products and in connection with
seeking such approval may claim that our patents are invalid, unenforceable or not infringed. In these circumstances, we may need
to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of
proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors are
competing in a non-infringing manner. Thus, even if we have valid and enforceable patents, these patents still may not provide
protection against competing products or processes sufficient to achieve our business objectives. If the patent protection provided
by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede
such competition, our ability to successfully commercialize our product candidates could be negatively affected, which could have
a material adverse effect on our business, financial condition, results of operations and prospects.
We cannot be sure that we were the first to make the anti-C5a and anti-C5aR technologies claimed in our patents or patent
applications or that we were the first to file for patent protection
Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled
to the patent. However, prior to March 16, 2013, in the United States, the first to invent was entitled to the patent. Publications of
discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other
jurisdictions are not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we
were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for
patent protection of such inventions. Similarly, we cannot be certain that parties from whom we may license or purchase patent
rights were the first to make relevant claimed inventions, or were the first to file for patent protection for them. If third parties
have filed patent applications on inventions claimed in our patents or applications on or before March 15, 2013, an interference
proceeding in the United States can be initiated by such third parties to determine who was the first to invent the subject matter
covered our patent applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding in the
United States can be initiated by such third parties to determine whether our invention was derived from theirs.
-34-
The patent application process is subject to numerous risks and there can be no assurance that we will be successful in
obtaining patents for which we have applied
Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications
unless and until such patent is issued. The patent application process is subject to numerous risks and uncertainties, and there can
be no assurance that we or any of our future development partners will be successful in protecting our product candidates by
obtaining and defending patents. These risks and uncertainties include the following:
●
the USPTO and various foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance
can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights
in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise
have been the case;
●
the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be
reinterpreted after issuance;
●
patent applications may not result in any patents being issued;
●
patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, narrowed,
found to be unenforceable or otherwise may not provide any competitive advantage;
●
our competitors, many of whom have substantially greater resources and many of whom have made significant
investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or
eliminate our ability to make, use, and sell our potential product candidates;
●
there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of
patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of
public policy regarding worldwide health concerns; and
●
countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing product candidates.
Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations
and prospects.
It is difficult and costly to protect our intellectual property and our proprietary anti-C5a and anti-C5aR technologies, and we
may not be able to ensure their protection
Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for the
composition, use and structure of our product candidates, the methods used to manufacture them, the related therapeutic targets
and associated methods of treatment as well as on successfully defending these patents against potential third-party challenges.
Our ability to protect our product candidates from unauthorized making, using, selling, offering to sell or importing by third
parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities.
The ultimate determination by the USPTO or by a court or other trier of fact in the United States, or any corresponding
foreign patent offices or courts or other triers of fact, on whether a claim meets all requirements of patentability cannot be assured.
Although our C5a and C5aR inhibitor portfolio consists of six families of patents and patent applications that we own directed to
C5a and C5aR inhibitors and related methods of use, we cannot predict the breadth of claims that may be allowed or enforced in
our patents or patent applications, in our future licensed patents or patent applications or in third-party patents.
-35-
We cannot provide assurances that any of our patent applications will be found to be patentable, including over our own prior
art patents, publications or other disclosures. Furthermore, given the differences in patent laws in the United States, Europe and
other foreign countries, for example, the availability of grace periods for filing patent applications and what can be considered as
prior art, we cannot make any assurances as to the scope of any claims that may issue from our pending and future patent
applications in the United States or in other jurisdictions. Similarly, we cannot make any assurances as to the scope of any claims
that may survive a proceeding initiated by a third party challenging the patentability, validity or enforceability of our patents and
patent applications in the United States or in other jurisdictions. Any such challenge, if successful, could limit patent protection
for our product candidates and/or materially harm our business.
The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and
may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:
●
we may not be able to generate sufficient data to support patent applications that protect the entire breadth of
developments in one or more of our programs;
●
it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the
patent(s) will be insufficient to protect our technology or products, provide us with a basis for commercially viable
products or provide us with any competitive advantages;
●
if our pending patent applications issue as patents, they may be challenged by third parties as not infringed, invalid or
unenforceable under United States or foreign laws; or
●
if issued, the patents under which we hold rights may not be valid or enforceable.
In addition, to the extent that we are unable to obtain and maintain patent protection for one of our product candidates or in
the event that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional
development of a product or product candidate for follow-on indications. Any of the foregoing could have a material adverse
effect on our business, financial condition, results of operations and prospects.
Obtaining and maintaining patent protection of our anti-C5a and anti-C5aR technologies depends on compliance with various
procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent
protection could be reduced or eliminated for non-compliance with these requirements
Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are
required to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the
lifetime of the patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with
a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a
patent has issued. There are situations in which non-compliance can result in abandonment or lapse of the patent or patent
application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. We may enter into certain license
agreements where we will not have the ability to maintain or prosecute patents in the portfolio and must therefore rely on third
parties to take such actions and comply with certain requirements. Failure by us or our future or any existing licensors to maintain
protection of our patent portfolio could have a material adverse effect on our business, financial condition, results of operations
and prospects.
In addition, it is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or
may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term
adjustments. If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be
reduced, eliminated, invalid and/or unenforceable. If any of our present or future partners, collaborators, licensees, or licensors,
are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent
rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or
patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable
patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have a material
adverse effect on our business, financial condition, results of operations and prospects.
-36-
Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
and if we do not obtain protection under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman
Amendments, and similar non-U.S. legislation for extending the term of patents covering each of our product candidates, our
business may be materially harmed.
Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed.
Various extensions may be available, however, the life of a patent, and the protection it affords, is limited. Given the amount of
time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates
might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with
adequate and continuing patent protection sufficient to exclude others from commercializing products similar to our product
candidates.
Depending upon the timing, duration and conditions of the FDA marketing approval of our product candidates, one or more
of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term
Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU and other jurisdictions.
The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as
compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term
extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one
patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it
may be extended. In Europe, a maximum of five and a half years of supplementary protection can be achieved for an active
ingredient or combinations of active ingredients of a medicinal product protected by a basic patent, if a valid marketing
authorization exists (which must be the first authorization to place the product on the market as a medicinal product) and if the
product has not already been the subject of supplementary protection. However, we may not receive an extension if we fail to
apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable
requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension
or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product
will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from
applicable products could be reduced and could have a material adverse effect on our business, financial condition, results of
operations and prospects.
Others may claim an ownership interest in our intellectual property and proprietary anti-C5a and anti-C5aR technologies
which could expose us to litigation and have a significant adverse effect on our prospects
A third party may claim an ownership interest in one or more of our, or our future or any existing licensors’, patents or other
proprietary or other intellectual property rights. A third party could bring legal actions against us and seek monetary damages
and/or enjoin clinical testing, manufacturing and marketing of the affected product or products. While we are presently unaware of
any material claims or assertions by third parties with respect to our patents or other intellectual property, we cannot guarantee
that a third party will not assert a claim or an interest in any of such patents or other intellectual property. If we become involved
in any litigation, it could consume a substantial portion of our resources, and could cause a significant diversion of effort by our
technical and management personnel. If any of these actions are successful, in addition to any potential liability for damages, we
could be required to obtain a license to continue to manufacture or market the affected product, in which case we may be required,
for example, to pay substantial royalties or grant cross-licenses to our patents. We cannot, however, assure you that any such
license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or be
forced to cease some aspect of our business operations as a result of claims of patent infringement or other violations of other
intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be
adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This
is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts
may reasonably disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of
operations and prospects.
If we are sued for infringing, misappropriating, or otherwise violating intellectual property rights of third parties, such
litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product
candidates
Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates
without infringing, misappropriating, or otherwise violating the proprietary or any other intellectual property rights of third
parties. Third parties may have U.S. and non-U.S. issued patents and pending patent applications relating to compounds, methods
of manufacturing compounds and/or methods of use for the treatment of the disease indications for which we are developing our
product candidates that may cover our product candidates or approach to complement inhibition. If any third-party patents or
patent applications are found to cover our product candidates or their methods of use or manufacture, or our approach to
complement inhibition, we may not be free to manufacture or market our product candidates as planned without obtaining a
license, which may not be available on commercially reasonable terms or at all.
-37-
There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we
may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with
respect to our product candidates, including interference and post-grant proceedings before the USPTO. There may be third-party
patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to
the composition, use or manufacture of our product candidates. Because patent applications can take many years to issue, there
may be pending patent applications which may later result in issued patents that our product candidates may be accused of
infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these
patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or
arise in the future. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in
advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always
be clear to industry participants, including us, which patents cover various types of products or methods of use or manufacture.
The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always uniform.
If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do
not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able
to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and
convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these
proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be
diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we may not
have sufficient resources to bring these actions to a successful conclusion.
If we are found to infringe, misappropriate, or otherwise violate a third party’s intellectual property right, we could be forced,
including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product.
Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue
developing, manufacturing or commercializing the infringing product candidate or product. However, we may not be able to
obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-
exclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally, it could
include terms that impede or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be
found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a
patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our
business operations, which could harm our business. Claims that we have misappropriated the trade secrets or other confidential
information of any third parties could have a similar negative impact on our business. Any of the foregoing could have a material
adverse effect on our business, financial condition, results of operations and prospects.
We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual
property, or claiming ownership of what we regard as our own intellectual property and proprietary anti-C5a and anti-C5aR
technologies
Many of our current and former employees and our licensors’ current and former employees, including our senior
management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some
which may be competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary
information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or
disclosed intellectual property, including trade secrets or other proprietary information, of any such third party. Litigation may be
necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may
lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a
third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such
a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such
claims, litigation could result in substantial costs and be a distraction to management.
-38-
In addition, while we typically require our employees, consultants and contractors who are involved in the development of
intellectual property for us within the scope of such employees’, consultants’ and contractors’ employment or other engagement
by us to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement
with each party who in fact develops intellectual property that we regard as our own, or such agreements may be breached or
alleged to be ineffective, which may result in claims by or against us related to the ownership of such intellectual property. If we
fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial
costs and be a distraction to our senior management and scientific personnel. Any of the foregoing could have a material adverse
effect on our business, financial condition, results of operations and prospects.
We may lose exclusivity to certain of our intellectual property rights to the German federal government
We hold all of our intellectual property through our wholly owned subsidiary InflaRx GmbH in Germany. In the event of a
national epidemic or pandemic, the German federal government, and the Federal Ministry of Health and other authorities have the
right to order the use of our owned and in-licensed patents in the interest of the public welfare or the security of the Federal
Republic of Germany. The German federal government may issue such an order with respect to our owned and in-licensed patents
and we may lose exclusivity with respect to the technologies covered by such patents.
Additionally, the research resulting in certain of our patents and technology, including patents and technology relating to our
clinical development in severe COVID-19, was funded in part by the German federal government. Results of such government
funded research projects must, subject to certain conditions, be made available free of charge for academic research and teaching
in Germany and must be published in bi-annual interim reports and a final report following completion of the funded work.
Information relating to intellectual property generated, commercial expectations, scientific chances of success, next steps and
certain additional information must be disclosed to the German government and to third parties for academic research and
teaching upon request under a written confidentiality agreement. The German federal government additionally has, in the case of a
special public interest, a non-exclusive and transferable right to use intellectual property generated as part of the funded work.
Certain of our employees and directors are subject to German law, including as it relates to the ownership of, and
compensation for, inventions
A number of our personnel, including some of our directors, work in Germany and may be subject to German employment
law. Inventions that may be the subject of a patent or of protection as a utility model as well as technical improvement proposals
for other technical innovations that may not be the subject of a patent or of protection as a utility model made by such employees
are subject to the provisions of the German Act on Employees’ Inventions (Gesetz über Arbeitnehmererfindungen), which
regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes may occur
between us and our current or past employees pertaining to the sufficiency of compensation paid by us, allocation of rights to
inventions under the German Act on Employee’s Inventions or alleged non-adherence to the provisions of this act, any of which
may be costly to resolve and take up our management’s time and efforts whether we prevail or fail in such dispute. In addition,
under the German Act on Employees’ Inventions, certain employees retain rights to patents they invented or co-invented and
disclosed to us prior to October 1, 2009. While we believe that all of our current and past German employee inventors have
subsequently assigned to us their interest in patents and inventions they invented or co-invented, there can be no assurance that all
such assignments are fully effective. Even if we lawfully own all inventions of our employee inventors who are subject to the
German Act on Employees’ Inventions, we are required under German law to reasonably compensate such employees for the use
of the patents.
If any of our current or past employees obtain or retain ownership of any inventions or other intellectual property rights that
we believe we own, we may lose valuable intellectual property rights and may be required to obtain and maintain licenses from
such employees to such inventions or intellectual property rights, which may not be available on commercially reasonable terms
or at all, or may be non-exclusive. If we are unable to obtain and maintain a license to any such employee’s interest in such
inventions or intellectual property rights, we may need to cease the development, manufacture, and commercialization of one or
more of the product candidates we may develop. In addition, any loss of exclusivity of our intellectual property rights could limit
our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing events
could have a material adverse effect on our business, financial condition, results of operations and prospects.
-39-
We may not be able to enforce our intellectual property rights throughout the world
Filing, prosecuting, maintaining, enforcing and defending patents on our product candidates in all countries throughout the
world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be
less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in
developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will
issue with claims that cover our product candidates.
Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes
in the United States and foreign intellectual property laws. Additionally, laws of some countries outside of the United States and
Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign
jurisdictions. The legal systems of some countries, including India, China and other countries, do not favor the enforcement of
patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the
misappropriation or other violations of our other intellectual property rights. For example, many countries outside the United
States have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not
be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe.
Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop and market their
own products and, further, may export otherwise infringing products to jurisdictions where we have patent protection, if our
ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
Agreements under which we may be granted a license to any patent rights may not give us sufficient rights to permit us to
pursue enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents (or control of
enforcement or defense) of such patent rights in all relevant jurisdictions as requirements may vary.
Proceedings to enforce our patent rights in the United States or foreign jurisdictions, whether or not successful, could result in
substantial costs and divert our efforts and resources from other aspects of our business. Moreover, such proceedings could put
our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies
awarded, if any, may not be commercially meaningful. Furthermore, while we intend to seek to protect our intellectual property
rights in major markets for our product candidates, we cannot ensure that we will be able to initiate or maintain similar efforts in
all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual
property rights in such countries may be inadequate. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations and prospects.
We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be
expensive, time consuming and unsuccessful
Our competitors and others may infringe, misappropriate or otherwise violate our patents or other intellectual property rights.
To counter infringement or unauthorized use, we may be required to file infringement or other claims, which can be expensive and
time consuming and divert the time and attention of our management and scientific personnel.
Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that
we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent
infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in
part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the
validity of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do not have the right to
stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse
outcome in a litigation or proceeding involving one or more of our patents could limit our ability to assert those patents against
those parties or other competitors and may curtail or preclude our ability to exclude third parties from developing, making and
selling similar or competitive products. Even if we establish infringement, the court may decide not to grant an injunction against
further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during litigation. There could also be public announcements
of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could adversely affect the price of our ordinary shares. Moreover, there can be no assurance that we will
have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they
are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention
of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. Any such
litigation could have a material adverse effect on our business, financial condition, results of operations and prospects.
-40-
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our
marks of interest and our business may be adversely affected
Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing
on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these
names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark
registration proceedings, we may receive rejections that we are unable to overcome, in the USPTO and in comparable agencies in
many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel
registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not
survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be
able to compete effectively and our business may be adversely affected.
If we fail to comply with our obligations under any future or other intellectual property licenses with third parties, we could
lose license rights that are important to our business
We may be reliant upon licenses to certain patent rights and proprietary anti-C5a and anti-C5aR technologies and other
intellectual property from third parties that are important or necessary to the development of our product candidates and the
manufacture and other commercialization of our products. These and other licenses may not provide exclusive rights to use such
intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop,
manufacture or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors
from developing, manufacturing and commercializing competitive products in territories included in all of our licenses. Our
licensors may have sublicensed patents and other intellectual property owned by a third party, or relied on third-party consultants
or collaborators or funds from third parties that have an ownership or other right, title or interest in or to such in-licensed
intellectual property, such that our licensors are not the sole and exclusive owners of the patents and other intellectual property we
in-license. This could have a material adverse effect on our competitive position, business, financial conditions, results of
operations and prospects.
In addition, agreements under which we may license patent rights may not give us control over patent filings prosecution or
maintenance, so that we may not be able to control which claims or arguments are presented and may not be able to secure,
maintain, or successfully enforce and defend necessary or desirable patent protection from those patent rights. We cannot be
certain that patent filing prosecution and maintenance activities by our licensors will be conducted in compliance with applicable
laws and regulations or will result in valid and enforceable patents. Even if we are permitted to pursue such enforcement or
defense, we will require the cooperation of our future or any existing licensors, and cannot guarantee that we would receive it and
on what terms. We cannot be certain that our future licensors will allocate sufficient resources or prioritize their or our
enforcement of such patents or defense of such claims to protect our interests in any licensed patents. If we cannot obtain patent
protection or enforce existing or future patents against third parties, it could have a material adverse effect on our business,
financial condition, results of operations and prospects.
Further, agreements under which we may license technology or any other intellectual property to or from third parties are
complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract
interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant technology or
any other intellectual property, or increase what we believe to be our financial or other obligations under the relevant agreement.
Moreover, if disputes over technology or other intellectual property that we may license prevent or impair our ability to maintain
our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop manufacture and
commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions,
results of operations and prospects.
-41-
Disputes may arise regarding intellectual property subject to a licensing agreement, including:
●
the scope of rights that may be granted under license agreements and other interpretation-related issues;
●
the extent to which our technology and processes infringe on intellectual property rights of the licensor that is not subject
to the licensing agreement;
●
the sublicensing of patent and other rights under current and any future collaborative development relationships;
●
our diligence obligations under any license agreement and what activities satisfy such obligations;
●
the inventorship and ownership of inventions and know-how and other intellectual property resulting from the joint
creation or use of intellectual property by our license counterparties and us and our partners; and
●
the priority of invention of patented technology.
In spite of our best efforts, our license counterparties might conclude that we have materially breached our license agreements
and might therefore terminate the license agreements, which may remove our ability to develop manufacture- and commercialize
the product candidates and technology covered by these license agreements. If any in-licenses are terminated, competitors may be
able to seek regulatory approval of, and to market, products identical to ours. It is possible that we may be unable to obtain any
additional licenses that we require at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to
expend significant time and resources to redesign our product candidates, technology, or the methods for manufacturing them or
to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are
unable to do so, we may be unable to develop, manufacture or commercialize the affected product candidates, which could harm
our competitive position, business, financial conditions, results of operations and prospects.
If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be negatively impacted
and our business would be harmed
In addition to the protection afforded by patents, we also rely on trade secret protection for certain aspects of our intellectual
property. However, trade secrets are difficult to protect. We seek to protect these trade secrets, in part, by entering into non-
disclosure and confidentiality agreements with parties who have access to them, such as our employees, consultants, independent
contractors, advisors, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or
patent assignment agreements with employees and certain consultants and independent contractors. Any party with whom we have
executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and
we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Additionally, if the
steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for
misappropriating the trade secret. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a
competitor or other third party, we would have no right to prevent such third party, or those to whom they communicate such
technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be
disclosed to or independently developed or otherwise obtained by a competitor or other third party, it could have a material
adverse effect on our business, financial condition, results of operations and prospects.
-42-
4.
Risks related to employee matters and managing growth
We only have a limited number of employees to manage and operate our business
As of December 31, 2024, we had 74 full-time or part-time employees. Our focus on the development and commercialization
of vilobelimab requires us to optimize cash utilization and to manage and operate our business with limited personnel. We cannot
assure you that we will be able to hire additional employees and/or retain adequate staffing levels to develop and commercialize
vilobelimab or run our operations or to accomplish all the objectives that we otherwise would seek to accomplish.
We depend heavily on our executive officers and directors, and the loss of their services would materially harm our business
Our success depends, and will likely continue to depend, upon our ability to hire and retain the services of our current
executive officers, directors, principal consultants and others. We are highly dependent on the management, development, clinical,
financial and business development expertise of Niels Riedemann, our Chief Executive Officer, Renfeng Guo, our Chief Scientific
Officer, Thomas Taapken, our Chief Financial Officer, and, Camilla Chong, our Chief Medical Officer. Our ability to compete in
the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial,
scientific and medical personnel.
Our industry has experienced a high rate of turnover of management personnel in recent years. Any of our personnel may
terminate their employment at will. If we lose one or more of our executive officers or other key employees, our ability to
implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers or other key
employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry
with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products
successfully.
Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional
key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for
similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research
institutions.
We rely on consultants and advisors, including scientific, strategic, regulatory and clinical advisors, to assist us in formulating
our research and development and commercialization strategy. Our consultants and advisors may be employed by other entities
and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we
are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product
candidates will be limited.
We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could
disrupt our operations
We expect to expand scope of our operations, particularly in the areas of clinical development and regulatory affairs. To
manage such growth, we must continue to implement and improve our managerial, operational and financial systems, expand our
facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a significant
amount of its attention to managing these growth activities. Moreover, our expected growth could require us to relocate to a
different geographic area of the country. Due to our limited financial resources and the limited experience of our management
team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion or relocation
of our operations, retain key employees, or identify, recruit, attract and train retain human capital. Competition for qualified,
motivated, and highly-skilled executives, professionals and other key personnel in biotechnology and pharmaceuticals industries is
significant. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our
infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among
remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources
from other projects, such as the development of additional product candidates. If we are unable to effectively manage our expected
growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able
to implement our business strategy, including the successful development and commercialization of our product candidates.
-43-
Our employees, independent contractors, consultants, collaborators and CROs may engage in misconduct or other improper
activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and
harm our reputation
We are exposed to the risk that our employees, independent contractors, consultants, collaborators and CROs may engage in
fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless or negligent conduct or
disclosure of unauthorized activities to us that violates: (i) the FDA regulations or similar regulations of comparable non-U.S.
regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities,
(ii) manufacturing and clinical trial conduct standards, (iii) federal and state healthcare fraud and abuse laws and regulations and
similar laws and regulations established and enforced by comparable non-U.S. regulatory authorities, and (iv) laws that require the
reporting of financial information or data accurately. Activities subject to these laws also involve the improper use of information
obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not
always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other
actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are
instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business and results of operations, including the imposition of civil, criminal and administrative
penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare
programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any
of which could have a material adverse effect on our ability to operate our business and our results of operations.
5.
Risks related to our ordinary shares and our status as a public company
The trading price of our ordinary shares has been and may in the future be highly volatile, which could result in substantial
losses for holders of our ordinary shares, and a decline in our share price and invite securities litigation against our company or
our management
Our share price has been and is likely to be highly volatile in the future. The stock market in general and the market for
smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been
unrelated to the operating performance of particular companies. You should consider an investment in our ordinary shares as risky
and invest only if you can withstand a significant loss and wide fluctuations in the market value of your investment. The market
price for our ordinary shares may be influenced by many factors, including:
●
the timing, enrollment and results of clinical trials of vilobelimab and any other product candidates;
●
regulatory actions with respect to vilobelimab, our other product candidates or our competitors’ products and product
candidates;
●
the success of the commercialization of GOHIBIC (vilobelimab);
●
the success of existing or new competitive products or technologies;
●
any delay in our development or regulatory filings for vilobelimab or any future product candidate and any adverse
development or perceived adverse development with respect to the applicable regulatory authority’s review of such
filings, including the FDA’s issuance of a “refusal to file” letter or a request for additional information;
●
announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations
or capital commitments;
●
commencement or termination of collaborations for our development programs;
●
failure or discontinuation of any of our development programs;
●
results of clinical trials of product candidates of our competitors;
●
regulatory or legal developments in the United States and other countries;
-44-
●
developments or disputes concerning patent applications, issued patents or other proprietary rights;
●
the recruitment or departure of key personnel;
●
the level of expenses related to any of our product candidates or clinical development programs;
●
the results of our efforts to develop additional product candidates or products;
●
actual or anticipated changes in estimates as to financial results or development timelines;
●
announcement or expectation of additional financing efforts;
●
sales of our ordinary shares by us, our insiders or other shareholders;
●
variations in our financial results or those of companies that are perceived to be similar to us;
●
changes in estimates or recommendations by securities analysts, if any, that cover our shares;
●
changes in the structure of healthcare payment systems;
●
market conditions in the pharmaceutical and biotechnology industries;
●
general economic, industry, market and political conditions; and
●
the other factors described in this ‘ITEM 3. KEY INFORMATION — D. Risk factors’ section.
In the past, securities class action litigation has often been brought against a company and its management following a decline
in the market price of its securities. This risk is especially relevant for biopharmaceutical companies, which have experienced
significant stock price volatility in recent years. Such litigation, if instituted against us, could cause us or members of our
management to incur substantial costs and divert management’s attention and resources from our business.
Future sales, or the possibility of future sales, of a substantial number of our ordinary shares could adversely affect the price
of the shares and dilute shareholders
Future sales of a substantial number of our ordinary shares, or the perception that such sales will occur, could cause a decline
in the market price of our ordinary shares. Pursuant to our at-the-market program subject to the Sales Agreement with Leerink
Partners LLC, or Leerink Partners, dated June 28, 2024, for the sale of ordinary shares for an aggregate offering price of up to
$75,000,000 from time to time through Leerink Partners acting as our agent, and potentially other offerings, we plan to continue to
raise money to fund our operations through the issuance of our equity securities. If we or our existing shareholders sell substantial
amounts of ordinary shares in the public market, or the market perceives that such sales may occur, the market price of our
ordinary shares and our ability to raise capital through an issue of equity securities in the future could be adversely affected.
In addition, we have registered on a Form S-8 registration statement all ordinary shares that we may issue under our equity
incentive plans. As a result, these shares can be freely sold in the public market upon issuance, subject to volume limitations
applicable to affiliates. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the
trading price of our ordinary shares could decline.
On June 30, 2023, we filed a shelf registration statement on a Form F-3. The Registration Statement was declared effective by
the SEC on July 11, 2023. Because the price per share of each share sold under the Registration Statement will depend on the
market price of our shares at the time of the sale and other market conditions, it is not possible at this stage to predict the number
of shares that ultimately may be offered and sold under the Registration Statement. If we sell ordinary shares, convertible
securities or other equity securities, existing shareholders may be diluted by such sales, and in certain cases new investors could
gain rights superior to those of our existing shareholders. Any sales of our ordinary shares, or the perception that such sales could
occur, could have a negative impact on the trading price of our shares.
-45-
We have broad discretion in the use of our cash on hand and may invest or spend it in a way with which you do not agree and
in ways that may not yield a return on your investment
As of December 31, 2024, we had €18.4 million in cash and cash equivalents and €36.8 million in marketable securities. Our
management will have broad discretion in the use of such cash and could spend it in ways that do not improve our results of
operations or enhance the value of our ordinary shares. You will not have the opportunity to influence our decisions on how to use
our cash on hand. The failure by our management to apply these funds effectively could result in financial losses that could harm
our business, cause the price of our ordinary shares to decline and delay the development of our product candidates. Pending its
use, we may invest our cash on hand in a manner that does not produce income or that loses value.
We are a foreign private issuer and, as a result, we are not subject to U.S. proxy rules and are subject to Exchange Act
reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company
We will report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with
foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain
provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i) the sections of the Exchange
Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act, (ii)
the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and
liability for insiders who profit from trades made in a short period of time and (iii) the rules under the Exchange Act requiring the
filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current
reports on Form 8-K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to
file their Annual Report on Form 20-F until four months after the end of each fiscal year, while U.S. domestic issuers that are
accelerated filers are required to file their Annual Report on Form 10-K within 75 days after the end of each fiscal year. Foreign
private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures
of material information. As a result of the above, you may not have the same protections afforded to shareholders of companies
that are not foreign private issuers.
As a foreign private issuer and as permitted by the listing requirements of Nasdaq, we follow certain home country
governance practices rather than the corporate governance requirements of Nasdaq
We are a foreign private issuer. As a result, in accordance with the listing requirements of Nasdaq we rely on home country
governance requirements and certain exemptions thereunder rather than relying on the corporate governance requirements of
Nasdaq. In accordance with Dutch law and generally accepted business practices, our Articles of Association do not provide
quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the
requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum,
and that such quorum may not be less than one-third of the outstanding voting stock. Although we must provide shareholders with
an agenda and other relevant documents for the general meeting of shareholders, Dutch law does not have a regulatory regime for
the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands; thus, our
practice will vary from the requirement of Nasdaq Listing Rule 5620(b). As permitted by the listing requirements of Nasdaq, we
have also opted out of the requirements of Nasdaq Listing Rule 5605(d), which requires, among other things, an issuer to have a
compensation committee that consists entirely of independent directors and makes determinations regarding the independence of
any compensation consultants, Nasdaq Listing Rule 5605(e), which requires independent director oversight of director
nominations, and Nasdaq Listing Rule 5605(b)(2), which requires an issuer to have a majority of independent directors on its
board. In addition, we have opted out of shareholder approval requirements, as included in the Nasdaq Listing Rules, for the
issuance of securities in connection with certain events such as the acquisition of shares or assets of another company, the
establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private
placements. To this extent, our practice varies from the requirements of Nasdaq Rule 5635, which generally requires an issuer to
obtain shareholder approval for the issuance of securities in connection with such events. Accordingly, you may not have the same
protections afforded to shareholders of companies that are subject to these Nasdaq requirements.
-46-
We do not anticipate paying any cash dividends on our share capital in the foreseeable future. Accordingly, shareholders must
rely on capital appreciation, if any, for any return on their investment
We have never declared nor paid cash dividends on our share capital. We plan to retain all of our future earnings, if any, to
finance the operation, development and growth of our business. In addition, the terms of any future debt or credit agreements and
any restrictions imposed by applicable law may preclude us from paying dividends. As a result, capital appreciation, if any, of our
ordinary shares will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase
our ordinary shares.
See “ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS —A. Major shareholders.”
elsewhere in this Annual Report for more information regarding the ownership of our outstanding ordinary shares by our
executive officers, directors and principal shareholders and their affiliates.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our
share price and trading volume could decline
The trading market for our ordinary shares depends in part on the research and reports that securities or industry analysts
publish about us or our business. We do not have any control over such analysts. There can be no assurance that analysts will
cover us or provide favorable coverage going forward. Securities or industry analysts may elect not to continue to provide
research coverage of our ordinary shares, and such lack of research coverage may negatively impact the market price of our
ordinary shares. In the event we do have analyst coverage, if one or more analysts downgrade our ordinary shares, change their
opinion of our ordinary shares or publish inaccurate or unfavorable research about our business, our share price would likely
decline. In addition, if one or more analysts cease coverage of our company or fail to regularly publish reports on us, we could
lose visibility in the financial markets, which could cause our share price or trading volume to decline.
Our ability to use our net operating loss carry forwards and other tax attributes may be limited
Our ability to utilize our NOLs, or NOLs, is limited, and may be limited further, under Section 8c of the German Corporation
Income Tax Act (Körperschaftsteuergesetz), or KStG, and Section 10a of the German Trade Tax Act (Gewerbesteuergesetz), or
GewStG. These limitations apply if a qualified ownership change, as defined by Section 8c KStG, occurs and no exemption is
applicable. Generally, a qualified ownership change occurs if more than 50% of the share capital or the voting rights are directly
or indirectly transferred to a shareholder or a group of shareholders within a period of five years. A qualified ownership change
may also occur in case of a transaction comparable to a transfer of shares or voting rights or in case of an increase in capital
leading to a respective change in the shareholding. In the case of such a qualified ownership change tax loss carry forwards expire
in full. To the extent that the hidden reserves (stille Reserven) taxable in Germany exceed the tax loss carry forward, they may be
further utilized despite a qualified ownership change. In case of a qualified ownership change within a group, tax loss carry
forwards will be preserved if certain conditions are satisfied. Alternatively, tax loss carry forwards may be retained upon
application under certain conditions, to the extent that the corporation has exclusively maintained the same business operations
since its establishment or at least since the beginning of the third year prior to qualified ownership change
(fortführungsgebundener Verlustvortrag). If the aforementioned application is made and, after the qualified change of ownership,
this business operation is discontinued, the most recently determined tax loss carry forward (fortführungsgebundener
Verlustvortrag) would be lost.
An appeal has been filed by the fiscal court of Hamburg dated August 29, 2017 – 2 K 245/17 with regard to Section 8c,
paragraph 1, sentence 2 KStG (in its superseded version, now: Section 8c paragraph 1 sentence 1 KStG) that is, the forfeiture of
all tax loss carryforwards in case more than 50% of shares/voting rights will be assigned to a new shareholder. The appeal is still
pending. It is unclear when the Federal Constitutional Court will decide this case. According to statements in German legal
literature, there are good reasons to believe that the Federal Constitutional Court may come to the conclusion that Section 8,
paragraph 1, sentence 2 KStG (in its superseded version) is not in line with the German constitution.
As of December 31, 2024, we had NOL carry forwards for German corporate tax purposes of €238.4 million and for trade tax
purposes €206.7 million available. Future changes in share ownership may also trigger an ownership change and, consequently, a
Section 8c KStG, or a Section 10a GewStG limitation. Any limitation may result in the expiration of the complete tax operating
loss carry forwards before they can be utilized. As a result, if we earn net taxable income, our ability to use our pre-change net
operating loss carry forwards to reduce German income tax may be subject to limitations, which could potentially result in
increased future cash tax liability to us.
-47-
As of December 31, 2024, our U.S. subsidiary, InflaRx Pharmaceuticals, Inc., had €15.75 million or $16.36 million of NOLs
for U.S. federal income tax purposes. Transfers or issuances of our equity may impair or reduce the ability of InflaRx
Pharmaceuticals, Inc. to utilize U.S. federal net operating loss carryforwards and certain other tax attributes in the future. Section
382 of the Internal Revenue Code of 1986, as amended, or the Code, contains rules that limit the ability of a company that
undergoes an “ownership change” to utilize its net operating loss and tax credit carry forwards and certain built-in losses
recognized in years after the ownership change. An “ownership change” is generally defined as an increase in ownership of a
corporation’s stock by more than 50 percentage points over a rolling three-year period by stockholders that own (directly,
indirectly or constructively) 5% or more of the stock of a corporation at any time during the relevant rolling three-year period. If
an ownership change occurs, Section 382 imposes an annual limitation on the use of pre-ownership change NOLs, credits and
certain other tax attributes to offset taxable income earned after the ownership change. The annual limitation is generally equal to
the product of the applicable long-term tax-exempt rate in effect for the month in which the ownership change occurs and the
value of the company’s stock immediately before the ownership change (subject to some adjustments). For example, this annual
limitation may be adjusted to reflect any unused annual limitation for prior years and certain recognized (or treated as recognized)
built-in gains and losses for the year. In addition, Section 383 generally limits the amount of tax liability in any post-ownership
change year that can be reduced by pre-ownership change tax credit carryforwards or capital loss carryforwards. No assurance can
be given that prior transactions have not resulted in an ownership change for purposes of Section 382 of the Code or that future
transactions will not result in an ownership change. Even if a subsequent transaction does not result in an ownership change, it
may materially increase the likelihood that we will undergo an ownership change in the future. Sales of our ordinary shares by
stockholders, whose interests may differ from our interests, may increase the likelihood that we or one of our subsidiaries
undergoes an ownership change. If we or our subsidiaries have or were to undergo an ownership change, it could result in
increased future tax liability to us.
We may become taxable in a jurisdiction other than Germany and this may increase the aggregate tax burden on us
Since incorporation we intend to have, on a continuous basis, our place of effective management in Germany. We will
therefore be a tax resident of Germany under German national tax law. By reason of our incorporation under Dutch law, we are
also deemed tax resident in the Netherlands under Dutch tax law. However, based on our current management structure and
current tax laws of the United States, Germany and the Netherlands, as well as applicable income tax treaties, and current
interpretations thereof, we should be tax resident solely in Germany for the purposes of the convention between the Federal
Republic of Germany and the Netherlands of 2012 for the avoidance of double taxation with respect to taxes on income, or the
German-Dutch tax treaty.
Our sole tax residency in Germany for purposes of the German-Dutch tax treaty is subject to the application of the provisions
on tax residency as stipulated in the German-Dutch tax treaty as amended from time to time. The Multilateral Convention to
Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting or the MLI, Germany and the Netherlands
entered into, among other countries, should not, as of this date, affect the German-Dutch tax treaty’s rules regarding tax residency.
The applicable tax laws, tax treaties or interpretations thereof may change, including the MLI choices and reservation.
Furthermore, whether we have our place of effective management in Germany and are as such solely tax resident in Germany is
largely a question of fact and degree based on all the circumstances, rather than a question of law, which facts and degree may
also change. Changes to applicable laws or interpretations thereof and changes to applicable facts and circumstances (for example,
a change of board members or the place where board meetings take place), or changes to applicable tax treaties, including a
change to the application of the MLI may result in us becoming a tax resident of a jurisdiction other than Germany. As a
consequence, our overall effective income tax rate and income tax expense could materially increase, which could have a material
adverse effect on our business, results of operations, financial condition and prospects, which could cause our share price and
trading volume to decline.
-48-
We believe it is likely that we were a passive foreign investment company, or a PFIC, for U.S. federal income tax purposes in
2021, 2022, 2023 and 2024, and we may be a PFIC in one or more future taxable years, which could result in adverse U.S. federal
income tax consequences to U.S. investors
Under the U.S. Internal Revenue Code of 1986, as amended, or the Code, we will be a PFIC for any taxable year in which,
after the application of certain look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income consists
of “passive income” or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for
the production of, “passive income.” Passive income generally includes, among other things, dividends, interest, certain non-
active rents and royalties, and capital gains. Based on the nature of our business, our financial statements, our expectations about
the nature and amount of our income, assets and activities and the expected price of our ordinary shares in this offering, we
believe it is likely we were a PFIC in 2021, 2022 and 2023 and 2024, and we may be a PFIC for our current taxable year or in one
or more future taxable years. In addition, we may, directly or indirectly, hold equity interests in other PFICs. Whether we or any
of our subsidiaries will be a PFIC in 2025 or any future year is a factual determination that must be made annually at the close of
each taxable year, and, thus, is subject to significant uncertainty; because a determination of whether a company is a PFIC must be
made annually after the end of each taxable year and will depend on the composition of our income and assets and the market
value of our assets from time to time, we cannot assure you that we will not be a PFIC for the current or any future taxable year.
Accordingly, there can be no assurance that we will not be a PFIC in 2025 or any future taxable year.
If we are a PFIC for any taxable year during which a U.S. Holder (as defined below in “Material U.S. Federal Income Tax
Considerations”) holds our ordinary shares, we generally would continue to be treated as a PFIC with respect to that U.S. Holder
for all succeeding years during which the U.S. Holder holds our ordinary shares, even if we ceased to meet the threshold
requirements for PFIC status, unless certain exceptions apply. Such a U.S. Holder may be subject to adverse U.S. federal income
tax consequences, including (i) the treatment of all or a portion of any gain on disposition as ordinary income, (ii) the application
of a deferred interest charge on such gain and the receipt of certain dividends and (iii) compliance with certain reporting
requirements. There is no assurance that we will provide information that will enable investors to make a qualified electing fund
election, also known as a “QEF Election,” which could mitigate the adverse U.S. federal income tax consequences should we be
classified as a PFIC.
For further discussion, see “ITEM 10. ADDITIONAL INFORMATION — E. Taxation — Material U.S. Federal Income Tax
Considerations for U.S. Holders of Ordinary Shares.”
We may lose our foreign private issuer status which would then require us to comply with the Exchange Act’s domestic
reporting regime and cause us to incur significant legal, accounting and other expenses
We are a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current
reporting requirements of the Exchange Act applicable to U.S. domestic issuers. If in the future we are not a foreign private issuer
as of the last day of the second fiscal quarter in any fiscal year, we would be required to comply with all of the periodic disclosure,
current reporting requirements and proxy solicitation rules of the Exchange Act applicable to U.S. domestic issuers. In order to
maintain our current status as a foreign private issuer, either (a) a majority of our ordinary shares must be either directly or
indirectly owned of record by non-residents of the United States or (b)(i) a majority of our directors and executive officers may
not be United States citizens or residents, (ii) more than 50% of our assets cannot be located in the United States and (iii) our
business must be administered principally outside the United States. If we were to lose this status, we would be required to
comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and
extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance
practices in accordance with various SEC and stock exchange rules. The regulatory and compliance costs to us if we are required
to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the costs we
would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal
and financial compliance costs and would make some activities highly time consuming and costly. These rules and regulations
could also make it more difficult for us to attract and retain qualified directors.
-49-
If we ever pay dividends, we may need to withhold tax on such dividends payable to holders of our shares in both Germany
and the Netherlands
We do not intend to pay any dividends to holders of our shares. However, if we do pay dividends, we may need to withhold
tax on such dividends both in Germany and the Netherlands. As an entity incorporated under Dutch law any dividends distributed
by us are subject to Dutch dividend withholding tax on the basis of Dutch domestic law. However, on the basis of the double tax
treaty between Germany and the Netherlands, the Netherlands will be restricted from imposing dividend withholding tax if we
continue to be a tax resident of Germany and our place of effective management is in Germany. However, Dutch dividend
withholding tax is still required to be withheld from dividends if and when paid to Dutch resident holders of our shares (and non-
Dutch resident holders of our shares that have a permanent establishment in the Netherlands to which their shareholding is
attributable). As a result, upon a payment (or deemed payment) of dividends, we will be required to identify our shareholders in
order to assess whether there are Dutch residents (or non-Dutch residents with a permanent establishment to which the shares are
attributable) in respect of which Dutch dividend tax has to be withheld. Such identification may not always be possible in practice.
If the identity of our shareholders cannot be determined, withholding of both German and Dutch dividend tax from such dividend
may occur, upon a payment of dividends.
Furthermore, the withholding tax restriction referred to above is based on the current choices and reservation made by
Germany under the MLI. If Germany changes its MLI choices and reservation, we may not be entitled to any benefits of the
double tax treaty between Germany and the Netherlands, including the withholding tax restriction, as long as Germany and the
Netherlands do not reach an agreement on our tax residency for purposes of the double tax treaty between Germany and the
Netherlands, except to the extent and in such manner as may be agreed upon by the authorities. As a result, any dividends
distributed by us during the period no such agreement has been reached between Germany and the Netherlands, may be subject to
withholding tax both in Germany and the Netherlands.
We are a Dutch public company with limited liability. The rights of our shareholders are different from the rights of
shareholders in companies governed by the laws of U.S. jurisdictions and may not protect investors in a similar fashion afforded
by incorporation in a U.S. jurisdiction
We are a public company with limited liability (naamloze vennootschap) organized under the laws of the Netherlands. Our
corporate affairs are governed by our Articles of Association and by the laws governing companies incorporated in the
Netherlands. However, there can be no assurance that Dutch law will not change in the future or that it will serve to protect
investors in a similar fashion afforded under corporate law principles in the United States, which could adversely affect the rights
of investors.
The rights of shareholders and the responsibilities of directors may be different from the rights and obligations of
shareholders and board members in companies governed by U.S. law. In the performance of its duties, our executive officers and
board of directors are required by Dutch law to consider the interests of our company, its shareholders, its employees and other
stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these
parties will have interests that are different from, or in addition to, your interests as a shareholder.
Provisions of our Articles of Association or Dutch corporate law might deter acquisition bids for us that might be considered
favorable and prevent, delay or frustrate any attempt to replace or remove the members of our board of directors
Under Dutch law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch
case law. Our governance arrangements include several provisions that may have the effect of making a takeover of our company
more difficult or less attractive. In this respect, our general meeting of shareholders granted the right to an independent foundation
under Dutch law, or protective foundation, to acquire preferred shares pursuant to a call option agreement, or the call option
agreement, entered into between us and such foundation. This call option under the call option agreement shall be continuous in
nature and can be exercised repeatedly on multiple occasions.
If the protective foundation exercises the call option pursuant to the call option agreement, an amount of preferred shares up
to 100% of our issued capital held by others than the protective foundation, minus one share, will be issued to the protective
foundation. These preferred shares will be issued to the protective foundation under the obligation to pay up to 25% of their
nominal value upon issuance. In order for the protective foundation to finance the issue price in relation to the preferred shares,
the protective foundation is expected to enter into a finance arrangement with a bank. As an alternative to securing financing with
a bank, subject to applicable restrictions under Dutch law, the call option agreement provides that the protective foundation may
request us to provide, or cause our subsidiaries to provide, sufficient funding to the protective foundation to enable it to satisfy the
payment obligation (or part thereof) in cash and/or to charge an amount equal to the payment obligation (or part thereof) against
our profits and/or reserves in satisfaction of such payment obligation.
-50-
The protective foundation’s articles of association provide that it will promote and protect the interests of the company, the
business connected with the company and the company’s stakeholders from time to time, and repressing possible influences which
could threaten the strategy, continuity, independence and/or identity of the company or the business connected with it, to such an
extent that this could be considered to be damaging to the aforementioned interests. These influences may include a third party
acquiring a significant percentage of our ordinary shares, the announcement of an unsolicited public offer for our ordinary shares,
shareholder activism, other concentration of control over our ordinary shares or any other form of undue pressure on us to alter
our strategic policies. The protective foundation shall be structured to operate independently of us.
If the protective foundation were to exercise its call option, the preferred shares to be issued pursuant thereto would be issued
against the obligation to pay up to 25% of their nominal value. The voting rights of our shares are based on nominal value and, as
we expect our ordinary shares to trade substantially in excess of nominal value, preferred shares issued at 25% of their nominal
value can carry significant voting power for a substantially reduced price compared to the price of our ordinary shares and thus
can be used as a defensive measure. These preferred shares will have both a liquidation and dividend preference over our ordinary
shares and will accrue cash dividends at a pre-determined rate. The protective foundation would be expected to require us to
cancel its preferred shares once the perceived threat to the company and its stakeholders has been removed or sufficiently
mitigated or neutralized. However, subject to the same limitations described above, the protective foundation would continue to
have the right to exercise the call option in the future in response to a new threat to the interests of us, our business and our
stakeholders from time to time.
In addition, certain provisions of our Articles of Association may make it more difficult for a third party to acquire control of
us or effect a change in our board of directors. These provisions include: a provision that our directors are appointed on the basis
of a binding nomination prepared by our board of directors which can only be overruled by a two-thirds majority of votes cast
representing more than 50% of our issued share capital; a provision that our directors may only be removed by the general
meeting of shareholders by a two-thirds majority of votes cast representing more than 50% of our issued share capital (unless the
removal is proposed by the board in which case a simple majority of the votes can be sufficient); and a requirement that certain
matters, including an amendment of our Articles of Association, may only be brought to our shareholders for a vote upon a
proposal by our board of directors.
We are not obligated to and do not comply with all the best practice provisions of the Dutch Corporate Governance Code, or
DCGC. This may affect your rights as a shareholder.
We are a Dutch public company with limited liability (naamloze vennootschap), and we are subject to the DCGC. The DCGC
contains both principles and best practice provisions that regulate relations between the board of directors and the shareholders
(such as the general meeting of shareholders). The DCGC is based on a “comply or explain” principle. Accordingly, companies
are required to disclose in their annual reports, filed in the Netherlands, whether they comply with the provisions of the DCGC. If
they do not comply with those provisions (for example, because of a conflicting Nasdaq requirement), the company is required to
give the reasons for such non-compliance.
The DCGC applies to all Dutch companies listed on a government-recognized stock exchange, whether in the Netherlands or
elsewhere, including Nasdaq. We do not comply with all the best practice provisions of the DCGC. For a list of DCGC best
practices that we do not comply with including explanations for why not doing so, see the section “Corporate Governance” in the
Dutch Board Report published on the Company’s website. This may affect your rights as a shareholder and you may not have the
same level of protection as a shareholder in a Dutch company that fully complies with the DCGC.
-51-
Claims of U.S. civil liabilities may not be enforceable against us
We are incorporated under the laws of the Netherlands, and our headquarters are located in Germany. Substantially all of our
assets are located outside the United States. The majority of our directors and executive officers reside outside the United States.
As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to
enforce against them or us in U.S. courts, including judgements predicated upon the civil liability provisions of the federal
securities laws of the United States.
There is no treaty between the United States and the Netherlands for the mutual recognition and enforcement of judgements
(other than arbitration awards) in civil and commercial matters. Therefore, a final judgement for the payment of money rendered
by any federal or state court in the United States based on civil liability, whether or not predicated solely upon the U.S. federal
securities laws, would not be enforceable in the Netherlands unless the underlying claim is relitigated before a Dutch court of
competent jurisdiction. Under current practice, however, a Dutch court will generally, subject to compliance with certain
procedural requirements, grant the same judgement without a review of the merits of the underlying claim if such judgement (i) is
a final judgement and has been rendered by a court which has established its jurisdiction vis-à-vis the relevant Dutch companies or
Dutch company, as the case may be, on the basis of internationally accepted grounds of jurisdiction, (ii) has not been rendered in
violation of principles of proper procedure (behoorlijke rechtspleging), (iii) is not contrary to the public policy of the Netherlands,
and (iv) is not incompatible with (a) a prior judgement of a Netherlands court rendered in a dispute between the same parties, or
(b) a prior judgement of a foreign court rendered in a dispute between the same parties, concerning the same subject matter and
based on the same cause of action, provided that such prior judgement is capable of being recognized in the Netherlands. Dutch
courts may deny the recognition and enforcement of punitive damages or other awards.
Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize damages only to the
extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of judgements of U.S. courts
in the Netherlands are solely governed by the provisions of the Dutch Code of Civil Procedure. Based on the foregoing, there can
be no assurance that U.S. investors will be able to enforce any judgements obtained in U.S. courts in civil and commercial matters,
including judgements under the U.S. federal securities.
The United States and Germany do not have a treaty providing for the reciprocal recognition and enforcement of judgements
in civil and commercial matters. Consequently, a final judgement for payment or declaratory judgements given by a court in the
United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in
Germany. German courts may deny the recognition and enforcement of a judgement rendered by a U.S. court if they consider the
U.S. court not to be competent or the decision to be in violation of German public policy principles. For example, judgements
awarding punitive damages are generally not enforceable in Germany. A German court may reduce the amount of damages
granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages.
In addition, actions brought in a German court against us, our directors, our executive officers and the experts named herein
to enforce liabilities based on U.S. federal securities laws may be subject to certain restrictions. In particular, German courts
generally do not award punitive damages. Litigation in Germany is also subject to rules of procedure that differ from the U.S.
rules, including with respect to the taking and admissibility of evidence, the conduct of the proceedings and the allocation of costs.
German procedural law does not provide for pre-trial discovery of documents, nor does Germany support pre-trial discovery of
documents under the 1970 Hague Evidence Convention. Proceedings in Germany would have to be conducted in the German
language and all documents submitted to the court would, in principle, have to be translated into German. For these reasons, it
may be difficult for a U.S. investor to bring an original action in a German court predicated upon the civil liability provisions of
the U.S. federal securities laws against us, our directors, our executive officers and the experts named in this Annual Report.
Based on the lack of a treaty as described above, U.S. investors may not be able to enforce against us or directors, executive
officers or certain experts named herein who are residents of or possessing assets in the Netherlands, Germany, or other countries
other than the United States any judgements obtained in U.S. courts in civil and commercial matters, including judgements under
the U.S. federal securities laws.
-52-
6.
General Risk Factors
General economic, political and social conditions. Our business and results of operations may be adversely affected by
disruptions in the financial markets, changes to political and regulatory policies and economic conditions generally
General economic, political and social conditions affect the United States, Europe and other global markets and our business.
In particular, U.S., European and other global markets, as well as our access to financing, may be affected by factors, including
economic growth or its sustainability, persistent inflation, supply chain disruptions, employment levels, work stoppages, labor
shortages and labor disputes, labor costs, wage stagnation, energy prices, oil, gas and fuel prices, fluctuations or other significant
changes in both debt and equity capital markets and currencies, liquidity of the global financial markets, the growth of global trade
and commerce, trade policies, the availability and cost of capital and credit (including as a result of increased interest rates) and
investor sentiment and confidence. Additionally, global markets may be adversely affected by the current or anticipated impact of
cyber incidents or campaigns, military conflict, including the Russia-Ukraine conflict as well as the Hamas-Israel conflict and
rising tensions between China and Taiwan and the relationship between China and the United States, or other geopolitical
uncertainty and instability. Any sudden or prolonged market downturn in the United States or elsewhere could adversely affect
our business, results of operations and financial condition, including capital and liquidity levels.
Legal, regulatory or market measures to address environmental and other objectives may negatively affect our business or
operations
Regulatory and legislative bodies in the United States, Europe and elsewhere continue to focus on environmental, social and
governance, or ESG, matters including increasing attention on relating to climate change, greenhouse gas emissions, carbon taxes,
emissions trading schemes, sustainable manufacturing, human rights and equity matters, and disclosure regarding the foregoing,
many of which policies may be ambiguous, inconsistent, dynamic or conflicting. We expect to experience increased restrictions,
compliance costs, legal costs and expenses related to such new or changing legal or regulatory requirements. Moreover,
compliance with any such legal or regulatory requirements would require us to devote substantial time and attention to these
matters. In addition, we may still be subject to penalties or potential litigation if such laws and regulations are interpreted or
applied in a manner inconsistent with our practices. Additionally, we are subject to increased attention from the media,
stockholders, activists and other stakeholders on climate change, social and sustainability matters, which could negatively affect
our reputation or investor confidence.
We may not be able to maintain sufficient insurance to cover us for potential litigation or other risks
We may not be able to maintain sufficient insurance on commercially reasonable terms or with adequate coverage levels
against potential liabilities we may face in connection with potential claims, which could have a material adverse effect on our
business. We may face a risk of loss from a variety of claims, including related to securities, antitrust, contracts, cybersecurity,
fraud and various other potential claims, whether or not such claims are valid. Insurance and other safeguards might only partially
reimburse us for our losses, if at all, and if a claim is successful and exceeds or is not covered by our insurance policies, we may
be required to pay a substantial amount in respect of such successful claim. Certain losses of a catastrophic nature, such as losses
arising as a result of wars, earthquakes, typhoons, terrorist attacks or other similar events, may be uninsurable or may only be
insurable at rates that are so high that maintaining coverage would cause an adverse impact on our business, our investment funds
and their investments. In general, losses related to terrorism are becoming harder and more expensive to insure against. Some
insurers are excluding terrorism coverage from their all-risk policies. In some cases, insurers are offering significantly limited
coverage against terrorist acts for additional premiums, which can greatly increase the total cost of casualty insurance for a
property. As a result, we, our products and their investments may not be insured against terrorism or certain other catastrophic
losses.
Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to
our technologies or product candidates
We expect our expenses may increase in connection with expansion of operations. To the extent that we raise additional
capital through the issuance of ordinary shares, convertible securities or other equity securities, your ownership interest may be
diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could
adversely affect your rights as an ordinary shareholder. In addition, debt financing, if available, may result in fixed payment
obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as
incurring additional debt, making capital expenditures, creating liens, redeeming shares or declaring dividends, that could
adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time
and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities,
which may adversely affect our management’s ability to oversee the development of our product candidates.
-53-
If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we
may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms
that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce
or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates
that we would otherwise prefer to develop and market ourselves.
We face substantial competition, which may result in others discovering, developing or commercializing products before or
more successfully than we do, and reducing or eliminating our commercial opportunity
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are
safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we,
or any future collaborators, may develop. Our competitors also may obtain the FDA or other marketing approval for their products
before we, or any future collaborators, are able to obtain approval for ours, which could result in our competitors establishing a
strong market position before we, or any future collaborators, are able to enter the market.
Many of our existing and potential future competitors have significantly greater financial resources and expertise in research
and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing
approved products than we do, and may be able to reduce the price at which they sell their products. Mergers and acquisitions in
the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number
of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly if acquired by, or
through collaborative arrangements with, large and established companies. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, the development of our product candidates.
The development and commercialization of new products is highly competitive. We expect that we, and any future
collaborators, will face significant competition from major pharmaceutical companies, specialty pharmaceutical companies and
biotechnology companies worldwide with respect to any of our product candidates that we, or any future collaborators, may seek
to develop or commercialize in the future. For example, other pharmaceutical companies may commence development efforts for
product candidates targeting the same indications as vilobelimab, including PG and severe COVID-19 or any other indications we
may target. For a detailed analysis of the competitive environment in which we operate, see “ITEM 4. INFORMATION ON THE
COMPANY — B. Business Overview — Competition.”
If any product liability lawsuits are successfully brought against us or any of our collaboration partners, we may incur
substantial liabilities and may be required to limit commercialization of our product candidates
We face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients
and will face an even greater risk if our product candidates are approved by regulatory authorities and introduced commercially.
Product liability claims may be brought against us or our partners by participants enrolled in our clinical trials, patients, health
care providers or others using, administering or selling any of our future approved products. If we cannot successfully defend
ourselves against any such claims, we may incur substantial liabilities.
If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions
of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity associated
with illness or other adverse effects resulting from patients’ use or misuse of our products or any similar products distributed by
other companies.
-54-
Although we maintain product liability insurance coverage, this insurance may not fully cover potential liabilities that we may
incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will
need to increase our insurance coverage if we commercialize any product that receives marketing approval. In addition, insurance
coverage is becoming increasingly expensive and difficult to obtain. If we are unable to maintain sufficient insurance coverage at
an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and
commercial production and sale of our product candidates, which could harm our business, financial condition, results of
operations and prospects.
We may be unsuccessful in evaluating material risks involved in future acquisitions
We may, in the future, acquire companies, products and/or platforms that are complementary to our operational and customer
needs. As part of the process, we may conduct business, legal and financial due diligence to identify and evaluate material risks
involved in any particular transaction. Despite these efforts, we may be unsuccessful in ascertaining or evaluating all such risks.
As a result, the intended advantages of any given acquisition may not be realized. If we fail to identify certain material risks from
one or more acquisitions we may be exposed to significant costs and our business could be negatively impacted.
Cyber incidents or other failures in IT systems could result in information theft, data corruption and significant disruption of
our business operations
We utilize information technology, or IT, systems and networks to process, transmit and store electronic information in
connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate cyber-
attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and
sophistication, both internal and those provided by third-party service provider. These threats pose a risk to the security of our
systems and networks, the confidentiality and the availability and integrity of our data. The wars in Europe and in the Middle East,
as well as the tensions between China and Taiwan may also result in heightened cybersecurity risk across our networks and
platforms. We have implemented processes, procedures and internal control to mitigate cybersecurity risks and cyber intrusions
and rely on industry accepted security measures and technology to securely maintain confidential and proprietary information
maintained on our information systems. However, these measures, as well as our increased awareness of the nature and extent of a
risk of a cyber-incident, do not guarantee that a cyber-incident will not occur or that our financial results, operations or
confidential information will not be negatively impacted by such an incident, especially because cyber threats change frequently
or are not recognized until launched and because cyber incidents can originate from a wide variety of sources. Similarly, there can
be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants
will be successful in protecting our clinical and other data that is stored on their systems.
If a cyber incident were to occur and cause interruptions in our operations or any destruction or loss, corruption or
unavailability of data, it could result in loss or misappropriation of confidential information, including trade secrets, other
intellectual property or financial information, and a material disruption of our development programs and business operations, any
of which could lead to significant delays or setbacks in our research and other further development and commercialization of our
product candidates. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in
delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Finally, there has
been significant evolution and developments in the use of artificial intelligence technologies, such as artificial generative chatbots.
We cannot fully determine the impact or cybersecurity risk of such evolving technology to our business at this time.
Any such cyber incident or destruction or loss of data could have a material adverse effect on our business and prospects. In
addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber incidents, including
cyber-attacks or other data security breaches, and may incur significant additional expense to implement further data protection
measures.
-55-
The legal and regulatory environment related to data privacy is becoming stricter, which could result in additional costs or
changes to the manner in which we handle personal information, and a failure to comply with such laws or regulations, or to
otherwise protect personal data in our possession or control, could result in fines, litigation, or other penalties as well as
reputational damage
We are subject to laws, regulations, and contractual obligations related to privacy, data protection, information security,
including (i) the EU General Data Protection Regulation, which came into effect on May 25, 2018 and which provides for greater
penalties for noncompliance than previous European data protection laws, with potential fines of up to the greater of €20 million
or 4% of total annual worldwide turnover and (ii) the California Consumer Privacy Act, which came into effect on January 1,
2020 and provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to
increase data breach litigation.
As privacy, data protection and information security laws evolve and are implemented, interpreted and applied, our
compliance costs may increase, particularly in the context of ensuring that adequate data protection and data transfer mechanisms
are in place. Additionally, compliance with such obligations and regulations could significantly impact our current and planned
privacy and information security practices, our collection, use, sharing, retention and safeguarding of personal data, and our
current and planned business activities and operations. A failure to comply with such obligations or regulations could result in
fines, litigation, or other penalties and adversely impact our reputation.
If our internal controls over financial reporting fail to be effective, such failure could result in material misstatements in our
financial statements, cause investors to lose confidence in our reported financial and other public information and have a negative
effect on the trading price of our ordinary shares
Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with
adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved
controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. Section 404
of the Sarbanes-Oxley Act of 2002 requires management of public companies to develop and implement internal controls over
financial reporting and evaluate the effectiveness thereof. If we fail to design and operate effective internal controls, it could result
in material misstatements in our financial statements, impair our ability to raise revenue, result in the loss of investor confidence
in the reliability of our financial statements and subject us to regulatory scrutiny and sanctions, which in turn could harm the
market value of our ordinary shares.
Banking system risk
We regularly maintain cash balances at third-party financial institutions in excess of the FDIC or other comparable foreign
country (i.e., Germany) deposit insurance limits. If any banks or financial institutions at which we maintain cash balances enter
receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial
markets, our ability to access our existing cash, cash equivalents and investments, or to draw on our existing lines of credit, may
be threatened and could have a material adverse effect on our business and financial condition.
-56-
ITEM 4. INFORMATION ON THE COMPANY
A.
History and development of the company
We are a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system. We do
this by applying our proprietary technologies to discover, develop and commercialize first-in-class, highly potent and specific
inhibitors of the complement activation factor known as C5a and its receptor C5aR. The complement system is an integral part of
the innate immune system and protects the body, for example by recognizing and removing bacteria, viruses, and other infectious
agents, collectively referred to as pathogens. Terminal complement activation, to which the cleavage of C5 by C5-convertases is
also referred to, leads to the release of C5a, which acts through its receptor C5aR. In addition, terminal complement activation,
i.e., the cleavage of C5a from C5, can also be achieved directly through the extrinsic pathway by naturally occurring enzymes
present throughout the body but not considered part of the complement system. With our therapeutic product candidates, we target
C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune
and other inflammatory diseases elicited through C5a/C5aR activation.
Our lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that
selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
We are and have been developing vilobelimab in a wide array of complement-mediated diseases with significant unmet medical
need. These include PG, a chronic inflammatory skin disorder for which we started a Phase 3 study with the first patient treated in
November 2023, the treatment of critically ill COVID-19 patients, for which we concluded a Phase 3 study in March 2022 and
subsequently were granted the EUA by the FDA in April 2023, and marketing authorization, under exceptional circumstances, by
the European Commission in January 2025. GOHIBIC is also being evaluated in a Phase 2 clinical platform study in broader
ARDS, funded by the Biomedical Advanced Research and Development Authority (BARDA).
We are also developing INF904, an orally administered, small-molecule inhibitor of C5aR, for which we have completed
Phase 1 study in healthy volunteers. Based on its mode of action, INF904 is a promising product candidate for being developed in
several disease areas of inflammation, where orally available therapeutics are not available or do not meet the medical need. We
decided to initially focus the INF904 development at chronic spontaneous urticaria, or CSU, and HS, with a single Phase 2a
basket study ongoing that targets both indications.
We are also developing IFX002, a life-cycle management product for vilobelimab, which is currently in advanced pre-clinical
stage.
Our legal and commercial name is InflaRx N.V and we were incorporated under the laws of the Netherlands on June 6, 2017,
and our headquarters, as registered with the local court of Jena, is located in Jena, Germany. InflaRx was founded in 2007 as
InflaRx GmbH by Professor Niels Riedemann and Professor Renfeng Guo in Jena, Germany. Our agent for service of process in
the United States is InflaRx Pharmaceuticals, Inc. located at 600 South Wagner Road, Ann Arbor, Michigan 48103. Our principal
executive offices and laboratories are located in Winzerlaer Str. 2, 07745 Jena, Germany, telephone: (+49) 3641 508 180. We
have additional offices in Planegg-Martinsried (Munich), Germany and in Ann Arbor, Michigan, United States, where we also
have laboratories.
We employ a total of 74 employees, 21 of whom have M.D. or Ph.D. degrees. Our management team has extensive
experience in the field of complement research, clinical research and the biopharmaceutical industry. Both our Chief Executive
Officer and founder, Professor (Dr.) Niels Riedemann, and our Chief Scientific Officer and founder, Professor Renfeng Guo, have
over 20 years of complement research experience, having published extensively on the role and function of C5a and its receptors.
Our Chief Financial Officer, Dr. Thomas Taapken, has served in executive positions and boards for various private and public
European biotechnology companies over the last 20 years and has over 25 years total experience in managerial roles in the
biopharmaceutical and venture capital industries. Our Chief Medical Officer, Dr. Camilla Chong, has 25 years of experience in the
global pharmaceutical industry in the areas of clinical development, medical affairs, clinical operations, regulatory and
pharmacovigilance as well as the launch of new medicines.
The SEC maintains a website that contains reports and other information about issuers, like us, that file Electronically with
the SEC. The address of that website is www.sec.gov. Our website can be found at www.inflarx.de. The information on our
website is not incorporated by reference into this Annual Report, and you should not consider information contained on our
website to be a part of this Annual Report.
-57-
B.
Business overview
Overview
C5a is a central mediator of the complement system and therefore a critical component of the innate immune system. The
most prominent role of the complement system is to help the body defend itself against invading microorganisms through several
mechanisms, including the rapid creation of an inflammatory environment and the production of factors that directly kill
pathogens and recruit immune cells to sites of infection. Activation of the complement system ultimately results in the generation
of C5a by cleavage from C5. C5a creates an inflammatory environment by attracting and strongly activating neutrophils as well as
by causing many different cell types to generate pro-inflammatory molecules. Such inflammation normally benefits the body by
helping to fight infection, but excessive or uncontrolled generation of C5a, as it occurs in certain diseases, can cause severe
damage to the body’s own tissue, thereby contributing to the pathophysiology of many autoimmune and inflammatory diseases.
While the mode of action of C5a in inflammation has been intensely researched and confirmed, developing a highly specific
antibody with the ability to fully block C5a while preserving a critical innate defense mechanism, the formation of the Membrane
Attack Complex, or MAC, has been challenging. As such, there are currently no approved drugs other than vilobelimab that
specifically target C5a. We identified antibodies, including our lead product candidate vilobelimab, that potently and selectively
bind to a conformational epitope that is formed by C5a upon the cleavage of C5a from C5 that completely blocks C5a without
compromising important upstream functions of the complement system, as well as MAC formation.
Unlike its ligand C5a, C5aR can also be pharmacologically inhibited by small molecules. It is generally believed that
blockade of C5a using antibodies offers a fast, complete, and safe way to control C5a-induced inflammation. The advantage of a
small molecule inhibitor to C5aR is that it can be administered orally, thereby offering broad, long-term ease of administration to
patients, especially for the treatment of chronic diseases.
Through our in-house drug discovery efforts, we identified a potent inhibitor of the C5a receptor, INF904, which we believe
is a promising candidate for development. We plan on targeting complement-mediated, chronic auto-immune and inflammatory
conditions where an oral small molecule is needed for patients.
Given the different advantages of blocking C5a and C5aR, we believe that the development of both, C5a and C5aR blocking
agents is possible and potentially helpful to address a broader range of C5a/C5aR-molecular signaling axis-associated diseases.
-58-
Based on the broad anti-inflammatory properties, we are currently developing our lead anti-C5a antibody and our low
molecular weight compound INF904 in several diseases. An overview can be found in the pipeline description below.
Vilobelimab for the treatment of PG
We are developing vilobelimab for the treatment of PG. PG is a rare, chronic inflammatory form of neutrophilic dermatosis
characterized by accumulation of neutrophils in the affected skin areas. Vilobelimab was granted orphan drug designation for the
treatment of PG by both the FDA in the United States and the EMA in Europe as well as fast track designation by the FDA. After
a series of interactions with the FDA on the results of our successfully conducted Phase 2 clinical study and our plans for the
further development towards a potential BLA submission, in 2023 we announced the start of a Phase 3 study with vilobelimab in
ulcerative PG. In November 2023, we announced the enrollment of the first patient in the study. In March 2025, we announced
that the Phase 3 blinded interim analysis is expected by the end of May 2025.
Vilobelimab for the treatment of severe COVID-19
In April 2023, we received an EUA from FDA for GOHIBIC (vilobelimab) for the treatment of critically ill, invasively
mechanically ventilated COVID-19 patients. The EUA is supported by the previously announced results of the multicenter Phase
3 PANAMO trial, which demonstrated a relative reduction in 28-day all-cause mortality by 23.9%. Subsequently, in June 2023,
we began the commercialization of GOHIBIC (vilobelimab) in the United States under the EUA. In January 2025, the European
Commission (EC) granted marketing authorization under exceptional circumstances for GOHIBIC for the treatment of adult
patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as
part of standard of care and receiving invasive mechanical ventilation (IMV) with or without extracorporeal membrane
oxygenation (ECMO).
Anti-Ca5R inhibitor INF904
To expand the breadth of our anti-C5a/C5aR technologies, we are also developing INF904, a product candidate that targets
the C5a receptor. In INF904, we discovered a small molecule C5aR inhibitor that in pre-clinical studies has shown potential for
superior characteristics to the only approved C5aR inhibitor, avacopan. INF904 has provided higher plasma exposure in animals,
including non-human primates, and improved inhibitory activity in a hamster neutropenia model compared to avacopan.
Furthermore, in contrast to avacopan, in vitro experiments showed INF904 has substantially less inhibition of the cytochrome
P450 enzymes 3A4/5 (CYP3A4/5). INF904 demonstrated potential for anti-inflammatory therapeutic effects in several preclinical
disease models. In January 2024, we announced the positive results of a single and multiple ascending dose study with INF904 in
healthy volunteers. In December 2024, we announced that the first patient was dosed in the Phase 2a basket study in CSU and HS
with initial data anticipated in summer 2025. INF904 is a promising product candidate for being developed in several disease
areas of inflammation, where orally available therapeutics are not available or a medical need exists despite availability of other
therapies.
-59-
INF904 for the treatment of CSU
We are pursuing development of INF904 for the treatment of CSU in a Phase 2a trial. CSU is a debilitating and unpredictable
skin disease characterized by intensely itchy hives / wheals and angioedema. The burden of this chronic disease is high and
impacts sleep, mental health, quality of life and productivity due to absences from school and work. CSU is estimated to affect
around 40 million people worldwide. CSU patients have been reported to show elevated C5a levels, a major activator of mast cells
and basophils which are thought to be significant contributors to CSU pathogenesis. In addition, studies suggest that complement
activation (including C5a) in CSU can lead to histamine release. Current treatments are limited, and a significant unmet need
exists in a sizable proportion of patients.
INF904 for the treatment of HS
We are also pursuing development of INF904 for the treatment of HS in a Phase 2a trial. HS is a chronic, recurrent,
debilitating neutrophil-driven inflammatory disease that can persist for years and tremendously impacts quality of life; it is
characterized by abscesses, nodules and draining tunnels which can flare and cause scarring. INF904 inhibits the known C5a-
induced effects on neutrophil activation and tissue accumulation of immune cells, including generation of tissue damaging
mechanisms (enzyme release and oxidative radical formation) as well as induction of NETosis – mechanisms thought to be
involved in HS progression and draining tunnel formation. Clinical evidence with existing C5a/C5aR products also supports that
blocking this pathway reduces lesion counts. Patients’ responses to treatment with approved anti-TNF-alpha or anti-IL17 drugs
are known to wane over time in a significant number of cases; and treatment with new therapeutics acting through other molecular
mechanisms are needed for these patients.
Anti-C5a antibody IFX002
We are developing IFX002 for the treatment of chronic inflammatory diseases. IFX002 is a highly potent anti- C5a antibody,
which binds to the same domain of the C5a protein as vilobelimab, but which has a higher humanization grade and altered
pharmacokinetic properties compared to vilobelimab. IFX002 is currently in preclinical development. We consider IFX002 to be a
life-cycle management product to vilobelimab, given the long remaining patent life of IFX002.
For more information on our technology or our development programs please refer to the detailed information included herein
below.
Our technology
C5a is a central mediator of the complement system and therefore a critical component of the innate immune system. The
most prominent role of the complement system is to help the body defend itself against invading microorganisms through several
mechanisms, including the rapid creation of an inflammatory environment and the production of factors that directly kill
pathogens and recruit immune cells to sites of infection. Activation of the complement system ultimately results in the generation
of C5a by cleavage from C5. C5a creates an inflammatory environment by attracting and strongly activating neutrophils as well as
by causing many different cell types to generate pro-inflammatory molecules.
The complement system and role of the C5a/C5aR axis as critical component in the immune system and the need for control
The complement cascade consists of approximately 30 interacting proteins and forms a critical component of the innate
immune system. This system protects the body, for example by recognizing and removing bacteria, viruses and other infectious
agents, collectively referred to as pathogens. Activation of the complement system leads to a series of enzyme-like reactions that
produce factors that both directly kill pathogens and recruit immune cells to sites of infection. This activation can be triggered via
three major pathways: the so called classical pathway, the mannose binding lectin, or MBL, pathway and the so called alternative
pathway. Activation of any of these three pathways will lead to the cleavage of C3 and formation of C5-convertases. Terminal
complement activation, which is also referred to as cleavage of C5, can be achieved by these C5 convertases. In addition, terminal
complement activation can also be achieved directly through the extrinsic pathway by naturally occurring proteolytic enzymes
present throughout the body but not considered part of the complement system.
-60-
Cleavage of C5 results in the generation of C5a and C5b, two molecules with distinct biological activities. C5a is a strong
inflammatory amplifier that exerts its biological functions by binding to two different receptors, C5aR and C5L2. C5b on the other
hand assembles with C6, C7, C8 and many C9 molecules to form the MAC, an important intrinsic defense mechanism that causes
the membranes of microorganisms to become permeable, leading to their disintegration, or lysis.
Overview of critical functions of the complement system
The complement system serves many crucial functions within the innate immune response, such as:
●
Rapid creation of an inflammatory environment. Production of pro-inflammatory molecules, such as C5a, optimizes the
conditions under which enzymatic and other processes can act against microorganisms. These inflammatory conditions
include the onset of a fever or release of aggressive enzymes and oxygen radicals by neutrophils.
●
Lysis of microorganisms through formation of the MAC. A rapid, first-line defense mechanism resulting in the formation
of pores in the cell membranes of invading microorganisms, leading to their disintegration.
●
Bridge to the adaptive immune system. This function is promoted by an activation product of C3, called C3b, which tags
particles and makes them visible and more easily processed by immune stimulatory cells. Such cells then present these
particles to B-cells, which in turn generate antibodies against the particles, leading to targeted elimination. This
mechanism takes a few weeks to take full effect.
●
Clearance of dead cell particles. The complement system also serves various other purposes, including the clearance of
dead cell particles from the body. This function is especially important because uncleared cell particles are believed to
potentially induce generation of antibodies against normal cells and tissues, leading to autoimmune inflammatory
responses and diseases.
Need for control
Complement activation is a double-edged sword: the fast acting and relatively non-specific functions of pro-inflammatory
responses driven by C5a and the lysis of microorganisms through MAC formation are usually very tightly controlled. However,
inappropriate activation of the system can quickly turn it from a beneficial defense system into an uncontrolled inflammatory
response. C5a’s uncontrolled activity in certain disease states can generate an inflammatory environment within the body that
results in tissue damage and promotes pro-inflammatory T-cell autoimmune responses. The resulting tissue damage is believed to
critically contribute to the disease progression of many acute as well as chronic inflammatory and autoimmune diseases,
particularly during flare-up phases. Examples of this include Lupus disease, inflammatory bowel disease and neutrophil-driven
diseases.
-61-
Despite the MAC’s role as a rapid, first-line defense mechanism, MAC formation can also result in damage to our body’s
cells in some diseases. Normally, the body’s cells and tissues are protected from MAC-mediated lysis through surface inhibitors
that prevent MAC formation. However, in paroxysmal nocturnal hemoglobinurea, or PNH, the patients’ cells lack the ability to
hold MAC inhibitors on their cell surface, resulting in extreme susceptibility to MAC-related cell lysis. In addition, patients with
diseases involving the kidney endothelial cells, such as atypical hemolytic uremic syndrome and certain forms of
glomerulonephritis, also often appear to be burdened by MAC-related damage. Blockade of MAC formation in these very rare
diseases can be lifesaving.
While blockade of MAC formation can be beneficial in certain circumstances, substantially blocking MAC formation can
also result in susceptibility to life-threatening infections. For example, patients dosed with drugs that block MAC formation, such
as with the marketed antibody eculizumab, must be immunized against meningococcal disease, which also carries the risk of side
effects. Therefore, it is desirable to leave MAC formation intact when blocking complement-mediated damage in the broad variety
of diseases in which an uncontrolled inflammatory response, and especially C5a, has been described as key driver of the damage.
We believe that C5a is a key inflammatory mediator driving tissue damage in many inflammatory diseases and thus
represents a very meaningful drug target with large therapeutic potential. Therefore, we have conducted substantial research since
our inception to generate highly specific antibodies targeting only C5a while leaving MAC formation intact, to deliver an ideal
therapeutic approach for this attractive target.
Mechanisms of C5 activation
C5 can be produced by many cells, including epithelial cells of various organs, T-cells and other immune competent cells.
Terminal C5 activation does not require activation of the three complement pathways and related formation of C5-convertases.
Other enzymes can also directly cleave and activate C5, such that functionally active C5a can be generated in the complete
absence of other complement components. For example, in the absence of other complement factors in the cell culture, lung
epithelial cells can generate C5 upon stimulation, and lung macrophages can cleave and activate C5, leading to generation of C5a.
This example illustrates that C5 can be activated and C5a can be generated independently from the complement pathways.
We further demonstrated that direct enzymatic cleavage of C5 occurs uninhibited in the presence of eculizumab, a known C5
inhibitor that binds to the MG-7 domain of C5 and hinders the C5 convertases from engaging and binding to C5. This research
suggests that direct enzymatic cleavage of C5a from C5 works through a mechanism that is not blocked by C5 inhibitors such as
eculizumab. Our studies further demonstrate that patients sufficiently dosed with eculizumab may still display elevated plasma
C5a levels, implying that C5 inhibitors like eculizumab are not capable of fully blocking and controlling the C5a signaling
pathway. Therefore, in diseases in which it plays a key promoting role, we believe targeting C5a directly may yield a meaningful
therapeutic benefit.
C5a and its role in disease and inflammation
C5a is a small, 74-amino acid-spanning protein whose biochemical and immunological properties have been well documented
in the scientific literature. C5a creates an inflammatory environment by attracting and strongly activating neutrophils as well as by
causing many different cell types to generate pro-inflammatory and inflammation-related molecules. While this can help the body
to respond strongly and rapidly to infections by optimizing the defense environment, uncontrolled C5a generation can induce
damage to the body’s tissues in a broad variety of diseases. As a result, we believe that controlling and limiting C5a generation in
the body may prevent the negative effects of an over-activated C5a immune response.
C5a quickly interacts with at least two independent receptors—C5aR and C5L2 (sometimes referred to as C5aR2). C5aR and
C5L2 serve as a large signaling pool for effects elicited by C5a. C5aR has been well characterized as a signaling receptor that can
be strongly upregulated in almost any cell across a variety of disease settings. Although less understood, C5L2 has also been
shown to promote inflammation and negatively affect outcomes in various experimental disease settings by promoting the adverse
effects, or AEs, elicited by uncontrolled C5a. Importantly, various other complement activation products (e.g., C3a, C3a-desArg
and C4a) have been shown to bind to C5L2 and elicit effects different from those elicited by C5a. Thus, blocking specifically C5a
as achieved by use of vilobelimab will eliminate only C5a mediated effects.
-62-
Role of C5a in neutrophil-driven inflammatory diseases
In the inflammatory response, C5a is an accelerator or “booster” of inflammation. This role of C5a extends to a broad variety
of responses, including the following mechanisms:
●
C5a boosts the generation of many different cytokines such as IL-8, IL-6, IL17, TNF-alpha and others in a variety of cell
types as well as within the bloodstream;
●
C5a induces a complex change in the cell-signaling cascade of immune-competent cells that leads to an altered and often
intensified signal transduction of other known signaling stimuli, such as the toll-like receptor signaling;
●
C5a affects T-cell responses and causes a pro-inflammatory response, leading to the generation of further pro-
inflammatory cytokines; and
●
C5a is capable of inducing adhesion molecule expression on the surfaces of blood vessels, leading to neutrophil
adherence to the internal vessel wall and migration through the vessel to the site of infection.
When C5a binds to its receptors on neutrophils, they are strongly activated and move to the source of damage or infection,
through a process referred to as chemotaxis, generating oxygen radicals and activated enzymes both believed to be major
contributors to cellular and tissue damage in the body. In addition, C5a has been suggested to induce neutrophil extracellular trap,
or NET, formation and a process in which neutrophils undergo a certain form of cell death while forming NETs called Netosis,
which is believed to cause additional inflammation and damage in the tissue. Given this central function, C5a is a powerful tool
that, when inappropriately activated, is capable of promoting damage to the body, ultimately leading to organ dysfunction and
failure.
Neutrophil activation is assessed by observing the upregulation of the neutrophil surface marker CD11b (an established
method to demonstrate neutrophil activation). In studies conducted in 2013 and 2014 as part of an investigative project in
collaboration with an investigator from the University of Athens, we found that CD11b, as a marker for neutrophil activation, was
greatly enhanced in fresh human whole blood from healthy volunteers when either recombinant human C5a was added or when
plasma from HS patients was added. Vilobelimab, our highly specific anti-C5a antibody, completely inhibited neutrophil
activation resulting from the addition of the HS plasma, suggesting that C5a may be the key mediator in plasma from patients
affected by this disease, leading to neutrophil activation.
Flow cytometry assay in fresh human whole blood demonstrating CD11b increase on blood neutrophils as marker of
neutrophil activation: recombinant human C5a strongly activates human neutrophils in whole blood (huPP-ctr + 20 nM rhC5a),
which can be fully blocked by addition of vilobelimab (“IFX-1” in the above graph) (huPP-ctr + 20 nM rhC5a + 20 nM
vilobelimab) (open white bars). Plasma from two different HS patients (pat088 and pat092) also activates human neutrophils in
whole blood and this effect can be fully blocked by the addition of vilobelimab (middle and darker grey bars) thus implying that
C5a in HS patient plasma is the key neutrophil activating factor.
-63-
Various chronic inflammatory and autoimmune diseases in humans are characterized by flare-up phases during which
substantial tissue damage occurs. Given C5a’s numerous inflammatory promoting functions, blocking it in chronic inflammatory
diseases may have a positive effect on T-cell function, overall control of the inflammatory status of the disease and a strong anti-
inflammatory effect on neutrophils, which may reduce tissue damage during the flare-up phases. It has been demonstrated that in
various inflammatory animal models that blocking the C5a/C5aR signaling axis leads to reduced inflammation, improved organ
performance and favorable outcomes on clinical endpoints, including improved mortality rate, disease severity or damage scores.
C5a also has been described as a potential disturbing factor for a balanced T-cell response by down-regulating regulatory T-
cells and promoting pro-inflammatory T-cell responses. Research published in 2013 in Nature Immunology and the Journal of
Experimental Medicine demonstrated that blocking the C5a/C5aR signaling axis in mice restored regulatory T-cell function,
inhibiting the progression of induced autoimmune diseases. Therefore, C5a is a potential drug target for the treatment of
autoimmune and chronic inflammatory diseases associated with T-cell imbalance.
Role of C5aR in chronic spontaneous urticaria
C5a, a potent complement component, plays a crucial role in immune responses by activating mast cells and basophils,
leading to their degranulation. This process results in the release of histamine and other inflammatory mediators, which contribute
to the symptoms of chronic spontaneous urticaria, a condition characterized by recurrent hives and itching. Given its role in
promoting inflammation and hypersensitivity reactions, C5a is considered a promising drug target for CSU. Therapeutic strategies
aimed at inhibiting C5a signaling could potentially reduce mast cell and basophil activation, thereby limiting histamine release
and alleviating CSU symptoms.
Role of C5aR as potential target for therapeutic intervention
Two C5a receptors, C5aR (also known as C5aR1 or CD88) and C5aR2 (also known as C5L2 or GPR77), mediate the
biological activities of C5a. Activation of C5aR has broadly acknowledged proinflammatory effects, while the role of activation of
C5aR2 remains less well understood and recent scientific work has suggested a potential regulatory role on C5aR1 activation. In
animal models of sepsis, anti-C5a treatment ameliorated the development of inflammatory responses and improved survival. In
addition, experimental evidence suggests that blockade of C5aR signaling similarly improves survival in animals with sepsis.
Finally, C5aR antagonists have shown excellent therapeutic effects in numerous models of inflammatory diseases involving
complement activation.
Unlike its ligand C5a, C5aR can be pharmacologically inhibited by small molecules. In October 2021, avacopan, an oral
C5aR antagonist, received market approval in the United States as an adjunctive treatment in adults for severe active ANCA-
associated vasculitis (specifically MPA and GPA) in combination with standard therapy including glucocorticoids.
It is generally believed that blockade of C5a using antibodies offers a fast, complete, and safe way to control C5a-induced
inflammation. The advantage of a low molecular weight compound inhibitor to C5aR is that it can be administered orally, thereby
offering broad, long-term ease of administration to patients.
Our proprietary anti-C5a/C5aR technologies and product candidates
Our anti-C5a technology
Despite C5a’s well-characterized role in promoting inflammation and related tissue and organ damage in different diseases,
no marketed drug targeting C5a exists. Based on more than 17 years of research in this field, we believe the challenge in targeting
C5a is to fully block the biological functions of C5a in its natural environment and leave MAC formation intact. We believe our
proprietary anti-C5a technology enables us to overcome this challenge through our discovery of a novel epitope, or binding site,
on C5a. We believe this conformational epitope is formed only after the cleavage of C5a from the C5 molecule, suggesting that
the three-dimensional structure of C5a changes upon release from C5, creating new epitopes that are only present on the free C5a
molecule. This permits binding to free C5a only after it is cleaved from C5 and thus allows blocking of C5a while keeping MAC
formation intact. We believe that this represents a breakthrough in the field of terminal complement C5a inhibition and that this
may be particularly valuable when treating diseases that are driven by C5a, such as PG and severe COVID-19, cSCC, HS, AAV
and others.
-64-
We identified antibodies, including our lead product candidate vilobelimab, that potently and selectively bind to a
conformational epitope that is formed by C5a upon the cleavage of C5a from C5 to completely block C5a without compromising
important upstream functions of the complement system, as well as MAC formation. We intend to discover and develop
treatments leveraging our proprietary anti-C5a technology to address a wide array of complement-mediated diseases with
significant unmet needs.
A conformational epitope on the surface of the C5a molecule allows for generation of highly specific blocking antibodies
directed against C5a.
Our anti-C5a monoclonal antibodies are designed to have the following properties:
●
Complete immunological blockade and inhibition of C5a-induced effects: The human body has an abundant capacity to
generate C5a, and induce inflammatory effects through its two receptors, C5aR and C5L2. Therefore, our anti-C5a
antibodies are designed to:
○
generate complete immunological blockade of the C5a molecule to achieve potent and effective treatments.
Antibodies or inhibitors lacking this quality may leave a “signaling gap” for C5a, which, in a disease setting, will
likely be sufficient to allow for strong pro-inflammatory effects. This signaling gap would limit the ability to silence
the C5a/C5aR and C5a/C5L2 signaling axis to achieve the desired therapeutic effect; and
○
bind with high affinity to C5a to counteract the molecule’s rapid interactions with its two receptors, C5aR and C5L2,
which are abundantly present on the vast majority of cell types in the human body and that can be upregulated in
various disease settings.
●
Limited effect on MAC formation: C5 blocking molecules that inhibit MAC formation in the blood increase the risk of
life-threatening infections caused by encapsulated bacteria such as meningococci. Therefore, leaving MAC formation
intact may offer a significant advantage in C5a driven diseases.
We believe that all these features are necessary for any drug targeting C5a, in order to achieve clinically meaningful
pharmacological performance for the treatment of C5a-driven diseases such as PG, severe COVID-19 or several others.
Furthermore, we believe that C5a-driven diseases may not be effectively targeted with complement inhibitory approaches that do
not specifically and fully block C5a. These approaches such as blocking the complement pathway-driven cleavage of C5 or
inhibiting the complement pathways upstream of C5, are characterized by two fundamental shortcomings set forth below.
-65-
●
Inability to fully block C5a without targeting it directly: C5a can be generated through C5 activation by various enzymes
in the complete absence of the complement pathways. For example, blocking the complement C5-convertase-driven
cleavage with the C5 inhibitor eculizumab cannot block direct enzymatic C5 activation and C5a generation in an
experimental setting. This may explain why elevated C5a levels remain measurable in patients effectively dosed with
eculizumab. Therefore, non-specific approaches that do not bind and inhibit C5a directly may fail to fully block its
effects.
●
Lack of control over C5a’s signaling ability: C5a receptors are abundantly present on the majority of cells in humans and
can be strongly and rapidly upregulated in certain disease states. As such, even with low levels of C5a, the receptors
create a large “signaling sink” providing an abundant ability for even small amounts of C5a to transmit a signal.
Therefore, a fully blocking targeted C5a approach is warranted in order to achieve full control over C5a-induced
signaling events that may be especially important in highly acute inflammatory settings.
Vilobelimab as first-in-class anti-C5a monoclonal antibody
Our lead product candidate, vilobelimab, is an intravenously delivered monoclonal anti-C5a antibody. It is based on our
proprietary anti-C5a technology and was the first C5a monoclonal antibody to enter clinical development. Vilobelimab is
differentiated by its ability to:
●
fully inhibit C5a-induced signaling and derived biological functions, as evidenced by its ability to completely prevent
C5a-induced neutrophil activation in human whole blood; and
●
leave MAC formation intact, as evidenced by testing the intact complement pathway driven MAC formation on red blood
cells, leading to the lysis of these cells.
We completed one placebo-controlled, single-center Phase 1 study of vilobelimab in healthy volunteers and completed two
double-blind, placebo-controlled, multi-center Phase 2a studies in two acute care indications, early septic organ dysfunction and
complex cardiac surgery. We also completed a Phase 2a and a Phase 2b clinical study in HS, two Phase 2 studies in AAV, a Phase
2a study in PG and a Phase 2/3 clinical study in critically ill, mechanically ventilated COVID-19 patients.
In all completed studies, vilobelimab was observed to be well tolerated. The placebo-controlled, multi-center Phase 2a studies
in the two acute care indications demonstrated that vilobelimab blocked C5a with high statistical significance (p-values < 0.001)
and that MAC formation, as demonstrated by a CH50 assay (as described below), in the groups treated with vilobelimab was not
influenced, with mean CH50 values for treatment groups and control groups within the normal range.
To determine whether data is statistically significant, we use a “p-value,” which represents the probability that random chance
could explain the results. The FDA utilizes the reported statistical measures when evaluating the results of a clinical trial,
including statistical significance as measured by p-value as an evidentiary standard of efficacy, to evaluate the reported evidence
of a product candidate’s safety and efficacy. If not otherwise specified, we used a conventional 5% or lower p-value (p < 0.05) to
define statistical significance for the clinical trials and studies and data presented in this Annual Report.
Based on our clinical trials completed to date as well as the results from an EpiScreen ex vivo immunogenicity T-cell
response assay, we believe that vilobelimab carries a low risk of provoking an immune response following administration. The
immunogenicity assay used peripheral blood mononuclear cells from 21 donors and tested how many donors’ cells showed a
CD4+ T-cell response following introduction of vilobelimab ex vivo. A response rate of over 10% (or more than three out of 21)
means the applicable protein is considered to be high risk for immunogenicity, while a response rate of less than 10% means the
protein is considered to be low risk. The results of the assay for vilobelimab showed that zero out of the 21 donors had a T-cell
response rate, as compared to a control arm (using the A33 antibody), which showed a 30% response rate. In addition, based on an
ADA detection assay conducted in connection with our Phase 2b clinical trial in HS, 10% of patients had ADAs at any time
during the study. Only one participant the presence of ADAs was associated with any specific AE pattern indicating symptoms
possibly related to the presence or emergence of ADAs leading to an immune reaction.
We are currently evaluating vilobelimab in various disease indications. In all ongoing and completed clinical studies so far,
we have never observed effects that would raise doubts on the established safety of vilobelimab as a therapeutic drug candidate.
-66-
We will also continue to assess the potential for development of vilobelimab in other disease settings where we believe an
anti-C5a antibody could be successfully developed into a marketed therapy.
Development of small molecule inhibitors of C5aR
Two C5a receptors, C5aR (also known as C5aR1 or CD88) and C5aR2 (also known as C5L2 or GPR77), mediate the
biological activities of C5a. Activation of C5aR has broadly acknowledged proinflammatory roles, while activation of C5aR2
remains less well understood and recent scientific work has suggested a potential regulatory role on C5aR activation. C5aR is a G-
protein-coupled-receptor expressed primarily by granulocytes, and, especially under disease conditions, broadly in various tissues
and other immune cell types, which mediates the pathophysiological effects of C5a.
In animal models of sepsis, anti-C5a treatment ameliorated the development of inflammatory responses and improved
survival. In addition, experimental evidence suggests that blockade of C5aR signaling similarly improves survival in animals with
sepsis. Unlike its ligand C5a, C5aR can also be pharmacologically inhibited by low molecular weight compounds.
Low molecular weight C5aR antagonists have shown excellent therapeutic effects in numerous in vitro and in vivo animal
models of inflammatory diseases involving complement activation. The advantage of a low molecular weight inhibitor of C5aR is
that it can be administered orally, thereby offering broad, long-term ease of administration to patients, especially for the treatment
of chronic diseases. Through proper clinical investigation of these small molecule C5aR antagonists in diseases induced by the
activation of C5a/C5aR axis, the safety and efficacy of these agents can be established.
Avacopan is the first oral C5aR antagonist, which has market approval in the United States as an adjunctive treatment in
adults for severe active ANCA-associated vasculitis (specifically MPA and GPA) in combination with standard therapy, including
glucocorticoids.
Through our in-house drug discovery efforts, we identified a potent inhibitor of the C5a receptor, INF904, which we believe
is a promising candidate for development. We are currently developing INF904, an oral, low molecular weight drug candidate that
targets the C5aR receptor. We plan on targeting complement-mediated, chronic auto-immune and inflammatory conditions where
an oral small molecule is needed for patients.
Given the different advantages of blocking C5a and C5aR, we believe that the development of both C5a and C5aR blocking
agents is possible and potentially helpful to address a broader range of C5a/C5aR-molecular signaling axis-associated diseases.
Our preclinical and clinical development programs
Vilobelimab for the treatment of PG
We are developing vilobelimab for the treatment of PG. PG is a rare, chronic inflammatory form of neutrophilic dermatosis
characterized by accumulation of neutrophils in the affected skin areas. The exact pathophysiology is not fully understood, but it is
postulated that inflammatory cytokine production as well as neutrophil activation and dysfunction contribute to a sterile
inflammation in the skin. PG often presents as painful pustule or papule, mainly on the lower extremities, which can rapidly
progress to an extremely painful enlarging ulcer. Associated symptoms include fever, malaise, weight loss and myalgia. PG
usually has a devastating effect on a patient’s life due to the severe pain and induction of significant movement impairment
depending on lesions’ location. The exact prevalence of PG is not yet known but is estimated that up to 51,000 patients in the
United States and Europe are affected by this disease.
There are 4 disease types recognized: ulcerative (the classical variant, which is the focus of our development), bullous
(atypical), pustular, and vegetative (superficial, granulomatous). The ulcerative variant is the most frequent and typical form of
PG, with lesions predominantly on the lower extremities.
There are currently no drugs approved for the treatment of PG in the US or in Europe. The only locally approved treatment is
adalimumab, which has been approved in Japan but in no other country. There is no established standard of care based on
controlled studies in PG. However, due to the high medical need associated with the disease, certain drugs are used in medical
practice as treatment attempts for affected patients. These include certain orally administered drugs such as immunosuppressants,
including cyclosporine or corticosteroids which are sometimes also used concomitantly, as well as topically applied drugs such as
tacrolimus and others. Lastly intravenously administered TNF-alpha inhibitors such as infliximab or adalimumab or other
biological drugs are also used as treatment attempt, despite the fact that no formal regulatory approvals are in place.
-67-
In February 2019, we initiated an open label, multi-center Phase 2a exploratory study enrolling 19 patients with moderate to
severe PG in Canada, the United States and Poland. The objectives of this study were to evaluate the safety and efficacy of
vilobelimab in this patient population in three different doses and to determine the appropriate dose for the future development of
vilobelimab in registrational Phase 3 studies for the treatment of PG.
In April 2021, the study reached its enrollment target with 19 patients. In October 2021, we announced preliminary results
from the study. In the third dosing cohort at 2400mg biweekly, six of the seven patients achieved clinical remission with a PGA
score of ≤ 1, which reflected a closure of the target ulcer. All patients in the third dosing cohort had elevated C5a levels at baseline
that were continuously suppressed after initiation of treatment with vilobelimab.
From all three dose cohorts in the study, two patients had related SAEs that were reported: one patient experienced an
erysipelas leading to hospitalization (judged as non-drug related by us), another developed a rash due to a delayed hypersensitivity
reaction and withdrew from the study. No dose-related AEs were found. Overall, the observed AE profile was in line with the
underlying disease.
Final results from all patients were presented at the American Academy of Dermatology Association, AAD), Annual Meeting
in March 2022 in an oral late-breaker session by Afsaneh Alavi, MD, Associate Professor of Dermatology, Mayo Clinic. The
reported final results showed a dose-dependent effect in the highest dose cohort of 2400 mg, confirming the preliminary results
with six out of seven patients showing a clinical remission (Physician Global Assessment, or PGA, score ≤ 1) and closure of the
target ulcer in this dose cohort. The seventh patient showed a slight improvement (PGA score 4) with a decrease of the target ulcer
area of over 50%. During the follow-up period, ulcers remained closed two months after treatment completion in all but one
patient, and a sustained suppression of C5a was observed for up to 20 days after the last dosing.
With these results, vilobelimab was granted orphan drug designation for the treatment of PG by both the FDA in the United
States and the EMA in Europe as well as fast-track designation be the FDA. Furthermore, we announced that we had a productive
end-of-phase 2 meeting with the FDA related to our plans for a Phase 3 development program in PG in June 2022. In January
2023, we announced details related to the design of our planned Phase 3 study with vilobelimab in ulcerative PG.
The Phase 3 study is designed to enroll patients in the United States, Europe and selected countries in other regions. The
study design is based on detailed feedback and recommendations from the FDA Division of Dermatology and Dentistry and was
developed in close collaboration with the Company´s advisors from the United States, Europe and other regions. The multi-
national, randomized, double-blind, placebo-controlled Phase 3 trial has two arms: vilobelimab (2,400mg every other week) plus a
low dose of corticosteroids and placebo plus the same low dose of corticosteroids. In both arms, corticosteroid treatment will be
initiated on day one and will be tapered off within the first eight weeks of the treatment period. The primary endpoint of the study
will be complete closure of the target ulcer at any time up to 26 weeks after initiation of treatment. Treatment will be discontinued
for patients whose disease progresses or fails to improve at defined time points during the study. The study has an adaptive trial
design with an interim analysis blinded for the sponsor and investigators (but unblinded for the independent data safety
monitoring committee), which is planned upon enrollment of approximately 30 patients, divided equally between the two arms of
the study. The interim analysis with a set of predefined rules will take into account the then-observed difference in complete target
ulcer closure between the two arms and will then determine whether the trial sample size will be adapted or whether the trial
should be stopped due to futility. The enrollment period is projected to last at least two years, and its overall period will depend on
the total trial size after sample size adaptation.
In November 2023, we announced the enrollment of the first patient in the trial and in November 2024, we announced the
achievement of the 30-patient recruitment milestone. An interim analysis that will define the final sample size for the trial, or
declare the trial fuile, is expected to be completed and released in Q2 2025.
-68-
Vilobelimab for the treatment of critically ill, invasively mechanically ventilated COVID-19 patients
Severe COVID-19 is characterized by severe lung inflammation and activation of coagulation, frequently requiring
mechanical ventilation while the patient is in the intensive care unit. Mortality and morbidity rates are high among critically ill,
invasively mechanically ventilated patients with COVID-19, despite the established broad use of corticosteroids and other anti-
inflammatory agents. Poor disease outcomes have been associated with activation of the complement system, specifically the
C5a/C5aR molecular signaling axis. Experimental studies in other viral lung diseases have shown that C5a is a potent
anaphylatoxin, attracting neutrophils and monocytes to the site of infection that causes tissue damage, endothelialitis, and micro-
thrombosis. Mouse studies also showed that blockade of the C5a/C5aR1 molecular signaling axis limits the infiltration of myeloid
cells in damaged organs and prevents excessive lung inflammation and endothelialitis.
During the COVID-19 pandemic, it became clear that effective therapies for the treatment of severely or critically ill COVID-
19 patients were not available or had not tested for this indication. In an effort to provide a contribution to this medical emergency
and based on our existing pre-clinical research on the role of C5a in viral-induced pneumonia, we decided to initiate a clinical
development program with vilobelimab in critically ill COVID-19 patients with severely progressed pneumonia.
Clinical development
In March 2020, we initiated a randomized open label multi-center trial Phase 2/3 clinical development program with
vilobelimab in severe COVID-19 patients with severely progressed pneumonia. In the Phase 2 part of the study, we evaluated
vilobelimab treatment plus best supportive care compared to best supportive care alone for up to 28 days. Relative change (%)
from baseline to day 5 in oxygenation index (defined as PaO2/FiO2 ratio) was assessed as the primary endpoint along with
additional clinical parameters until day 28. In the study, patients were randomized to two treatment arms, either Arm A, best
supportive care and vilobelimab or Arm B, best supportive care alone. The primary endpoint was the relative percentage change
from baseline to day 5 in the oxygenation index (PaO2 / FiO2).
On June 17, 2020, we announced results from the Phase 2 part of the study. A total of 30 patients were randomized in the
trial, and 15 patients were treated in each arm: vilobelimab plus best supportive care or best supportive care alone. Over a
treatment period of 28 days, patients in the vilobelimab arm received a maximum of seven doses of 800 mg vilobelimab
intravenously on separate days. At randomization, 18 patients were intubated (60%), and 12 patients (40%) had other oxygen
supply. A higher number of patients with two or more comorbidities associated with increased COVID-19 mortality were reported
in the vilobelimab treatment group compared to best supportive care group. Relative change in the oxygenation index at day 5
showed no differences between treatment groups. However, vilobelimab treatment was associated with a lower 28-day all-cause
mortality when compared to the best supportive care group, along with trends in disease improvement, as evidenced by fewer
patients experiencing renal impairment assessed by estimated glomerular filtration rates, more patients showing reversal of blood
lymphocytopenia and a greater lowering of lactate dehydrogenase concentrations. In vilobelimab-treated patients, pulmonary
embolisms reported as SAEs occurred less compared to the best supportive care arm. Also, a temporary increase of D-dimer
levels, as potential expression of induction of blood clot lysis, was detected in the first days after initiation of vilobelimab
treatment. Twenty-eight-day all-cause mortality in the vilobelimab treatment group was 13% (2 out of 15) versus 27% (4 out of
15) in the control group. In the best supportive care group, four patients died of COVID-19-induced multi-organ failure, and three
of them had pulmonary embolisms reported as a SAE. In the vilobelimab arm, one patient died after an acute ventilator tube
complication (leakage) and one patient with a history of severe chronic obstructive pulmonary disease died of pulmonary failure.
SAE rates were comparable between groups, but the rate of pulmonary embolisms reported as SAEs was substantially lower
in the vilobelimab treatment group. Upon review of the safety data, the independent data safety monitoring board recommended
continuation of the trial into the Phase 3 part.
In March 2022, we announced that the Phase 3 part of the Phase 2/3 PANAMO study which enrolled 369 mechanically
ventilated patients with COVID-19 across sites in the European Union, South America and other regions was successfully
completed and showed a relative reduction in 28-day all-cause mortality of 23.9% (p = 0.094), which was the primary endpoint. In
the study, Patients were randomized 1:1 to receive either vilobelimab or placebo; most patients received standard of care (97%
glucocorticosteroids, 98% anti-thrombotic agents). At the recommendation of regulatory authorities during the course of the trial,
we changed the statistical analysis method for the primary endpoint. The original protocol specified a non-stratified Cox
regression analysis, and the final statistical analysis plan specified a site-stratified analysis intended to account for the site
stratification of patients at randomization. The original protocol specified analysis would have resulted in a p-value of 0.027
(statistically significant), whereas the site-stratified Cox regression led to a p-value of 0.094 (not statistically significant).
Additionally, pre-specified logistic regression analyses of the 28-day mortality resulted in p-values of <0.05 for three out of the
four pre-specified analyses. Furthermore, a pre-specified analysis of patients from Western European countries (n=209) showed a
relative reduction in 28-day all-cause mortality of 43% (vilobelimab 21.2% versus placebo 37.2%, hazard ratio: 0.5, p=0.014),
suggesting an improvement in mortality in line with the reported Phase 2 data of the PANAMO Phase 2/3 study.
-69-
Regulatory activities
for vilobelimab for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients.
In April 2023, the FDA issued an EUA for GOHIBIC (vilobelimab) for the treatment of COVID-19 in hospitalized adults
when initiated within 48 hours of receiving IMV or ECMO.
In January 2025, the EC granted marketing authorization under exceptional circumstances for GOHIBIC (vilobelimab) for the
treatment of adult patients with SARS-CoV-2-induced ARDS who are receiving systemic corticosteroids as part of standard of
care and receiving IMV (with or without ECMO).
To achieve full commercial scale and successfully reach the full market potential of the product in the future, we also aspire
to obtain full market approval for GOHIBIC (vilobelimab) in the United States. We are therefore planning the submission of the
BLA for full approval of GOHIBIC (vilobelimab) in our COVID-19 indication and potentially, in the future, in similar indications
that may apply to other virally induced acute respiratory distress conditions. In October 2023, in furtherance of our continued
efforts to obtain a BLA, we had an encouraging Type C meeting with the FDA. In that meeting, the FDA indicated their
willingness to collaborate with us in identifying a development pathway towards a BLA for a broader ARDS label. To achieve
this, we would need to conduct an additional well-controlled and adequately powered study in a broader ARDS setting that
demonstrates the safety and efficacy of vilobelimab. During the meeting, we discussed different options for such a trial, including
potential trial designs, patient population and trial power aspects. In June 2024, GOHIBIC (vilobelimab) was selected for a
Biomedical Advanced Research Development Authority, or BARDA, sponsored clinical trial to evaluate novel host-directed
therapeutics for ARDS.
Commercialization
In June 2023, we began the commercialization of GOHIBIC (vilobelimab) in the United States for the treatment of COVID-
19 in hospitalized adults when initiated within 48 hours of receiving IMV or ECMO under the granted EUA. We entered into
agreements with certain subsidiaries of Cencora Inc., or Cencora (formerly known as AmerisourceBergen Corp.) to act as our U.S.
distributor and to make GOHIBIC (vilobelimab) available for order by U.S. hospital customers under the EUA. Cencora provides
cold storage, cold-chain distribution services, inventory management and secondary labeling/packaging, among other services. To
support our commercial efforts, we employ experts with relevant experience in the commercialization of medical products in the
hospital market, including in the areas of sales, sales operations, marketing, market access, distribution, medical affairs and others
in the United States. In addition, we are adapting and integrating our infrastructure, including IT systems, supply chain, financial
reporting systems and inventory management systems both, internally and with the assistance of external service providers. We
continue to refine our commercial strategic plan, preparing relevant promotional and medical education materials to target
healthcare providers and other stakeholders, and continue refining our medical affairs strategy to increase awareness of the EUA
among the medical community, while continuing our sales efforts.
Outside of the United States, we intend to seek partners to support our commercialization efforts, including partnerships in
select regions. In Europe, we are currently considering commercial distribution partnerships for GOHIBIC and do not expect to
establish internal infrastructure to support our commercialization beyond the minimally required investments to uphold our
regulatory approval.
Vilobelimab for additional indications
In addition to PG, severe COVID-19 / ARDS and previous studies in HS, AAV and cSCC, we continue to explore the
possibility of advancing the clinical development of vilobelimab in additional inflammatory and complement-mediated disease
indications for which a good pre-clinical or clinical proof of concept exists and where C5a has been demonstrated as a critical
disease promoting factor or where similar mechanisms, such as neutrophil-driven systemic diseases affecting the skin and or other
organs, have been identified.
-70-
INF904 as orally administered low molecular weight molecule for inhibition of C5aR
Inhibition of the C5a/C5aR axis provides strong anti-inflammatory effects in a variety of diseases. Blockade of C5a using
highly specific antibodies, such as vilobelimab, may offer a fast, effective, and safe way to control C5a-induced inflammation. In
addition to this approach, inhibition of C5aR by oral small molecules may provide the ease of administration required for effective
long-term treatment for more chronic inflammatory diseases. To expand the breadth of our anti-C5a/C5aR technologies, we are
also developing INF904, an oral, small molecule drug candidate that targets the C5aR receptor. C5aR, a G-protein-coupled-
receptor expressed primarily by granulocytes, mediates the pathophysiological effects of C5a. In INF904, we discovered a small
molecule C5aR inhibitor that in pre-clinical studies has shown potential for superior characteristics to the only approved C5aR
inhibitor, avacopan. INF904 has provided higher plasma exposure in animals, including non-human primates, and improved
inhibitory activity in a hamster neutropenia model compared to avacopan. Furthermore, in contrast to avacopan, in vitro
experiments showed INF904 has substantially less inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play an
important role in the metabolism of a variety of drugs, including glucocorticoids. No obvious toxicological findings, even in the
highest dose groups tested in required GLP toxicity analyses, were identified. INF904 demonstrated potential for anti-
inflammatory therapeutic effects in several preclinical disease models.
Most IND-enabling studies, including certain GLP-toxicological studies, have been completed, and we conducted a Phase 1
single and multiple ascending dose clinical study from November of 2022 to January 2024.
In September 2023, we announced the topline results from the single ascending dose, or SAD part of a randomized, double-
blind, placebo-controlled Phase 1 trial with INF904. The SAD part of the Phase 1 first-in-human trial enrolled 62 healthy
volunteers within six different dosing groups from 3 mg to 240 mg who were randomly assigned to receive INF904 or a placebo.
Different drug concentrations were tested for the 60 mg dosing group. The main objectives were to assess safety and tolerability
of single ascending doses under fasting conditions. Secondary endpoints included several pharmacokinetic, or PK, parameters,
and the effect of INF904 on C5a-induced neutrophil activation in blood samples from treated volunteer’s ex vivo also was
explored.
The results show that INF904 was well tolerated in treated patients and resulted in no safety signals of concern in single doses
ranging from 3 mg to 240 mg. The overall percentage of adverse events (AEs) was lower in the INF904 treated patients compared
to the placebo group, and no serious or severe AEs were observed at any dosing level. No related AEs were reported in
conjunction with INF904 dosing.
Analysis of INF904 PK in subject plasma samples revealed sustained exposure to INF904 with six hours to maximum
concentration, or tmax. INF904 plasma levels were dose proportional for systemic exposure (AUClast) and nearly dose
proportional for maximum concentration (Cmax) over the dose range used in the study. With the 30 mg dose, INF904 reached a
Cmax of 289 ng/ml with an AUClast of 5197 h.ng/ml, which are approximately 3-fold and 10-fold, respectively, higher than the
published Phase 1 data from the only marketed comparator, avacopan.
Single doses of 30 mg or higher of INF904 achieved ≥90% blocking of C5a induced up-regulation of the activation marker
CD11b on neutrophils in plasma samples from subject’s ex vivo at 24 hours post dosing. This inhibition was achieved when 12.6
nM recombinant C5a was added as stimulus in this assay, a C5a concentration which can be observed in patients with severe
inflammatory conditions such as the immuno-dermatological disease, HS, or during life-threatening inflammation (e.g., in
critically ill COVID-19 patients or septic patients). Thus, INF904 inhibition of C5a-induced neutrophil activation in human
plasma achieved the set goal for effective C5aR control at disease relevant C5a levels.
In January 2024, we announced topline results from the multiple ascending dose, or MAD, part a randomized, double-blind,
placebo-controlled Phase 1 trial for INF904. The PK and pharmacodynamic, or PD parameters confirm the favorable data we
observed during the SAD part of the study, which provides support for the best-in-class potential of INF904. INF904 was well
tolerated and there were no adverse safety events of concern after repeated dosing in participants over the entire tested dose range.
In the MAD part of the randomized, double-blind, placebo-controlled Phase 1 trial, 24 participants received multiple doses of
INF904 for 14 days of either 30 mg once per day, or QD, 30 mg twice per day, or BID, or 90 mg BID. The study’s primary
objective was to evaluate the safety and tolerability of repeated dosing. Several PK parameters were analyzed as secondary
endpoints, and the effect of the dosing scheme on C5a-induced neutrophil activation in blood samples from the participants was
also explored in an ex vivo assay.
-71-
The safety analysis of INF904 in the MAD part of the Phase 1 study demonstrated that it was well tolerated in participants
over the entire dose range and resulted in no safety signals of concern. The overall percentage of AEs in INF904 treated
participants was 77.8%, which was lower than the 83.3% observed in the placebo group. There were no serious or severe AEs
observed at any dosing level.
Analysis of the PK profile showed that potential target AUC0-12h, Cmax, and trough values were achieved rapidly within 14
days of 30 mg BID dosing. INF904 exposure further increased proportionally with dosing up to 90 mg BID. These results were
demonstrated even when participants ingested the drug in a fasted state, suggesting that food is not required to achieve potentially
therapeutic drug levels.
Analysis of the PD profile showed that the blocking activity of C5a-induced neutrophil activation by INF904 reached equal to
or above 90% over the 14-day dosing period for all tested doses in an ex vivo challenge assay where physiological and disease-
relevant levels of C5a were added to blood samples provided by the trial participants.
We are currently conducting additional required pre-clinical studies, including long-term chronic toxicology studies, to enable
longer-term dosing of INF904 for chronic inflammatory diseases. In December 2024, we announced the first patient dosing of a
Phase 2a basket study in CSU and HS, utilizing a commercially viable drug formulation. Data from this study are expected in the
summer of 2025, with a goal of informing the planning and design of a larger, longer-term Phase 2b study by year-end 2025.
IFX002 as follow-on anti-C5a monoclonal antibody product candidate
To expand the breadth of our anti-C5a technologies, we are also developing IFX002 for the treatment of chronic
inflammatory indications. IFX002 is an advancement of the anti-C5a technology. It is a highly potent anti-C5a antibody with a
higher humanization grade and altered pharmacokinetic properties and is currently in pre-clinical development.
IFX002 is an injectable product candidate with a prolonged blood plasma half-life than vilobelimab, making it potentially
more amenable for the treatment of chronic inflammatory indications with less severe flares or closer to the onset of the disease.
IFX002 shares the same mechanism of action as vilobelimab in its potential to block C5a with high specificity but is designed for
a dosing regimen that may be more suitable for chronic therapy. Furthermore, IFX002 binds to the same epitope of free C5a as
vilobelimab with comparable selectivity. The pre-clinical development of IFX002 was partly supported by a grant from the
German government. IFX002 will keep the performance relevant properties to fully block C5a-induced biological effects while
leaving MAC formation intact. We believe that IFX002 holds the potential to treat various chronic inflammatory diseases and
could benefit from a dosing regimen more suitable for chronic therapy. We also consider IFX002 to be a life-cycle management
product to vilobelimab, given the long remaining patent life of IFX002.
Pipeline
We intend to leverage our expertise within the complement field as well as our proprietary technologies to sustain our lead in
the anti-C5a/anti-C5aR space by developing a diverse pipeline focused on complement-mediated autoimmune and inflammatory
diseases with high unmet need. Rights to our proprietary anti-C5a/anti-C5aR technologies are currently expected to extend at least
up to 2041 on the basis of our latest patents granted.
-72-
The figure below summarizes key information about and the development status of our current pipeline of product candidates:
Our strategy
Our goal is to maintain and further advance our leadership position within the anti-C5a/anti-C5aR complement space,
delivering first-in-class autoimmune and anti-inflammatory therapies to market. To achieve this goal, we expect to execute the
strategies set forth below.
●
Advance vilobelimab in PG. Based on the positively concluded open label Phase 2a study, we are conducting a Phase 3
pivotal clinical program after having received advice related to the clinical trial design from the FDA.
●
Proceed with clinical development of INF904. We have conducted a single and multiple ascending dose study of our
C5aR antagonist INF904 and currently are conducting a Phase 2a trial and required non-clinical studies to proceed to
Phase 2 trials in patients.
●
Continue to optimize the manufacturing process for vilobelimab. We established a fully validated manufacturing process
for vilobelimab with a reputable international CDMO, with the goal of fulfilling and upholding the quality criteria to gain
and maintain regulatory approval for such process. We have established the final manufacturing of the finished
pharmaceutical product (i.e., “fill and finish”) in Germany and are considering the transfer of the drug substance
manufacturing process or other steps of the manufacturing process from China to Germany or to other countries.
●
Assess development options for vilobelimab in further indications beyond PG. Following our decision to halt
development programs in HS, AAV and cSCC due to the resources required to conduct these on our own, we are
nevertheless continuously evaluating options regarding the development of vilobelimab in indications beyond PG. Based
on the logistical and financial effort necessary to successfully complete pivotal Phase 3 development programs in each
indication, such options include potential collaborations with a pharmaceutical partner.
●
Pursue the further development of IFX002 to get prepared for potential clinical development. We are developing IFX002,
a fully humanized antibody version of vilobelimab, as an injectable with a longer half-life than vilobelimab, making it
suitable for chronic inflammatory indications with less severe flares or closer to the onset of disease. Based on a patent
lifetime potentially beyond 2040, we see this project as life-cycle management for vilobelimab and are conducting pre-
clinical development work to get closer to the possible start of clinical development.
●
Solidify and continue to expand the breadth of our leadership position in the anti-C5a/anti-C5aR space by leveraging the
full potential of our proprietary technologies and expertise in complement and inflammation research. We intend to
continue to discover and develop treatments that have the potential to address a broad spectrum of complement-mediated
or immune response mediated indications with significant unmet need, either internally or in collaboration with a partner.
To accomplish this, we continue to supplement our research and development activities with our discovery unit in Ann
Arbor, Michigan and we are further building out our intellectual property portfolio and our business development
capabilities.
-73-
●
Commercialize GOHIBIC (vilobelimab) either independently or in collaboration with pharmaceutical partners. We are
commercializing GOHIBIC (vilobelimab) for severe COVID-19 in the United States independently, and assessing the
options to commercialize our product in Europe in collaboration with potential partners. We have employed a targeted
commercial infrastructure in the United States to promote access to vilobelimab through hospitals that treat patients
suffering from the disease within core markets in United States. Outside of the United States and Europe, we have
received approval in Europe and plan to commercialize the product in collaboration with partners. For other indications,
we intend to develop and commercialize vilobelimab either independently or through collaborations with other parties.
●
Explore the possibility to expand the applications of vilobelimab in the area of ARDS. We intend to explore the
possibility of expanding the label into other critical care indications for which we have generated pre-clinical data in the
past. Most notably, we are considering the utility of additional studies such as the Phase 2 BARDA study in broader
ARDS, or studies with or commercial partners, to expand the label into a product for virally induced ARDS.
Our intellectual property
We aim to protect our product candidates and other commercially important proprietary anti-C5a and C5aR technologies by
seeking and maintaining U.S. and foreign patents that are intended to cover our product candidates and compositions, and their
methods of use, the methods used to manufacture them, the related therapeutic targets and associated methods of treatment and
any other inventions that are commercially important to our business. We also rely on trade secrets and know-how and other
intellectual property rights to protect aspects of our business that are not amenable to, or that we do not consider appropriate for,
patent protection. Furthermore, we aim to protect our trademarks, service marks, and trade names by seeking and maintaining U.S.
and foreign trademark registrations. Our success will depend significantly on our ability to obtain and maintain such patent and
other proprietary protection, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate our
business without infringing, misappropriating or otherwise violating any patents or other intellectual property, including any
proprietary rights of third parties. See the section titled “ITEM 3. KEY INFORMATION — D. Risk factors—Risks related to our
intellectual property” for additional information.
As of December 31, 2024, we owned 13 issued U.S. patents and three pending U.S. non-provisional patent applications, 46
issued foreign patents, including four granted European patents validated in 88 countries and three granted Eurasian patent
validated in 25 countries, as well as 41 foreign patent applications, including six European patent applications and three Eurasian
patent applications covering C5a and C5aR inhibitors and associated methods of use.
Our patent portfolio relating to vilobelimab, IFX002 and INF904, as of December 31, 2024, is summarized below.
As of December 31, 2024, we owned four issued U.S. patents covering the composition of matter of antibodies that block C5a
and their use in blocking C5a-induced biological effects in patients with diseases that involve acute or chronic inflammation,
which would include in their scope HS and AAV. In addition, we owned 20 issued foreign patents, including two granted
European patents validated in 74 countries and one Eurasian patent validated in nine countries, two pending foreign patent
applications, including one pending European patent application, covering the composition of matter of antibodies that block C5a
and their use in the treatment of various diseases that involve acute or chronic inflammation, which would include in their scope
HS and AAV, and, depending on the jurisdiction of the applicable patent, specifically cover the use of such antibodies in treating
diseases such as ischemia and reperfusion related injuries, acute lung injury and pneumonia.
The issued U.S. and foreign patents are expected to expire in 2030, excluding any additional term for patent term adjustments
or patent term extensions. If granted, the pending U.S. and foreign patents applications would be expected to expire in 2030,
excluding any additional term for patent term adjustments or patent term extensions.
-74-
As of December 31, 2024, we owned two granted U.S. patents and four granted foreign patents, including one European
patent validated in three countries and one foreign patent application covering the use of certain binding moieties, such as
antibodies, that inhibit C5a for the treatment of viral pneumonia.
If issued, the U.S. and foreign patents are expected to expire in 2035, excluding any additional term for patent term
adjustments or patent term extension.
As of December 31, 2024, we owned four granted U.S. patents, one pending U.S. non-provisional patent application, 16
granted foreign patents, including one European patent validated in 11 countries and one granted Eurasian patent validated in eight
countries, nine pending foreign patent applications, including three pending European patent applications covering the use of an
inhibitor of C5a activity, for example, vilobelimab, for treating HS and other cutaneous, neutrophilic inflammatory diseases.
The issued U.S. and foreign patents are expected to expire in 2038, excluding any additional term for patent term adjustments
or patent term extensions.
As of December 31, 2024, we owned one U.S. patent application and seven foreign patent applications including one
European patent application covering an improved C5a specific antibody.
If issued, the U.S. and foreign patents are expected to expire in 2041, excluding any additional term for patent term
adjustments or patent term extensions.
As of December 31, 2024, we owned one granted foreign patent, one pending U.S. non-provisional patent application and
nine foreign patent applications including one European and one Eurasian patent application covering the use of inhibitor of C5a
activity, for example vilobelimab, for treating Corona viral diseases.
If issued, the U.S. and foreign patents based on the application under the PCT are expected to expire in 2040, excluding any
additional term for patent term adjustments or patent term extensions.
As of December 31, 2024, we owned two granted U.S. patents, one pending U.S. non-provisional patent application, five
granted foreign patents, including one granted Eurasian patent validated in eight countries, one pending U.S. non-provisional
patent application, and 14 foreign patent applications including one European patent application covering inhibitors of C5aR.
The issued U.S. and foreign patents are expected to expire in 2040, excluding any additional term for patent term adjustments
or patent term extensions.
As of December 31, 2024, we owned one issued U.S. patent application and one international patent application covering the
use of an inhibitor of C5a activity and standard of care inhibitors in the treatment of infectious pneumonia and infectious ARDS.
The issued U.S. and foreign patents are expected to expire in 2043, excluding any additional term for patent term adjustments
or patent term extensions.
As of December 31, 2024, we owned two European patent applications and one international patent application covering the
use of inhibitors of C5aR for the treatment of various diseases.
The U.S. and foreign patents are expected to expire in 2043, excluding any additional term for patent term adjustments or
patent term extensions.
As of December 31, 2024, we owned one trademark registration application for two trademarks, “GOHIBIC” and “Vilwaysi”
in the United States and one international trademark registration designating the United States and covering 10 further registered
and one pending 29 foreign countries, four foreign trademark applications and 12 foreign registered trademarks including 23
European trademark registrations covering 54 European countries and seven foreign trademark applications for goods and services
in the field of pharmaceutical products, among others.
As of December 31, 2024, for “Vilwaysi”, we owned one International trademark registration designating the United States
and covering 10 further registered and one pending foreign countries, one foreign trademark application and five foreign
registered trademarks including one European trademark registration covering 27 European countries for goods and services in the
field of pharmaceutical products, among others.
-75-
As of December 31, 2024, we owned two trademark registrations for “InflaRx” in the United States for goods and services in
the field of pharmaceutical preparations for the treatment of inflammatory, inflammatory-related, oncological and neurological
diseases. Outside the United States, as of December 31, 2023, we owned trademark registrations for “InflaRx” in 30 countries.
UPC
Twenty-four member states of the 27 member EU states, with the exception of Poland, Spain and Croatia have acceded to the
Agreement on a Unified Patent Court, or UPCA, which provides for a Unitary Patent, or UP, and led to the establishment of a
Unified Patent Court, UPC. The UPCA has entered into force on June, 1 2023. 17 out of the 24 member states have fully ratified
the UPCA when it entered into force and participated in the UPCA from the start. Romania was the 18th state that ratified the
UPCA on May 31, 2024. The remaining six EU member states are expected to join within the next years. Since the start of the
UPCA, a conventional European patent can be enforced centrally at the UPC but may also face central revocation proceedings in
the UPC, unless it is opted-out of the jurisdiction of the new court system.
The UPC has exclusive competence in respect of civil litigation on matters relating to European patents, Unitary Patents,
supplementary protection certificates issued for a product covered by such patents and European patent applications (for details
see Article 32 of the UPCA). Therefore, the UPC is not only competent to hear cases concerning UPs but also cases concerning
traditional European patent applications and patents, or European patent(s), unless opted-out. The decision of the UPC in one
country is binding in all other states participating in the UPCA. The decision, however, does not have any legally binding effect in
EU member states not participating in the UPCA as well as in EPC contracting states which are not EU member states (e.g. Great
Britain and Switzerland) and, therefore, are not eligible to participate in the new system.
It is generally expected that the UPC will be patent holder friendly both when it comes to assessment of validity of granted
patents and infringement and that it may be beneficial for a patent holder to enforce and defend its patent at the UPC rather than at
the EPO and/or national nullity court or civil court. Presently, however, there is no case law of the UPC that would allow a
prediction of how the UPC may apply the patentability criteria when deciding on a central revocation action or a revocation
counterclaim or how it will construe a claim in a central infringement proceeding. In view of these uncertainties, which are
immanent to any new system on one hand, and the well-established practice of oppositions at the EPO as well as national
invalidity and infringement proceedings on the other, we consider it a cautious and recommendable approach to opt-out all
European patent applications and granted European patents from the UPC and to follow the case law of the UPC to determine the
pros-and-cons of the UPC system. In case that the UPC appears to come to more favorable decision on validity and/or
infringement than the EPO and national courts, it should be reconsidered to opt-in for one or more European patent or patent
applications that have been previously opted out.
Our collaboration agreements
Co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd. (as successor to Beijing Defengrei
Biotechnology Co. Ltd, or BDB)
In December 2015, we entered into a co-development agreement, or the Co-Development Agreement, with Beijing Defengrei
Biotechnology Co. Ltd., or BDB, for the use of the vilobelimab manufacturing cell line in BDB’s development of drug candidates
for sale in China. Pursuant to the agreement, we granted BDB an exclusive, non-transferable license to use the vilobelimab cell
line and related intellectual property solely to develop and commercialize in China BDB’s drug candidates BDB-001 and BDB-
002, as well as molecules that bind or interact with certain specified targets, or target-binding molecules.
Pursuant to the agreement, we are entitled to receive mid-single-digit percentage royalties on net sales of BDB’s products
containing BDB-001 or BDB-002. We retain the right to develop and manufacture vilobelimab and IFX002 in China solely for the
purpose of commercializing products outside of China and to use the vilobelimab cell line and IFX002 cell line in China for non-
commercial purposes. To the extent that we are granted regulatory approval outside of China for commercialization of a product
using vilobelimab or IFX002 for an indication, and BDB does not pursue regulatory approval for BDB-001 or BDB-002 in the
same or a substantially similar indication in China, by providing written notice to BDB, we may elect to pursue regulatory
approval to commercialize such products in the relevant indication in China. Should we exercise such right, we would be required
to pay BDB mid-single-digit percentage royalties on our net sales of such products.
-76-
Pursuant to the Co-Development Agreement, BDB has the right to use the vilobelimab cell line to manufacture an anti-C5a
antibody, namely BDB-001. BDB-001 may only be commercialized in China (PRC) by BDB, and InflaRx is not directly involved
in the BDB-001 development, which remains the sole responsibility of BDB. Pursuant to the Co-Development Agreement,
InflaRx owns all global commercial rights outside China to any and all discoveries derived from the development of BDB-001. To
support BDB’s development of BDB-001, in 2020, InflaRx allowed BDB to conduct clinical studies with BDB-001 in Spain,
India, Indonesia and Bangladesh. However, InflaRx remains the sole owner of all commercial rights to BDB-001 outside of
China, including in countries in which BDB is conducting clinical trials. BDB has no rights to seek marketing authorization or to
commercially exploit BDB-001 outside of China. Vilobelimab is not the product being tested in clinical trials by BDB in China.
Rather, it is BDB’s own antibody called BDB-001.
In addition, we reserved the right to commercialize products containing BDB-001 and BDB-002 outside of China in
indications for which we elect not to commercialize vilobelimab or IFX002. To the extent that we exercise this right, we would be
required to pay BDB low single-digit percentage royalties on our net sales of such products.
BDB must notify us without undue delay of tests it conducts on target-binding molecules. If any such test results in binding or
interaction with targets in a satisfactory manner to both BDB and us, BDB must notify us of such results and may, within a six-
month period following such notice, exercise an option to commence commercializing the successfully tested target-binding
molecules in China. To the extent that BDB exercises such option, BDB would be required to pay us low single-digit percentage
royalties on net sales of products containing such target-binding molecules. BDB also grants us the right to exploit any target-
binding molecules outside of China or, to the extent that BDB does not pursue regulatory approval in the same or a substantially
similar indication, in China. To the extent that we exercise such rights, we would be required to pay BDB low to mid single-digit
percentage royalties on our net sales of such products.
In November 2021, we entered into a second addendum to the Co-Development Agreement with BDB and Staidson (Beijing)
BioPharmaceuticals Co., Ltd., or Staidson. Under the second addendum, BDB, being a wholly-owned affiliate of Staidson,
assigned the Co-Development Agreement to Staidson together with all rights and obligations thereunder.
In December 2022, we amended our existing co-development agreement with Staidson to support Staidson in its regulatory
approval efforts for its proprietary drug candidate BDB-001 for the treatment of COVID-19 in China. Pursuant to the amendment,
we will receive increased royalties of 10% on net sales of BDB-001 for the treatment of COVID-19 in China. We granted
Staidson an exclusive license for use in China to certain of our clinical, manufacturing and regulatory data regarding vilobelimab
in order to support and facilitate the regulatory filing for BDB-001 for the treatment of severely ill COVID-19 patients with the
Chinese National Medical Products Administration, or NMPA. Under the existing Co-Development Agreement, BDB-001 is
being developed by Staidson for the treatment of severe COVID-19 and other inflammatory diseases in China. The agreement
continues to be in force unless earlier terminated. The agreement may be terminated upon the mutual agreement of the parties, or
by one party upon a breach by the other party that is not cured within 30 days after receiving notice of such breach. In addition,
either party may terminate the agreement if the other party challenges the terminating party’s ownership of any intellectual
property licensed to the non-terminating party under the agreement or undergoes certain bankruptcy or insolvency events.
Concomitantly to amending the Co-Development Agreement, in December 2022 we also entered into a share purchase
agreement with Staidson Hong Kong Investment Company Limited, an affiliate of Staidson and a limited liability company
organized under the law of Hong Kong, pursuant to which Staidson Hong Kong Investment Company Limited purchased ordinary
shares from us for an aggregate amount of $2.5 million (€2.3 million) at a price of $5.00 per share, resulting in the sale of 500,000
shares. The share purchase agreement also includes an option pursuant to which Staidson Hong Kong Investment Company
Limited may purchase additional ordinary shares, at our discretion, for an aggregate amount of an additional $7.5 million. The
option for such subsequent purchase will expire on the twelve-month anniversary of Staidson receiving regulatory approval for
BDB-001 in China. Such subsequent investment would be made at the greater of $5.00 per share or at a 20% premium to the
weighted average share price over the 15 trading days prior to the closing date of such subsequent investment.
-77-
Cell line sales agreement with Catalent Pharma Solutions LLC
On March 18, 2010 we signed a cell line sales agreement with Catalent Pharma Solutions, LLC, New Jersey, USA in which
InflaRx accepted a future milestone payment in the amount of $1m, independent of any transfer of the cell line in case of the
receipt of an marketing approval of vilobelimab in any major market.
Clinical trial collaboration and supply agreement with Merck & Co., Inc.
On March 20, 2020, we entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc. (known as
MSD outside the United States and Canada) to evaluate the combination of vilobelimab and Merck’s anti-PD-1 therapy,
KEYTRUDA®1 (pembrolizumab) in patients with cSCC. Under the terms of the agreement, we conducted a Phase 2 clinical
study with two vilobelimab arms, including one with pembrolizumab. In November 2023, we announced the development stop of
vilobelimab in cSCC to prioritize other programs. The trial has been finalized in 2024, all the patients recruited received therapy
according to the protocol.
Clinical Trials Collaboration Agreement with the U.S. Department of Health and Human Services, Administration for
Strategic Preparedness and Response, BARDA and PPD Development, L.P., or PPD
In June 2024, GOHIBIC (vilobelimab) was selected for the first BARDA-sponsored clinical trial to evaluate novel host-
directed therapeutics for ARDS. The Company, BARDA and PPD Development L.P. executed the clinical trial collaboration
agreement, according to which we will supply the amounts of investigational drug necessary to conduct the study. Vilobelimab,
which we will supply from our available stock under the terms of the agreement, will be one of three host-directed investigational
drugs assessed in this study, with the safety and efficacy of each investigational drug to be studied in its own patient cohort and
compared against placebo. Each cohort is expected to enroll 200 patients (100 on investigational drug and 100 on placebo), with
both arms in each cohort including standard of care as background therapy. The Company will receive certain clinical data
resulting from the study.
Sales and marketing
In June 2023, we began the commercialization of GOHIBIC (vilobelimab) in the United States for the treatment of COVID-
19 in hospitalized adults when initiated within 48 hours of receiving IMV or ECMO. In connection with the start of the
commercialization, we entered into agreements with certain subsidiaries of Cencora to act as our U.S. distributor and make
GOHIBIC (vilobelimab) available for order by U.S. hospital customers under the EUA. Cencora provides cold storage, cold-chain
distribution services, inventory management and secondary labeling/packaging, among other services.
To support our commercial efforts, we have hired and continue to utilize U.S. experts with relevant experience in the
commercialization of medical products in the hospital market, including in the areas of sales, sales operations, marketing, market
access, distribution, medical affairs and others.
We continue to refine our commercial strategic plan, preparing relevant promotional and medical education materials to target
healthcare providers and other stakeholders, and continue refining our medical affairs strategy to increase awareness of the EUA
among the medical community, while continuing our sales efforts. In Europe, InflaRx intends to commercialize and distribute
GOHIBIC (vilobelimab) through a partnership.
In 2024, we recognized revenues in the amount of €0.2 million from product sales. Revenues reported are sales to end
customers (hospitals) in the United States.
During the twelve months ended December 31, 2024 the Group incurred €6.8 million of sales and marketing expenses. These
expenses are mainly composed of €1.8 million in personnel costs, €1.6 million in marketing costs and €2.1 million in external
services for distribution of GOHIBIC (vilobelimab. The Group started with its commercialization activities when the EUA was
granted in April 2023. Prior to that, no sales and marketing expenses had been incurred.
-78-
We also intend to independently pursue the commercialization of vilobelimab for PG in the United States and Europe, if and
when approved by the applicable regulators, by employing a targeted commercial infrastructure to promote access to vilobelimab
through centers-of-excellence that treat PG in these core markets. We believe that such an organization will be able to address the
community of physicians who are key specialists in treating the patient populations for which vilobelimab and any other product
candidates are being developed. The responsibilities of the organization would include developing educational initiatives with
respect to approved products and establishing relationships with key specialists in PG and any other relevant fields of medicine.
Options to collaborate with larger pharmaceutical organizations with established commercial infrastructures will also be
evaluated.
We might also consider pursuing the commercialization of vilobelimab in other indications or commercialization of our other
development products independently. However, we are also considering potential partnerships with larger companies that have a
more established infrastructure and greater financial resources in different areas, including in sales and marketing.
Manufacturing
We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our
product candidates. We intend to rely on existing third-party contract manufacturers to produce our products and intend to recruit
additional personnel with experience to manage the third-party contract manufacturers producing our product candidates and other
product candidates or products that we may develop in the future. In addition, we engaged additional third-party manufacturers in
Germany, the United States and other countries for activities related to potential sales, e.g. packaging and labeling of any of our
approved products in the United States and elsewhere. We hold a manufacturing and importing license and participate in the drug
product release procedure for vilobelimab by running a key immunological release assay in-house, allowing us to release only
drug product batches that demonstrate the necessary, pre-specified high biological blocking activity. Thus, we are responsible for
overseeing the entire manufacturing process and we release final fill-finished drug product with our qualified person.
Competition
The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong
emphasis on proprietary products. While we believe that our technologies, knowledge, experience and scientific resources provide
us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical,
specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private
research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies
and new therapies that may become available in the future.
Competition in PG
There are currently no drugs approved for the treatment of PG in major markets. The only locally approved treatment is
adalimumab, which has been approved in Japan but in no other country on the basis of a small, locally conducted clinical trial.
However, due to the high medical need associated with the disease, certain drugs are used in regular medical practice as treatment
attempts for affected patients. These include certain orally administered drugs such as immunosuppressants, including
cyclosporine or corticosteroids or antibiotics such as dapsone. In addition, topically applied tacrolimus is used in certain cases.
Lastly intravenously administered TNF-alpha inhibitors such as infliximab or adalimumab or other biological drugs are also used,
despite the fact that no formal regulatory approvals are in place.
As of the date hereof, to our knowledge, other treatments in active clinical development include:
●
Spesolimab, an intravenously administered anti-IL-36R monoclonal antibody currently being clinically tested in Phase 3
●
Bactritinib, an orally administered JAK1/JAK2 inhibitor, currently in Phase 2 clinical trials
●
Canakinumab, a subcutaneously administered anti-IL-1beta antibody, currently being tested in Phase 2 clinical trials in
patients suffering from pyogenic arthritis, pyoderma gangreanosum and acne, or PAPA syndrome, which represents a
specific sub-population of PG patients
●
Deucravacitinib, an orally administered JAK2 inhibitor, currently being tested in an open label, exploratory Phase 1
clinical trial
-79-
Competition in the treatment of critically ill, invasively mechanically ventilated COVID-19 patients
For treatment of critically ill, invasively mechanically ventilated COVID-19 patients, vilobelimab faces competition from
currently used or approved therapeutics such as corticosteroids, the interleukin-1, or IL-1, inhibitor anakinra, IL-6 inhibitors such
as tocilizumab, JAK-inhibitors such as baricitinib and anti-thrombotic therapy. Given the high medical need for effective
treatments during the times of the COVID-19 pandemic, many different therapeutic entities and targets have been assessed for the
treatment of this patient population. While the performance of clinical trials in a particular patient population is the prerequisite to
be able to gain regulatory approval for the treatment of that particular patient population, several clinical trials have been
conducted in other patient populations (e.g., hospitalized patients as opposed to our targeted sub-group of critically ill, invasively
mechanically ventilated patients) and results of these trials have partly been extrapolated into our targeted population. Therefore,
we believe that competition will mainly be faced by products developed for the intended use population.
Competition in HS
The following systemically administered products are currently approved and marketed to treat moderate to severe HS
patients in the United States and Europe:
●
Adalimumab, a subcutaneously administered anti-TNF-alpha monoclonal antibody
●
Secukinumab, a subcutaneously administered anti-IL-17 alpha monoclonal antibody
●
Bimekizumab, a subcutaneously administered anti-IL-17A/F, monoclonal antibody
If we develop and receive approval for INF904 in HS, we would face competition from currently approved therapeutics such
as adalimumab, secukinumab and bimekizumab, from topical therapies, including clindamycin, resorcinol and others, from
intralesionally applied corticosteroids, from orally administered antibiotics such as tetracycline, clindamycin, rifampicin,
metronidazole, cephalosporin, dapsone and others. In addition, a range of surgical procedures, laser and radiotherapy procedures
are being investigated and used for the treatment of HS. Finally, we could face competition from additional systemically
administered product candidates with different mechanisms of action currently under development that might receive approvals
for HS before us:
●
Povorcitinib, an orally administered JAK1 inhibitor, currently in Phase 3 clinical development
●
Sonelokimab, a subcutaneously administered anti-IL-17A, IL-17F nanobody, currently in Phase 3 clinical development
●
Izokibep, a subcutaneously administered small therapeutic protein inhibitor of IL-17A, currently in Phase 3 clinical
development, one Phase 3 trial completed
●
Udapacitinib, an orally administered JAK inhibitor, currently in Phase 3 clinical development
●
Spesolimab, an intravenously administered anti-IL-36R antibody, currently in Phase 3 clinical development
●
Lutikizumab, a subcutaneously administered anti-IL-1 alpha/beta antibody, currently in Phase 3 clinical development
●
SAR442970, a subcutaneously administered anti-TNF-OX40L nanobody, in Phase 2 clinical development
●
SAR444656, an orally administered IRAK degrader, in Phase 2 clinical development
●
Amlitelimab (SAR445229), a subcutaneously administered anti-OX40L antibody, in Phase 2 clinical development
●
Iscalimab, a subcutaneously administered anti-CD40 antibody, in Phase 2 clinical development
●
LYS006, an orally administered LTA4H inhibitor, in Phase 2 clinical development
-80-
●
MAS825, an orally administered TIM3 inhibitor, in Phase 2 clinical development
●
Remibrutinib, an orally administered BTK inhibitor, in Phase 2 clinical development
●
Ianalumab, a subcutaneously administered anti-BAFF-R antibody, in Phase 2 clinical development
●
Eltrekibart, a subcutaneously administered anti-CXC antibody, in Phase 2 clinical development
●
AVTX-009, a subcutaneously administered anti-IL-1beta antibody, in Phase 2 clinical development
●
Ruxolitinib cream, a topically applied JAK1/JAK2 inhibitor in Phase 2 clinical development
●
Orismilast, an orally administered PDE-4 inhibitor, in Phase 2 clinical development
●
Tofacitinib, an orally administered JAK inhibitor, in an ongoing Phase 2 studies in patients with Down Syndrome
Competition in Chronic Spontaneous Urticaria (CSU)
As of today, only approved drugs for Chronic Spontaneous Urticaria are:
●
Omalizumab, anti-IgE antibody (SC), on the market
●
Dupilumab, anti IL-4/IL-13 antibody (SC) on the market
If we would develop and receive approval for INF904 in CSU, we would face competition from currently approved
systemically delivered therapeutics such as omalizumab and dupilumab, from systemic and/or topical anti-histaminic drugs,
corticosteroids and others. Finally, we could face competition from additional systemically administered product candidates with
varying mechanisms of action currently under development that might receive approvals for CSU before us.
●
Remibrutinib, an orally administered BTK inhibitor, currently in Phase 3 clinical development
●
Barzovolumab, a subcutaneously administered c-kit inhibitor, currently in Phase 3 clinical development
●
TLL-018, an orally administered JAK1/TYK2 inhibitor, currently in Phase 3 clinical development
●
Rilzabrutinib, an orally administered BTK inhibitor, currently in Phase 2 clinical development
●
TAS5315, an orally administered BTK inhibitor, currently in Phase 2 clinical development
●
Porvocitinib, an orally administered JAK1 inhibitor, currently in Phase 2 clinical development
●
HWH486, an orally administered BTK inhibitor, currently in Phase 2 clinical development
●
EP262, an orally administered MRGPRX2 antagonist, currently in Phase 2 clinical development
●
Briquilimab, c-kit inhibitor, currently in Phase 2 clinical development
●
AK006, an intravenously and subcutaneously administered anti-Siglec-6 antibody, completing Phase 1 clinical trials
Summary
The key competitive factors affecting the success of our product candidates, if approved or authorized, are likely to be their
efficacy, safety, dosing convenience, price and degree of market acceptance, as well as our or our partners marketing capabilities,
the level of competition and the availability of reimbursement from government and other third-party payors.
-81-
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are
safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we
may develop. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may
obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter
the market. In addition, even if our product candidates are approved for marketing and sale, they may fail to gain sufficient market
acceptance by physicians, patients, third-party payors and others in the medical community, including if physicians are reluctant
to switch their patients from existing therapies (such as adalimumab for the treatment of HS). See “ITEM 3. KEY
INFORMATION — D. Risk factors — Risks related to the discovery, development and commercialization of our product
candidates—Even if one of our product candidates receives marketing approval, it may fail to achieve the degree of market
acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in
which case we may not generate significant revenues or become profitable.”
Government regulation and product approval
Government authorities in all major pharmaceutical markets extensively regulate, among other things, the research,
development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing
and import and export of pharmaceutical products such as those we are developing. Although our initial focus will be on the
United States and Europe, we intend to develop and seek marketing approval for our products also in other countries and
territories, such as Canada or Japan, and for markets that follow the leading authorities, such as Brazil or South Korea. The
processes for obtaining regulatory approvals in the United States, Europe and other countries, along with subsequent compliance
with applicable statutes and regulations, require the expenditure of substantial time and financial resources.
FDA approval process
All of our current product candidates are subject to regulation in the United States by the FDA either as biological products,
or biologics, or as new chemical entities, or NCEs. The FDA subjects biologics and NCEs to extensive pre- and post-market
regulation. The Public Health Service Act, or PHSA, the Federal Food, Drug, and Cosmetic Act and other federal and state
statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping,
approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and
export of biologics and NCEs. Failure to comply with applicable U.S. requirements may subject a company to a variety of
administrative or judicial sanctions, such as FDA refusal to approve pending BLAs or NDAs, withdrawal of approvals, clinical
holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines
or civil or criminal penalties.
The PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined.
The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public
health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and
enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between
states.
BLA and NDA application and approval
The process required by the FDA before a new biologic or NCE may be marketed in the United States is long, expensive, and
inherently uncertain. Biologics and NCE development in the United States typically involves preclinical laboratory and animal
tests, the submission to the FDA of an IND (which must become effective before clinical testing may commence) and adequate
and well-controlled clinical trials to establish the safety, purity and potency (safety and effectiveness) of the biologic or NCE for
each indication for which FDA approval is sought. Developing the data to satisfy FDA pre-market approval requirements typically
takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product
or disease.
Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active
pharmaceutical ingredient and the formulated drug or drug product, as well as in vitro and animal studies to assess the safety and
activity of the drug candidate for initial testing in humans and to establish a rationale for therapeutic use. The conduct of
preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical
tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials,
among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of
reproductive adverse events and carcinogenicity, may continue after the IND is submitted.
-82-
An IND must become effective before United States clinical trials may begin. A 30-day waiting period after the submission of
each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor
questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.
Clinical trials involve the administration of the investigational new drug or biologic to healthy volunteers or patients with the
condition under investigation, all under the supervision of a qualified investigator. Clinical trials must be conducted (i) in
compliance with federal regulations, (ii) in compliance with good clinical practice, or GCP, which is an international standard
meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors, and
(iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted
to the FDA as part of the IND.
The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if
it believes that the clinical trial either is not being conducted in accordance with requirements or presents an unacceptable risk to
the clinical trial subjects. The study protocol and informed consent information for subjects in clinical trials must also be
submitted to an institutional review board (IRB) for approval. An IRB may also require the clinical trial at the site to be halted,
either temporarily or permanently, for failure to comply with the IRB’s requirements, or may impose other conditions. The study
sponsor may also suspend a clinical trial at any time on various grounds, including a determination that the subjects or patients are
being exposed to an unacceptable health risk.
Clinical trials to support BLAs or NDAs for marketing approval are typically conducted in three sequential phases, but the
phases may overlap or be combined. In Phase 1, the drug candidate is initially introduced into healthy human subjects or patients
and is tested to assess its pharmacokinetic, or PK, properties, pharmacological actions, side effects associated with increasing
doses, and, if possible, early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such
as cancer treatments, initial human testing has to be conducted in the intended patient population. Phase 2 usually involves trials in
a limited and well-specified patient population to determine the effectiveness of the biologic for a particular indication, dosage
tolerance and optimum dosage, and to identify common AEs and potential safety risks. If a drug candidate demonstrates evidence
of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain additional
information about clinical efficacy and safety in a larger number of patients, representing the future intended use population,
typically at geographically dispersed clinical trial sites. These Phase 3 clinical trials are intended to establish data sufficient to
demonstrate substantial evidence of the efficacy and safety of the product to permit the FDA to evaluate the overall benefit-risk
relationship of the biologic or NCE and to provide adequate information for the labeling of the drug. Trials conducted outside of
the United States under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to the
FDA in support of product licensing.
Sponsors of clinical trials for investigational drugs must publicly disclose certain clinical trial information, including detailed
trial design and trial results in public government databases. These requirements are subject to specific timelines and apply to
most controlled clinical trials of FDA-regulated products.
After completion of the required clinical testing, a BLA (for a biologic) or an NDA (for an NCE) is prepared and submitted to
the FDA. FDA review and approval of the BLA or NDA is required before marketing of the product may begin in the United
States. The BLA or NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to
the product’s pharmacology, chemistry, manufacture and controls, and must demonstrate the safety and efficacy of the product
based on these results. The BLA or NDA must also contain extensive manufacturing information. The cost of preparing and
submitting a BLA or NDA is substantial. Under federal law, the submission of most BLAs or NDAs is additionally subject to a
substantial application user fee, as well as an annual program user fee, which may total several million dollars and are typically
increased annually.
The FDA has 60 days from its receipt of a BLA or NDA to determine whether the application will be accepted for filing
based on the agency’s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is
accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs
and NDAs. Most such applications for standard review drug candidates are reviewed within 10 months from the date the
application is accepted for filing. Although the FDA often meets its user fee performance goals, it can extend these timelines if
necessary, and its review may not occur on a timely basis. The FDA usually refers applications for novel drugs, or drugs which
present difficult questions of safety or efficacy, to an advisory committee—typically a panel that includes clinicians and other
experts—for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound
by the recommendation of an advisory committee, but it frequently follows such recommendations. Before approving a BLA or
NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will
inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless it verifies that
compliance with cGMP standards is satisfactory and the BLA or NDA contains data that provide substantial evidence that the
drug is safe and effective in the indication studied.
-83-
After the FDA evaluates the BLA or NDA and the manufacturing facilities, it issues either an approval letter or a complete
response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial
additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been
addressed to the FDA’s satisfaction in a resubmission of the BLA or NDA, the FDA will issue an approval letter. The FDA has
committed to reviewing such resubmissions in two or six months depending on the type of information included. The FDA
approval is never guaranteed, and the FDA may refuse to approve a BLA or NDA if applicable regulatory criteria are not satisfied.
Under the PHSA, the FDA may approve a BLA or NDA if it determines that the product is safe, pure and potent and the
facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent.
An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. The
approval for a drug may be significantly more limited than requested in the application, including limitations on the specific
diseases and dosages or the indications for use, which could restrict the commercial value of the product. The FDA may also
require that certain contraindications, warnings, or precautions be included in the product labeling. In addition, as a condition of
BLA or NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits
of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals,
and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for
prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The
requirement for a REMS or use of a companion diagnostic with a drug can materially affect the potential market and profitability
of the drug. Moreover, product approval may require, as a condition of approval, substantial post-approval testing and surveillance
to monitor the drug’s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory
standards is not maintained or problems are identified following initial marketing.
After a BLA or NDA is approved, the product may also be subject to official lot release. As part of the manufacturing
process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the
product is subject to official lot release by the FDA, the manufacturer submits samples of each lot of product to the FDA together
with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer’s
tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines,
before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the
regulatory standards on the safety, purity, potency, and effectiveness of products. After approval of drugs, manufacturers must
address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection.
Emergency use authorization
The FDA can facilitate the availability and use of medical countermeasures needed during public health emergencies via
EUA. When The United States Secretary of Health and Human Services, or HHS Secretary, declares that an EUA is appropriate,
FDA may authorize unapproved medical products or unapproved uses of approved medical products to be used in an emergency
to diagnose, treat or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or
nuclear threat agents. For example, in January 2020, the HHS Secretary determined that a public health emergency, or PHE,
existed (and has subsequently extended the declaration on numerous occasions,) that had a significant potential to affect national
security or the health and security of U.S. citizens due to the emergence and spread of COVID-19. Based on this determination,
the HHS Secretary also declared that circumstances existed justifying EUA of certain medical products. The EUA declaration is
distinct from the PHE declaration. As long as the applicable EUA declaration and determination remains in effect, an EUA may
remain in effect beyond the duration of the PHE declaration if all other statutory conditions are met. Even if the EUA declaration
remains in effect ,the FDA may revoke the EUA at any time if certain circumstances or criteria are met. We have been granted the
EUA for GOHIBIC (vilobelimab), for the treatment of COVID-19 in hospitalized adults when initiated within 48hours of
receiving IMV or ECMO.
-84-
Adverse event reporting an cGMP compliance
Adverse event reporting and submission of periodic reports are required following FDA approval of a BLA or NDA. The
FDA also may require post-marketing testing, known as Phase 4 testing, REMS and surveillance to monitor the effects of an
approved product, or may place conditions on an approval that could restrict the distribution or use of the product. In addition,
manufacture, packaging, labeling, storage and distribution procedures must continue to conform to current cGMPs after approval.
Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state
agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency
inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time,
money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory authorities may
withdraw product approvals, request product recalls or impose marketing restrictions through labeling changes or product
removals if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if
previously unrecognized problems are subsequently discovered.
Orphan drug designation
Under the Orphan Drug Act, the FDA may grant orphan drug designation to biologics or NCEs intended to treat a rare disease
or condition—generally a disease or condition that affects fewer than 200,000 individuals annually in the United States. Orphan
drug designation must be requested before submitting a BLA or NDA. After the FDA grants orphan drug designation, the generic
identity of the drug candidate and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not
necessarily convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA or
NDA applicant to receive FDA approval for a particular product to treat a particular disease with FDA orphan drug designation is
entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year
exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in
limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug
exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a
different disease or condition or, a drug that is otherwise the same drug which may be clinically superior. Among the other
benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA or NDA application user fee.
Fast track designation
Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and
fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast track addresses a broad range of
serious conditions. Determining whether a condition is serious is a matter of judgment, but generally is based on whether the drug
will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will
progress from a less severe condition to a more serious one. Filling an unmet medical need is defined as providing a therapy
where none exists or providing a therapy which may be potentially better than available therapy. Any drug being developed to
treat or prevent a condition with no current therapy is directed at an unmet need. If there are available therapies, a fast track drug
must show some advantage over available therapy, such as: showing superior effectiveness, effect on serious outcomes or
improved effect on serious outcomes; avoiding serious side effects of an available therapy; improving the diagnosis of a serious
condition where early diagnosis results in an improved outcome; decreasing a clinical significant toxicity of an available therapy
that is common and causes discontinuation of treatment or ability to address an emerging or anticipated public health need. A drug
that receives fast track designation is eligible for some or all of the following: more frequent meetings with the FDA to discuss the
drug’s development plan and ensure collection of appropriate data needed to support drug approval; more frequent written
communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers; eligibility for
Accelerated Approval and Priority Review, if relevant criteria are met; Rolling Review, which means that a drug company can
submit completed sections of its BLA or NDA for review by FDA, rather than waiting until every section of the NDA is
completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has
submitted the entire application to the FDA. Fast track designation must be requested by the drug company. The request can be
initiated at any time during the drug development process. FDA will review the request and make a decision within sixty days
based on whether the drug fills an unmet medical need in a serious condition. Once a drug receives fast track designation, early
and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and
review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier
drug approval and access by patients.
-85-
We have been granted orphan drug status and fast track designation for the PG indication in the United States for vilobelimab.
We have also been granted fast track designation for the COVID-19 indication in the United States. Depending on the outcome
and available data of vilobelimab studies in the other indications, we may apply for orphan drug status in the United States.
Accelerated approval
The FDA instituted its accelerated approval program to allow for earlier approval of drugs that treat serious conditions, and
fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement,
radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical
benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. Drug
companies are still required to conduct studies to confirm the anticipated clinical benefit. These studies are known as Phase 4
confirmatory trials. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants
traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has
regulatory procedures in place that could lead to removing the drug from the market.
Priority review
In 1992, under the Prescription Drug User Act, or PDUFA, FDA agreed to specific goals for improving the drug review time
and created a two-tiered system of review times – standard review and priority review. A priority review designation means
FDA’s goal is to take action on an application within six months (compared to 10 months under standard review). A priority
review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would
be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when
compared to standard applications. Significant improvement may be demonstrated by the following examples: evidence of
increased effectiveness in treatment, prevention, or diagnosis of condition; elimination or substantial reduction of a treatment-
limiting drug reaction; documented enhancement of patient compliance that is expected to lead to an improvement in serious
outcomes; or evidence of safety and effectiveness in a new subpopulation. FDA decides on the review designation for every
application. However, an applicant may expressly request priority review. It does not affect the length of the clinical trial period.
FDA informs the applicant of a priority review designation within 60 days of the receipt of the BLA or NDA. Designation of a
drug as “priority” does not alter the scientific/medical standard for approval or the quality of evidence necessary.
Other healthcare laws and compliance requirements
In the United States, our activities are potentially subject to regulation by federal, state and local authorities in addition to the
FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human
Services (for example, the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices
within the Department of Justice, and state and local governments.
EU approval process
The European Medicines Agency, or EMA is a decentralized scientific agency of the European Union. It coordinates the
evaluation and monitoring of centrally-authorized medicinal products. It is responsible for the scientific evaluation of applications
for European marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to
sponsors. The EMA decentralizes its scientific assessment of medicines by working through a network of about 4,500 experts
throughout the European Union, nominated by the member states. The EMA draws on resources of over 40 National Competent
Authorities, or the NCAs, of EU member states. The Paul Ehrlich Institute, or PEI, is one of the NCAs for Germany, and
regulates, among others, antibody products.
-86-
The process regarding approval of medicinal products in the European Union follows roughly the same lines as in the United
States and generally involves satisfactorily completing each of the following:
●
preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU
Good Laboratory Practice regulations;
●
submission to the relevant national authorities of a clinical trial application or CTA for each trial in humans, which must
be approved before the trial may begin in each country where patient enrollment is planned;
●
performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each
proposed indication;
●
submission to the relevant competent authorities of a MAA, which includes the data supporting safety and efficacy as
well as detailed information on the manufacture and composition of the product in clinical development and proposed
labelling;
●
satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities,
including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMP;
●
potential audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and
●
review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment
of the product.
Preclinical studies
Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate
toxicity in animal studies, in order to assess the quality and potential safety and efficacy of the product. The conduct of the
preclinical tests and formulation of the compounds for testing must comply with the relevant international, EU and national
legislation, regulations and guidelines. The results of the preclinical tests, together with relevant manufacturing information and
analytical data, are submitted as part of the CTA.
Clinical trial approval
The Clinical Trials Regulation (EU) No 536/2014 repealed the Clinical Trials Directive 2001/20/EC, on January 31, 2022 and
applies to all new clinical trials from January 31, 2023. All ongoing trials must be transitioned to the new processes by 31 January
2025. The Clinical Trials Regulation harmonizes the processes and supervision of clinical trials throughout the EU. Sponsors
submit one application via the Clinical Trials Information System, or CTIS, for approval to run a clinical trial in several European
countries. The evaluation, authorization and supervision of clinical trials are the responsibilities of EU member states and
European Economic Area, or EEA, countries. The CTIS application must be supported by an investigational medicinal product
dossier, or IMPD, the study protocol and further supporting information prescribed by the Clinical Trials Regulation and other
applicable guidance documents. The CTIS process has predetermined timelines which may vary depending on the phase of the
study. The process includes timelines for one or more rounds of questions to be answered or requests to be met by the regulatory
authority.
Regulation (EU) No 536/2014, includes transparency requirements (the proactive publication of clinical trial data in the EU
database) with associated rules on the timing of the publication of submitted documents at the time of, during and after completion
of the clinical trial. The transparency requirement can apply to documents included in the clinical trial application, or CTA,
dossier provided in CTIS, and all the clinical trial information submitted during the trial life cycle, with the exception of the
quality related documents, financial arrangements and some supervision related information.
Manufacturing and import into the EU of investigational medicinal products is subject to the holding of appropriate
authorizations and must be carried out in accordance with cGMP.
-87-
Marketing authorization application
Authorization to market a product in the EU member states proceeds under one of four procedures: a centralized authorization
procedure, a mutual recognition procedure, a decentralized procedure or a national procedure. Since our products by their virtue of
being antibody-based biologics or NCEs, fall under the centralized procedure, only this procedure will be described here.
Centralized authorization procedure
Certain drugs, including medicinal products developed by means of biotechnological processes, must be approved via the
centralized authorization procedure for marketing authorization. A successful application under the centralized authorization
procedure results in a marketing authorization from the EC, which is automatically valid in all EU member states as well as in the
other EEA, member states (namely Norway, Iceland and Liechtenstein). The EMA and the EC administer the centralized
authorization procedure.
Under the centralized authorization procedure, the CHMP serves as the scientific committee that renders opinions about the
safety, efficacy and quality of human products on behalf of the EMA. The CHMP is composed of experts nominated by each
member state’s national drug authority, with one of them appointed to act as Rapporteur for the co-ordination of the evaluation
with the possible assistance of a further member of the committee acting as a Co-Rapporteur. After approval, the Rapporteur(s)
continue to monitor the product throughout its life-cycle. The CHMP is required to issue an opinion within 210 days of receipt of
a valid application, though the clock is stopped when it is necessary to ask the applicant for clarification or further supporting data.
The process is complex and involves extensive consultation with the regulatory authorities of member states and a number of
experts. Once the procedure is completed, a European Public Assessment Report, or EPAR, is produced. If the CHMP concludes
that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. The CHMP’s
opinion is sent to the EC, which uses the opinion as the basis for its decision whether or not to grant a marketing authorization. If
the opinion is negative, information is given as to the grounds on which this conclusion was reached.
Policy 0070, which is intended to promote transparency of EMA decision making and clinical data, governs how EMA
collects, reviews and publishes clinical data submitted by applicants and Marketing Authorization Holders, or MAHs, through the
centralized procedure.
After a drug has been authorized and launched, it is a condition of maintaining the marketing authorization that all aspects
relating to its quality, safety and efficacy must be kept under review. Sanctions may be imposed for failure to adhere to the
conditions of the marketing authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the
product from sale.
Marketing authorization under exceptional circumstances
In exceptional circumstances and following consultation with the applicant, an authorisation may be granted subject to certain
conditions, so called specific obligations (SOBs), in particular relating to the safety of the medicinal product, notification to
the national competent authorities of any incident relating to its use, and action to be taken. MAs under exceptional
circumstances can be granted under Article 14(8) of Regulation (EC) No 726/2004. An MA under exceptional circumstances is a
type of marketing authorisation granted to medicines where the applicant is unable to provide comprehensive data on the efficacy
and safety under normal conditions of use, because the condition to be treated is rare or because collection of full information is
not possible or is unethical.
Gohibic (vilobelimab) has been granted an MA under exceptional circumstances on January 13, 2025 for the treatment of
adult patients with SARS-CoV2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids
as part of Standard of Care and receiving invasive mechanical ventilation (IMV) (with or without extracorporeal membrane
oxygenation (ECMO)). The Specific Obligation to complete post authorisation measures for the Gohibic MA under exceptional
circumstances is to submit annually (within the annual reassessment) results for the vilobelimab cohort in Just Breathe platform
study, a double-blind, placebo controlled study enrolling patients with moderate to severe ARDS caused by COVID-19 and other
viral and bacterial pulmonary infections and to submit updates on any new information concerning the efficacy and safety of
Gohibic.
Continuation of the MA for Gohibic is linked to the annual re-assessment by EMA of the conditions mentioned above. The
outcome of the annual re-assessment will reflect the status of fulfilment of the SOB(s) and the impact of the SOB data on the
benefit / risk profile of the medicinal product and will conclude on whether the marketing authorisation should be maintained,
varied or suspended based on the review of these two elements.
-88-
Accelerated assessment procedure
When an application is submitted for a marketing authorization in respect of a drug for human use which is of major interest
from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request
an accelerated assessment procedure pursuant to Article 14(9) of Regulation (EC) 726/2004. Under the accelerated assessment
procedure, the CHMP is required to issue an opinion within 150 days of receipt of a valid application, subject to clock stops. We
believe that some of the disease indications in which our product candidates are currently being or may be developed in the future
qualify for this provision, and we will take advantage of this provision as appropriate.
Conditional approval
As per Article 14(7) of Regulation (EC) 726/2004, a medicine that would fulfill an unmet medical need may, if its immediate
availability is in the interest of public health, be granted a conditional marketing authorization on the basis of less complete
clinical data than are normally required, subject to specific obligations being imposed on the authorization holder. These specific
obligations are to be reviewed annually by the EMA. The list of these obligations shall be made publicly accessible. Such an
authorization shall be valid for one year, on a renewable basis.
Period of authorization and renewals
A marketing authorization is initially valid for five years and may then be renewed on the basis of a re-evaluation of the risk-
benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing
authorization holder shall provide the EMA or the competent authority with a consolidated version of the file in respect of quality,
safety and efficacy, including all variants introduced since the marketing authorization was granted, at least six months before the
marketing authorization ceases to be valid. Once renewed, the marketing authorization shall be valid for an unlimited period,
unless the Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with
one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in
case of centralized procedure) or on the market of the authorizing member state within three years after authorization shall cease
to be valid (the so-called sunset clause).
Orphan drug designation
Regulation (EC) 141/2000 states that a drug shall be designated as an orphan drug if its sponsor can establish:
●
that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition
affecting not more than five in 10,000 persons in the European Union when the application is made, or;
●
that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and
chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the
European Union would generate sufficient return to justify the necessary investment; and
●
that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been
authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by
that condition.
Regulation (EC) 847/2000 sets out criteria for the designation of orphan drugs. An application for designation as an orphan
product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for
an orphan drug leads to a 10-year period of market exclusivity, which means that no similar medicinal product can be authorized
in the same indication. This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the
product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to
justify continued market exclusivity. In addition, derogation from market exclusivity may be granted on an individual basis in
very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the
product or demonstration of “clinically relevant superiority” by a similar medicinal product. Medicinal products designated as
orphan drugs pursuant to Regulation (EC) 141/2000 are eligible for incentives made available by the European Union and by the
member states to support research into, and the development and availability of, orphan drugs.
-89-
If the MAA of a medicinal product designated as orphan drug pursuant to Regulation (EC) 141/2000 includes the results of all
studies conducted in compliance with an agreed PIP, and a corresponding statement is subsequently included in the marketing
authorization granted, the 10-year period of market exclusivity will be extended to 12 years.
We have been granted orphan drug status for the PG indication in the European Union for vilobelimab. Depending on the
outcome and available data of vilobelimab studies in the other indications, we may also apply for orphan drug status in Europe for
these indications.
Regulatory data protection
Without prejudice to the law on the protection of industrial and commercial property, marketing authorizations for new
medicinal products benefit from an 8+2+1 year period of regulatory protection.
This regime consists of a regulatory data protection period of eight years plus a concurrent market exclusivity of 10 years plus
an additional market exclusivity of one further year if, during the first eight years of those 10 years, the marketing approval holder
obtains an approval for one or more new therapeutic indications which, during the scientific evaluation prior to their approval, are
determined to bring a significant clinical benefit in comparison with existing therapies. Under the current rules, a third party may
reference the preclinical and clinical data of the reference product beginning eight years after first approval, but the third party
may market a generic version of the reference product after only 10 (or 11) years have lapsed.
Other international regulations
In addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial
sales, and distribution of pharmaceutical products. The approval process varies from country to country and the time to approval
may be longer or shorter than that required for FDA or EC approval.
Pharmaceutical coverage, pricing and reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other
government authorities. Sales of our products will depend, in part, on the extent to which third-party payors, including
government health programs in the United States such as Medicare and Medicaid, commercial private and public health insurers
and managed care organizations, provide coverage and establish adequate reimbursement levels for, such products. The process
for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or
reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors are increasingly
challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and
services and imposing controls to manage costs. Third-party payors may limit coverage to specific drug products on an approved
list, or formulary, which might not include all of the approved products for a particular indication.
In order to secure coverage and reimbursement for any pharmaceutical product approved for sale, a company may need to
conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product,
in addition to the costs required to obtain FDA or other comparable regulatory approvals. Nonetheless, product candidates may
not be considered medically necessary or cost effective. Additionally, a payor’s decision to provide coverage for a drug product
does not imply that an adequate reimbursement rate will be approved. Further, one payor’s determination to provide coverage for
a drug product does not assure that other payors will also provide coverage for the drug product. Third-party reimbursement may
not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development.
-90-
The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of
drugs have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs,
including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price
controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and
measures, could further limit our net revenue and results. Coverage policies and third-party reimbursement rates may change at
any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its
collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the
future.
Outside the United States, ensuring adequate coverage and payment for our products will face challenges. Pricing of
prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental
authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a
clinical trial that compares the cost effectiveness of our products or products to other available therapies. The conduct of such
clinical trials could be expensive and result in delays in our commercialization efforts.
In the European Union, pricing and reimbursement schemes to restrict the range of drug products for which their national
health insurance systems provide reimbursement and to control the prices of medicinal products for human use vary widely from
country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed.
Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug product
to currently available therapies. EU member states may also require approval of a specific price for a drug product or, instead,
may adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other
EU member states allow companies to fix their own prices for drug products but monitor and control company profits. The
downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly
high barriers are being erected to the market entry of new pharmaceutical products. In addition, in some countries, cross-border
imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price
controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.
C.
Organizational structure
InflaRx N.V. has two direct wholly-owned subsidiaries, InflaRx GmbH and InflaRx Pharmaceuticals, Inc., that are each listed
in Exhibit 8.1 filed herewith.
D.
Property, plant and equipment
Our headquarters are in Jena, Germany, where we occupy approximately 8,000 square feet of office and laboratory space
under a lease that expires in December 2025. In addition, we occupy approximately 13,700 square feet of office space in Planegg-
Martinsried (near Munich), Germany under a lease that expires in May 2027. Furthermore, we have leased office and laboratory
space in Ann Arbor, Michigan, United States under a lease that expires in April 2026.
-91-
ITEM 4A. UNRESOLVED STAFF COMMENTS
Not applicable.
ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS
A.
Operating results
You should read the following discussion and analysis of our financial condition and results of operations together with the
information in our consolidated financial statements and the notes thereto.
The following discussion is based on our financial information prepared in accordance with IFRS as issued by the IASB,
which may differ in material respects from generally accepted accounting principles in the United States and other jurisdictions.
The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results
may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those
described under “ITEM 3. KEY INFORMATION — D. ‘Risk factors’ and Forward-Looking Statements.’”
For more information regarding our consolidated results, segment results, and liquidity and capital resources for the year
ended December 31, 2024 as compared to the year ended December 31, 2023, refer to “ITEM 5. OPERATING AND
FINANCIAL REVIEW AND PROSPECTS” in the Company’s 2024 Annual Report on Form 20-F, which information is
incorporated herein by reference.
Overview
We are a biotechnology company pioneering anti-inflammatory therapeutics focused on applying our proprietary anti-C5a
and C5aR technologies to discover, develop and commercialize first-in-class, potent and specific inhibitors of the complement
activation factor known as C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a
wide variety of autoimmune and other inflammatory diseases. Our lead product candidate, vilobelimab, is a novel intravenously
delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying
clinical activity and tolerability in multiple clinical settings. In April 2023, we received the EUA from the FDA for GOHIBIC
(vilobelimab) for the treatment of critically ill, invasively mechanically ventilated COVID-19 patients. Subsequently, in June
2023, we began the commercialization of GOHIBIC (vilobelimab) in the United States. In January 2025, we received EC approval
for vilobelimab for the treatment of SARS-CoV-2-induced ARDS, under exceptional circumstances.
We are also developing vilobelimab for the treatment of PG, a chronic inflammatory skin disorder for which we are currently
conducting a Phase 3 study.
Beyond PG, we have been developing vilobelimab to generate proof of concept data in a wide array of complement-mediated
diseases with significant unmet medical needs. For this purpose, we have previously conducted Phase II studies with vilobelimab
in HS, a chronic debilitating systemic inflammatory skin disease, in ANCA-associated vasculitis, or AAV, a rare and life-
threatening autoimmune disease and in cSCC, where we have recently decided to cease the development for the time being, since
further clinical development would require substantial resources and significantly extend the timeline of the ongoing clinical
program. We decided to prioritize our efforts and to reallocate our resources towards the development of our orally available
C5aR inhibitor INF904, an oral small-molecule drug candidate that targets the C5aR receptor. We plan on targeting complement-
mediated, chronic autoimmune and inflammatory conditions for which an oral small molecule is the preferred route of
administration for patients. We have recently completed a Phase I single ascending dose, or SAD, and multiple ascending dose, or
MAD, study in healthy volunteers in which we were able to confirm the favorable safety profile and the superior pharmacokinetic
and pharmacodynamic profile of INF904. We are currently conducting a Phase IIa trial with INF904 in CSU and HS, as well as
additional required pre-clinical studies, including long-term chronic toxicology studies, to enable longer-term dosing of INF904
for chronic inflammatory diseases. We are also developing IFX002, a life-cycle management product for vilobelimab.
Since our inception in December 2007, we have devoted substantially all our resources to establishing our company, raising
capital, developing our proprietary anti-C5a/C5aR technologies, identifying and testing potential product candidates and
conducting clinical trials of our lead product candidate, vilobelimab and additional product candidates IFX002 and INF904. To
date, we have only generated minimal product revenue and so far have primarily financed our operations through the issuance of
securities in public offerings and private placements and through other income from various grants, including a grant awarded by
the German federal government for certain research and development activities during the period from October 2021 to June
2023. Through this grant, we had received a total of €33.3 million to support the development of vilobelimab for the treatment of
critically ill COVID-19 patients.
-92-
As of December 31, 2024, we had cash and cash equivalents of €18.4 million and €36.8 million in marketable securities.
Through an underwritten public offering in February 2025, we sold and issued an aggregate of 8,250,000 ordinary shares, at a
price of $2.00 per share which have a nominal value of €0.12 per share and in lieu of ordinary shares to certain investors, pre-
funded warrants to purchase up to 6,750,000 of the Company’s ordinary shares. The purchase price of each pre-funded warrant
was equal to the price per share at which ordinary shares were sold to the public in this offering, minus $0.001, which is the
exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering were approximately $30 million, before
deducting underwriting discounts and offering expenses.
As of December 31, 2024, we had an accumulated deficit of €332.2 million. We have incurred significant net operating losses
in every year since our inception and expect to continue to incur comparable or increasing net operating losses for the foreseeable
future. Our net losses may fluctuate significantly from quarter to quarter and year to year.
B.
Financial operations overview
A discussion of our financial condition and results of operations for the year ended December 31, 2023 can be found in our
annual report on form 20-F, filed with the SEC on March 21, 2024.
Revenue
In June 2023, we began the commercialization of GOHIBIC (vilobelimab) in the United States. In connection with the start of
the commercialization, we entered into agreements with certain subsidiaries of Cencora Inc. to act as a Group’s U.S. distributor to
make GOHIBIC (vilobelimab) available for order by U.S. hospital customers.
Revenues reported are sales to end customers (hospitals). Sales to distributors do not constitute completion of the earnings
process and, thus, do not result in the recognition of revenue for the Company under IFRS 15.
Cost of sales
Cost of sales consists of material, personnel and other costs associated with inventory sold and inventory write-downs in the
period.
Other income
Other income as described herein results predominantly from government grants and research allowances recognized as
income during the period.
Sales and marketing expenses
Sales and marketing expenses have consisted principally of:
●
external services for distribution of GOHIBIC to build the necessary commercial and logistical infrastructure, including
external sales professionals;
●
marketing activities;
●
employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’
role within the organization; and
●
professional services fees in conjunction with making GOHIBIC available to hospitals and patients in the U.S.
-93-
Research and development expenses
Research and development expenses have consisted principally of:
●
expenses incurred under agreements with CROs, contract development and manufacturing organizations, or CDMOs,
consultants and independent contractors that conduct research and development, preclinical and clinical activities on our
behalf;
●
employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’
role within the organization; and
●
professional fees for lawyers related to the protection and maintenance of our intellectual property.
We expense research and development costs as incurred. We recognize costs for certain development activities, such as
preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information
provided to us by our vendors such as status of patient enrollment or clinical site activations for measuring services received and
efforts expended. Research and development activities are central to our business model.
General and administrative expenses
Our general and administrative expenses consist principally of:
●
employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’
role within the organization;
●
insurance expenses including directors´ and officers´ liability insurance premiums;
●
professional fees for auditors and consulting expenses not related to research and development activities;
●
professional fees for lawyers not related to the filing, prosecution, protection and maintenance of our intellectual
property; and
●
cost of facilities, travel, communication and office expenses.
Results of operations
The Group is exposed to the exchange rate between Euros and U.S. dollars. As a result of the Company’s various registered
offerings of ordinary shares in U.S. dollars, the Group holds significant cash, cash equivalents and marketable securities in U.S.
dollars. This could have a material impact on our operating results.
The numbers below have been derived from our consolidated financial statements included elsewhere herein. The discussion
below should be read along with these consolidated financial statements, and it is qualified in its entirety by reference to them.
-94-
Comparison of the years ended December 31, 2024 and 2023
2024
2023
Change
(in €)
Revenues
165,789
63,089
102,700
Cost of sales
(3,317,039)
(532,262) (2,784,777)
Gross profit
(3,151,250)
(469,173) (2,682,077)
Marketing and sales expenses
(6,756,595) (4,001,299) (2,755,296)
Research and development expenses
(35,363,897) (41,024,131) 5,660,234
General and administrative expenses
(13,024,441) (12,628,756)
(395,685)
Other income and expenses (net)
5,287,319 13,215,264 (7,927,945)
Loss before interest and income taxes
(53,008,864) (44,908,096) (8,100,768)
Net financial result
6,949,679
2,240,566 4,709,113
Loss before tax
(46,059,185) (42,667,529) (3,391,656)
Income tax expense
(5,217)
—
(5,217)
Loss for the period
(46,064,402) (42,667,529) (3,396,873)
Exchange differences on translating operations in
foreign currency
58,344
125,085
(66,741)
Total comprehensive loss
(46,006,058) (42,542,444) (3,463,614)
Revenues
2024
2023
Change
(in €)
Revenues
165,789
63,089
102,700
Total
165,789
63,089
102,700
For the twelve months ended December 31, 2024, we realized revenues from product sales of GOHIBIC (vilobelimab) in the
amount of €0.2 million, which represents an increase of €0.1 million compared to the prior year.
Cost of sales
2024
2023
Change
(in €)
Cost of sales
3,317,039
532,262
2,784,777
Total
3,317,039
532,262
2,784,777
Cost of sales expenses increased by €2.8 million for the year ended December 31, 2024 compared to the corresponding costs
for the year ended December 31, 2023 primarily due to higher inventory write-downs of €2.8 million. The write-down of
inventories is due to quantities on-hand exceeding quantities expected to be sold prior to expiry.
Marketing and sales expenses
2024
2023
Change
(in €)
Third-party expenses
2,010,120
1,021,082
989,038
Marketing expenses
1,573,628
830,076
743,552
Personnel expenses
1,806,151
1,040,587
765,564
Legal and consulting fees
910,146
1,054,971
(144,825)
Other expenses
456,550
54,581
401,969
Total marketing and sales expenses
6,756,595
4,001,299
2,755,296
-95-
Marketing and sales expenses for the twelve months ended December 31, 2024 increased by €2.8 million compared to the
twelve months ended December 31, 2023. This increase is due to 2024 being the first full year of commercial efforts for
GOHIBIC (vilobelimab) in the United States. For the twelve months ended December 31, 2023 marketing and sales expenses
were only incurred during the second half of the year.
Other expenses include mainly travel and related expenses.
Research and development expenses
2024
2023
Change
(in €)
Third-party expenses
23,113,874 31,802,983 (8,689,109)
Personnel expenses
8,390,010
6,776,853
1,613,157
Other expenses
3,860,013
2,444,295
1,415,718
Total
35,363,897 41,024,131 (5,660,234)
Research and development expenses decreased by €5.7 million for the year ended December 31, 2024 compared to the year
ended December 31, 2023 primarily due to lower third-party costs from manufacturing development activities and from clinical
trials, which decreased by €8.7 million, offset by €1.6 million higher personnel expenses and €1.4 million higher other expenses
compared to the previous year. Personnel expenses increased mainly due to increasing headcount as well as higher equity-settled
share-based compensation.
Other expenses include a one-off milestone payment of $1.0 million (€1.0 million) which became payable upon receiving
marketing authorization in Europe in 2025.
General and administrative expenses
2024
2023
Change
(in €)
Personnel expenses
6,339,421
5,392,905
946,516
Legal, consulting and audit fees
2,851,390
3,239,809
(388,419)
Other expenses
3,833,630
3,996,042
(162,412)
Total
13,024,441 12,628,756
395,685
General and administrative expenses increased by €0.4 million to €13.0 million for the year ended December 31, 2024, from
€12.6 million for the year ended December 31, 2023. This increase is comprised of higher personnel expense by €0.9 million and
offset by €0.4 million lower other expenses associated with insurance expenses, as well as by €0.4 million lower legal, consulting
and audit fees.
Other income
2024
2023
Change
(in €)
Other income from government grants and research allowances
5,081,772 13,155,250 (8,073,478)
Further other income
205,844
64,453
141,390
Total
5,287,616 13,219,704 (7,932,088)
Other income decreased by €7.9 million for the year ended December 31, 2024 compared to the year ended December 31,
2023 due primarily to lower income from government grants and research allowances. In June 2023, our grant from the German
Ministry of Education and Research and the German Ministry of Health to support the development of vilobelimab for the
treatment of severe COVID-19 patients ended. In 2024, upon qualifying for an allowance under the German Research Allowance
Act, we recognized €5.1 million in income relating to expenses, eligible for reimbursement, which were incurred in the years 2020
to 2024. We remain eligible for reimbursement of eligible expenses to be incurred from 2025 to 2027.
-96-
Net financial result
2024
2023
Change
(in €)
Interest income
3,196,813
3,804,827
(608,014)
Interest expenses
(885)
(16,538)
15,653
Interest on lease liabilities
(19,770)
(19,090)
(680)
Net interest result
3,176,159
3,769,199
(593,040)
Foreign exchange income
6,876,161
5,529,389
1,346,772
Foreign exchange expense
(3,205,926) (7,371,261)
4,165,335
Net foreign exchange result
3,670,235 (1,841,872)
5,512,107
Other financial result
103,285
313,240
(209,955)
Net financial result
6,949,679
2,240,566
4,709,114
Net financial result increased by €4.7 million to €6.9 million for the year ended December 31, 2024 compared to €2.2 million
for the year ended December 31, 2023. This overall net increase is mainly attributable to an increase of €5.5 million in foreign
exchange result, offset by €0.6 million lower interest income from marketable securities compared to the year ended December
31, 2023.
Comparison of the years ended December 31, 2023 and 2022
A discussion of the financial results for the year ended December 31, 2023 as compared to the year ended December 31, 2022
can be found in the section entitled “Item 5. Operating and Financial Review and Prospects—A. Operating Results— Financial
operations overview—Comparison of the years ended December 31, 2023 and 2022” in our annual report on form 20-F, filed with
the SEC on March 21, 2024.
C.
Liquidity and capital resources
Overview on cash requirements and sources of liquidity
Since inception, we have incurred significant operating losses mainly from our research and development activities and G&A
costs. For the years ended December 31, 2024 and 2023, we incurred net losses of €46.1 million and €42.7 million, respectively.
Our primary uses of cash are for working capital, operating leases and general corporate purposes.
Our primary sources of funds are proceeds from the sale of our shares including our initial public offering and follow-on
offerings. Additionally, in 2021, we were awarded a grant from the German federal government under which we received €33.3
million between October 2021 and June 2023. The grant period ended on June 30, 2023.
In 2024, we qualified for an allowance under the Forschungszulagengesetz (Research Allowance Act) in Germany, a law
designed to promote research and development. Under this allowance, we became eligible for reimbursement, by the German
federal government, of a portion of certain eligible R&D expenses incurred from 2020 through 2027. For financial reporting
purposes, under IFRS, we recognize the allowance as a government grant. Upon qualifying for the allowance, we recognized €5.1
million in income relating to eligible expenses which were incurred in the years 2020 to 2024. We remain eligible for
reimbursement of expenses to be incurred from 2025 to 2027.
Historically, we have been able to fund our capital needs with cash from equity financing through placement of shares.
On July 8, 2020, we filed a Form F-3 registration statement with the SEC with respect to the offer and sale of securities of the
Company, or 2020-Shelf Registration Statement. We also filed a prospectus supplement with the SEC relating to an at-the-market
program providing for the sales of our stock over time of up to $50.0 million of our ordinary shares pursuant to a Sales Agreement
with SVB Leerink LLC. During the fiscal year 2023, we issued 3,235,723 ordinary shares under its at-the-market program
resulting in €14.4 million or $15.7 million in net proceeds. As of December 31, 2023, and throughout the term of the at-the-market
program, we have issued an aggregate total of 5,803,931 ordinary shares, resulting in a total of €26.2 million in net proceeds to us.
The term of the at-the-market program expired on July 8, 2023.
-97-
Through an underwritten public offering in April 2023, we sold and issued an aggregate of 10,823,529 ordinary shares, at a
price of $4.25 per share and have a nominal value of €0.12 per share, of which 1,411,764 were sold pursuant to the exercise of an
overallotment option by the underwriters. Net proceeds of this offering amounted to €38.7 million, after accounting for
underwriting discounts and other offering expenses.
During the fiscal year 2023, we issued and registered a total of 120,257 ordinary shares resulting from the exercise of stock
option rights by former employees. All stock option rights had been granted under the 2017 Long-Term Incentive Plan. 14,930
stock options thereof were already exercised in December 2022 and 105,327 were exercised during fiscal year 2023. The ordinary
shares have a nominal value of €0.12 per share. 98,754 ordinary shares were sold at a price of $1.85 per share, and 21,503
ordinary shares were sold at a price of $3.35 per share.
On June 30, 2023, we filed a Form F-3 (2023-Registration Statement) with the SEC with respect to the offer and sale of
securities of the Company, which became effective on July 11, 2023. The aggregate initial offering price of the securities that the
Company may offer and sell under this prospectus will not exceed $250 million. In 2024, we subsequently filed a prospectus
supplement with the SEC relating to an at-the-market program providing for the sale of up to $75.0 million of our ordinary shares
over time pursuant a sales agreement with Leerink Partners LLC, or the Sales Agreement.
We did not issue any ordinary shares under the 2023-Registration Statement in 2023. As of December 31, 2024, we had
issued 468,438 ordinary shares under the Sales Agreement, resulting in €0.8 million in net proceeds with a remaining value
authorized for sale under the Sales Agreement of $73.8 million.
In January and February 2025, we issued an additional 145,420 ordinary shares under its Sales Agreement, resulting in
$353,000 in net proceeds.
In February 2025, we completed an underwritten public offering of an aggregate of 8,250,000 ordinary shares and pre-funded
warrants to purchase 6,750,000 ordinary shares. The ordinary shares were sold at a price of $2.00 per share with a nominal value
of €0.12 per share. The public offering price for each pre-funded warrant was equal to the price per share at which the ordinary
shares were sold to the public, minus $0.001, which is the exercise price of each pre-funded warrant. The gross proceeds from the
offering amounted to approximately $30 million before deducting underwriting discounts and offering expenses.
Our working capital did not include any indebtedness in 2024 or in 2023.
Our cash and cash equivalents amounted to €18.4 million as of December 31, 2024 (2023: €12.8 million). We also held
marketable securities valued at €36.8 million (2023: €85.6 million) as of December 31.2024. Our cash and cash equivalents
primarily consist of cash denominated in U.S. dollars and euros in bank deposit accounts. Our marketable securities consist of
quoted debt securities issued by financial institutions with investment grade credit ratings (BBB+ to AAA). Our cash is deposited
at banks with equally high credit ratings as assessed by international rating agencies.
We expect to finance our future operations and working capital needs in the near future predominantly with our cash and cash
equivalents and proceeds from the sale of our marketable securities and with the sale of new shares.
Cash flows - comparison of the years ended December 31, 2024 and 2023
The table below summarizes our consolidated statement of cash flows for the years ended December 31, 2024 and 2023:
2024
2023
(in €)
Net cash used in operating activities
(48,556,690) (37,812,966)
Net cash (used in)/from investing activities
52,364,354 (17,696,616)
Net cash from financing activities
386,446 52,986,269
Cash and cash equivalents at the beginning of the period
12,767,943 16,265,355
Exchange (losses)/gains on cash and cash equivalents
1,413,926
(974,099)
Cash and cash equivalents at the end of the period
18,375,979 12,767,943
-98-
Net cash used in operating activities
The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components
of working capital.
Net cash used in operating activities increased to €48.6 million in the year ended December 31, 2024, from €37.8 million in
the year ended December 31, 2023, mainly due to lower income recognized from the German federal government grants and
research allowances.
Net cash used in investing activities
Net cash used from investing activities during the year ended December 31, 2024 amounted to €52.4 million due to lower
purchases than proceeds of sales of marketable securities. During the previous year ending on December 31, 2023, we had a net
cash outflow of €-17.7 million due to more cash outflows from the purchase of marketable securities than inflows from the
proceeds from sales of marketable securities.
Net cash from financing activities
Net cash generated from financing activities decreased to €0.4 million in the year ended December 31, 2024 from
€53.0 million in the year ended December 31, 2023 primarily due to lesser proceeds from share issuances. In 2023, we had share
issuances through the underwritten public offering of April 2023 and through utilization of the at-the market offering program in
2023. Net cash generated from our at-the market offering program in 2024 amounted to €0.8 million.
Contractual obligations and commitments
The table below sets forth our operating expenses and capital expenditures from contractual obligations as of December 31,
2024.
Payments due by Period
Total
Less than
1 year
Between
1 and 3
Years
Between
3 and 5
Years
More than
5 years
(in €)
Unavoidable contractual (CRO, CDMO)
commitments and other contractual obligations
under operating contracts or services:
12,692,379
9,420,813
3,236,931
34,635
—
Contractual lease obligations (incl. capitalized
leases)
838,139
424,328
413,811
—
—
Total
13,530,518
9,845,141
3,650,742
34,635
—
We enter into contracts with CROs and clinical sites for the conduct of clinical trials, professional consultants for expert
advice and other vendors like CDMOs for clinical supply manufacturing or other services in the normal course of business. These
contracts can usually be terminated with 30 to 180 days notice. In addition to this minimum duration, these contracts require full
payment for services already commenced. In the table above, the amounts for unavoidable contractual obligations assumes that the
contracts were terminated on December 31, 2024 and would then continue to run for approximately 30 to 360 days.
Contractual lease obligations
Contractual lease obligations mainly consist of payments pursuant to non-cancellable lease agreements relating to our leases
of office and laboratory space. The lease term of our premises in Jena, Germany expires in December 2025. The lease term of our
premises in Planegg-Martinsried, Germany expires in May 2027. The lease term of our premises in Ann Arbor, Michigan, United
States expires in April 2026.
-99-
Funding requirements for future capital expenditure
We believe that our existing cash and cash equivalents and financial assets will enable us to fund our operating expenses and
capital expenditure requirements under our current business plan for at least the next 18 months.
We anticipate that our expenses will increase in the next years in connection with our ongoing activities. In particular, we
anticipate that we might expand our sales and marketing efforts for GOHIBIC (vilobelimab) in the United States, we might
advance our Phase 3 clinical development program with vilobelimab in PG, pursue the further clinical development for INF904
and will advance preparation of necessary submission documents for additional regulatory submissions to the EMA and for a full
BLA submission to the FDA beyond the received EUA as granted by the FDA in April 2023 for GOHIBIC (vilobelimab). We will
also explore clinical development of vilobelimab in several other indications. We also plan to continue clinical development of
INF904 and to initiate Phase 2 clinical trials once we selected the appropriate indications. We also plan to continue preclinical
development of IFX002. We plan to initiate new research and preclinical development efforts. If clinical data is supportive, we
may seek marketing approval for any product candidates that we successfully develop. In addition, if we obtain marketing
approval for any of our product candidates, we expect to incur significant commercialization expenses related to establishing
sales, marketing, distribution and other commercial infrastructure to commercialize such products. Accordingly, we will need to
obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed
or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future
commercialization efforts.
Until such time, if ever, that we can generate substantial meaningful product revenues, we expect to finance our cash needs
through a combination of equity offerings, debt financings, royalty-based financings, future collaborations, strategic alliances,
licensing arrangements and government grants. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, the interest of our current shareholders will be diluted, and the terms of these securities may include
voting or other rights that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt,
making capital expenditures, or declaring dividends. If we raise funds through additional collaborations, strategic alliances or
licensing arrangements with third parties, we may have to relinquish rights to our technologies, future revenue streams, research
programs or product candidates or to grant licenses on terms that may not be favorable to us. Money received through government
grants may require us to provide our product, if approved by regulatory authorities, at unfavorable conditions in such jurisdictions.
D.
Research and development, patents and licenses, etc.
See “ITEM 4. INFORMATION ON THE COMPANY — B. Business overview — Our intellectual property.”
E.
Trend information
Other than as disclosed elsewhere in this annual report on Form 20-F, we are not aware of any trends, uncertainties, demands,
commitments, or events for the year ended December 31, 2024 that are reasonably likely to have a material adverse effect on our
net revenue, income, profitability, liquidity, or capital resources, or that caused the disclosed financial information to be not
necessarily indicative of future operating results or financial condition (see “ITEM 5. OPERATING AND FINANCIAL REVIEW
AND PROSPECTS”).
F.
Critical accounting estimates
Our consolidated financial statements are prepared in conformity with IFRS, as issued by the IASB. In preparing our
consolidated financial statements, we make judgements, estimates and assumptions about the application of our accounting
policies which affect the reported amounts of assets, liabilities, revenue and expenses. Our critical accounting judgements and
sources of estimation uncertainty are described in note B.2. to our consolidated financial statements, which are included elsewhere
in this Annual Report.
-100-
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
A.
Directors and senior management
Board of Directors and senior management team
The following table presents information about our Board of Directors and senior management as of the date of this Annual
Report.
Name
Position
Age
Initial year of
appointment at
InflaRx GmbH, InflaRx N.V.
or
InflaRx Pharmaceuticals Inc.
(as applicable)
Niels Riedemann
Executive Director and Chief
Executive Officer
53
2007
Renfeng Guo
Executive Director and Chief
Scientific Officer
54
2007
Thomas Taapken
Chief Financial Officer
59
2020
Camilla Chong
Chief Medical Officer
59
2023
Derval O’Carroll
Senior Vice President, Global
Head of Regulatory Affairs and
Compliance
59
2023
Nicolas Fulpius
Non-Executive Director and Chairman of
the Board
51
2007
Richard Brudnick
Non-Executive Director
68
2019
Mark Kubler
Non-Executive Director
50
2015
Anthony Gibney
Non-Executive Director
54
2021
Hege Hellstrom
Non-Executive Director
59
2023
The terms for which Mark Kubler and Anthony Gibney have been appointed to the Board of Directors, will expire in 2028
and the terms for which Richard Brudnick, Nicolas Fulpius, Renfeng Guo, Niels Riedemann and Hege Hellstrom have been
appointed to the Board of Directors will expire in 2026.
Unless otherwise indicated, the current business address for our directors, senior management and key employees is InflaRx
N.V., Winzerlaer Strasse 2, 07745 Jena, Germany.
The following is a brief summary of the business experience of our directors, senior management and key employees. Each
director’s tenure reflects such director’s tenure on InflaRx GmbH’s board.
Non-executive directors
Nicolas Fulpius, Chairman. One of the co-founders of InflaRx, Nicolas Fulpius has served as Chairman of the Board since its
inception in 2007. Long active in the venture capital field between the United States and Europe, for the Lombard Odier
Immunology fund, for Ultreia Capital and as Partner at Affentranger Associates, Nicolas has become an entrepreneur at heart: he
created, developed and helped finance several companies in the Biotech, cleantech and ICT field. Recently, Mr. Fulpius was -
among others - CEO of Veltigroup, CDO of Swisscom and member of the Swisscom Ventures investment committee. In 2020,
Nicolas Fulpius co-founded the Ansam Group one of the leading ICT services company in Switzerland for which he is acting as
CEO and Chairman. Nicolas Fulpius holds an MBA from the University of St. Gallen, Switzerland, and a Masters in Science in
Engineering from Stanford University, USA.
Richard Brudnick. Richard Brudnick currently serves as Chief Business Officer for Prime Medicine, Inc., a leader in the field
of gene editing. Prior to joining Prime Medicine, Mr. Brudnick was Chief Business Officer and Head of Strategy for Codiak
BioSciences, a leader in the field of exosome therapeutics. Before Codiak, Mr. Brudnick was Executive Vice President of
Business Development and Alliance Management at Bioverativ, Inc., a company he helped found in 2016. Until Bioverativ’s
acquisition by Sanofi in March 2018, Mr. Brudnick led business development efforts to build a significant pipeline in rare blood
disorders, including an acquisition, a multi-product collaboration and additional scientific collaborations and licenses. Mr.
Brudnick joined Bioverativ at its spin-off from Biogen where, over the course of nearly 15 years, he initiated, led and completed
transactions that led to several of the company’s marketed products and late-stage pipeline. Mr. Brudnick also was CEO of a
regional pharmaceutical distribution business, which he sold to a strategic buyer; co-founded two companies; and was a strategy
consultant at Bain & Company. He holds bachelor and advanced degrees from MIT and serves on the board of directors of
Scholar Rock, Inc.
-101-
Mark Kubler. Mr. Kubler has served as a director on our board since 2015. Mr. Kubler has been a partner with the GIG Ltd., a
venture capital advisory firm with offices in Switzerland and Malta, since 2012. He previously served on the boards of WWM AG
and Jobydu AG, each based in Switzerland. Mr. Kubler was a managing director and corporate secretary of a private equity
holding company from 2003 to 2010. Before 2003, he held various roles in international investment banks and boutiques. Mr.
Kubler has a master’s degree in business and economics, as well as a master’s degree in law from the University of St. Gallen, in
Switzerland.
Anthony Gibney has served as a director of InflaRx since April 2021. Mr. Gibney is an experienced biotechnology executive
and former investment banker who brings over 25 years of experience dedicated to advising biotechnology companies in the U.S.
and Europe on business strategy, collaboration transactions, financings, and mergers and acquisitions. Most recently, Mr. Gibney
served as the Executive Vice President, Chief Business & Strategy officer of Iveric Bio, Inc. until the company’s acquisition by
Astellas Pharma Inc. in July 2023. Prior to that, Mr. Gibney served as Chief Financial Officer and Chief Business Officer at Fog
Pharmaceuticals, Inc., where he oversaw its business development, strategy and finance functions, and he served as Executive
Vice President and Chief Business Officer at Achillion Pharmaceuticals, where he led the sale of Achillion to Alexion
Pharmaceuticals, Inc. in 2020. Before Achillion, Mr. Gibney was a Managing Director and Co-head of the biotechnology
investment banking team at Leerink Partners LLC, and Managing Director of Merrill Lynch’s healthcare group. He currently
serves on the boards of directors of LAPIX Therapeutics, Inc. and Clearside Biomedical, Inc. Mr. Gibney received a B.A. in
Economics and a B.A. in History from Yale University.
Hege Hellstrom is currently Chief Commercial Officer in Advicenne, a French pharmaceutical company specializing in the
development of innovative treatments in Nephrology. She is a non-executive board member of Vivesto AB since 2019 and
Camurus AB since 2020, both public Swedish companies and she is also a member of the Audit Committee in both companies.
Mrs. Hellstrom is a non-executive board member of Guard Therapeutics, a Swedish public company since 2024. She is the
founder and managing director of Belnor BV, an investment and consulting company. Mrs. Hellstrom has more than 30 years’
experience in sales, marketing, strategy development, commercialization, partner alliances and executive management. From 2013
to 2018, she worked as President Europe, Middle East, North Africa and Russia in Sobi, a Swedish biopharmaceutical company
where she led several launches in rare diseases such as haemophilia and metabolic diseases. Before Sobi, she worked in Genzyme
for 11 years in roles ranging from General manager in Benelux to head of Renal and Endocrine business in Europe, LATAM and
JAPAC. When Genzyme was acquired by Sanofi she continued as Global Vice-president of Cardiovascular products in Sanofi.
Before Genzyme she worked in Baxter Healthcare for 13 years. Mrs. Hellstrom holds a B.Sc., Biomedical Laboratory Scientist
from Oslo Metropolitan University, Norway.
Executive directors
Niels Riedemann, Chief Executive Officer and Founder. Professor Riedemann is one of our co-founders and has served as our
Chief Executive Officer since our inception in 2007. Prof. Riedemann has over 15 years of experience in the biotech industry and
drug development as well as over 20 years of experience in complement immunology research. He founded InflaRx in 2007 and
has served as Chief Executive Officer since inception of the company. He has been instrumental in and led numerous private and
public financing rounds of the company and has been the responsible lead for its Nasdaq IPO in 2017. He is named inventor on
several internationally granted core patents of InflaRx. As physician he has been appointed Vice Director (Leitender Oberarzt) of
Intensive Care Medicine, and he has led a 50-bed University ICU unit for over 6 years at Friedrich Schiller University, Jena,
Germany until 2015. Before that, he received his board certification as General Surgeon upon completion of his surgical
fellowship at MHH (Hannover Medical School, Germany) in 2007 where he also received his habilitation (equivalent to Ph.D.)
and where he still holds an Adjunct Professorship (APL Professor). He spent three years as postdoctoral research fellow at the
University of Michigan, USA until 2003. He received his medical training at Albert Ludwig University (ALU), Freiburg,
Germany, and Stanford University, USA and graduated as Dr. med. (equivalent to M.D.) from ALU in 1998. His research has
been awarded with several national and international awards. He has received extensive extra-mural funding and published over
60 peer reviewed scientific publications in highly ranked journals. He has served as a member on a Board of Directors and a
Scientific Advisory Board of two large scientific governmental funded programs. He currently serves as Co-Chair of the Health
Politics working group of Bio-Deutschland and he serves as member of the board of trustees for the German Sepsis Foundation.
-102-
Renfeng Guo, Chief Scientific Officer and Founder. Prof. Renfeng Guo co-founded InflaRx in 2007. Since its inception, he
has headed scientific development at InflaRx as the full-time CSO. Prof. Guo leverages his expertise in antibody research and
inflammation, bringing together a highly effectual research team for drug development to build a focused pipeline based on
cutting-edge technology. His early research led to the discovery of InflaRx’s leading drug, vilobelimab. He continues to be the
driving force for the development of other pipeline drugs as well as a key inventor for InflaRx’s intellectual property portfolio.
Prof. Guo received his M.D. degree from Norman Bethune Medical School in China and conducted post-doctoral research in the
laboratory of Prof. Peter Ward at the University of Michigan, Ann Arbor. After stints as a junior and senior faculty member
beginning in 2001 at the University of Michigan, he is currently an Adjunct Research Associate Professor. Prof. Guo has over 80
high-impact, peer reviewed publications in the fields of cancer, infectious disease, and inflammation research.
Senior management
Thomas Taapken, Chief Financial Officer. Dr. Taapken joined lnflaRx as CFO in 2020. He has over 25 years of experience in
senior management positions within the life sciences sector and as a venture investor. He has previously held positions as CFO of
Medigene AG (publicly listed in Germany), as CEO and CFO of Epigenomics AG (publicly listed in Germany), where he led the
company’s efforts in gaining regulatory approval for the company’s lead product with the FDA and oversaw its subsequent
introduction into the US market, and as CFO at Biotie Therapies (publicly listed in Finland, now part of Acorda Therapeutics) and
its predecessor companies. Before that he was a venture investor for 7 years with Deutsche Venture Capital (DVC) and Burrill &
Co. in the US. Dr. Taapken started his career at Hoechst AG (now Sanofi). He holds a Ph.D. in organic chemistry from the
Technical University of Berlin and he also studied economics, chemistry and physics at the University of Göttingen. Dr. Taapken
is a Board member of Scibase AB since 2017, he was Chairman of the Board at lmcyse SA from June 2019 until May 2024.
Camilla Chong, Chief Medical Officer. Dr. Camilla Chong joined as Chief Medical Officer, or CMO, in July 2023. She is a
medical doctor with 25 years of experience in the global pharmaceutical industry. She has successfully led teams in clinical
development, medical affairs, clinical operations, regulatory and pharmacovigilance. Her extensive experience also includes the
development and launch of new medicines across different geographies in senior leadership roles at Kyowa Kirin,
GlaxoSmithKline, Pfizer and Teva. Dr. Chong received her medical degree from the Royal Free Hospital School of Medicine,
University College London, UK. She holds a Diploma in Pharmaceutical Medicine and was a member of the Faculty of
Pharmaceutical Medicine (MFPM).
Derval O’Carroll, Senior Vice President Regulatory Affairs and Quality Assurance. Ms. O’Carroll joined InflaRx as VP,
Head of Regulatory Affairs in 2022. She has over 30 years of experience in Regulatory Affairs with the last 19 years in senior
management positions contributing strategically to global product development and commercialization activities. She has
previously held positions as VP, Global Regulatory and Quality at rare disease company Amryt Pharmaceuticals for five years,
Senior Director of Regulatory Affairs at rare disease company Travere for 2 years and Managing Consultant at Regulatory
Consultancy, Real Regulatory for 11 years, where she worked on numerous drug development programs for international clients.
She gained prior experience in a number of roles which included drug, device and IVD products. Ms. O’Carroll has a proven track
record of leading global registration activities for innovative new products and is experienced in guiding teams through the FDA
and EMA regulatory agency interactions for pre-authorization, authorization and complex post marketing commitments. She holds
an M.Sc in Biochemistry and an M.B.A from University College, Dublin.
B.
Compensation
Compensation of directors and senior management
The aggregate compensation, including benefits in kind, accrued or paid to our executive management, or senior
management, with respect to the year ended December 31, 2024, for services in all capacities amounted to €5,746,059. In 2024,
we granted options to purchase 1,450,000 ordinary shares to our board of directors, or Board of Directors, and our Senior
Management.
-103-
The aggregate compensation, including benefits in kind, accrued or paid to our non-executive directors with respect to the
year ended December 31, 2024, for services in all capacities amounted to €601,879. In 2024 we granted options to purchase
165,000 ordinary shares to our non-executive Directors.
We refer to Note C.10. share-based payments of directors, senior management and non-executive directors.
Stock
options
outstanding
as of
January 1,
2024
Stock
options
granted in
2024
Stock
options
exercised
in 2024
Stock
options
outstanding
as of
December
31,
2024
weighted
average
exercise
price
in €
weighted
average
remaining
contractual
life
Stock options not exercised 2024
Senior Management including
executive directors
Prof. Niels C. Riedemann, CEO
2,837,714
635,000
3,472,714
1.73
5.97
Prof. Renfeng Guo, CSO
2,244,697
500,000
2,744,697
1.79
6.05
Thomas Taapken, CFO
507,002
210,000
717,002
1.81
7.06
Camilla Chong, CMO
150,000
60,000
210,000
3.04
8.66
Derval O’Carroll, Senior Vice
President, Global Head of
Regulatory Affairs and
Compliance
45,000
45,000
90,000
1.94
8.50
5,784,413 1,450,000
7,234,413
Non-executive Directors
Nicolas Fulpius, Chairman, and
Member of the Audit Committee
164,065
45,000
209,065
1.81
6.51
Anthony Gibney, Chairman of the
Audit Committee
88,085
30,000
118,085
1.82
7.14
Richard Brudnick, Member of the
Audit Committee
104,850
30,000
134,850
1.81
6.85
Mark Kübler, Member of the
Audit Committee
128,172
30,000
158,172
1.72
5.81
Hege Hellstrom
22,500
30,000
52,500
2.60
8.76
6,292,085 1,615,000
7,907,085
We established a policy in respect of the remuneration of our directors in accordance with Dutch law. Such policy addresses
the following topics: the fixed and variable components of the remuneration (if any), remuneration in the form of shares and
severance payments. The policy for the Board of Directors was adopted and approved by the general meeting of shareholders prior
to the consummation of our initial public offering. The Board of Directors determines the remuneration of the directors in
accordance with the compensation policy, with the understanding that executive directors will not participate in the decision-
making process regarding the determination of the compensation of executive directors. Compensation schemes in the form of
shares or rights to shares must be submitted by the Board of Directors to the general meeting for its approval. Any such proposal
must set out at least the maximum number of shares or rights to shares to be granted to the directors and the criteria for granting or
amendment.
As of December 31, 2024, we have no amounts set aside or accrued to provide pension, retirement or similar benefits to our
senior managers or directors.
-104-
Clawback policy
We have implemented a robust clawback policy to ensure accountability and alignment of executive compensation with long-
term sustainable financial performance. Under this policy, if our financial statements are restated due to material noncompliance
with financial reporting standards or as a result of fraudulent activities, the Board of Directors has the right to recover any
incentive-based compensation that was awarded to executive officers in excess of what they would have received under the
restated financial results. The clawback provisions apply to performance-based bonuses, equity-based compensation, and any
other compensation that is tied to achieving certain financial or non-financial targets. The policy is designed to discourage
excessive risk-taking or dishonest behavior that could harm the long-term interests of the company and its shareholders. The
clawback policy specifies the procedures, timelines, and criteria for determining when a clawback may be initiated, as well as the
process for calculating and recovering the amounts. The Board of Directors, in consultation with the Compensation Committee,
will review each individual case and make determinations based on the specific circumstances.
The clawback policy is disclosed in our corporate governance principles and is subject to oversight by the Compensation
Committee and the Board of Directors. We believe that the implementation of this policy reflects our commitment to maintaining
strong corporate governance practices and enhancing shareholder value.
Management and director service agreements
We entered into management services agreements with each of our executive management team members, including our two
executive directors that became effective upon the consummation of our initial public offering or at the time these managers
joined the Company. The management services agreements contain a termination notice period for us and the executive directors
appointed as such by a general meeting of shareholders. All of the management services agreements provide that the manager or
executive director, as the case might be, may be terminated in the event of an urgent cause (dringende reden) without advance
notice. In the event that an executive director no longer serves as an executive director but remains employed in his role as an
executive employee of the Company, the executive director will not be entitled to any contractual severance or termination
payments. Rather, we will enter into an employment agreement with the executive director, which may include substantially
similar compensation terms as provided under the management services agreements. The management services agreements
contain post-termination restrictive covenants, including perpetual confidentiality, and post-termination non-competition and non-
solicitation covenants.
In addition, we entered into letter agreements with each of our non-executive directors which became effective upon the
consummation of our initial public offering or at the time these directors were appointed to our board by a general meeting of
shareholders. The letter agreements may be terminated, without advance notice, if the non-executive director is removed from the
Board of Directors, resigns from the Board of Directors or such director’s term of office on the Board of Directors expires without
his reappointment as a non-executive director. Additionally, each letter agreement provides for compensation, including an annual
cash fee, an annual equity grant, an annual fee for membership on a committee of the Board of Directors, and an annual fee for
acting as a chairperson of a committee of the Board of Directors. Also, the letter agreements contain a perpetual confidentiality
covenant.
Share based compensation plans
2016 Plan
Under the stock option plan 2016 terms and conditions, or the 2016 Plan, we granted rights to subscribe for our ordinary
shares to directors, senior management and key employees.
All outstanding option awards under the 2016 Plan automatically vested upon closing of our initial public offering.
In conjunction with the corporate reorganization undertaken prior to our initial public offering, all outstanding awards granted
under the 2016 Plan or otherwise converted into awards exercisable for ordinary shares of InflaRx N.V. will be governed by the
terms of the 2016 Plan.
-105-
2017 Plan
In conjunction with the closing of our initial public offering, we established a new omnibus plan, the 2017 long term incentive
Plan, or the 2017 Plan, with the purpose of advancing the interests of our shareholders by enhancing our ability to attract, retain
and motivate individuals who are expected to make important contributions to us. The 2017 Plan governs issuances of equity
incentive awards from and after the closing of our initial public offering. The initial maximum number of ordinary shares
available for issuance under equity incentive awards granted pursuant to the 2017 Plan initially equaled 2,341,097 ordinary shares.
On January 1, 2021 and on January 1 of each calendar year thereafter, an additional number of shares equal to 4% of the total
outstanding ordinary shares on December 31 of the immediately preceding year (or any lower number of shares as determined by
the Board of Directors) will become available for issuance under equity incentive awards granted pursuant to the 2017 Plan.
The annual general meeting on July 16, 2020, approved an amendment to the 2017 Plan with effect from January 1, 2021:
●
increasing the maximum annual number of ordinary shares in the Company’s capital available for issuance under the
2017 Plan, starting on January 1, 2021, to 4% (from 3%) of the Company’s outstanding ordinary shares (determined as of
December 31 of the immediately preceding year); and
●
removing certain restrictions from the 2017 Plan, which will allow the committee administering the 2017 Plan and the
Board to (i) lower the exercise price per share of any options and/or share appreciation rights issued under the 2017 Plan
or take any other action treated as a ‘repricing’ of an award and (ii) cancel any option and/or share appreciation rights in
exchange for cash or another award granted under the 2017 Plan, in either case, without prior approval of the Company’s
shareholders.
Plan administration. The 2017 Plan is administered by a long-term incentive, or LTI, committee appointed by the Board of
Directors, which consists of not less than three directors.
Eligibility. Equity incentive awards may be granted to our employees, non-employee directors, consultants or other advisors,
as well as holders of equity compensation awards granted by a company that may be acquired by us in the future.
Awards. Equity incentive awards under the 2017 Plan may be granted in the form of stock options, stock appreciation rights,
restricted stock, restricted stock units, performance awards or other share-based awards. Stock options and stock appreciation
rights will have an exercise price determined by the plan committee but that is no less than fair market value of the underlying
ordinary shares on the date of grant.
Vesting. The vesting conditions for grants under the equity incentive awards under the 2017 Plan will be set forth in the
applicable award documentation. However, subject to the acceleration provisions under certain circumstances described below,
awards (other than replacement awards) may not vest in full prior to the first anniversary of the grant date, with the exception that
up to 5% of the shares available for issuance under the 2017 Plan may provide for alternative vesting conditions.
Termination of service and change in control. In the event of a participant’s termination of employment, the plan committee
may, in its discretion, determine the extent to which an equity incentive award may be exercised, settled, vested, paid or forfeited.
In the event of a change in control of the company (as defined in the 2017 Plan), any then successor or surviving corporation may
continue outstanding awards, or convert or substitute such awards for award or right with respect to the stock of the successor or
surviving corporation, in which case, if a participant is terminated by the successor or surviving corporation without “cause” or for
“good reason” (in each case, as defined in the 2017 Plan) within 24 months following the change in control, all equity incentive
awards held by the participant will immediately vest. If any outstanding awards are not continued or converted following a change
in control of the company, then such awards will immediately vest, and options and stock appreciation rights will become fully
exercisable. In connection with a change of control, the plan committee may, in its discretion, take a number of other actions,
including accelerating the vesting of any equity incentive award or terminating or cancelling any equity incentive award for cash
payment.
-106-
Insurance and indemnification
Our current and future directors (and such other officer or employee as designated by the Board of Directors) have the benefit
of indemnification provisions in our Articles of Association. These provisions give the indemnified persons the right to recover
from us amounts, including litigation expenses, and any damages they are ordered to pay, in relation to acts or omissions in the
performance of their duties. However, there is no entitlement to indemnification for acts or omissions which are considered to
constitute malice, gross negligence, intentional recklessness and/or serious culpability attributable to such indemnified person. In
addition, upon the closing of our initial public offering, we entered into agreements with our directors and executive officers to
indemnify them against expenses and liabilities to the fullest extent permitted by law. These agreements also provide, subject to
certain exceptions, for indemnification for related expenses, including attorneys’ fees, judgments, penalties, fines and settlement
amounts incurred by any of these individuals in any action or proceeding. In addition to such indemnification, we provide our
directors with directors’ and officers’ liability insurance.
Insofar as indemnification of liabilities arising under the Securities Act may be permitted to directors or persons controlling
us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is therefore unenforceable.
Compliance with Nasdaq listing requirements
We are a foreign private issuer. As a result, in accordance with Nasdaq listing requirements, we comply with certain home
country governance requirements rather than complying with certain Nasdaq corporate governance requirements. In accordance
with Dutch law and generally accepted business practices, our articles of association do not provide quorum requirements
generally applicable to general meetings of shareholders in the United States. To this extent, our practice varies from the
requirement of Nasdaq listing rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum,
and that such quorum may not be less than one-third of the outstanding voting stock. Although we must provide shareholders with
an agenda and other relevant documents for the general meeting of shareholders, Dutch law does not have a regulatory regime for
the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, and thus
our practice will vary from the requirement of Nasdaq listing rule 5620(b). As permitted by the listing requirements of Nasdaq, we
also opted out of the requirements of Nasdaq listing rule 5605(d), which requires an issuer to have a compensation committee that,
among other things, consists entirely of independent directors and makes determinations regarding the independence of any
compensation consultants, Nasdaq listing rule 5605(e), which requires an issuer to have independent director oversight of director
nominations, and Nasdaq listing rule 5605(b)(2), which requires an issuer to have a majority of independent directors on its board.
In addition, we opted out of shareholder approval requirements for the issuance of securities in connection with certain events
such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation
plans for employees and certain private placements. To this extent, our practice varies from the requirements of Nasdaq listing
rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such
events. For an overview of our corporate governance principles, see “ITEM 10. ADDITIONAL INFORMATION — B.
Memorandum and articles of association.”
C.
Board practices
Board of Directors
The Board of Directors is composed of seven members throughout the period under review, two of whom are executive
directors. Our executive directors and the chairman of our board shall initially serve for four-year terms and our other non-
executive directors shall initially serve for three-year terms, in each case until the earlier of their successors being duly appointed,
their resignation or their removal. After these terms, our directors may be nominated for re-appointment for such terms as may be
deemed appropriate by the Board of Directors. For the years of the directors’ initial appointment and term expiration dates, see A.
Directors and senior management.
Nasdaq’s board diversity rule
Nasdaq’s Board Diversity Rule, which was approved by the SEC on August 6, 2021, is a disclosure standard designed to
encourage minimum board diversity for companies and provide stakeholders with consistent, comparable disclosures concerning a
company’s current board composition. Nasdaq’s board diversity rule requires companies listed on Nasdaq to publicly disclose
board-level diversity statistics using a standardized template.
-107-
Board Diversity Matrix (As of March 20, 2025)
To be completed by Foreign Issuers (with principal executive offices outside of the U.S.) and Foreign Private Issuers
Country of Principal Executive Offices
Germany
Foreign Private Issuer
Yes
Disclosure Prohibited Under Home Country Law
No
Total Number of Directors
7
Female
Male
Non-
Binary
Did Not
Disclose
Gender
Part I: Gender Identity
Directors
1
6
0
0
Part II: Demographic Background
Underrepresented Individual in Home Country Jurisdiction
1
LGBTQ+
0
Did Not Disclose Demographic Background
6
The Board of Directors adopted a diversity policy in December 2021 as amended to become a diversity & inclusion policy in
October 2023, which is published on the Company’s website. This policy sets out diversity and inclusion aspects including our
targets relating to diversity in the composition of the Board of Directors. We believe that diversity encompasses acceptance and
respect, recognizing that each individual is unique. We are committed to supporting, valuing and leveraging diversity throughout
the Company and in the composition of the Board of Directors.
Board committees
Audit committee
The audit committee currently consists of Mr. Richard Brudnick, Mr. Nicolas Fulpius, Mr. Anthony Gibney, and Mr. Mark
Kubler. Mr. Anthony Gibney is the audit committee’s chair. The audit committee assists the Board of Directors in overseeing our
accounting and financial reporting processes and the audits of our financial statements. In addition, the audit committee is directly
responsible for the recommendation for appointment, compensation, retention and oversight of the work of our independent
registered public accounting firm. The Board of Directors has determined that each member of the audit committee satisfies the
“independence” requirements set forth in Rule 10A-3 under the Exchange Act and each qualifies as an “audit committee financial
expert,” as such term is defined in the rules of the SEC. The audit committee is governed by a charter that complies with
applicable Nasdaq rules, which charter has been posted on our website.
The audit committee’s responsibilities include:
●
recommending the appointment of the independent auditor to the general meeting of shareholders;
●
the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or
issuing an audit report or performing other audit services;
●
pre-approving the audit services and non-audit services to be provided by our independent auditor before the auditor is
engaged to render such services;
●
evaluating the independent auditor’s qualifications, performance and independence, and presenting its conclusions to the
full supervisory board on at least an annual basis;
●
reviewing and discussing with the Board of Directors and the independent auditor the audit plan as well as our annual
audited financial statements and quarterly financial statements prior to the filing of the respective annual and quarterly
reports;
●
overseeing the effectiveness and integrity of the internal audit function, ensuring its independence, objectivity, and
adherence to established policies and procedures;
●
reviewing our compliance with laws and regulations, including major legal and regulatory initiatives and also reviewing
any major litigation or investigations against us that may have a material impact on our financial statements;
-108-
●
reviewing internal audit results, including the effectiveness of the design and operation of our internal controls;
●
reviewing the operation of and our compliance with our code of ethics;
●
reviewing the operation of our compliance with our investment policy regulating all cash investment decisions regarding
the investment of available cash amounts and the maintenance of the cash investment portfolio of all Company’s entities
including all currency exchange transactions; and
●
reviewing the operation of our risk management system;
●
approving or ratifying any related person transaction (as defined in our related person transaction policy) in accordance
with our related person transaction policy and reviewing potential conflicts of interest involving our directors.
The audit committee meets as often as one or more members of the audit committee deem necessary, but in any event meets
at least quarterly. The audit committee meets at least once per year with our independent accountant without our executive
directors being present.
Compensation committee
The compensation committee consists of Mr. Richard Brudnick, Mr. Nicolas Fulpius and Mr. Mark Kubler. Mr. Nicolas
Fulpius is the compensation committee’s chair. The compensation committee assists the Board of Directors in determining
compensation for the directors. The committee recommends to the Board of Directors for determination the compensation of each
of our directors. Under SEC and Nasdaq rules, there are heightened independence standards for members of the compensation
committee, including a prohibition against the receipt of any compensation from us other than standard director fees. As permitted
by the listing requirements of Nasdaq, we opted out of Nasdaq Listing Rule 5605(d), which requires that a compensation
committee consist entirely of independent directors. The compensation committee is governed by a charter that has been posted on
our website.
The compensation committee’s responsibilities include:
●
identifying, reviewing and approving corporate goals and objectives relevant to compensation of our executive officers
and directors;
●
analyzing the possible outcomes of the variable remuneration components and how they may affect the remuneration of
our executive officers;
●
determining any long-term incentive component of each executive officer’s compensation in line with the compensation
policy and reviewing our executive officer compensation and benefits policies generally;
●
preparing periodic compensation reports for the Board of Directors;
●
review and recommendation to the Board of Directors for approval of the amendment or modification of the Company’s
“clawback” policy;
●
reviewing and assessing risks arising from our employee compensation policies and practices and whether any such risks
are reasonably likely to have a material adverse effect on us; and
●
retaining or obtaining advice from a compensation consultant, legal counsel or other advisor as the compensation
committee deems necessary or appropriate to carry out its responsibilities.
Nomination and corporate governance committee
The nomination and corporate governance committee consists of Mr. Nicolas Fulpius, Ms. Hege Hellstrom and Mr. Mark
Kubler. Mr. Nicolas Fulpius is the nomination and corporate governance committee’s chair. The nomination and corporate
governance committee assists the Board of Directors in identifying individuals qualified to become members of the Board of
Directors consistent with criteria established by the Board of Directors and in developing our corporate governance principles. As
permitted by the listing requirements of Nasdaq, we opted out of Nasdaq Listing Rule 5605(e), which requires independent
director oversight of director nominations. The nominating and corporate governance committee is governed by a charter that has
been posted on our website.
-109-
The nomination and corporate governance committee’s responsibilities include:
●
preparing and reviewing selection criteria and appointment procedures for the Board of Directors;
●
reviewing the size and composition of the Board of Directors by taking into account any diversity and inclusion criteria
and submitting proposals for the composition profile of the Board of Directors;
●
leading the Board of Directors in self-evaluation to determine whether it and its committees are functioning effectively;
●
preparing and reviewing a plan for succession of directors by taking into account any diversity and inclusion criteria; and
●
submitting proposals for the appointment or reappointment of directors.
D.
Employees
As of December 31, 2024, we had 74 employees, including 21 with M.D. or Ph.D. degrees. As of December 31, 2023, we had
66 employees, including 22 with M.D. or Ph.D. degrees.
E.
Share ownership
See “ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS —A. Major shareholders.”
F.
Disclosure of a registrant’s action to recover erroneously awarded compensation
As of December 31, 2024, we did not have an accounting restatement that required recovery of erroneously awarded
incentive-based compensation pursuant to our clawback policy. As of as of December 31, 2024, there were no outstanding
balances of erroneously awarded incentive-based compensation to be recovered from the application of the policy to a prior
restatement.
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
A.
Major shareholders
The following table presents information relating to the beneficial ownership of our ordinary shares as of December 31, 2024:
●
each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary
shares (as of the date of such shareholder’s Schedule 13G filing for InflaRx N.V. with the SEC);
●
each of our directors and senior management; and
●
all directors and senior management as a group.
The number of ordinary shares beneficially owned by each entity, person or director is determined in accordance with the rules of
the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules,
beneficial ownership includes any ordinary shares over which the individual has sole or shared voting power or investment power
or to receive the economic benefit of ownership of the shares, as well as any ordinary shares that the individual has the right to
acquire within 60 days of December 31, 2024 through the exercise of any option, warrant or other right. The percentage of shares
beneficially owned is computed on the basis of 59,351,710ordinary shares outstanding as of December 31, 2024. Ordinary shares
that a person has the right to acquire within 60 days of December 31, 2024 are deemed outstanding for purposes of computing the
percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage
ownership of any other person, except with respect to the percentage ownership of all directors and senior management as a group.
Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting
and investment power with respect to all ordinary shares held by that person. All shareholders have similar voting rights. As of
December 31, 2024, 14,296,756 ordinary shares, representing approximately 24.1% of our issued and outstanding ordinary shares,
were held by 10 U.S. record holders.
-110-
This table is based upon information supplied by our named senior management, directors, and principal shareholder, and
Schedules 13D, and 13G filed with the SEC. The percentage of outstanding ordinary shares is computed on the basis of
59,351,710 ordinary shares outstanding as of December 31, 2024. Ordinary shares that a person has the right to acquire within 60
days of December 31, 2024 are deemed outstanding for purposes of computing the percentage ownership of the person holding
such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person.
Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o InflaRx N.V., Winzerlaer Str.
2, 07745 Jena, Germany.
Ordinary Shares
Beneficially Owned
Number
Percent of
5% Shareholders
Entities affiliated with Suvretta Capital Management LLC(1)
5,733,910
9.7%
Directors and senior management
Niels Riedemann(2)
4,541,622
7.2%
Renfeng Guo(3)
4,506,841
7.3%
Thomas Taapken(4)
720,502
1.2%
Camilla Chong(5)
135,000
*
Derval O’Carroll(6)
90,000
*
Nicolas Fulpius(7)
676,986
1.1%
Richard Brudnick(8)
184,850
*
Mark Kubler(9)
1,118,187
1.9%
Anthony Gibney(10)
128,085
*
Hege Hellstrom(11)
52,500
*
All directors and senior management as a group (10 persons)
12,154,573
18.2%
*
Indicates beneficial ownership of less than 1% of the total outstanding ordinary shares.
(1) As per filing on Schedule 13G as of April 12, 2023, Aaron Cowen has beneficial ownership by virtue of his role as a control
person of Suvretta Capital Management LLC. The address of Suvretta Capital Management LLC is 540 Madison Avenue, 7th
Floor, New York, New York 10022.
(2) Consists of (a) 1,068,908 ordinary shares, (b) 404,040 ordinary shares that may be acquired pursuant to the exercise of
options which were issued pursuant to the 2016 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022
from $3.35 per share), which shall expire on November 18, 2031, (c) 126,005 ordinary shares that may be acquired pursuant
to the exercise of options which were issued pursuant to the Series B financing at an exercise price of €0.0012 per share, (d)
689,253 ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan
at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall expire on
December 13, 2025, (e) 5,409 ordinary shares that may be acquired pursuant to the exercise of options which were issued
pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from $3.35 per share),
which shall expire on November 20, 2026, (f) 350,000 ordinary shares that may be acquired pursuant to the exercise of
options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022
from $5.14 per share), which shall expire on January 4, 2031, (g) 112,007 ordinary shares that may be acquired pursuant to
the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on
April 13, 2022 from $2.99 per share), which shall expire on July 1, 2031, (h) 548,000 ordinary shares that may be acquired
pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after
re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January 11, 2032, (i) 55,000 ordinary shares that
may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $2.44
per share, which shall expire on November 21, 2032, (j) 548,000 ordinary shares that may be acquired pursuant to the
exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $2.37 per share, which shall expire on
January 24, 2033, and (k) 635,000 ordinary shares that may be acquired pursuant to the exercise of options which were issued
pursuant to the 2017 Plan at an exercise price of $1.79 per share, which shall expire on January 5, 2034.
-111-
(3) Consists of (a) 1,762,144 ordinary shares, (b) 336,672 ordinary shares that may be acquired pursuant to the exercise of
options which were issued pursuant to the 2016 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022
from $3.35 per share), which shall expire on November 18, 2031, (c) 623,610 ordinary shares that may be acquired pursuant
to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing
on April 13, 2022 from $3.35 per share), which shall expire on December 13, 2025, (d) 5,409 ordinary shares that may be
acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per
share (after re-pricing on April 13, 2022 from $3.35 per share), which shall expire on November 20, 2026, (e) 275,000
ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an
exercise price of $1.86 per share (after re-pricing on April 13, 2022 from $5.14 per share), which shall expire on January 4,
2031, (f) 88,006 ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to the
2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from $2.99 per share), which shall expire
on July 1, 2031, (g) 430,500 ordinary shares that may be acquired pursuant to the exercise of options which were issued
pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from $4.13 per share),
which shall expire on January 11, 2032, (h) 55,000 ordinary shares that may be acquired pursuant to the exercise of options
which were issued pursuant to the 2017 Plan at an exercise price of $2.44 per share, which shall expire on November 21,
2032, (i) 430,500 ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to the
2017 Plan at an exercise price of $2.37 per share, which shall expire on January 24, 2033, and (k) 500,000 ordinary shares
that may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of
$1.79 per share, which shall expire on January 5, 2034.
Consists of (a) 3,500 ordinary shares, (b) 150,000 ordinary shares that may be acquired pursuant to the exercise of options
which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from
$4.83 per share), which shall expire on September 17, 2028, (c) 50,000 ordinary shares that may be acquired pursuant to the
exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on
April 13, 2022 from $5.14 per share), which shall expire on January 4, 2031, (d) 32,002 ordinary shares that may be acquired
pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after
re-pricing on April 13, 2022 from $2.99 per share), which shall expire on July 1, 2031, (e) 110,000 ordinary shares that may
(4)
be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per
share (after re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January 11, 2032, (f) 55,000 ordinary
shares that may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise
price of $2.44 per share, which shall expire on November 21, 2032, (g) 110,000 ordinary shares that may be acquired
pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $2.37 per share, which
shall expire on January 24, 2033, and (h) 210,000 ordinary shares that may be acquired pursuant to the exercise of options
which were issued pursuant to the 2017 Plan at an exercise price of $1.79 per share, which shall expire on January 5, 2034.
(5) Consists of (a) 75,000 ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to
the 2017 Plan at an exercise price of $3.89 per share, which shall expire on July 7, 2033, and (b) 60,000 ordinary shares that
may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.79
per share, which shall expire on January 5, 2034.
(6) Consists of (a) 20,000 ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to
the 2017 Plan at an exercise price of $2.44 per share, which shall expire on November 21, 2032, (b) 25,000 ordinary shares
that may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of
$2.37 per share, which shall expire on January 24, 2033, and (c) 45,000 ordinary shares that may be acquired pursuant to the
exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.79 per share, which shall expire on
January 5, 2034.
-112-
(7) Consists of (a) 467,921 ordinary shares, (b) 34,464 ordinary shares that may be acquired pursuant to the exercise of options
which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from
$3.35 per share), which shall expire on December 13, 2025, (c) 30,000 ordinary shares that may be acquired pursuant to the
exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on
April 13, 2022 from $5.14 per share), which shall expire on January 4, 2031, (d) 9,601 ordinary shares that may be acquired
pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after
re-pricing on April 13, 2022 from $2.99 per share), which shall expire on July 1, 2031, (e) 45,000 ordinary shares that may be
acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per
share (after re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January 11, 2032, (f) 45,000 ordinary
shares that may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise
price of $2.37 per share, which shall expire on January 24, 2033, and (g) 45,000 ordinary shares that may be acquired
pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.79 per share, which
shall expire on January 5, 2034.
(8) Consists of (a) 50,000 ordinary shares, (b) 18,450 ordinary shares that may be acquired pursuant to the exercise of options
which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from
$3.35 per share), which shall expire on February 4, 2027, (c) 20,000 ordinary shares that may be acquired pursuant to the
exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on
April 13, 2022 from $5.14 per share), which shall expire on January 4, 2031, (d) 6,400 ordinary shares that may be acquired
pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after
re-pricing on April 13, 2022 from $2.99 per share), which shall expire on July 1, 2031, (e) 30,000 ordinary shares that may be
acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per
share (after re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January 11, 2032, and (f) 30,000
ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an
exercise price of $2.37 per share, which shall expire on January 24, 2033, and (g) 30,000 ordinary shares that may be
acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.79 per
share, which shall expire on January 5, 2034.
(9) Consists of (a) 960,015 ordinary shares, (b) 7,308 ordinary shares that may be acquired pursuant to the exercise of options
which were issued pursuant to the Series B financing at an exercise price of €0.0012 per share, (c) 34,464 ordinary shares that
may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86
per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall expire on December 13, 2025, (d) 20,000
ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an
exercise price of $1.86 per share (after re-pricing on April 13, 2022 from $5.14 per share), which shall expire on January 4,
2031, (e) 6,400 ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to the
2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from $2.99 per share), which shall expire
on July 1, 2031, (f) 30,000 ordinary shares that may be acquired pursuant to the exercise of options which were issued
pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from $4.13 per share),
which shall expire on January 11, 2032, and (g) 30,000 ordinary shares that may be acquired pursuant to the exercise of
options which were issued pursuant to the 2017 Plan at an exercise price of $2.37 per share, which shall expire on January 24,
2033, and (h) 30,000 ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to
the 2017 Plan at an exercise price of $1.79 per share, which shall expire on January 5, 2034.
Consists of (a) 10,000 ordinary shares, (b) 11,667 ordinary shares that may be acquired pursuant to the exercise of options
which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on April 13, 2022 from
$22.75 per share), which shall expire on February 7, 2026, (c) 16,418 ordinary shares that may be acquired pursuant to the
(10)
exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing on
April 13, 2022 from $2.99) per share, which shall expire on July 1, 2031, (d) 30,000 ordinary shares that may be acquired
pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after
re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January 11, 2032, and (e) 30,000 ordinary shares
that may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of
$2.37 per share, which shall expire on January 24, 2033, and (f) 30,000 ordinary shares that may be acquired pursuant to the
exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.79 per share, which shall expire on
January 5, 2034.
(11) Consists of (a) 22,500 ordinary shares that may be acquired pursuant to the exercise of options which were issued pursuant to
the 2017 Plan at an exercise price of $4.19 per share, which shall expire on May 31, 2033, and (b) 30,000 ordinary shares that
may be acquired pursuant to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.79
per share, which shall expire on January 5, 2034.
-113-
Significant changes in ownership by major shareholders
In January and February 2025, the Company issued 145,420 ordinary shares under its at-the-market program, resulting in
$353k in net proceeds. In February 2025, the company completed an underwritten public offering of an aggregate of 8,250,000
ordinary shares and pre-funded warrants to purchase 6,750,000 ordinary shares. The ordinary shares were sold at a price of $2.00
per share with a nominal value of €0.12 per share. The public offering price for each pre-funded warrant was equal to the price per
share at which the ordinary shares were sold to the public, minus $0.001, which is the exercise price of each pre-funded warrant.
In addition, InflaRx granted the underwriters a 30-day option to purchase up to an additional 2,250,000 ordinary shares. The gross
proceeds from the offering were approximately $30 million before deduction of the underwriting discount and estimated offering
expenses.
Suvretta Capital Management LLC and affiliated entities filed a Schedule 13G as of April 12, 2023, stating a shareholding of
5,733,910 shares, which resulted in a holding of 9.7% in the Company as of December 31, 2024.
B.
Related party transactions
The following is a description of related party transactions we have entered since January 1, 2024 with any of our officers,
directors and the holders of more than 5% of our ordinary shares.
1.
Indemnification agreements
We entered into indemnification agreements with our directors and senior management. The indemnification agreements and
our Articles of Association require us to indemnify our directors to the fullest extent permitted by law. See “ITEM 6.
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES — B. Compensation — Insurance and indemnification” for a
description of these indemnification agreements.
2.
Interests of experts and counsel
Not applicable.
-114-
ITEM 8. FINANCIAL INFORMATION
A.
Consolidated statements and other financial information
1.
Financial statements
See “ITEM 18. FINANCIAL STATEMENTS,” which contains our audited financial statements prepared in accordance with
IFRS-IASB.
2.
Legal proceedings
From time to time we are involved in legal proceedings that arise in the ordinary course of business. We believe that the
outcome of these proceedings, if determined adversely, will not have a material adverse effect on our financial position. During
the period covered by the audited and approved financial statements contained herein, we have not been a party to or paid any
damages in connection with litigation that has had a material adverse effect on our financial position. Any future litigation may
result in substantial costs and be a distraction to management and our employees. No assurance can be given that future litigation
will not have a material adverse effect on our financial position. For an additional discussion of certain risks associated with legal
proceedings, see “ITEM 3. KEY INFORMATION — D. Risk factors.”
3.
Dividends and dividend policy
We have never paid or declared any cash dividends on our ordinary shares, and we do not anticipate paying any cash
dividends on our ordinary shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund
the development and expansion of our business. Under Dutch law, we may only pay dividends to the extent our shareholders’
equity (eigen vermogen) exceeds the sum of the paid-up and called-up share capital plus the reserves required to be maintained by
Dutch law or by our Articles of Association. Subject to such restrictions, any future determination to pay dividends will be at the
discretion of the Board of Directors and will depend upon a number of factors, including our results of operations, financial
condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the Board of
Directors deems relevant.
B.
Significant changes
A discussion of the significant changes in our business can be found under “ITEM 4. INFORMATION ON THE COMPANY
— A. History and development of the company.”
-115-
ITEM 9. THE OFFER AND LISTING
A.
Offering and listing details
Not applicable.
B.
Plan of distribution
Not applicable.
C.
Markets
Our ordinary shares began trading on the Nasdaq Global Select Market under the symbol “IFRX” on November 8, 2017.
D.
Selling shareholders
Not applicable.
E.
Dilution
Not applicable.
F.
Expenses of the issue
Not applicable.
-116-
ITEM 10. ADDITIONAL INFORMATION
A.
Share capital
Not applicable.
B.
Memorandum and articles of association
Our shareholders adopted the Articles of Association included as Exhibit 1.1. to the Annual Report on form 20-F for the year
ended December 31, 2023 filed with the SEC on March 21, 2024.
We incorporate by reference into this Annual Report the description of our Articles of Association contained in our F-3
registration statement (File No. 333-273058) originally filed with the SEC on June 30, 2023, and effective as of July 11, 2023, as
amended. Such description sets forth a summary of certain provisions of our Articles of Association as currently in effect.
The Company’s Articles of Association in effect for the period under review was adopted by the annual general meeting on
April 25, 2024, and is available on our website.
C.
Material contracts
Except as otherwise disclosed in this Annual Report (including the Exhibits), we are not currently, and have not been in the
last two years, party to any material contract, other than contracts entered into in the ordinary course of business.
D.
Exchange controls
Not applicable.
E.
Taxation
The following summary contains a description of certain U.S. federal income, Dutch and German tax consequences of
ownership and disposition of our ordinary shares. The summary is based upon the tax laws of the United States, The Netherlands
and Germany, and regulations thereunder as of the date hereof, which are subject to change.
MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR U.S. HOLDERS OF ORDINARY SHARES
The following is a description of the material U.S. federal income tax consequences to the U.S. Holders, as defined below, of
owning and disposing of ordinary shares. It does not set forth all tax considerations that may be relevant to a particular person’s
decision to hold the ordinary shares.
This section applies only to a U.S. Holder that holds ordinary shares as capital assets for U.S. federal income tax purposes. In
addition, it does not set forth all of the U.S. federal income tax consequences that may be relevant in light of the U.S. Holder’s
particular circumstances, including alternative minimum tax consequences, the potential application of the provisions of the Code
known as the Medicare contribution tax and tax consequences applicable to U.S. Holders subject to special rules, such as:
●
certain financial institutions;
●
dealers or traders in securities who use a mark-to-market method of tax accounting;
●
persons holding ordinary shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other
integrated transaction or persons entering into a constructive sale with respect to the ordinary shares;
●
persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;
●
entities classified as partnerships for U.S. federal income tax purposes or other pass-through entities;
●
tax-exempt entities, including an “individual retirement account” or “Roth IRA”;
-117-
●
persons that own or are deemed to own 10% or more of our shares (by vote or value);
●
persons that acquire our shares directly or indirectly in connection with the performance of services;
●
persons who are subject to Section 451(b) of the Code; or
●
persons holding ordinary shares in connection with a trade or business conducted outside of the United States.
If an entity that is classified as a partnership for U.S. federal income tax purposes holds ordinary shares, the U.S. federal
income tax treatment of a partner will depend on the status of the partner and the activities of the partnership. Partnerships holding
ordinary shares and partners in such partnerships should consult their tax advisers as to the particular U.S. federal income tax
consequences of owning and disposing of the ordinary shares.
This section is based on the Code, administrative pronouncements, judicial decisions, final, temporary and proposed Treasury
regulations, and the income tax treaty between Germany and the United States and the income tax treaty between the Netherlands
and the United States (as applicable and as the context requires the “Treaty”) all as of the date hereof, any of which is subject to
change or differing interpretations, possibly with retroactive effect. No assurance can be given that the IRS will agree with the
views expressed in this discussion, or that a court will not sustain any challenge by the IRS in the event of litigation. We have not
obtained, nor do we intend to obtain, a ruling from the IRS with respect to the statements made and the conclusions reached in the
following summary.
A “U.S. Holder” is a holder who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares, who is
eligible for the benefits of the Treaty and who is:
●
a citizen or individual resident of the United States;
●
a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any
state therein or the District of Columbia;
●
an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source; or
●
a trust, if a U.S. court can exercise primary supervision over the trust’s administration and one or more U.S. persons are
authorized to control all substantial decisions of the trust.
U.S. Holders should consult their tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of
owning and disposing of ordinary shares in their particular circumstances. In particular, because our group includes a U.S.
subsidiary, InflaRx Pharmaceuticals, Inc., and therefore under current law our subsidiary InflaRx GmbH is treated as a controlled
foreign corporation (regardless of whether we are or are not treated as a controlled foreign corporation), any U.S. Holder that
owns or is deemed to own 10% or more of our shares (by vote or value) is urged to consult its tax advisor regarding the potential
application of the “Subpart F income” and “global intangible low-taxed income” rules to an investment in our ordinary shares.
-118-
1.
Taxation of distributions
As discussed above under “ITEM 8. FINANCIAL INFORMATION — A. Consolidated statements and other financial
information — 1.3 Dividends and dividend policy,” we do not currently expect to make distributions on our ordinary shares. In
the event that we do make distributions of cash or other property, subject to the PFIC rules described below, distributions paid on
ordinary shares, other than certain pro rata distributions of ordinary shares, will be treated as dividends to the extent paid out of
our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). For so long as we are
treated as a PFIC with respect to a U.S. Holder (or were treated as a PFIC with the respect to the U.S. Holder in the preceding
taxable year), dividends paid to certain non-corporate U.S. Holders will not be eligible for taxation as “qualified dividend
income.” To the extent we are not treated as a PFIC with respect to a U.S. Holder and were not treated as a PFIC with the respect
to the U.S. Holder in the preceding taxable year (if for example in future years we cease to meet the threshold requirements for
PFIC status and the U.S. Holder initially acquires our ordinary shares in a year in which we are not treated as a PFIC and we are
not so treated thereafter or we were a PFIC with respect to a U.S. Holder for a year during which a U.S. Holder holds ordinary
shares but the U.S. Holder makes a valid deemed sale or deemed dividend election under the applicable Treasury regulations with
respect to its ordinary shares), for so long as our ordinary shares are listed on Nasdaq or another established securities market in
the United States or we are eligible for benefits under the Treaty, dividends paid to such a U.S. Holder that is not a corporation
would generally be eligible for taxation as “qualified dividend income” if certain other requirements are met, which is generally
taxable at rates not in excess of the long-term capital gain rate applicable to such U.S. Holders. The amount of a dividend will
include any amounts withheld by us in respect of German or Dutch income taxes. Subject to the PFIC rules described below, the
amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the
dividends-received deduction available to U.S. corporations under the Code and dividends will be included in a U.S. Holder’s
income on the date of the U.S. Holder’s receipt of the dividend. The amount of any dividend income paid in euros will be the U.S.
dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of
whether the payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency gain or loss if the
dividend is converted into U.S. dollars after the date of receipt. Generally, gain or loss, if any, resulting from currency exchange
fluctuations during the period from the date the dividend is paid to the date such payment is converted into U.S. dollars will be
treated as U.S. source ordinary income or loss.
Subject to applicable limitations, German or Dutch income taxes withheld from dividends on ordinary shares at a rate not
exceeding the rate provided by the Treaty will be eligible for credit against the U.S. Holder’s U.S. federal income tax liability.
German or Dutch taxes withheld in excess of the rate applicable under the Treaty will not be eligible for credit against a U.S.
Holder’s federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders should consult their
tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit,
U.S. Holders may deduct foreign taxes, including any German or Dutch income tax, in computing their taxable income, subject to
generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies
to all foreign taxes paid or accrued in the taxable year. See “ITEM 3. KEY INFORMATION — 3. Risk factors — Risks related to
our ordinary shares and our status as a public company if we ever pay dividends, we may need to withhold tax on such dividends
payable to holders of our shares in both Germany and the Netherlands.”
2.
Sale or other disposition of ordinary shares
Subject to the PFIC rules described below, gain or loss realized on the sale or other disposition of ordinary shares will be
capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the ordinary shares for more than one year.
The amount of the gain or loss will equal the difference between the U.S. Holder’s tax basis in the ordinary shares disposed of and
the amount realized on the disposition, in each case as determined in U.S. dollars.
3.
PFIC rules
We believe it is likely that we were a PFIC for U.S. federal income tax purposes in 2022, 2023 and 2024, and we may be a
PFIC in one or more future taxable years. In addition, we may, now or in the future directly or indirectly, hold equity interests in
other PFICs, or a Lower-tier PFIC. Under the Code, generally a non-U.S. corporation will be a PFIC for any taxable year in
which, after the application of certain look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income
consists of passive income or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are
held for the production of, “passive income.” For purposes of the above calculations, we will be treated as if we hold our
proportionate share of the assets of, and receive directly our proportionate share of the income of, any other corporation in which
we directly or indirectly own at least 25%, by value, of the shares of such corporation. Passive income includes, among other
things, dividends, interest, certain non-active rents and royalties, and capital gains. It is also possible that we will be a PFIC in any
future taxable year because, among other things, (i) we currently own a substantial amount of passive assets, including cash and
securities that may give rise to passive income, (ii) the valuation of our assets that generate non-passive income for PFIC
purposes, including our intangible assets, is uncertain and may vary substantially over time, and (iii) the composition of our
income may vary substantially over time. Accordingly, there can be no assurance that we will not be a PFIC for any taxable year.
If we are a PFIC for any year during which a U.S. Holder holds ordinary shares, we would continue to be treated as a PFIC with
respect to that U.S. Holder for all succeeding years during which the U.S. Holder holds ordinary shares, even if we ceased to meet
the threshold requirements for PFIC status, unless under certain circumstances the U.S. Holder makes a valid deemed sale or
deemed dividend election under the applicable Treasury regulations with respect to its ordinary shares.
-119-
Under attribution rules, assuming we are a PFIC, U.S. Holders will be deemed to own their proportionate shares of any
Lower-tier PFICs and will be subject to U.S. federal income tax according to the rules described in the following paragraphs on (i)
certain distributions by a Lower-tier PFIC and (ii) a disposition of shares of a Lower-tier PFIC, in each case as if the U.S. Holder
held such shares directly, even if the U.S. Holder has not received the proceeds of those distributions or dispositions.
If we were a PFIC for any taxable year during which a U.S. Holder held ordinary shares (assuming such U.S. Holder has not
made a timely mark-to-market election, as described below), gain recognized by a U.S. Holder on a sale or other disposition
(including certain pledges) of the ordinary shares, or an indirect disposition of shares of a Lower-tier PFIC, would be allocated
ratably over the U.S. Holder’s holding period for the ordinary shares. The amounts allocated to the taxable year of the sale or
other disposition and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each
other taxable year would be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that
taxable year, and an interest charge would be imposed on the amount allocated to that taxable year. Further, to the extent that any
distribution received by a U.S. Holder on its ordinary shares (or a distribution by a Lower-tier PFIC to its shareholder that is
deemed to be received by a U.S. Holder) exceeds 125% of the average of the annual distributions on the ordinary shares received
during the preceding three years or the U.S. Holder’s holding period, whichever is shorter, that distribution would be subject to
taxation in the same manner as gain, described immediately above.
A U.S. Holder can avoid certain of the adverse rules described above by making a mark-to-market election with respect to its
ordinary shares, provided that the ordinary shares are “marketable.” Ordinary shares will be marketable if they are “regularly
traded” on a “qualified exchange” or other market within the meaning of applicable Treasury regulations. Our ordinary shares will
be treated as “regularly traded” in any calendar year in which more than a de minimis quantity of the ordinary shares is traded on a
qualified exchange on at least 15 days during each calendar quarter. Nasdaq, on which the ordinary shares are currently listed, is a
qualified exchange for this purpose. If a U.S. Holder makes the mark-to-market election, it will recognize as ordinary income any
excess of the fair market value of the ordinary shares at the end of each taxable year over their adjusted tax basis, and will
recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ordinary shares over their fair market value at
the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-
market election). If a U.S. Holder makes the election, the U.S. Holder’s tax basis in the ordinary shares will be adjusted to reflect
the income or loss amounts recognized. Any gain recognized on the sale or other disposition of ordinary shares in a year when we
are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net
amount of income previously included as a result of the mark-to-market election). U.S. Holders should consult their tax advisers
regarding the availability and advisability of making a mark-to-market election in their particular circumstances.
In addition, in order to avoid the application of the foregoing rules, a United States person that owns stock in a PFIC for U.S.
federal income tax purposes may make an election to treat the PFIC and each PFIC in which the PFIC holds equity interests as a
qualified electing fund (any such election, a QEF Election) with respect to each such PFIC if the PFIC provides the information
necessary for such election(s) to be made. In order to make such an election, a United States person would be required to make the
QEF Election for each PFIC by attaching a separate properly completed IRS Form 8621 for each PFIC to the United States
person’s timely filed U.S. federal income tax return generally for the first taxable year that the entity is treated as a PFIC with
respect to the United States person. A U.S. Holder generally may make a separate election to defer payment of taxes on the
undistributed income inclusion under the QEF rules, but if deferred, any such taxes are subject to an interest charge.
If a United States person makes a QEF Election with respect to a PFIC, the United States person will be currently taxable on
its pro rata share of the PFIC’s ordinary earnings and net capital gain (at ordinary income and capital gain rates, respectively) for
each taxable year that the entity is classified as a PFIC and will not be required to include such amounts in income when actually
distributed by the PFIC. If a U.S. Holder makes a QEF Election with respect to us, any distributions paid by us out of our earnings
and profits that were previously included in the U.S. Holder’s income under the QEF Election will not be taxable to the U.S.
Holder. A U.S. Holder will increase its tax basis in its ordinary shares by an amount equal to any income included under the QEF
Election and will decrease its tax basis by any amount distributed, if any, on the ordinary shares that is not included in its income.
In addition, a U.S. Holder will recognize capital gain or loss on the disposition of ordinary shares in an amount equal to the
difference between the amount realized and its adjusted tax basis in the ordinary shares. U.S. Holders should note that if they
make QEF Elections with respect to us and Lower-tier PFICs, if any, they may be required to pay U.S. federal income tax with
respect to their ordinary shares for any taxable year significantly in excess of any cash distributions, if any, received on the shares
for such taxable year. U.S. Holders should consult their tax advisers regarding making QEF Elections in their particular
circumstances.
-120-
In addition, if we were a PFIC or, with respect to a particular U.S. Holder, were treated as a PFIC for the taxable year in
which we paid a dividend or for the prior taxable year, the preferential dividend rates with respect to dividends paid to certain non-
corporate U.S. Holders would not apply.
If a U.S. Holder owns ordinary shares during any year in which we are a PFIC, the U.S. Holder must file annual reports,
containing such information as the U.S. Treasury may require on IRS Form 8621 (or any successor form) with respect to us, with
the U.S. Holder’s federal income tax return for that year, unless otherwise specified in the instructions with respect to such form.
The U.S. federal income tax rules relating to PFICs are very complex. U.S. Holders are strongly urged to consult their tax
advisors with respect to the impact of PFIC status on the purchase, ownership and disposition of our ordinary shares, the
consequences to them of an investment in a PFIC (and any Lower-tier PFICs), any elections available with respect to our ordinary
shares and the IRS information reporting obligations with respect to the purchase, ownership and disposition of ordinary shares of
a PFIC.
The IRS has finalized Treasury Regulations that address various issues related to determining whether a foreign corporation is
a PFIC and whether a U.S. shareholder holds PFIC stock and released proposed Treasury Regulations that address various issues
related to determining whether a foreign corporation is a PFIC. These Treasury Regulations and proposed Treasury Regulations (if
finalized) may affect whether we are a PFIC in in any future year. You should consult your tax adviser regarding the effect, if any,
these Treasury Regulations may have, or such proposed Treasury Regulations would have, on the determination of our PFIC
status.
4.
Information reporting and backup withholding
Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial
intermediaries are subject to information reporting, and may be subject to backup withholding, unless (i) the U.S. Holder is a
corporation or other exempt recipient or (ii) in the case of backup withholding, the U.S. Holder provides a correct taxpayer
identification number and certifies that it is not subject to backup withholding.
The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the holder’s U.S.
federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS.
5.
Information reporting with respect to foreign financial assets
Certain U.S. Holders who are individuals and certain entities may be required to report information relating to an interest in
our ordinary shares, subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by
certain U.S. financial institutions). U.S. Holders should consult their tax advisers regarding whether or not they are obligated to
report information relating to their ownership and disposition of the ordinary shares.
6.
Material Dutch tax considerations
General
The following is a general summary of section outlines certain material Dutch tax consequences of the acquisition, holding
and disposal of our ordinary shares. This summary section does not purport to describe all possible tax considerations or
consequences that may be relevant to a holder or prospective holder of ordinary shares and does not purport to deal with the tax
consequences applicable to all categories of investors, some of which (such as trusts or similar arrangements) may be subject to
special rules. In view of its general nature, this general summary section should be treated with corresponding caution. To the
extent this summary relates to legal conclusions under current Netherlands tax law, and subject to the qualifications it contains, it
represents the opinion of NautaDutilh N.V., our special Dutch counsel. Holders or prospective holders of shares should consult
with their own tax advisors with regard to the tax consequences of investing in the shares in their particular circumstances. The
discussion below is included for general information purposes only.
-121-
For the purposes of this discussion, it is assumed that we are a tax resident of Germany under German national tax laws since
we intended to have, from our incorporation and on a continuous basis, our place of effective management in Germany. See Risk
Factor “We may become taxable in a jurisdiction other than Germany and this may increase the aggregate tax burden on us.”
Please note that this summary section does not describe the Dutch tax considerations for:
●
holders of our ordinary shares if such holders, and in the case of individuals, his or her partner or certain of their relatives
by blood or marriage in the direct line (including foster children), have a substantial interest (aanmerkelijk belang) or
deemed substantial interest (fictief aanmerkelijk belang) in the Company in us under the Dutch Income Tax Act 2001
(Wet inkomstenbelasting 2001). Generally speaking, a holder of securities in a company is considered to hold a
substantial interest in such company, if such holder alone or, in the case of individuals, together with his or her partner
(as defined in the Dutch Income Tax Act 2001, directly or indirectly, holds (i) an interest of 5% or more of the total
issued and outstanding capital of that company or of 5% or more of the issued and outstanding capital of a certain class
of shares of that company; or (ii) rights to acquire, directly or indirectly, such interest; or (iii) certain profit sharing rights
in that company that relate to 5% or more of the company’s annual profits and/or to 5% or more of the company’s
liquidation proceeds. A deemed substantial interest may arise if a substantial interest (or part thereof) in a company has
been disposed of, or is deemed to have been disposed of, on a non-recognition basis;
●
holders of our ordinary shares if the shares held by such holders qualify or qualified as a participation (deelneming) for
purposes of the Dutch Corporate Income Tax Act 1969 (Wet op de vennootschapsbelasting 1969). Generally, a
taxpayer’s holder’s shareholding, or right to acquire, of 5% or more in a company’s nominal paid-up share capital (or, in
certain cases, in voting rights) qualifies as participation. A holder may also have a participation if such holder does not
have a shareholding of 5% or more but a related entity (statutorily defined term) has a participation or if the company in
which the shares are held is a related entity (statutorily defined term);
●
holders of our ordinary shares who are individuals for whom the shares or any benefit derived from the shares are a
remuneration or deemed to be a remuneration for (employment) activities or services performed by such holders or
certain individuals related to such holders, whether within or outside an employment relation, that provides the holder,
economically speaking, with certain benefits that have a relation to the relevant work activities or services (as defined in
the Dutch Income Tax Act 2001); and
●
holders of our ordinary shares which are entitled to the dividend withholding tax exemption (inhoudingsvrijstelling) with
respect to any income (opbrengst) derived from the ordinary shares (as defined in Article 4 of the Dutch Dividend
Withholding Tax Act 1965 (Wet op de dividendbelasting)). Generally, a holder of our ordinary shares may be entitled or
required to apply, subject to certain other requirements, the dividend withholding tax exemption if it is an entity and
holds an interest of 5% or more in our nominal paid-up share capital;
pension funds, investment institutions (fiscale beleggingsinstellingen), and tax-exempt investment institutions
(vrijgestelde beleggingsinstellingen) (each as defined in the Dutch Corporate Income Tax Act 1969) and other entities
●
that are, in whole or in part, not subject to or exempt from corporate income tax in the Netherlands, entities that have a
function comparable to an investment institution or a tax-exempt investment institution, as well as entities that are
exempt from corporate income tax in their country of residence, such country of residence being another state of the
European Union, Norway, Liechtenstein, Iceland or any other state with which the Netherlands have agreed to exchange
information in line with international standards.
Except as otherwise indicated, this summary only addresses Dutch national tax legislation and published regulations, whereby
the Netherlands and Dutch law means the part of the Kingdom of the Netherlands located in Europe and its law respectively, as in
effect on the date hereof and as interpreted in published case law (of the Dutch Supreme Court (Hoge Raad der Nederlanden) until
this date, without prejudice to any amendment introduced (or to become effective) at a later date and/or implemented with or
without retroactive effect. The applicable tax laws or interpretations thereof may change, or the relevant facts and circumstances
may change, and such changes may affect the contents of this section, which will not be updated to reflect any such changes.
-122-
This discussion is for general information purposes and is not tax advice or a complete description of all Dutch tax
consequences relating to the acquisition, holding and disposal of our shares. Holders or prospective holders of our shares should
consult their own tax advisor regarding the tax consequences relating to the acquisition, holding and disposal of our shares in light
of their particular circumstances.
Dividend withholding tax
We are incorporated under the laws of the Netherlands, and therefore a Dutch tax resident for Dutch domestic tax law
purposes, including the Dutch Dividend Withholding Tax Act 1969. As such, we are required to withhold Dutch dividend
withholding tax at a rate of 15% from dividends distributed by us (which withholding tax will not be borne by us but will be
withheld by us from the gross dividends paid on the shares). We are however also treated as a German tax resident for German
domestic tax law purposes, since our place of effective management is located in Germany. As long as we continue to have our
place of effective management in Germany, and not in the Netherlands, under the convention Based on the so-called tie-breaker
provision, or the Tie-Breaker Provision, included in Section 4(3) of the 2012 Convention between the Federal Republic of
Germany and the Kingdom of the Netherlands for the avoidance of double taxation with respect to taxes on income of 2012, or the
double tax treaty between Germany and the Netherlands, as in effect on the date hereof, our tax residence in either the Netherlands
or Germany for the purposes of the double tax treaty between Germany and the Netherlands should be determined based on our
place of effective management. As long as we have our place of effective management continuously in Germany, and the Tie-
Breaker Provision is not changed (for instance, by change in the reservations and choices made by Germany with respect to the
application of the Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit
Shifting), we will be considered to be exclusively tax resident in Germany for purposes of the double tax treaty between Germany
and the Netherlands. Consequently, the Netherlands will be restricted to impose Dutch dividend withholding tax on dividends
distributed by us pursuant to Section 10(5) of the double tax treaty between Germany and the Netherlands (and we will not be
required to withhold Dutch dividend withholding tax). This exemption from withholding restriction does not apply to dividends
distributed by us to a holder of our ordinary shares who is resident or deemed to be resident in the Netherlands for Dutch personal
income tax purposes or Dutch corporate income tax purposes or to a holder of our ordinary shares that is neither resident nor
deemed to be resident of the Netherlands if the ordinary shares are attributable to a Dutch permanent establishment of such non-
resident holder, in which events the following applies. See Risk Factor “If we ever pay dividends, we may need to withhold tax on
such dividends payable to holders of our shares in both Germany and the Netherlands.”
Dividends distributed by us to individuals and corporate legal entities who are resident or deemed to be resident in the
Netherlands for Dutch tax purposes (“Dutch Resident Individuals” and “Dutch Resident Entities” as the case may be) or to holders
of our ordinary shares that are neither resident nor deemed to be resident of the Netherlands if the ordinary shares are attributable
to a Dutch permanent establishment of such non-resident holder are subject to Dutch dividend withholding tax at a rate of 15%.
The expression “dividends distributed” includes, among other things but it is not limited to:
●
distributions in cash or in kind, deemed and constructive distributions and repayments of paid-in capital not recognized
for Dutch dividend withholding tax purposes;
●
liquidation proceeds, proceeds of redemption of shares, or proceeds of the repurchase of shares (other than as temporary
portfolio investment; tijdelijke belegging) by us or one of our subsidiaries or other affiliated entities, in each case to the
extent such proceeds exceed the average paid-in capital of those shares as recognized for purposes of Dutch dividend
withholding tax, unless in case of a repurchase, a particular statutory exemption applies;
●
an amount equal to the par value of shares issued or an increase of the par value of shares, to the extent that it does not
appear that a contribution, recognized for purposes of Dutch dividend withholding tax, has been made or will be made;
and
●
partial repayment of the paid-in capital, recognized for purposes of Dutch dividend withholding tax, if and to the extent
that we have net profits (zuivere winst), unless the holders of shares have resolved in advance at a general meeting to
make such repayment and the par value of the shares concerned has been reduced by an equal amount by way of an
amendment of our Articles of Association. The term “net profits” includes anticipated profits that have yet to be realized.
-123-
Dutch Resident Individuals and Dutch Resident Entities can generally credit the Dutch dividend withholding tax against their
income tax or corporate income tax liability. The credit in any given year is, however, limited to the amount of Dutch corporate
income tax payable in respect of the relevant year with an indefinite carry forward of any excess amount. Dutch Resident
Individuals generally are entitled to a credit for any Dutch dividend withholding tax against their Dutch personal income tax
liability and to a refund of any residual Dutch dividend withholding tax. The same applies to holders of our ordinary shares that
are neither resident nor deemed to be resident of the Netherlands if the shares are attributable to a Dutch permanent establishment
of such non-resident holder.
Pursuant to legislation to counteract “Dutch domestic anti-dividend stripping rules,” a reduction, exemption, credit or refund
of Dutch dividend withholding tax is denied if the recipient of the dividend is not the beneficial owner (uiteindelijk gerechtigde)
as described in the Dutch Dividend Withholding Tax Act 1965 (Wet op de dividendbelasting 1965). This legislation generally
targets situations in which a shareholder retains its economic interest in shares but reduces the withholding tax costs on dividends
by a transaction with another party. It is not required for these rules to apply that the recipient of the dividends is aware that a
dividend stripping transaction took place. The Dutch State Secretary for Finance takes the position that the definition of beneficial
ownership introduced by this legislation will also apply in the context of a double taxation convention. As of January 1, 2024,
more stringent rules apply to the setoff, exemption from, and reduction or refund of The burden of proof with respect to beneficial
ownership of dividends rests on the Dutch tax authorities. If, however, a shareholder would receive dividends, including dividends
on our ordinary shares, in a calendar year in respect of which an aggregate amount of EUR 1,000 in Dutch dividend withholding
tax would otherwise be due based on the rate of 15%, to address situations where a claim for setoff, exemption, reduction or
refund may align with the letter of Dutch tax law or a double taxation convention but goes against the underlying intention or
spirit of the dividend stripping rules, as perceived by the legislator. In addition, the burden of proof in cases related to dividend
stripping and beneficial owner status has in certain circumstances been shifted from the tax inspector to the person making a claim
for a setoff, reduction or refund of or exemption from Dutch dividend withholding tax with respect to beneficial ownership of
such dividends lies with the shareholder. Furthermore, for shares traded on a regulated market, including our ordinary shares, it
has been codified that the record date is used when determining the person who is entitled to the dividend.
Conditional withholding tax on dividends (as of January 1, 2024)
Furthermore, it cannot be excluded that dividends distributed by us to certain related entities which are not resident in the
Netherlands for Dutch tax purposes will become subject to a Dutch conditional withholding tax in certain specific situations (see
below), irrespectively of the fact that we have our place of effective management in Germany and, therefore, are a tax resident of
Germany under German national tax laws. As of January 1, 2024, a Dutch conditional withholding tax will be imposed on
dividends distributed by us to a related entities Related Entity (as defined below) resident in certain listed jurisdictions or in case
of abusive arrangements (all within the meaning of the Dutch Withholding Tax Act 2021; Wet bronbelasting 2021). The Dutch
conditional withholding tax on dividends will be imposed at the highest Dutch corporate income tax rate in effect at the time of
the distribution (20242025: 25.8%). The Dutch conditional withholding tax on dividends will be reduced, but not below zero, by
any regular Dutch dividend withholding tax withheld in respect of the same dividend distribution. As such, based on the currently
applicable rates, the overall effective tax rate of withholding the regular Dutch dividend withholding tax (as described above) and
the Dutch conditional withholding tax on dividends will not exceed the highest corporate income tax rate in effect at the time of
the distribution (20242025: 25.8%).
For purposes of the Dutch Withholding Tax Act 2021; Wet bronbelasting 2021):
“Related Entity” means an entity (i) that has a Qualifying Interest in us or (ii) in which a third party has a Qualifying Interest
if such third party also has a Qualifying Interest in us.
“Qualifying Interest” means a direct or indirectly held interest – either by an entity individually or, if an entity is part of a
Qualifying Unity, jointly – that enables such entity or such Qualifying Unity to exercise a definitive influence over another
entity’s decisions and allows it to determine that other entity’s activities (as interpreted by the European Court of Justice in case
law on the right of freedom of establishment (vrijheid van vestiging)).
“Qualifying Unity” means entities acting together with the main purpose or one of the main purposes of avoiding Dutch
conditional withholding tax at the level of any of those entities (kwalificerende eenheid).
-124-
Taxes on income and capital gains
Dutch resident entities
Any benefit derived or deemed to be derived from the ordinary shares held by a Dutch Resident Entity, including any capital
gains realized on the disposal or deemed disposal thereof, will generally be subject to Dutch corporate income tax at a rate of 19%
with respect to taxable profits up to €200,000 and 25.8% with respect to taxable profits in excess of that amount (rates and
brackets for 20242025).
Dutch resident individuals
If a holder of ordinary shares is a Dutch Resident Individual, any benefit derived or deemed to be derived from the ordinary
shares or any capital gains realized on the disposal or deemed disposal of the ordinary shares is taxable subject to Dutch personal
income tax at the progressive income tax rates (with a maximum of 49.5%, rate for 2025), if:
i.
the ordinary shares are attributable to an enterprise from which the holder of such shares derives a share of the profit,
whether as an entrepreneur (ondernemer) or as a person who has a co-entitlement to the net worth (medegerechtigd
tot het vermogen) of such enterprise, without being a shareholder, as defined in the Dutch Income Tax Act 2001); or
ii.
the holder of the ordinary shares is considered to perform activities with respect to such shares that go beyond
ordinary asset management (normaal, actief vermogensbeheer) or otherwise derives benefits from the ordinary
shares that are taxable as benefits from other activities (resultaat uit overige werkzaamheden).
Taxation of savings and investments
If the above-mentioned conditions (i.) and (ii.) do not apply to the Dutch Resident Individual, the ordinary shares will be
subject to an annual Dutch income tax under the regime for savings and investments (inkomen uit sparen en beleggen). Taxation
only occurs insofar the Dutch Resident Individual’s net investment assets for the year exceed a statutory threshold (heffingvrij
vermogen). The net investment assets for the year are the fair market value of the investment assets less the fair market value of
the liabilities on January 1 of the relevant calendar year (reference date; peildatum). Actual income or capital gains realized in
respect of the ordinary shares are as such not subject to Dutch income tax.
The Dutch Resident Individual’s assets and liabilities taxed under this regime, including the ordinary shares, are allocated
over the following three categories: (a) bank savings (banktegoeden), (b) other investments (overige bezittingen), including the
ordinary shares, and (c) liabilities (schulden). The taxable benefit for the year (voordeel uit sparen en beleggen) is equal to the
product of (x) the total deemed return divided by the sum of bank savings, other investments and liabilities and (b) the sum of
bank savings, other investments and liabilities minus the statutory threshold, and is taxed at a flat rate of 36% (rate for 2025).
The deemed return applicable to other investments, including the ordinary shares, is set at 5.88% for the calendar year 2025.
Transactions in the three-month period before and after January1 of the relevant calendar year implemented to arbitrate between
the deemed return percentages applicable to bank savings, other investments and liabilities will for this purpose be ignored if the
holder of ordinary shares cannot sufficiently demonstrate that such transactions are implemented for other than tax reasons.
The current Dutch income tax regime for savings and investments was implemented in Dutch tax law following the decision
of the Dutch Supreme Court (Hoge Raad) of December 24, 2021 (ECLI:NL:2021:1963), or the Decision. In the Decision, the
Dutch Supreme Court ruled that the (old) system of taxation for savings and investments based on a deemed return may under
specific circumstances contravene with Section 1 of the First Protocol to the European Convention on Human Rights in
combination with Section 14 of the European Convention on Human Rights, or the EC-Human Rights. A new court procedure is
pending before the Dutch Supreme Court questioning whether the current tax system for savings and investments is in line with
the Decision. On September 18, 2023 (ECLI:NL:PHR:2023:655) the Attorney General Wattel concluded that the new tax system
is not in line with the Decision, except for the taxation of bank savings, as the system is, in short, still based on a deemed return
rather than actual returns, and as a result, the regime contravenes with the EC-Human Rights. The decision of the Dutch Supreme
Court is expected mid-2024. In addition, on September 8, 2023, the former cabinet published a law proposal for a new tax system
for savings and investments on the basis of actual returns according to an asset accumulation system, the ‘Actual Return Box 3
Act’ (Wet werkelijk rendement box 3). The proposed system is expected to come into effect on January 1, 2027 at the earliest. On
6 and 14 June 2024, the Dutch Supreme Court (Hoge Raad) ruled that the current Dutch income tax regime for savings and
investments in certain specific circumstances contravenes with Section 1 of the First Protocol to the European Convention on
Human Rights in combination with Section 14 of the European Convention on Human Rights, or the “Rulings. This is, in short,
the case in the event the deemed return on the investment assets exceeds the actual return realized in respect thereof (calculated in
line with the rules set out in the Rulings and successfully demonstrated by the taxpayer).
-125-
Holders of ordinary shares are advised to consult their own tax advisor to ensure that the tax in respect of the ordinary shares
is levied in accordance with the applicable Dutch tax rules at the relevant time.
Non-residents of the Netherlands
A holder of our ordinary shares that is neither a Dutch Resident Entity nor a Dutch Resident Individual will not be subject to
Dutch income tax taxes on income or capital gains in respect of any payment under income derived or deemed to be derived from
the ordinary shares or in respect of any gain or loss realized on the disposal or deemed disposal of the ordinary shares, provided
that:
i.
such holder does not have an interest in an enterprise or a deemed enterprise (as defined in the Dutch Income Tax
Act 2001 and the Dutch Corporate Income Tax Act 1969) which, in whole or in part, is either effectively managed in
the Netherlands or is carried out through a permanent establishment, a deemed permanent establishment or a
permanent representative in the Netherlands and to which enterprise or part of an enterprise the ordinary shares are
attributable; and
ii.
in the event such holder is an individual, such holder does not carry out any activities in the Netherlands with respect
to the ordinary shares that go beyond ordinary asset management (normaal, actief vermogensbeheer) and does not
otherwise derive benefits from the ordinary shares that are taxable as benefits from other activities in the Netherlands
(resultaat uit overige werkzaamheden).
Gift and inheritance tax
Residents of the Netherlands
Gift or inheritance taxes will arise in the Netherlands with respect to a transfer of the ordinary shares by way of a gift by, or
on the death of, a holder of our ordinary shares who is resident or deemed to be resident in the Netherlands at the time of the gift
or such holder’s death.
Non-residents of the Netherlands
No Dutch gift or inheritance taxes will arise on the transfer of our ordinary shares by way of gift by, or on the death of, a
holder of the ordinary shares who is neither resident nor deemed to be resident in the Netherlands, unless:
●
in the case of a gift of ordinary shares by an individual who at the date of the gift was neither resident nor deemed to be
resident in the Netherlands, such individual dies within 180 days after the date of the gift, while being resident or deemed
to be resident in the Netherlands; or
●
in the case of a gift of ordinary shares is made under a condition precedent, the holder of such ordinary shares is resident
or is deemed to be resident of the Netherlands at the time the condition is fulfilled; or
the transfer is otherwise construed as a gift or inheritance made by, or on behalf of, a person who, at the time of the gift or
death, is or is deemed to be resident of the Netherlands.
For purposes of Dutch gift and inheritance taxes, amongst others, a person that holds the Dutch nationality will be deemed to
be resident in the Netherlands if such person has been resident in the Netherlands at any time during the 10 years preceding the
date of the gift or his/her such person’s death. Additionally, for purposes of Dutch gift tax, amongst others, a person not holding
the Dutch nationality will be deemed to be resident in the Netherlands if such person has been resident in the Netherlands at any
time during the 12 months preceding the date of the gift. Applicable tax treaties may override deemed residency.
-126-
Furthermore, for purposes of Netherlands gift and inheritance tax, a gift that is made under a condition precedent is deemed to
have been made at the moment such condition precedent is satisfied. If the condition precedent is fulfilled after the death of the
donor, the gift is deemed to be made upon the death of the donor.
Other taxes and duties
No Dutch value added tax and no Dutch registration tax, stamp duty or any other similar documentary tax or duty will be
payable by a holder of our ordinary shares on any payment in consideration for the holding or disposal of the ordinary shares.
The following is a general summary of certain material Dutch tax consequences of the acquisition, holding and disposal of
our ordinary shares. This summary does not purport to describe all possible tax considerations or consequences that may be
relevant to a holder or prospective holder of ordinary shares and does not purport to deal with the tax consequences applicable to
all categories of investors, some of which (such as trusts or similar arrangements) may be subject to special rules. In view of its
general nature, this general summary should be treated with corresponding caution. To the extent this summary relates to legal
conclusions under current Netherlands tax law, and subject to the qualifications it contains, it represents the opinion of
NautaDutilh N.V., our special Dutch counsel. Holders or prospective holders of shares should consult with their own tax advisors
with regard to the tax consequences of investing in the shares in their particular circumstances. The discussion below is included
for general information purposes only.
For the purposes of this discussion, it is assumed that we are a tax resident of Germany under German national tax laws since
we intended to have, from our incorporation and on a continuous basis, our place of effective management in Germany. See Risk
Factor “We may become taxable in a jurisdiction other than Germany and this may increase the aggregate tax burden on us.”
Please note that this summary does not describe the Dutch tax considerations for:
●
holders of our ordinary shares if such holders, and in the case of individuals, his or her partner or certain of their relatives
by blood or marriage in the direct line (including foster children), have a substantial interest (aanmerkelijk belang) or
deemed substantial interest (fictief aanmerkelijk belang) in the Company under the Dutch Income Tax Act 2001 (Wet
inkomstenbelasting 2001). Generally speaking, a holder of securities in a company is considered to hold a substantial
interest in such company, if such holder alone or, in the case of individuals, together with his or her partner (as defined in
the Dutch Income Tax Act 2001, directly or indirectly, holds (i) an interest of 5% or more of the total issued and
outstanding capital of that company or of 5% or more of the issued and outstanding capital of a certain class of shares of
that company; or (ii) rights to acquire, directly or indirectly, such interest; or (iii) certain profit sharing rights in that
company that relate to 5% or more of the company’s annual profits and/or to 5% or more of the company’s liquidation
proceeds. A deemed substantial interest may arise if a substantial interest (or part thereof) in a company has been
disposed of, or is deemed to have been disposed of, on a non-recognition basis;
●
holders of our ordinary shares if the shares held by such holders qualify or qualified as a participation (deelneming) for
purposes of the Dutch Corporate Income Tax Act 1969 (Wet op de vennootschapsbelasting 1969). Generally, a
taxpayer’s shareholding of 5% or more in a company’s nominal paid-up share capital (or, in certain cases, in voting
rights) qualifies as participation. A holder may also have a participation if such holder does not have a shareholding of
5% or more but a related entity (statutorily defined term) has a participation or if the company in which the shares are
held is a related entity (statutorily defined term);
●
holders of shares who are individuals for whom the shares or any benefit derived from the shares are a remuneration or
deemed to be a remuneration for (employment) activities or services performed by such holders or certain individuals
related to such holders, whether within or outside an employment relation, that provides the holder, economically
speaking, with certain benefits that have a relation to the relevant work activities or services (as defined in the Dutch
Income Tax Act 2001); and
●
pension funds, investment institutions (fiscale beleggingsinstellingen), exempt investment institutions (vrijgestelde
beleggingsinstellingen) (as defined in the Dutch Corporate Income Tax Act 1969) and other entities that are, in whole or
in part, not subject to or exempt from corporate income tax in the Netherlands, as well as entities that are exempt from
corporate income tax in their country of residence, such country of residence being another state of the European Union,
Norway, Liechtenstein, Iceland or any other state with which the Netherlands have agreed to exchange information in
line with international standards.
-127-
Except as otherwise indicated, this summary only addresses Dutch national tax legislation and published regulations, whereby
the Netherlands and Dutch law means the part of the Kingdom of the Netherlands located in Europe and its law respectively, as in
effect on the date hereof and as interpreted in published case law (of the Dutch Supreme Court (Hoge Raad der Nederlanden) until
this date, without prejudice to any amendment introduced (or to become effective) at a later date and/or implemented with or
without retroactive effect. The applicable tax laws or interpretations thereof may change, or the relevant facts and circumstances
may change, and such changes may affect the contents of this section, which will not be updated to reflect any such changes.
This discussion is for general information purposes and is not tax advice or a complete description of all Dutch tax
consequences relating to the acquisition, holding and disposal of our shares. Holders or prospective holders of our shares should
consult their own tax advisor regarding the tax consequences relating to the acquisition, holding and disposal of our shares in light
of their particular circumstances.
Dividend withholding tax
We are incorporated under the laws of the Netherlands, and therefore a Dutch tax resident for Dutch domestic tax law
purposes, including the Dutch Dividend Withholding Tax Act 1969. As such, we are required to withhold Dutch dividend
withholding tax at a rate of 15% from dividends distributed by us (which withholding tax will not be borne by us but will be
withheld by us from the gross dividends paid on the shares). We are however also treated as a German tax resident for German
domestic tax law purposes, since our place of effective management is located in Germany. As long as we continue to have our
place of effective management in Germany, and not in the Netherlands, under the convention between the Federal Republic of
Germany and the Netherlands for the avoidance of double taxation with respect to taxes on income of 2012, we will be considered
to be exclusively tax resident in Germany. Consequently, the Netherlands will be restricted to impose Dutch dividend withholding
tax on dividends distributed by us (we will not be required to withhold Dutch dividend withholding tax). This exemption from
withholding does not apply to dividends distributed by us to a holder of our ordinary shares who is resident or deemed to be
resident in the Netherlands for Dutch income tax purposes or Dutch corporation tax purposes or to a holder of our ordinary shares
that is neither resident nor deemed to be resident of the Netherlands if the ordinary shares are attributable to a Dutch permanent
establishment of such non-resident holder, in which events the following applies. See Risk Factor “If we ever pay dividends, we
may need to withhold tax on such dividends payable to holders of our shares in both Germany and the Netherlands.”
Dividends distributed by us to individuals and corporate legal entities who are resident or deemed to be resident in the
Netherlands for Dutch tax purposes (“Dutch Resident Individuals” and “Dutch Resident Entities” as the case may be) or to holders
of our ordinary shares that are neither resident nor deemed to be resident of the Netherlands if the ordinary shares are attributable
to a Dutch permanent establishment of such non-resident holder are subject to Dutch dividend withholding tax at a rate of 15%.
The expression “dividends distributed” includes, among other things:
●
distributions in cash or in kind, deemed and constructive distributions and repayments of paid-in capital not recognized
for Dutch dividend withholding tax purposes;
●
liquidation proceeds, proceeds of redemption of shares, or proceeds of the repurchase of shares by us or one of our
subsidiaries or other affiliated entities to the extent such proceeds exceed the average paid-in capital of those shares as
recognized for purposes of Dutch dividend withholding tax, unless in case of a repurchase, a particular statutory
exemption applies;
●
an amount equal to the par value of shares issued or an increase of the par value of shares, to the extent that it does not
appear that a contribution, recognized for purposes of Dutch dividend withholding tax, has been made or will be made;
and
●
partial repayment of the paid-in capital, recognized for purposes of Dutch dividend withholding tax, if and to the extent
that we have net profits (zuivere winst), unless the holders of shares have resolved in advance at a general meeting to
make such repayment and the par value of the shares concerned has been reduced by an equal amount by way of an
amendment of our Articles of Association.
-128-
Dutch Resident Individuals and Dutch Resident Entities can generally credit the Dutch dividend withholding tax against their
income tax or corporate income tax liability. The same applies to holders of our ordinary shares that are neither resident nor
deemed to be resident of the Netherlands if the shares are attributable to a Dutch permanent establishment of such non-resident
holder.
Pursuant to legislation to counteract “dividend stripping,” a reduction, exemption, credit or refund of Dutch dividend
withholding tax is denied if the recipient of the dividend is not the beneficial owner (uiteindelijk gerechtigde) as described in the
Dutch Dividend Withholding Tax Act 1965 (Wet op de dividendbelasting 1965). This legislation generally targets situations in
which a shareholder retains its economic interest in shares but reduces the withholding tax costs on dividends by a transaction
with another party. It is not required for these rules to apply that the recipient of the dividends is aware that a dividend stripping
transaction took place. The Dutch State Secretary for Finance takes the position that the definition of beneficial ownership
introduced by this legislation will also apply in the context of a double taxation convention.
Conditional withholding tax on dividends (as of January 1, 2024)
Furthermore, it cannot be excluded that dividends distributed by us to certain related entities which are not resident in the
Netherlands for Dutch tax purposes will become subject to a Dutch conditional withholding tax in certain specific situations (see
below), irrespectively of the fact that we have our place of effective management in Germany and, therefore, are a tax resident of
Germany under German national tax laws. As of January 1, 2024, a Dutch conditional withholding tax will be imposed on
dividends distributed by us to related entities (gelieerd) resident in certain listed jurisdictions or in case of abusive arrangements
(all within the meaning of the Dutch Withholding Tax Act 2021; Wet bronbelasting 2021). The Dutch conditional withholding tax
on dividends will be imposed at the highest Dutch corporate income tax rate in effect at the time of the distribution (2022: 25.8%).
The Dutch conditional withholding tax on dividends will be reduced, but not below zero, by any regular Dutch dividend
withholding tax withheld in respect of the same dividend distribution. As such, based on the currently applicable rates, the overall
effective tax rate of withholding the regular Dutch dividend withholding tax (as described above) and the Dutch conditional
withholding tax on dividends will not exceed the highest corporate income tax rate in effect at the time of the distribution (2022:
25.8%).
Taxes on income and capital gains
Dutch resident entities
Any benefit derived or deemed to be derived from the shares held by a Dutch Resident Entity, including any capital gains
realized on the disposal thereof, will generally be subject to Dutch corporate income tax at a rate of 19% with respect to taxable
profits up to €200,000 and 25.8% with respect to taxable profits in excess of that amount (rates and brackets for 2023).
Dutch resident individuals
If a holder of shares is a Dutch Resident Individual, any benefit derived or deemed to be derived from the ordinary shares is
taxable at the progressive income tax rates (with a maximum of 49.5%, rate for 2023), if:
i.
the ordinary shares are attributable to an enterprise from which the holder of such shares derives a share of the profit,
whether as an entrepreneur (ondernemer) or as a person who has a co-entitlement to the net worth (medegerechtigd
tot het vermogen) of such enterprise, without being a shareholder, as defined in the Dutch Income Tax Act 2001); or
ii.
the holder of the ordinary shares is considered to perform activities with respect to such shares that go beyond
ordinary asset management (normaal, actief vermogensbeheer) or derives benefits from the shares that are taxable as
benefits from other activities (resultaat uit overige werkzaamheden).
Taxation of savings and investments
If the above-mentioned conditions (i) and (ii) do not apply to the Dutch Resident Individual, the ordinary shares will be
subject to an annual Dutch income tax under the regime for savings and investments (inkomen uit sparen en beleggen). Taxation
only occurs insofar the Dutch Resident Individual’s net investment assets for the year exceed a statutory threshold (heffingvrij
vermogen). The net investment assets for the year are the fair market value of the investment assets less the fair market value of
the liabilities on January 1 of the relevant calendar year (reference date; peildatum). The ordinary shares are included as
investment assets. The taxable benefit for the year (voordeel uit sparen en beleggen) is taxed at a flat rate of 32% (rate for 2023).
Actual income or capital gains realized in respect of the ordinary shares are as such not subject to Dutch income tax.
-129-
The taxable benefit for the year is calculated as follows:
i.
The Dutch Resident Individual’s assets and liabilities taxed under this regime, including the ordinary shares, are
allocated over the following three categories: (a) bank savings, (b) other investments, including the ordinary shares,
and (c) liabilities.
ii.
The return (rendement) in respect of these assets and liabilities is calculated as follows (the return is at a minimum
nihil):
●
a deemed return on the fair market value of the actual amount of bank savings and cash on January 1 of the
relevant calendar year; plus
●
a deemed return on the fair market value of the actual amount of other investments, including the ordinary
shares, on January 1 of the relevant calendar year; minus
●
a deemed return on the sum of the fair market value of the actual amount of liabilities on January 1 of the
relevant calendar year less the statutory threshold for liabilities (drempel).
iii. The return percentage (%) (rendementspercentage) is calculated as follows:
o
by dividing the return calculated under (ii) above by the net investment assets for the year of the Dutch Resident
Individual; multiplied by 100.
iv. The taxable base (grondslag sparen en beleggen) is calculated as follows:
o
the net investment assets for the year of the Dutch Resident Individual; minus
o
the applicable statutory threshold.
v.
The taxable benefit for the year is equal to the taxable base calculated under (iv) above multiplied by the return
percentage calculated under (iii) above.
At the date hereof, the deemed returns for the different investment categories mentioned under (ii) above have been
temporarily set at: (a) 0.01%, (b) 5.69% and (c) 2.46%. The definitive percentages for the year 2023 will be published in the first
months of 2024 and will have retroactive effect to January 1, 2023. Transactions in the three-month period before and after
January 1 of the relevant calendar year implemented to arbitrate between the deemed return percentages applicable to bank
savings, other investments and liabilities will for this purpose be ignored if the holder of ordinary shares cannot sufficiently
demonstrate that such transactions are implemented for other than tax reasons.
Non-residents of the Netherlands
A holder of our ordinary shares that is neither a Dutch Resident Entity nor a Dutch Resident Individual will not be subject to
Dutch taxes on income or capital gains in respect of any payment under the ordinary shares or in respect of any gain or loss
realized on the disposal or deemed disposal of the ordinary shares, provided that:
i.
such holder does not have an interest in an enterprise or a deemed enterprise (as defined in the Dutch Income Tax
Act and the Dutch Corporate Income Tax Act 1969) which, in whole or in part, is either effectively managed in the
Netherlands or is carried out through a permanent establishment, a deemed permanent establishment or a permanent
representative in the Netherlands and to which enterprise or part of an enterprise the ordinary shares are attributable;
and
ii.
in the event such holder is an individual, such holder does not carry out any activities in the Netherlands with respect
to the ordinary shares that go beyond ordinary asset management (normaal, actief vermogensbeheer) and does not
derive benefits from the ordinary shares that are taxable as benefits from other activities in the Netherlands (resultaat
uit overige werkzaamheden).
-130-
Gift and inheritance tax
Residents of the Netherlands
Gift or inheritance taxes will arise in the Netherlands with respect to a transfer of the ordinary shares by way of a gift by, or
on the death of, a holder of our ordinary shares who is resident or deemed to be resident in the Netherlands at the time of the gift
or such holder’s death.
Non-residents of the Netherlands
No Dutch gift or inheritance taxes will arise on the transfer of our ordinary shares by way of gift by, or on the death of, a
holder of the ordinary shares who is neither resident nor deemed to be resident in the Netherlands, unless in the case of a gift of
shares by an individual who at the date of the gift was neither resident nor deemed to be resident in the Netherlands, such
individual dies within 180 days after the date of the gift, while being resident or deemed to be resident in the Netherlands.
For purposes of Dutch gift and inheritance taxes, amongst others, a person that holds the Dutch nationality will be deemed to
be resident in the Netherlands if such person has been resident in the Netherlands at any time during the 10 years preceding the
date of the gift or his/her death. Additionally, for purposes of Dutch gift tax, amongst others, a person not holding the Dutch
nationality will be deemed to be resident in the Netherlands if such person has been resident in the Netherlands at any time during
the 12 months preceding the date of the gift. Applicable tax treaties may override deemed residency.
Furthermore, for purposes of Netherlands gift and inheritance tax, a gift that is made under a condition precedent is deemed to
have been made at the moment such condition precedent is satisfied. If the condition precedent is fulfilled after the death of the
donor, the gift is deemed to be made upon the death of the donor.
Other taxes and duties
No Dutch value added tax and no Dutch registration tax, stamp duty or any other similar documentary tax or duty will be
payable by a holder of our ordinary shares on any payment in consideration for the holding or disposal of the ordinary shares.
7.
Material German tax Considerations
The following section is a description of the material German tax considerations that become relevant when purchasing,
holding or transferring the Company’s shares. The Company has its sole place of management in Germany and, therefore,
qualifies as a corporation subject to German unlimited corporate income taxation; however, because a company’s tax residency
depends on future facts regarding the location in which the company is managed and controlled the German unlimited corporate
income tax liability may change in the future. This section does not set forth all German tax aspects that may be relevant for
shareholders. The section is based on the German tax law applicable as of the date of this document. It should be noted that the
law may change following the date of this Annual Report and that such changes may have retroactive effect.
The material German tax principles of purchasing, owning and transferring of shares are set forth in the following. This
section does not purport to be a comprehensive or complete analysis or listing of all potential tax effects of the purchase,
ownership or disposition of shares and does not set forth all tax considerations that may be relevant to a particular person’s
decision to acquire ordinary shares. All of the following is subject to change. Such changes could apply retroactively and could
affect the consequences set forth below. This section does not refer to any foreign account tax compliance act (or FATCA)
aspects.
Shareholders are advised to consult their own tax advisers with regard to the application of German tax law to their particular
situations, in particular with respect to the procedure to be complied with to obtain a relief of withholding tax on dividends and on
capital gains (Kapitalertragsteuer) and with respect to the influence of double tax treaty provisions, as well as any tax
consequences arising under the laws of any state, local or other foreign jurisdiction. For German tax purposes, a shareholder may
include an individual who or an entity that does not have the legal title to the shares, but to whom nevertheless the shares are
attributed, based either on such individual or entity owning a beneficial interest in the shares or based on specific statutory
provisions.
-131-
This section does not constitute particular tax advice. Potential purchasers of the Company’s shares are urged to consult their
own tax advisers regarding the tax consequences of the purchase, ownership and disposition of shares in light of their particular
circumstances.
Taxation of dividends
Withholding tax on dividends
Dividends distributed from a company to its shareholders are subject to withholding tax, subject to certain exemptions (for
example, repayments of capital from the tax equity account (steuerliches Einlagekonto)), as further described. The withholding tax
rate is 25% plus a 5.5% solidarity surcharge (Solidaritätszuschlag) thereon (for a total of 26.375%) of the gross dividend approved
by the ordinary shareholders’ meeting. Withholding tax is to be withheld and passed on for the account of the shareholders by a
domestic branch of a domestic or foreign credit or financial services institution (Kredit- und Finanzdienstleistungsinstitut), by the
domestic securities trading company (inländisches Wertpapierhandelsunternehmen) or a domestic securities trading bank
(inländische Wertpapierhandelsbank) which keeps and administers the shares and disburses or credits the dividends or disburses
the dividends to a foreign agent, or by the securities custodian bank (Wertpapiersammelbank) to which the shares were entrusted
for collective custody if the dividends are distributed to a foreign agent by such securities custodian bank, or the Dividend Paying
Agent. In case the shares are not held in collective deposit with a Dividend Paying Agent, the Company is responsible for
withholding and remitting the tax to the competent tax office.
Such withholding tax is levied and withheld irrespective of whether and to what extent the dividend distribution is taxable at
the level of the shareholder and whether the shareholder is a person residing in Germany or in a foreign country.
In the case of dividends distributed to a company within the meaning of Art. 2 of the amended EU Directive 2011/96/EU of
the Council of November 30, 2011, or the EU Parent Subsidiary Directive, domiciled in another Member State of the European
Union, an exemption from the withholding tax will be granted upon request if further prerequisites are satisfied (Freistellung im
Steuerabzugsverfahren). This also applies to dividends distributed to a permanent establishment located in another Member State
of the European Union of such a parent company or of a parent company tax resident in Germany if the participation in the
Company is effectively connected with this permanent establishment. The key prerequisite for the application of the EU Parent
Subsidiary Directive is that the shareholder has held a direct participation in the share capital of the Company of at least 10% for
at least one year.
The withholding tax on distributions to other foreign resident shareholders is reduced in accordance with a double taxation
treaty if Germany has concluded such double taxation treaty with the country of residence of the shareholder and if the
shareholder does not hold his shares either as part of the assets of a permanent establishment or a fixed place of business in
Germany or as business assets for which a permanent representative has been appointed in Germany. The reduction of the
withholding tax is procedurally granted in such a manner that the difference between the total amount withheld, including the
solidarity surcharge, and the tax liability determined on the basis of the tax rate set forth in the applicable double taxation treaty
(15% unless further qualifications are met) is refunded by the German tax administration upon request (Federal Central Office for
Taxes (Bundeszentralamt für Steuern), main office in Bonn-Beuel, An der Küppe 1, D-53225 Bonn).
In the case of dividends received by corporations whose statutory seat and effective place of management are not located in
Germany and who are therefore not tax resident in Germany, two-fifths of the withholding tax deducted and remitted are refunded
without the need to fulfill all prerequisites required for such refund under the EU Parent Subsidiary Directive or under a double
taxation treaty or if no double taxation treaty has been concluded between Germany and the state of residence of the shareholder.
In order to receive a refund pursuant to a double taxation treaty or the aforementioned option for foreign corporations, the
shareholder has to submit a completed form for refund (available at the Federal Central Office for Taxes (www.bzst.de) as well as
at the German embassies and consulates) together with a withholding tax certificate (Kapitalertragsteuerbescheinigung) issued by
the institution that withheld the tax.
-132-
The availability of an exemption from withholding tax in accordance with the EU Parent Subsidiary Directive or a double tax
treaty and the aforementioned options for a refund of the withholding tax (with or without protection under a double taxation
treaty) depends on whether certain additional prerequisites are fulfilled. The applicable withholding tax relief will only be granted
if the preconditions of the German anti-avoidance rules, or Directive Override or Treaty Override, in particular Section 50d,
paragraph 3 of the German Income Tax Act (Einkommensteuergesetz), are fulfilled.
The aforementioned reductions of (or exemptions from) withholding tax are further restricted if (i) the applicable double
taxation treaty provides for a tax reduction resulting in an applicable tax rate of less than 15% and (ii) the shareholder is not a
corporation that directly holds at least 10% in the equity capital of the Company and is subject to tax on its income and profits in
its state of residence without being exempt. In this case, the reduction of (or exemption from) withholding tax is subject to the
following three cumulative prerequisites: (i) the shareholder must qualify as beneficial owner of the shares in the Company for a
minimum holding period of 45 consecutive days occurring within a period of 45 days prior and 45 days after the due date of the
dividends, (ii) the shareholder has to bear at least 70 % of the change in value risk related to the shares in the Company during the
minimum holding period without being directly or indirectly hedged, and (iii) the shareholder must not be required to fully or
largely compensate directly or indirectly the dividends to third parties. However, these further prerequisites do not apply if the
shareholder has been the beneficial owner of the shares in the Company for at least one uninterrupted year upon receipt of the
dividends. Furthermore, the special rules on the restriction of withholding tax credit do not apply to a shareholder whose overall
dividend earnings within an assessment period do not exceed €20,000 or that has been the beneficial owner of the shares in the
Company for at least one uninterrupted year upon receipt of the dividends.
For individual or corporate shareholders tax resident outside Germany not holding the shares through a permanent
establishment (Betriebsstätte) in Germany or as business assets (Betriebsvermögen) for which a permanent representative
(ständiger Vertreter) has been appointed in Germany, the remaining and paid withholding tax (if any) is final (i.e., not refundable)
and settles the shareholder’s limited tax liability in Germany. For individual or corporate shareholders tax resident in Germany
(for example, those shareholders whose residence, domicile, registered office or place of management is located in Germany)
holding their shares as business assets, as well as for shareholders tax resident outside of Germany holding their shares through a
permanent establishment in Germany or as business assets for which a permanent representative has been appointed in Germany,
the withholding tax withheld (including solidarity surcharge) can be credited against the shareholder’s personal income tax or
corporate income tax liability in Germany. Any withholding tax (including solidarity surcharge) in excess of such tax liability is
refunded. For individual shareholders tax resident in Germany holding the Company’s shares as private assets, the withholding tax
is a final tax (Abgeltungsteuer), subject to the exceptions described in the following section.
Pursuant to special rules on the restriction of withholding tax credit, the credit of withholding tax is subject to the following
three cumulative prerequisites: (i) the shareholder must qualify as beneficial owner of the shares in the Company for a minimum
holding period of 45 consecutive days occurring within a period of 45 days prior and 45 days after the due date of the dividends,
(ii) the shareholder has to bear at least 70% of the change in value risk related to the shares in the Company during the minimum
holding period without being directly or indirectly hedged, and (iii) the shareholder must not be required to fully or largely
compensate directly or indirectly the dividends to third parties. Absent of the fulfillment of all of the three prerequisites, three
fifths of the withholding tax imposed on the dividends must not be credited against the shareholder’s (corporate) income tax
liability, but may, upon application, be deducted from the shareholder’s tax base for the relevant assessment period. A shareholder
that has received gross dividends without any deduction of withholding tax due to a tax exemption without qualifying for a full tax
credit has to notify the competent local tax office accordingly and has to make a payment in the amount of the omitted
withholding tax deduction.
Taxation of dividend income of shareholders tax resident in Germany holding the Company’s shares as private assets
For individual shareholders (individuals) resident in Germany holding the Company’s shares as private assets, dividends are
subject to a flat rate tax which is satisfied by the withholding tax actually withheld (Abgeltungsteuer). Accordingly, dividend
income will be taxed at a flat tax rate of 25% plus 5.5% solidarity surcharge thereon (in total 26.375%) and church tax
(Kirchensteuer) in case the shareholder is subject to church tax because of his individual circumstances. An automatic procedure
for deduction of church tax by way of withholding will apply to shareholders being subject to church tax unless the shareholder
has filed a blocking notice (Sperrvermerk) with the German Federal Tax Office (details related to the computation of the concrete
tax rate including church tax are to be discussed with the individual tax adviser of the relevant shareholder). Except for an annual
lump sum savings allowance (Sparer-Pauschbetrag) of up to €1,000 (for individual filers) or up to €2,000 (for married couples and
for partners in accordance with the registered partnership law (Gesetz über die Eingetragene Lebenspartnerschaft) filing jointly),
private individual shareholders will not be entitled to deduct expenses incurred in connection with the capital investment from
their dividend income.
-133-
The income tax owed for the dividend income is satisfied by the withholding tax withheld by the Dividend Paying Agent.
However, if the flat tax results in a higher tax burden as opposed to the private shareholder’s individual tax rate, the private
shareholder can opt for taxation at his individual personal income tax rate. In that case, the final withholding tax will be credited
against the income tax. However, pursuant to the German tax authorities and a court ruling, private shareholders are nevertheless
not entitled to deduct expenses incurred in connection with the capital investment from their income. The option can be exercised
only for all capital income from capital investments received in the relevant assessment period uniformly and married couples as
well as partners in accordance with the registered partnership law filing jointly may only jointly exercise the option.
Exceptions from the flat rate tax (satisfied by withholding at source) (Abgeltungsteuer) may apply—that is, only upon
application—for shareholders who have a shareholding of at least 25% in a company and for shareholders who have a
shareholding of at least 1% in the Company, work for that company in a professional capacity and have a material influence in the
economic activity of aforementioned company. In such a case, the same rules apply as for sole proprietors holding the shares as
business assets (see below “—Taxation of dividend income of shareholders tax resident in Germany holding the Company’s
shares as business assets—(ii) Sole proprietors”).
Taxation of dividend income of shareholders tax resident in Germany holding the Company’s shares as business assets
If a shareholder holds the Company’s shares as business assets, the taxation of the dividend income depends on whether the
respective shareholder is a corporation, a sole proprietor or a partnership.
a)
Corporations
Dividend income of corporate shareholders is exempt from corporate income tax, provided that the incorporated entity holds a
direct participation of at least 10% in the share capital of a company at the beginning of the calendar year in which the dividends
are paid. The acquisition of a participation of at least 10% in the course of a calendar year is deemed to have occurred at the
beginning of such calendar year for the purpose of this rule. Participations in the share capital of the Company which a corporate
shareholder holds through a partnership, including co-entrepreneurships (Mitunternehmerschaften), are attributable to such
corporate shareholder only on a pro rata basis at the ratio of the interest share of the corporate shareholder in the assets of the
relevant partnership. However, 5% of the tax exempt dividends are deemed to be non-deductible business expenses for tax
purposes and therefore are subject to corporate income tax (plus solidarity surcharge) and trade tax; i.e. tax exemption of 95%.
Business expenses incurred in connection with the dividends received are entirely tax deductible.
For trade tax purposes the entire dividend income is subject to trade tax (i.e. the tax exempt dividends must be added back
when determining the trade taxable income), unless the corporation shareholder holds at least 15% of the Company’s registered
share capital at the beginning of the relevant tax assessment period (Erhebungszeitraum). In case of an indirect participation via a
partnership please refer to the section “Partnerships” below.
If the shareholding is below 10% in the share capital, dividends are taxable at the applicable corporate income tax rate of 15%
plus 5.5% solidarity surcharge thereon and trade tax (the rate of which depends on the municipalities the corporate shareholder
resides in).
Special regulations apply which abolish the 95% tax exemption, if the Company’s shares are held as trading portfolio assets
in the meaning of Section 340e German commercial code (Handelsgesetzbuch) by (i) a credit institution (Kreditinstitut), (ii) a
security institution (Wertpapierinstitut), (iii) a financial service institution (Finanzdienstleistungsinstitut) or (iv) a financial
enterprise within the meaning of the German Banking Act (Kreditwesengesetz), in case more than 50% of the shares of such
financial enterprise are held directly or indirectly by a credit institution, a security institution or a financial service institution, as
well as by a life insurance company, a health insurance company or a pension fund in case the shares are attributable to the capital
investments, resulting in fully taxable income.
-134-
b)
Sole proprietors
For sole proprietors (individuals) resident in Germany holding shares as business assets dividends are subject to the partial
income rule (Teileinkünfteverfahren). Accordingly, only (i) 60% of the dividend income will be taxed at his/her individual
personal income tax rate plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business
expenses related to the dividend income are deductible for tax purposes. In addition, the dividend income is entirely subject to
trade tax if the shares are held as business assets of a permanent establishment in Germany within the meaning of the GewStG,
unless the shareholder holds at least 15% of the Company’s registered share capital at the beginning of the relevant assessment
period. The trade tax levied will be eligible for credit against the shareholder’s personal income tax liability based on the
applicable municipal trade tax rate and the individual tax situation of the shareholder.
c)
Partnerships
In case shares are held by a partnership, the partnership itself is not subject to corporate income tax or personal income tax
(Unless the option according to section 1a of the German Corporate Income Tax Act was applied for that the partnership is taxed
as a corporation). In this regard, corporate income tax or personal income tax (and church tax, if applicable) as well as solidarity
surcharge are levied only at the level of the partner with respect to their relevant part of the profit and depending on their
individual circumstances.
If the partner is a corporation, the dividend income will be subject to corporate income tax plus solidarity surcharge (see “(i)
Corporations”).
If the partner is a sole proprietor (individual), the dividend income will be subject to the partial income rule (see “(ii) Sole
proprietors”).
The dividend income is subject to trade tax at the level of the partnership (provided that the partnership is liable to trade tax),
unless the partnership holds at least 15% of a company’s registered share capital at the beginning of the relevant assessment
period, in which case the dividend income is exempt from trade tax. There are no clear statutory provisions concerning the
taxation of dividends with regard to a corporate shareholder of the partnership. However, trade tax will be levied on 5% of the
dividends to the extent they are attributable to the shares of such corporate partners to whom at least 10% of the shares of the
Company are attributable on a look-through basis, since such portion of the dividends will be deemed to be non-deductible
business expenses.
If a partner is an individual, depending on the applicable municipal trade tax rate and the individual tax situation, the trade tax
paid at the level of the partnership is partly or entirely be credited against the partner’s personal income tax liability.
In case of a corporation being a partner, special regulations will apply with respect to trading portfolio assets of credit
institutions, security institution, financial service institutions or financial enterprises within the meaning of the German Banking
Act (Kreditwesengesetz) or life insurance companies, health insurance companies or pension funds (see “(i) Corporations”).
Thus, the actual trade tax charge, if any, at the level of the partnership depends on the shareholding quota of the partnership
and the nature of the partners (e.g. individual or corporation).
Taxation of dividend income of shareholders tax resident outside of Germany
For foreign individual or corporate shareholders tax resident outside of Germany not holding the shares through a permanent
establishment in Germany or as business assets for which a permanent representative has been appointed in Germany, the
deducted withholding tax (possibly reduced by way of a tax relief under a double tax treaty or domestic tax law, such as in
connection with the EU Parent Subsidiary Directive) is final (that is, not refundable) and settles the shareholder’s limited tax
liability in Germany, unless the shareholder is entitled to apply for a withholding tax refund or exemption.
In contrast, individual or corporate shareholders tax resident outside of Germany holding the Company’s shares through a
permanent establishment in Germany or as business assets for which a permanent representative has been appointed in Germany
are subject to the same rules as applicable (and described above) to shareholders resident in Germany holding the shares as
business assets. The withholding tax withheld (including solidarity surcharge) is credited against the shareholder’s personal
income tax or corporate income tax liability in Germany.
-135-
8.
Taxation of capital gains
Withholding tax on capital gains
For individual shareholders (individuals) resident in Germany holding shares as private assets, capital gains realized on the
disposal of shares are subject to final withholding tax. Accordingly, capital gains will be taxed at a flat tax rate of 25% plus 5.5%
solidarity surcharge thereon (in total 26.375%) and church tax, in case the shareholder is subject to church tax because of his
individual circumstances. An automatic procedure for deduction of church tax by way of withholding will apply to shareholders
being subject to church tax unless the shareholder has filed a blocking notice (Sperrvermerk) with the German Federal Tax Office
(details related to the computation of the concrete tax rate including church tax are to be discussed with the individual tax adviser
of the relevant shareholder). The taxable capital gain is calculated by deducting the acquisition costs of the shares and the
expenses directly related to the disposal from the proceeds of the disposal. Apart from that, except for an annual lump sum savings
allowance (Sparer- Pauschbetrag) of up to €1,000 (for individual filers) or up to €2,000 (for married couples and for partners in
accordance with the registered partnership law (Gesetz über die Eingetragene Lebenspartnerschaft) filing jointly), private
individual shareholders will not be entitled to deduct expenses incurred in connection with the capital investment from their
capital gain.
Taxation of capital gains realized by shareholders tax resident in Germany holding shares as private assets
For individual shareholders (individuals) resident in Germany holding shares as private assets, capital gains realized on the
disposal of shares are subject to final withholding tax. Accordingly, capital gains will be taxed at a flat tax rate of 25% plus 5.5%
solidarity surcharge thereon (in total 26.375%) and church tax, in case the shareholder is subject to church tax because of his
individual circumstances. An automatic procedure for deduction of church tax by way of withholding will apply to shareholders
being subject to church tax unless the shareholder has filed a blocking notice (Sperrvermerk) with the German Federal Tax Office
(details related to the computation of the concrete tax rate including church tax are to be discussed with the individual tax adviser
of the relevant shareholder). The taxable capital gain is calculated by deducting the acquisition costs of the shares and the
expenses directly related to the disposal from the proceeds of the disposal. Apart from that, except for an annual lump sum savings
allowance (Sparer- Pauschbetrag) of up to €1,000 (for individual filers) or up to €2,000 (for married couples and for partners in
accordance with the registered partnership law (Gesetz über die Eingetragene Lebenspartnerschaft) filing jointly), private
individual shareholders will not be entitled to deduct expenses incurred in connection with the capital investment from their
capital gain.
In case the flat tax results in a higher tax burden as opposed to the private shareholder’s individual tax rate the private
shareholder can opt for taxation at his individual personal income tax rate. In that case, the withholding tax (including solidarity
surcharge) withheld will be credited against the income tax. However, pursuant to the German tax authorities the private
shareholders are nevertheless not entitled to deduct expenses incurred in connection with the capital investment from their income.
The option can be exercised only for all capital income from capital investments received in the relevant assessment period
uniformly and married couples as well as for partners in accordance with the registered partnership law filing jointly may only
jointly exercise the option.
Capital losses arising from the sale of the shares can only be offset against other capital gains resulting from the disposition of
the shares or shares in other stock corporations during the same calendar year. Offsetting of overall losses with other income (such
as business or rental income) and other capital income is not possible. Such losses are to be carried forward and to be offset
against positive capital gains deriving from the sale of shares in stock corporations in future years.
The final withholding tax will not apply if the seller of the shares or in case of gratuitous transfer, its legal predecessor has
held, directly or indirectly, at least 1% of the Company’s registered share capital at any time during the five years prior to the
disposal. In that case capital gains are subject to the partial income rule. Accordingly, only (i) 60% of the capital gains will be
taxed at his individual personal income tax rate plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60%
of the business expenses related to the capital gains are deductible for tax purposes. The withholding tax withheld (including
solidarity surcharge) will be credited against the shareholder’s personal income tax liability in Germany.
-136-
Taxation of capital gains realized by shareholders tax resident in Germany holding the Company’s shares as business assets
If a shareholder holds shares as business assets, the taxation of capital gains realized on the disposal of such shares depends
on whether the respective shareholder is a corporation, a sole proprietor or a partnership:
a)
Corporations
Capital gains realized on the disposal of shares by a corporate shareholder are generally exempt from corporate income tax
and trade tax. However, 5% of the tax exempt capital gains are deemed to be non-deductible business expenses for tax purposes
and therefore are subject to corporate income tax (plus solidarity surcharge) and trade tax; i.e. tax exemption of 95%. Business
expenses incurred in connection with the capital gains are entirely tax deductible.
Capital losses incurred upon the disposal of shares or other impairments of the share value are not tax deductible. A reduction
of profit is also defined as any losses incurred in connection with a loan or security in the event the loan or the security is granted
by a shareholder or by a related party thereto or by a third person with the right of recourse against the before mentioned persons
and the shareholder holds directly or indirectly more than 25% of the company’s registered share capital.
Special regulations apply, if the shares are held as trading portfolio assets by a credit institution, a security institution, a
financial service institution or a financial enterprise within the meaning of the German Banking Act (Kreditwesengesetz) as well
as by a life insurance company, a health insurance company or a pension fund (see “—(i) Corporations”).
b)
Sole proprietors
If the shares are held by a sole proprietor, capital gains realized on the disposal of the shares are subject to the partial income
rule. Accordingly, only (i) 60% of the capital gains will be taxed at his /her individual personal income tax rate plus 5.5%
solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses related to the dividend income
are deductible for tax purposes. In addition, 60% of the capital gains are subject to trade tax if the shares are held as business
assets of a permanent establishment in Germany within the meaning of the GewStG. The trade tax levied, depending on the
applicable municipal trade tax rate and the individual tax situation, is partly or entirely credited against the shareholder’s personal
income tax liability.
c)
Partnerships
In case the shares are held by a partnership, the partnership itself is not subject to corporate income tax or personal income tax
as well as solidarity surcharge (and church tax) since partnerships qualify as transparent for German tax purposes (Unless the
option according to section 1a of the German Corporate Income Tax Act was applied for that the partnership is taxed as a
corporation). In this regard, corporate income tax or personal income tax as well as solidarity surcharge (and church tax, if
applicable) are levied only at the level of the partner with respect to their relevant part of the profit and depending on their
individual circumstances.
If the partner is a corporation, the capital gains will be subject to corporate income tax plus solidarity surcharge (see “—(i)
Corporations”). Trade tax will be levied additionally at the level of the partner insofar as the relevant profit of the partnership is
not subject to trade tax at the level of the partnership. However, with respect to both corporate income and trade tax, the 95%-
exemption rule as described above applies.
If the partner is a sole proprietor (individual), the capital gains are subject to the partial income rule (see “—(ii) Sole
proprietors”).
In addition, if the partnership is liable to trade tax, 60% of the capital gains are subject to trade tax at the level of the
partnership, to the extent the partners are individuals, and 5% of the capital gains are subject to trade tax, to the extent the partners
are corporations. However, if a partner is an individual, depending on the applicable municipal trade tax rate and the individual tax
situation, the trade tax paid at the level of the partnership is credited against the partner’s personal income tax liability.
-137-
With regard to corporate partners, special regulations apply if they are held as trading portfolio assets by credit institutions, a
security institution, financial service institutions or financial enterprises within the meaning of the German Banking Act or life
insurance companies, health insurance companies or pension funds, as described above.
d)
Taxation of capital gains realized by shareholders tax resident outside of Germany
Capital gains realized on the disposal of the shares by a shareholder tax resident outside of Germany are subject to German
taxation provided that (i) the Company’s shares are held as business assets of a permanent establishment or as business assets for
which a permanent representative has been appointed in Germany, or (ii) the shareholder or, in case of a gratuitous transfer, its
legal predecessor has held, directly or indirectly at least 1% of the company’s shares capital at any time during a five years period
prior to the disposal. In these cases, capital gains are generally subject to the same rules as described above for shareholders
resident in Germany. However, it is unclear whether in case of a corporation being shareholder of the Company the 5% taxation
(see “— Corporations— Taxation of capital gains realized by shareholders tax resident in Germany holding the Company’s shares
as business assets) applies or whether the capital gains are fully exempt from German tax.
However, except for the cases referred to in (i) above, some of the double tax treaties concluded with Germany provide for a
full exemption from German taxation.
Inheritance and gift tax
The transfer of the Company’s shares to another person by way of succession or donation is subject to German inheritance
and gift tax (Erbschaft- und Schenkungsteuer) if:
i.
the decedent, the donor, the heir, the donee or any other beneficiary has his /her /its residence, domicile, registered
office or place of management in Germany at the time of the transfer, or is a German citizen who has not stayed
abroad for more than five consecutive years without having a residence in Germany; or
ii.
(irrespective of the personal circumstances) the shares are held by the decedent or donor as business assets for which
a permanent establishment in Germany is maintained or a permanent representative is appointed in Germany; or
iii. (irrespective of the personal circumstances) at least 10% of the shares are held directly or indirectly by the decedent
or person making the gift, himself or together with a related party in terms of Section 1 paragraph 2 Foreign Tax Act.
Special regulations apply to qualified German citizens who maintain neither a residence nor their domicile in Germany but in
a low tax jurisdiction and to former German citizens, also resulting in inheritance and gift tax. The few double tax treaties on
inheritance and gift tax which Germany has entered into provide that German inheritance and gift tax is levied only in case of
(i) and, with certain restrictions, in case of (ii).
Other taxes
No German capital transfer tax (Kapitalverkehrsteuer), value added tax (Umsatzsteuer), stamp duty (Stempelgebühr) or
similar taxes are levied when acquiring, holding or transferring the Company’s shares. No value added tax will be levied unless
the shareholder validly opts for it. Net wealth tax (Vermögensteuer) is currently not levied in Germany.
On January 22, 2013, the Council of the European Union approved the resolution of the ministers of finance from 11 EU
member states (including Germany) to introduce Financial Transaction Tax, or FTT, within the framework of enhanced
cooperation. On February 14, 2013, the EC accepted the proposal for a Council Directive implementing enhanced cooperation in
the area of financial transaction tax. The plan focuses on levying a financial tax of 0.1% (0.01% for derivates) on the purchase and
sale of financial instruments.
A joint statement issued by 10 of the 11 participating EU member states in October 2016 reaffirmed the intention to introduce
FTT. However, at the moment not many details are available. Thus, it is not known to what extent the elements of the EC’s
proposal outlined in the preceding paragraph will be followed in relation to the taxation of shares. The FTT proposal remains
subject to negotiation between the participating Member States and is subject to political discussion. It may therefore be altered
prior to the implementation, the timing of which remains unclear. The EC has committed to putting forward a proposal by January
1, 2024 and has published a working paper in June 2023. However, it is not expected that any proposal would be agreed on in the
short term. Additional EU member states may decide to participate. Prospective holders of the shares are advised to seek their own
professional advice in relation to FTT.
-138-
9.
Dividends and paying agents
Not applicable.
10. Statement by experts
Not applicable.
11. Documents on display
We are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other
information with the SEC, including Annual Reports and reports on Form 6-K. The SEC maintains a website that contains reports
and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.
12. Subsidiary information
Not applicable.
ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market risk arises from our exposure to fluctuation in currency exchange rates. We are exposed to such market risks in the
ordinary course of our business as our exposure to the U.S. dollar broadens from future expenses and revenues that may be
derived from the United States. Currently, we do not have any exchange rate hedging arrangements in place.
We do not engage in activities involving other market price risks. For additional information on market risk, refer to Note
D.12 ‘Risk’ within our audited financial statements and notes prepared in accordance with IFRS-IASB, included in “ITEM 18.
FINANCIAL STATEMENTS.”
ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
A.
Debt securities
Not applicable.
B.
Warrants and rights
Not applicable.
C.
Other securities
Not applicable.
D.
American Depositary Shares
Not applicable.
-139-
PART II
ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
A.
Defaults
No matters to report.
B.
Arrears and delinquencies
No matters to report.
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
A.
Material modifications to instruments
Not applicable.
B.
Material modifications to rights
Not applicable.
C.
Withdrawal or substitution of assets
Not applicable.
D.
Change in trustees or paying agents
Not applicable.
E.
Use of proceeds
Not applicable
-140-
ITEM 15. CONTROLS AND PROCEDURES
A.
Disclosure controls and procedures
As of December 31, 2024, under the supervision of and with the participation of our management, including our Chief
Executive Officer and Chief Financial Officer, we performed an evaluation of the effectiveness of the design and operation of our
disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). There are inherent limitations to the
effectiveness of any disclosure controls and procedures system, including the possibility of human error and circumventing or
overriding them. Even if effective, disclosure controls and procedures can provide only reasonable assurance of achieving their
control objectives.
Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and
procedures are effective to provide reasonable assurance that the information we are required to disclose in the reports we file or
submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the
SEC’s rules and forms and (2) accumulated and communicated to our management to allow timely decisions regarding required
disclosures.
B.
Management’s annual report on internal control over financial reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such
term is defined in Rule 13a-15(f) of the Exchange Act. Under the supervision and with the participation of our management,
including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal
control over financial reporting based upon criteria established in Internal Control – Integrated Framework (2013) by the
Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that
our internal control over financial reporting was effective as of December 31, 2024.
C.
Attestation report of the registered public accounting firm
EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft, or EY, an independent registered accounting firm, has issued an
attestation report on the effectiveness of our internal control over financial reporting as of December 31, 2024, which expressed an
unqualified opinion thereon, as stated in their report included herein. See “Reports of independent registered public accounting
firm” on page F-2.
D.
Changes in internal control over financial reporting
There have been certain changes in our internal control over financial reporting during the period covered by this Annual
Report, primarily relating to the implementation and expansion of internal controls over financial reporting for our operating
subsidiary InflaRx Pharmaceuticals Inc. in the U.S.
ITEM 16. RESERVED
ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT
The Board of Directors has determined that each of Mr. Anthony Gibney, Mr. Richard Brudnick, Mr. Nicolas Fulpius and
Mr. Mark Kubler are audit committee financial experts, as that term is defined by the SEC, and all four are independent for the
purposes of SEC and Nasdaq rules relating to the independence of the audit committee.
ITEM 16B. CODE OF ETHICS
We adopted a code of ethics that applies to all of our employees, officers and directors and posted the full text of our code of
ethics on the investor relations section of our website, www.inflarx.com. We intend to disclose future amendments to our code of
ethics, or any waivers of such code, on our website or in public filings. The information on our website is not incorporated by
reference into this Annual Report, and you should not consider information contained on our website to be a part of this Annual
Report.
-141-
ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
A.
Audit fees
The audit committee has adopted a policy that requires the pre-approval of all services performed for us by our independent
registered public accounting firm. All audit-related services rendered by our independent registered public accounting firm were
pre-approved by the audit committee and are compatible with maintaining the auditor’s independence.
Set forth below are the total fees billed (or expected to be billed), on a consolidated basis, by the independent registered
public accounting firm or their affiliates for providing audit and other professional services in each of the last two years.
Audit fees in 2024 and 2023 amounted to €1.2 million and €1 million, respectively, to our principal accountants, EY GmbH
& Co. KG Wirtschaftsprüfungsgesellschaft in connection with our annual audit, quarterly reviews, issuances of comfort letters
and reviews of registration statements for the Company.
B.
Audit-related fees
None.
C.
Tax fees
None.
D.
All other fees
None.
E.
Audit Committee’s pre-approval policies and procedures
The audit committee is responsible for the appointment, replacement, compensation, evaluation and oversight of the work of
the independent auditors. As part of this responsibility, the audit committee pre-approves all audit and non-audit services
performed by the independent auditors in order to assure that they do not impair the auditor’s independence from the Company in
accordance with the audit committee’s pre-approval policy.
F.
Audit work performed by other than principal accountant if greater than 50%
Not Applicable.
ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
Not applicable.
ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
None.
ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT
Not applicable
ITEM 16G. CORPORATE GOVERNANCE
For a description of the significant ways in which our corporate governance practices differ from those required for U.S.
companies listed on Nasdaq, see “ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES — C. Board practices
— Corporate governance practices.”
-142-
ITEM 16H. MINE SAFETY DISCLOSURE
Not applicable.
ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable
ITEM 16J. INSIDER TRADING POLICIES
On December 11, 2024 we adopted an amended insider trading policy to promote compliance with applicable securities laws
and regulations, including those that prohibit insider trading. The policy applies to our managing directors, supervisory directors,
all employees and contractors and consultants and any of our direct or indirect subsidiaries. A copy of the insider trading policy is
filed as an exhibit to this Annual Report.
ITEM 16K. CYBERSECURITY RISK MANAGEMENT AND STRATEGY
Our Board of Directors is responsible for reviewing the Company’s cybersecurity risk management and control systems in
relation to the financial reporting by the Company, including the Company’s cybersecurity strategy. Our Board of Directors has
delegated periodic oversight of, as appropriate cybersecurity risk management to the Audit Committee, who reports to our Board
of Directors.
Our IT department is responsible for targeted and regular monitoring of cybersecurity risks. They independently and
continuously monitor cybersecurity risks and countermeasures to defend against such threats and, in the event of a cybersecurity
threat or cybersecurity incident, inform executive management, our Audit Committee and our Board of Directors. In addition to
the regular meetings between executive management and the individual risk owners mainly consisting out of the various
departments’ heads, a comprehensive cybersecurity risk analysis for internal and external risks is carried out as appropriate.
The cybersecurity risks identified and evaluated by the IT department are included in an overall risk catalogue. The identified
cybersecurity risks are recorded, described, documented and evaluated in the overall risk catalogue. Changes are also documented
accordingly. According to the priority of the cybersecurity risks as result of the risk evaluation, risks are addressed by concrete
actions and, if appropriate and possible, necessary countermeasures. In order to be able to react quickly and flexibly to
cybersecurity risks, risk management is integrated into existing processes and reporting channels. Our risk management program
considers cybersecurity risks alongside other company risks, and our enterprise risk professionals consult with company subject
matter experts to gather information necessary to identify cybersecurity risks and evaluate their nature and severity, as well as
identify mitigations and assess the impact of those mitigations on residual risk. We may engage third parties from time to time to
conduct risk assessments.
The main cybersecurity risks we continuously monitor include threats and potential incidents resulting in the unavailability of
central IT systems, the loss of critical business data, data theft, intellectual property theft, fraud, extortion, harm to employees and
patients, violation of privacy laws and other litigation and legal risks, and risks to our reputation. The materialization of these
cybersecurity threats may materially affect or may be reasonably likely to materially affect the Company, including its business
strategy, results of operations, or financial condition. The unavailability of central IT systems for example, would result in an
interruption or delay of any clinical development activities of the Company. The loss of critical business data such as the results of
clinical study reports and underlying information, such as tables, listings and filings, could retrospectively destroy our work of
several years of clinical development and respective cost. Data theft could, if critical, confidential or proprietary business data is
concerned, result in a loss in strength of competition. Intellectual property theft can jeopardize our ability to generate revenue for
our shareholders. Breach of privacy laws can put our employees and patients at risk of additional cybersecurity and personal risks,
which could lead to a litigation and further costs for the Company. Cybersecurity risks may also result in our Company’s
reputation being affected.
Executive management, our IT department and employees are the foundation of an effective cybersecurity risk management.
We implemented IT security guidelines, which stipulate measures to securely handle personal data, the settings for a reasonably
secure password for devices and software, the handling of mobile IT devices as well as the proper use of the internet and e-mail
communication software. The Company also implemented two-factor-authentication to access and use a Company user account,
including e-mail. All employees as well as all members of executive management are trained on IT security on a regular basis.
While we do not believe that our business strategy, results of operations or financial condition have been materially adversely
affected by any cybersecurity incidents, we describe whether and how future incidents could have a material impact on our
business strategy, results of operations or financial condition in “ITEM 3D. Risk factors—General risk factors—Cyber incidents
or other failures in IT systems could result in information theft, data corruption and significant disruption of our business
operations.” Additionally, although we have insurance coverage for cybersecurity events, there can be no assurance that we will
be able to maintain our insurance coverage or it will be enough to cover the cost associated with one or more cybersecurity events.
See “ITEM 3D. Risk factors—General risk factors—We may not be able to maintain sufficient insurance to cover us for potential
litigation or other risks.”
-143-
PART III
ITEM 17. FINANCIAL STATEMENTS
We responded to item 18 in lieu of this item.
ITEM 18. FINANCIAL STATEMENTS
Financial statements are filed as part of this Annual Report, see pages F-1 to F-36 to this Annual Report.
ITEM 19. EXHIBITS
Exhibit No. Description
1.1
Articles of Association of InflaRx N.V., dated August 25, 2021 (English language translation) (incorporated herein
by reference to Exhibit 1.1. to the Annual Report on Form 20-F for the year ended December 31, 2022 filed with the
SEC on March 22, 2023).
2.1
Registration Rights Agreement (incorporated herein by reference to Exhibit 4.2 to the post-effective amendment to
the Company’s Registration Statement on Form F-1 (File No. 333-220962) filed with the SEC on November 9,
2017).
2.2+
Form of Senior Indenture (incorporated herein by reference to Exhibit 4.2 to the Company’s Registration Statement
on Form F-3 (File No. 333-273058) filed with the SEC on June 30, 2023).
2.3+
Form of Subordinated Indenture (incorporated herein by reference to Exhibit 4.3 to the Company’s Registration
Statement on Form F-3 (File No. 333-273058) filed with the SEC on June 30, 2023).
2.4
Description of Rights of Each Applicable Class of Securities Registered under Section 12 of the Securities Exchange
Act of 1934 (incorporated herein by reference to Exhibit 2.4 to our Annual Report on Form 20-F for the year ended
December 31, 2022).
4.3†
Co-Development Agreement, dated December 28, 2015, between InflaRx GmbH and Beijing Defengrei
Biotechnology Co. Ltd., as supplemented by Addendum No. 1 dated December 28, 2015 (incorporated herein by
reference to Exhibit 10.3 to the Company’s Amendment No. 4 to the Registration Statement on Form F-1 (File No.
333-220962) filed with the SEC on November 7, 2017).
4.4
Addendum No. 2, dated as of November 9, 2022, between InflaRx GmbH and Beijing Defengrei Biotechnology Co.
Ltd. (incorporated herein by reference to Exhibit 4.4 to the Annual Report on Form 20-F for the year ended
December 31, 2022 filed with the SEC on March 22, 2023).
4.5
Addendum No. 3, dated as of December 21, 2022, between InflaRx GmbH and Staidson (Beijing)
BioPharmaceuticals Co., Ltd., to the Co-Development Agreement, dated as of December 28, 2015 between InflaRx
GmbH and Staidson (Beijing) BioPharmaceuticals Co., Ltd. (as successor to Beijing Defengrei Biotechnology Co.
Ltd. (BDB)) (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 6-K with
the SEC on December 21, 2022).
4.6
Share Purchase Agreement, dated as of December 21, 2022, between InflaRx N.V. and Staidson Hong Kong
Investment Company Limited (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on
Form 6-K with the SEC on December 21, 2022).
4.7
Form of Indemnification Agreement for directors and executive officers (incorporated herein by reference to Exhibit
10.4 to the Company’s Registration Statement on Form F-1 (File No. 333-220962) filed with the SEC on October 13,
2017).
4.8
InflaRx Long-Term Incentive Plan (incorporated herein by reference to Exhibit 99 to the Company’s Registration
Statement on Form S-8 (File No. 333-221656) filed with the SEC on November 17, 2017).
4.9
Amendment to InflaRx Long-Term Incentive Plan (incorporated herein by reference to Exhibit 99.2 to the
Company’s Registration Statement on Form S-8 (File No. 333-240185) filed with the SEC on July 30, 2020).
4.10
Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to our Current Report on Form 6-K,
dated February 18, 2025).
8.1*
List of Subsidiaries.
11.1*
Insider Trading Policy
12.1*
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
12.2*
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
13.1*
Certification pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
2002.
13.2*
Certification pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of
2002.
15.1*
Consent of EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft.
97.1*
Clawback Policy.
101
The following materials from our Annual Report on Form 20-F for the year ended December 31, 2024 formatted as
inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Financial Statements and (ii) the Notes
to the Consolidated Financial Statements, tagged as blocks of text and in detail.
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
*
Filed herewith.
+
Previously filed.
†
Confidential treatment granted as to portions of the exhibit. Confidential materials omitted and filed separately with the SEC.
-144-
SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and
authorized the undersigned to sign this Annual Report on Form 20-F on its behalf.
InflaRx N.V.
By: /s/ Niels Riedemann
Name:Niels Riedemann
Title: Chief Executive Officer and Director
Date: March 20, 2025
By:/s/ Thomas Taapken
Name:Thomas Taapken
Title: Chief Financial Officer
Date: March 20, 2025
-145-
Index to consolidated financial statements
Index to consolidated financial statements
F-1
Reports of independent registered public accounting firm (PCAOB ID:1251)
F-2
Consolidated statements of operations and comprehensive loss for the years ended December 31, 2024, 2023 and 2022
F-6
Consolidated statements of financial position as of December 31, 2024 and 2023
F-7
Consolidated statements of changes in shareholders’ equity for the years ended December 31, 2024, 2023 and 2022
F-8
Consolidated statements of cash flows for the years ended December 31, 2024, 2023 and 2022
F-10
Notes to consolidated financial statements
F-11
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and the Board of Directors of InflaRx N.V.
Opinion on the Financial Statements
We have audited the accompanying consolidated statements of financial position of InflaRx N.V. and subsidiaries (the Company)
as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in
shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes
(collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present
fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its
operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with IFRS
Accounting Standards as issued by the International Accounting Standards Board.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in
Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013
framework) and our report dated March 20, 2025 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the
Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements,
whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a
test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that
were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are
material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The
communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a
whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit
matters or on the accounts or disclosures to which they relate.
F-2
Recognition of expenses from contract research organizations (“CROs”)
Description of the Matter
As discussed in Note B.3 to the consolidated financial statements, the Company recognizes
research and development (R&D) expenses, which include costs charged by CROs for clinical
trial activities. Total CRO expenses recognized in the year-ended December 31, 2024, amounted
to €23.1 million and the related prepayments and accrued liabilities were €4.6 million and €6.6
million, respectively, as of December 31, 2024.
The Company’s determination of CRO expenses involves estimating a percentage-of-completion,
whereby the degree to which services have been rendered for the individual project activities
contracted from the CROs is assessed and estimated by management. While the Company’s
estimates of CRO expenses are primarily based on information received related to each study
from its CROs, the Company may need to make an estimate for costs incurred based on
management judgment. Payments for these activities are based on the terms of the individual
arrangements, which differ from the pattern of costs incurred.
Auditing CRO expenses was challenging, due to the judgement and subjectivity involved in
management’s assessment of the progress of clinical trial activities, relative to the costs incurred,
to estimate the related accrued liabilities and prepayments, and the evaluation of the completeness
and accuracy of the data used in the estimate.
How We Addressed the Matter
in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of
controls related to the Company’s estimation of CRO expenses. For example, we tested controls
over management’s review of the estimated percentage-of-completion used in determining the
amount of CRO expenses and the related impacts to prepayments and accrued liabilities.
To assess the accounting for CRO expenses, our audit procedures included, among others, testing
the accuracy and completeness of the underlying data used in the percentage-of-completion
estimates, by assessing the progress of the clinical trial activities through discussion with the
Company’s R&D project managers and by reviewing progress reports, invoices, and other
correspondence provided by the CROs to the R&D project managers. We inspected the
Company’s CRO contracts, amendments, and pending change orders to assess whether the key
financial and contractual terms align with the amounts recognized. We obtained, from certain of
the Company’s CROs, external confirmation of information used by the Company in estimating
the degree to which services have been rendered as of the reporting date. We also performed
analytical reviews of quarterly fluctuations in the percentage-of-completion by CRO activity. We
compared invoices received from and cash disbursements made to CROs prior to and following
the end of the reporting period and evaluated credit memos received from CROs prior to and
following the end of the reporting period.
F-3
Net realizable value of unfinished goods inventory
Description of the Matter
As discussed in Notes B.2, B.3 and D.5 of the consolidated financial statements, in 2024, the
Company recognized a €2.7 million write-down of unfinished goods inventory resulting in a
remaining carrying value of €6.8 million at December 31, 2024, all of which relates to its severe
COVID-19 treatment GOHIBIC (vilobelimab). In order to value inventory, including unfinished
goods, at the lower of cost or net realizable value, the Company reviews its inventory for excess
amounts or obsolescence, primarily using estimates of expected future sales, which are sensitive
to significant inputs and assumptions, such as expected medical need and expected market
penetration. The amount of the inventory write-down recognized by the Company was
determined by a multiple scenario analysis.
Auditing management’s estimate of the net realizable value of unfinished goods inventory, which
is based, in part, on estimates of expected future sales, was complex and highly judgmental, due
to the Company having a limited sales history. Additionally, these estimates rely, in part, on
management’s assumptions about future events outside of the Company’s control, such as
continuation of the emergency use authorization in the United States.
How We Addressed the Matter
in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of
controls over management’s estimate of the net realizable value of unfinished goods inventory.
To test management’s estimate of the net realizable value of unfinished goods inventory, we
performed audit procedures that included, among others, comparing inputs used in developing
assumptions of medical need to data points observable from United States government COVID-
19 data and the Company’s clinical trial results for GOHIBIC (vilobelimab). We also compared
inputs used in developing assumptions for market penetration, to studies on market share
achievable in the pharmaceutical industry. We performed sensitivity analyses over the medical
need and market penetration assumptions. We compared management’s historical forecast to
actual sales. We developed alternative scenarios of expected future sales and compared these
scenarios to management’s scenarios to assess their sensitivity. We evaluated management’s
comparison of unfinished goods inventory to the estimates of expected future sales, which
included consideration of applicable inventory expiration dates. Additionally, we evaluated the
reasonableness of management’s assessment of the probability that the emergency use
authorization in the United States remains in place, by reference to correspondence with the
relevant regulatory authorities and inquiries of management in relation to the Company’s actions
to maintain the authorization. We performed inquiries of senior management and of the
Company’s sales personnel regarding future expected sales and we evaluated the consistency of
the Company’s operating budget, as approved by its Supervisory Board, with management’s
commercialization plans. We also tested the clerical accuracy of the calculations underlying the
Company’s estimates of expected future sales.
/s/ EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft
We have served as the Company’s auditor since 2020.
Munich, Germany
March 20, 2025
F-4
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and the Board of Directors of InflaRx N.V.
Opinion on Internal Control Over Financial Reporting
We have audited InflaRx N.V. and subsidiaries’ internal control over financial reporting as of December 31, 2024, based on
criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission (2013 framework) (the COSO criteria). In our opinion, InflaRx N.V. and subsidiaries (the Company)
maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the
COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated statements of financial position of the Company as of December 31, 2024 and 2023, the related
consolidated statements of operations and comprehensive loss, changes in shareholders’ equity and cash flows for each of the
three years in the period ended December 31, 2024, and the related notes and our report dated March 20, 2025 expressed an
unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual
Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control
over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all
material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material
weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and
performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a
reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that
(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of
the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the
company are being made only in accordance with authorizations of management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s
assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft
Munich, Germany
March 20, 2025
F-5
InflaRx N.V. and subsidiaries
Consolidated statements of operations and comprehensive loss for the years ended December 31, 2024, 2023 and 2022
Note
2024
2023
2022
(in €, except for share data)
Revenues
C.1.
165,789
63,089
—
Cost of sales
C.2.
(3,317,039)
(532,262)
—
Gross profit
(3,151,250)
(469,173)
—
Sales and marketing expenses
C.3.
(6,756,595) (4,001,299)
—
Research and development expenses
C.4.
(35,363,897) (41,024,131) (37,526,090)
General and administrative expenses
C.5.
(13,024,441) (12,628,756) (14,869,564)
Other income
C.6.
5,287,616 13,219,704 20,159,169
Other expenses
(297)
(4,440)
(1,381)
Operating result
(53,008,864) (44,908,096) (32,237,866)
Finance income
C.8.
3,196,813
3,804,827
608,679
Finance expenses
C.8.
(20,655)
(35,628)
(45,250)
Foreign exchange result
C.8.
3,670,235 (1,841,872)
2,442,297
Other financial result
C.8.
103,285
313,240
(252,471)
Income taxes
(5,217)
—
—
Loss for the period
(46,064,402) (42,667,529) (29,484,611)
Other comprehensive income (loss) that may be reclassified to
profit or loss in subsequent periods:
Exchange differences on translation of foreign currency
58,344
125,085
4,206,810
TOTAL COMPREHENSIVE LOSS
(46,006,058) (42,542,444) (25,277,801)
Share information
C.9.
Weighted average number of shares outstanding
58,919,958 54,940,137 44,207,873
Loss per share (basic/diluted)
(0.78)
(0.78)
(0.67)
The accompanying notes are an integral part of these consolidated financial statements.
F-6
InflaRx N.V. and subsidiaries
Consolidated statements of financial position as of December 31, 2024 and 2023
Note
December 31,
2024
December 31,
2023
ASSETS
(in €)
Non-current assets
Property and equipment
D.1.
256,280
289,577
Right-of-use assets
D.2.
758,368
1,071,666
Intangible assets
D.3.
50,781
68,818
Other assets
D.6.
204,233
257,267
Financial assets
D.8.
3,092,290
9,052,741
Total non-current assets
4,361,952
10,740,069
Current assets
Inventories
D.5.
6,897,666
11,367,807
Current other assets
D.6.
5,103,402
4,036,649
Other assets from government grants and research allowance
D.6.
5,081,772
—
Tax receivable
D.7.
1,735,335
3,791,564
Other financial assets
D.8.
34,462,352
77,504,518
Cash and cash equivalents
D.9.
18,375,979
12,767,943
Total current assets
71,656,505 109,468,482
TOTAL ASSETS
76,018,457 120,208,551
EQUITY AND LIABILITIES
Equity
D.10.
Issued capital
D.10.(a).
7,122,205
7,065,993
Share premium
D.10.(a).
334,929,685 334,211,338
Other capital reserves
D.10.(a).
44,115,861
40,050,053
Accumulated deficit
D.10.(a).
(332,192,221) (286,127,819)
Other components of equity
D.10.(a).
7,440,510
7,382,166
Total equity
61,416,039 102,581,730
Non-current liabilities
Lease liabilities
E.2.
399,066
745,716
Other liabilities
36,877
36,877
Total non-current liabilities
435,943
782,593
Current liabilities
Trade and other payables
D.11.
11,394,232
11,974,362
Lease liabilities
E.2.
406,020
374,329
Employee benefits
2,064,678
1,609,766
Other liabilities
D.11.
301,544
2,885,772
Total current liabilities
14,166,475
16,844,228
Total liabilities
14,602,417
17,626,822
TOTAL EQUITY AND LIABILITIES
76,018,457 120,208,552
The accompanying notes are an integral part of these consolidated financial statements.
F-7
InflaRx N.V. and subsidiaries
Consolidated statements of changes in shareholders’ equity for the years ended December 31, 2024, 2023 and 2022
Note
Shares
outstanding
Issued
capital
Share
premium
(in €)
Balance as of January 1, 2022
44,203,763
5,304,452 280,310,744
Loss for the period
—
—
—
Exchange differences on
translation of foreign currency
—
—
—
Total comprehensive loss
—
—
—
Issuance of ordinary shares
D.10.(a).
500,000
60,000
2,289,624
Transaction costs
—
—
(47,735)
Equity-settled share-based payments
C.10.
—
—
—
Balance as of December 31, 2022
44,703,763
5,364,452 282,552,633
Loss for the Period
—
—
—
Exchange differences on
translation of foreign currency
—
—
—
Total comprehensive loss
—
—
—
Issuance of ordinary shares
D.10.(a).
14,059,252
1,687,110 54,796,819
Transaction costs
—
—
(3,360,626)
Equity-settled share-based payments
C.10.
—
—
—
Share options exercised
120,257
14,431
222,512
Balance as of December 31, 2023
58,883,272
7,065,993 334,211,338
Loss for the Period
—
—
—
Exchange differences on
—
—
—
translation of foreign currency
Total comprehensive loss
—
—
—
Issuance of ordinary shares
D.10.(a).
468,438
56,213
1,042,076
Transaction costs
—
—
(323,729)
Equity-settled share-based payments
C.10.
—
—
—
Balance as of December 31, 2024
59,351,710
7,122,205 334,929,685
The accompanying notes are an integral part of these consolidated financial statements.
F-8
InflaRx N.V. and subsidiaries
Consolidated statements of changes in shareholders’ equity for the years ended December 31, 2024, 2023 and 2022
Note
Other
capital
reserves
Accumulated
deficit
Other
components
of
equity
Total
equity
(in €)
Balance as of January 1, 2022
30,591,209 (213,975,679) 3,050,270 105,280,996
Loss for the period
— (29,484,611)
— (29,484,611)
Exchange differences on translation of foreign
currency
—
— 4,206,810
4,206,810
Total comprehensive Loss
— (29,484,611) 4,206,810 (25,277,801)
Issuance of ordinary shares
D.10.(a).
—
—
—
2,349,624
Transaction costs
—
—
—
(47,735)
Equity-settled share-based payments
C.10.
6,044,356
—
—
6,044,356
Balance as of December 31, 2022
36,635,564 (243,460,290) 7,257,080 88,349,440
Loss for the period
— (42,667,529)
— (42,667,529)
Exchange differences on translation of foreign
currency
—
—
125,085
125,085
Total comprehensive loss
— (42,667,529)
125,085 (42,542,444)
Issuance of ordinary shares
D.10.(a).
—
—
— 56,483,929
Transaction costs
—
—
—
(3,360,626)
Equity-settled share-based payments
C.10.
3,414,489
—
—
3,414,489
Share options exercised
—
—
—
236,943
Balance as of December 31, 2023
40,050,053 (286,127,819) 7,382,166 102,581,730
Loss for the period
— (46,064,402)
— (46,064,402)
Exchange differences on translation of foreign
currency
—
—
58,344
58,344
Total comprehensive loss
— (46,064,402)
58,344 (46,006,058)
Issuance of ordinary shares
D.10.(a).
—
—
—
1,098,289
Transaction costs
—
—
—
(323,729)
Equity-settled share-based payments
C.10.
4,065,807
—
—
4,065,807
Balance as of December 31, 2024
44,115,861 (332,192,221) 7,440,510 61,416,039
The accompanying notes are an integral part of these consolidated financial statements.
F-9
InflaRx N.V. and subsidiaries
Consolidated statements of cash flows for the years ended December 31, 2024, 2023 and 2022
Note
2024
2023
2022
(in €)
Operating activities
Loss for the period
(46,064,402) (42,667,529) (29,484,611)
Adjustments for:
Depreciation & amortization of property and equipment, right-
of-use assets and intangible assets
485,114
567,780
596,597
Net finance income
C.8.
(6,949,679)
(2,240,566) (2,753,255)
Share-based payment expense
C.10.
4,065,807
3,414,489
6,044,356
Net foreign exchange differences
(37,101)
413,017
385,359
Changes in:
Other assets from government grants and research allowances
D.6.
(5,081,772)
732,971
(732,971)
Other assets
1,042,513
7,825,181 (3,308,485)
Employee benefits
454,912
297,518
(64,024)
Other liabilities
(2,584,228)
2,738,164
9,403
Liabilities from government grants received
D.6.
—
(6,209,266) (2,090,734)
Trade and other payables
D.11.
(580,129)
6,986,824 (3,586,706)
Inventories
D.5.
4,470,141 (11,367,807)
—
Interest received
2,243,197
1,732,284
1,287,200
Interest paid
(21,064)
(36,025)
(44,946)
Net cash used in operating activities
(48,556,690) (37,812,966) (33,742,817)
Investing activities
Purchase of intangible assets and property and equipment
(46,871)
(81,100)
(162,391)
Purchase of current and non-current financial assets
(35,340,107) (104,051,972) (64,474,543)
Proceeds from the maturity of current financial assets
87,751,331
86,436,456 83,995,029
Net cash from / (used in) investing activities
52,364,354 (17,696,616) 19,358,095
Financing activities
Proceeds from issuance of ordinary shares
D.10.
1,098,289
56,483,929
2,349,624
Transaction costs from issuance of ordinary shares
(323,729)
(3,360,626)
(47,735)
Proceeds from exercise of share options
C.10.
—
236,943
—
Repayment of lease liabilities
(388,114)
(373,977)
(364,430)
Net cash from financing activities
386,446
52,986,269
1,937,459
Net in-/decrease in cash and cash equivalents
4,194,110
(2,523,313) (12,447,262)
Effect of exchange rate changes on cash and cash equivalents
1,413,926
(974,099)
2,462,622
Cash and cash equivalents at beginning of period
12,767,943
16,265,355 26,249,995
Cash and cash equivalents at end of period
D.9.
18,375,979
12,767,943 16,265,355
The accompanying notes are an integral part of these consolidated financial statements.
F-10
InflaRx N.V. and subsidiaries
A. Notes to the consolidated financial statements
1. Corporate information
The consolidated financial statements of InflaRx N.V. and its subsidiaries (collectively, the “Group”) for the year ended
December 31, 2024 were authorized for issue in accordance with a resolution of the Board of Directors on March 19, 2025.
InflaRx N.V. (the “Company”) is a Dutch public company with limited liability (naamloze vennootschap) with its corporate seat
in Amsterdam, The Netherlands, and is registered in the Commercial Register of The Netherlands Chamber of Commerce
Business Register under CCI number 68904312. The Company’s registered office is at Winzerlaer Straße 2 in 07745 Jena,
Germany. Since November 10, 2017, the Company’s ordinary shares have been listed on the Nasdaq Global Select Market under
the symbol “IFRX”.
The Company and its subsidiaries, collectively, are a biotechnology group pioneering anti-inflammatory therapeutics by
applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific
inhibitors of the complement activation factor known as C5a and its receptor C5aR.
Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or
has rights to, variable returns from its involvement with the entity and could affect those returns through its power to direct the
activities of the entity. Subsidiaries are fully consolidated from the date on which control is obtained by the Group. They are
deconsolidated from the date control ceases. The acquisition method of accounting is used to account for business combinations
by the Group. Intercompany transactions, balances and unrealized gains on transactions between Group companies are eliminated.
Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset.
The Group’s subsidiaries as at December 31, 2024 are set out below. Unless otherwise stated, such subsidiaries have share
capital consisting solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held
equals the voting rights held by the Company.
Place of business/
country of
Functional
Ownership
interest held by
the Company
Name
incorporation
currency
2024
2023
Principal activities
InflaRx GmbH
Jena and Munich,
Germany
EUR
100%
100%
Operating subsidiary,
R&D, holder of all IP
InflaRx Pharmaceuticals,
Inc.
Ann Arbor, MI, United
States
USD
100%
100%
Operating subsidiary,
R&D, US
commercialization
B. Material accounting policies
1. Basis of preparation
The consolidated financial statements of the Group have been prepared in accordance with IFRS Accounting Standards as
issued by the International Accounting Standards Board (herein “IFRS”).
The consolidated financial statements have been prepared on a historical cost basis. These consolidated financial statements
of the Group comprise the Company and its wholly owned subsidiaries, InflaRx GmbH and InflaRx Pharmaceuticals, Inc. The
consolidated financial statements are presented in Euro (€). The presentation currency of the Group is the Euro, as the functional
currency of the largest operating company, InflaRx GmbH, continues to be the Euro. Effective January 1, 2023, the functional
currency of InflaRx N.V. changed from the U.S. dollar to the Euro due to a change in the Company’s operational function and, in
turn, a change in the primary currency of its underlying transactions. This change in functional currency has been accounted for
prospectively. The functional currency of InflaRx Pharmaceuticals, Inc. is the U.S. dollar ($), as most of their income and
expenses occur in U.S. dollars in 2024. All financial information presented in Euro has been rounded to the nearest Euro, unless
stated otherwise.
F-11
2. Summary of material accounting policies
This section describes material accounting policies adopted in the preparation of these consolidated financial statements.
These policies have been consistently applied to all the years presented, unless otherwise stated.
(a) New and amended standards adopted by the Group
The following amendments were adopted effective January 1, 2024, and do not have a material impact on the consolidated
financial statements of the Group:
●
Amendments to IFRS 16 Leases: leases on sale and leaseback
●
Amendments to IAS 1 presentation of financial statements: classification of liabilities as current or non-current and non-
current liabilities with covenants
●
Amendments to IAS 7, statement of cash flows and IFRS 7, -supplier finance arrangements
(b) New standard not yet adopted
The following standards issued will be adopted in a future period, and the potential impact on the Group’s consolidated
financial statements, if any, is being assessed:
●
Amendments to IAS 21 effects of changes in foreign exchange rates: lack of exchangeability
●
IFRS 18 presentation and disclosure in financial statements
(c) Current and non-current classification
The Group presents assets and liabilities in the statement of financial position based on current/non-current classification.
Current assets include assets that are sold, consumed or realized as part of the normal operating cycle (operating cycle is
assumed to be 12 months), or cash and cash equivalent unless restricted from being exchanged or used to settle a liability for at
least 12 months after the reporting period. All other assets are classified as non-current.
Current liabilities, such as trade payables, lease liabilities or employee benefits with a term of up to 12 months, and payables
for operating costs or social security charges, are part of the working capital used in the Company’s normal operating cycle. Such
operating items are classified as current liabilities even if they are due to be settled more than 12 months after the reporting period.
All other liabilities are classified as non-current.
(d) Foreign currency transactions
Transactions in a foreign currency are initially translated into the respective functional currency using the spot rate prevailing
on the dates of the transaction. Monetary items which are not denominated in the functional currency are subsequently translated
using the rate applicable at the end of the period. The resulting currency gains and losses are recognized directly in profit or loss.
On consolidation, the assets and liabilities of operations in a currency other than Euro (the presentation currency of the
Company) are translated into Euros at the rate of exchange prevailing at the reporting date and their statements of operations are
translated with monthly average exchange rates during the reporting period. The exchange differences arising on translation for
consolidation are recognized in ‘other comprehensive income’ (OCI). On disposal of a foreign operation, the component of OCI
relating to that particular foreign operation is reclassified to profit or loss. OCI is disclosed as ‘other components of equity’ in
consolidated statements of financial position.
F-12
(e) Grants from government and similar bodies
The Group receives grants from government agencies and similar bodies for the active participation in specific research and
development projects. The grants are recognized when there is reasonable assurance that the grant will be received and all grant
conditions will be met.
According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group up
to five years after concluding the project sponsored by the government.
(f) Notes to the cash flow statement, cash, and cash equivalents
The consolidated statements of cash flows have been prepared using the indirect method for cash flows from operating
activities. The cash disclosed in the consolidated statements of cash flows is comprised of cash and cash equivalents. Cash
comprises cash on hand and demand deposits. Cash equivalents are short-term bank deposits that are readily convertible to a
known amount of cash and are not subject to a significant risk of changes in value with an original maturity of three months or
less. Interest paid and received is included in the cash from operating activities.
(g) Research and development expenses
Research and development expenses comprise third party services, wages and salaries, cost of materials, intellectual property
related expenses, depreciation and amortization of relevant equipment and intangibles as well as overhead. Research and
development expenses mainly consist of costs for clinical trials and manufacturing of the Company’s clinical drug products;
additionally, costs are incurred for pre-clinical activities as well as basic research activities.
Development expenses must be capitalized if the criteria of IAS 38 are met. In the periods presented, no development
expenses were capitalized because management assessed that not all the recognition criteria of IAS 38 had been met. This
assessment is due to the general uncertainties in drug development and the unpredictability of regulatory requirements. Therefore,
research and development expenditures are expensed when incurred.
(h) Employee benefits
(i) Short-term employee benefits
Liabilities for wages and salaries and cash bonuses are measured at the amounts expected to be paid when the liabilities are
settled. The liabilities are presented as employee benefits in the consolidated statements of financial position. A liability is
recognized if the Group has a present legal or constructive obligation to pay such amount as a result of past service provided by
the employee and if such obligation can be estimated reliably.
(ii) Share-based payment transactions
The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as
an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense
is adjusted to reflect the number of awards for which the related service conditions are expected to be met, including an estimate
of forfeitures, such that the amount ultimately recognized is based on the number of awards that meet the related service
conditions at the vesting date. For share-based payment awards with immediate vesting, the grant-date fair value of the share-
based payment is measured to reflect such conditions and there is no gain or loss recognized for differences between expected and
actual outcomes.
(i) Lease arrangements
The Group leases various properties, laboratory and office equipment and cars. Rental contracts are typically made for fixed
periods of one to three years but may have renewal options. The lease agreements do not impose any covenants, but leased assets
may not be used as collateral for borrowing purposes.
(i) Right-of-use assets
The Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is
available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and
adjusted for any re-measurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities
recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives
received. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the
recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease
term. On December 31, 2024, the remaining useful lives of the Company’s right-of-use assets ranged between 3 and 38 months.
Right-of-use assets are subject to impairment.
F-13
(ii) Lease liabilities
At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments
to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease
incentives receivable, variable lease payments which depend on an index or a rate, and amounts expected to be paid under residual
value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the
Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate.
The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or
condition that triggers the payment occurs.
In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement
date, since the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease
liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount
of lease liabilities is re-measured if there is a modification, a change in the lease term, a change in the in-substance fixed lease
payments or a change in the assessment to purchase the underlying asset.
(iii) Short-term leases and leases of low-value assets
The Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that
have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the
lease of low-value assets recognition exemption to leases of office equipment that are considered of low value. Lease payments on
short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term.
(iv) Determining the lease term of contracts
After the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances
that is within its control and affects its ability to exercise the option to renew.
The Group further determines the lease term as the non-cancellable term of the lease, together with any periods covered by an
option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it
is reasonably certain not to be exercised.
The leases which currently also result in the capitalization of a right of use asset, do not include any renewal options. For
future lease contracts with potential renewal options the Company applies judgement in evaluating whether it is reasonably certain
to exercise the option to renew. In doing so, management would consider all relevant factors that create an economic incentive for
it to exercise the renewal.
(j) Interest income
Interest income is derived from interest-bearing financial assets, including cash equivalents. Interest income on cash and cash
equivalents, financial assets at amortized cost calculated using the effective interest rate method is recognized in the consolidated
statements of operations and comprehensive loss as part of finance income.
(k) Intangible assets
Intangible assets mainly comprise purchased IT software. Intangible assets are initially measured at acquisition cost,
including any directly attributable costs of preparing the asset for its intended use less accumulated amortization and accumulated
impairment losses, if any. Amortization begins when an asset is available for use and amortization is calculated using the straight-
line method to allocate cost over the estimated useful lives. The useful lives of intangible assets are reviewed at each reporting
date. Software is amortized over three years. The effect of any adjustment to useful lives is recognized prospectively as a change
of accounting estimate. The Group only owns intangible assets with a definite useful life.
F-14
(l) Property and equipment
Laboratory and office equipment are stated at historical cost less accumulated depreciation and accumulated impairment
losses, if any. Historical cost includes expenditure that is directly attributable to the acquisition of the items.
All repairs and maintenance are recognized in profit or loss during the financial period in which they are incurred, because
they do not constitute a separate asset.
Depreciation on laboratory and office equipment is calculated using the straight-line method to allocate their cost over their
estimated useful lives, as follows:
●
Laboratory equipment: three to 13 years
●
Office equipment: one to five years
The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.
Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized within
‘other income’ or ‘other expenses’ in the consolidated statements of operations and comprehensive loss.
(m) Inventory
Inventories are valued at the lower of cost or net realizable value. Net realizable value for product inventories comprises the
estimated sales proceeds from final products less the necessary expected costs up to the time of sale. Inventories are comprised of
raw materials, unfinished goods, and finished goods. Costs incurred in bringing each product to its present location and condition
are accounted for, as follows:
●
Raw materials: purchase cost on a first-in/first-out basis
●
Finished goods and work in progress: cost of direct materials and labor and a proportion of manufacturing overhead
based on normal operating capacity
(n) Impairment of assets
At each reporting date, the Group assesses whether there is an indication that an asset may be impaired. If there is any
indication of impairment or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The
recoverable amount of an asset is the higher of the asset’s fair value less costs of disposal and its value-in-use. It is determined for
an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or
groups of assets, in which case it is determined at the level of the cash-generating unit. If the carrying amount of an asset exceeds
its recoverable amount, the asset is impaired and written down to its recoverable amount. In assessing value in use, the estimated
future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the
time value of money and the risks specific to the asset.
When there has been a change in the estimates used to determine the asset’s recoverable amount since the last impairment
loss was recognized, any impairment loss previously recognized is reversed. The reversal may not exceed the carrying amount that
would have been determined after amortization or depreciation had no impairment loss been recognized for the asset in prior
periods. The amount of the reversal is recognized in profit or loss for the period.
There were no impairments or reversals of impairments in 2022, 2023 or 2024.
(o) Financial assets and liabilities (financial instruments)
(i) Definition
A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity
instrument of another entity. The Group’s financial assets include predominantly quoted fixed-interest debt securities. The
financial liabilities comprise trade and other payables (incl. accrued liabilities from the R&D projects).
F-15
(ii) Criteria for the recognition and derecognition, initial measurement
In general purchases or sales of financial assets are recognized on the settlement date, i.e., the date that the Group renders or
receives the counter performance (typically cash). The Group initially measures a financial asset at its fair value plus transaction
costs.
The Group initially recognizes non-derivative financial liabilities on the date that they are originated at fair value net of
directly attributable transaction costs. The Group derecognizes a financial liability when its contractual obligations are discharged,
cancelled, or expire.
(iii) Subsequent measurement method
Considering the Group’s business model for managing the financial assets, with an objective to hold them in order to collect
contractual cash flows, and their contractual cash flow characteristics, that are solely payments of principal and interest on the
principal amount outstanding, the Group classifies the quoted debt securities with fixed interest rates as subsequently measured at
amortized cost using the effective interest method (EIR). The financial assets are also subject to impairment.
The Group’s financial liabilities are classified as subsequently measured at amortized cost which is calculated by considering
any discount or premium on acquisition and fees or costs that are an integral part of the EIR.
An analysis of the carrying amounts from the consolidated statements of financial position by measurement category is
disclosed under ‘under ‘D.8 Financial assets and financial liabilities.’
(iv) Criteria for realization of income and expenses
Interest income is accrued using the relevant effective interest rate. Interest expense on liabilities, if any, is also accrued based
on the effective interest rate.
Gains and losses on the disposal of financial instruments are recognized in full when all significant risks and rewards have
been transferred. In the case of a partial transfer of risks and rewards, a distinction would be made as to whether control remains
with the company or is transferred.
Impairment losses on financial assets are recognized in profit or loss. The Group recognizes an allowance for expected credit
losses (ECLs) for the financial assets held, see Note ‘C.8. Net Financial Result’.
ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash
flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally
recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial
recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-
month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a
loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the
default (a lifetime ECL). For the quoted debt securities with fixed interest rates, which have high credit ratings and no significant
increases in credit risk since initial recognition, the Group determines the exposure to credit default using CDS pricing
information (i.e., credit default swap values) published by credit agencies and recognizes a 12-month ECL.
(p) Fair value measurement
The Group does not measure any financial asset or liability at fair value. The carrying amount of all financial instruments
approximates their fair value, with the exception of quoted debt securities for which fair values are disclosed (see Note’D.8.
Financial assets and financial liabilities’).
F-16
When measuring the fair value of an asset or a liability, the Group would use observable market data as far as possible. Fair
values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as
follows:
●
Level 1, quoted prices in active markets for identical assets or liabilities.
●
Level 2, inputs other than quoted prices included within Level 1 that are observable for the instrument, either directly (as
prices) or indirectly (derived from prices).
●
Level 3, inputs for instruments that are not based on observable market data (unobservable inputs).
If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then
the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that
is significant to the entire measurement.
The Group would recognize transfers between levels of the fair value hierarchy at the end of the reporting period during
which the change has occurred.
(q) Income tax
Income taxes comprise current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the
extent that they relate to items recognized directly in equity or in other comprehensive loss.
(i) Current income tax
Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation
authorities. Expected tax payable or receivable on the taxable income or loss for the year, are calculated using tax rates enacted or
substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.
In the periods presented; the Group did not incur income tax expense. Taxes withheld by banks and remitted to tax authorities
were reimbursed after filing of the annual tax declaration.
(ii) Deferred income tax
Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences
associated with assets and liabilities if the transaction which led to their initial recognition is a transaction that is not a business
combination and that affects neither accounting nor tax profit or loss.
Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on
the laws that have been enacted or substantively enacted by the reporting date.
Deferred tax assets arising from tax loss carryforwards are recognized only to the extent that the Group has sufficient taxable
temporary differences or there is convincing evidence that sufficient future taxable profit will be available against which the
unused tax losses can be utilized. As of December 31, 2024 and 2023, based on management’s judgment, it was not probable that
taxable profit will be available against which the unused tax losses can be utilized; no deferred tax assets were therefore
recognized in the consolidated statements of financial position.
3. Significant accounting judgements, estimates and assumptions
The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments,
estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income
and expenses. Actual results may differ from these estimates.
F-17
Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in
the period in which the estimates are revised and in any future periods affected. In preparing these consolidated financial
statements, the critical judgments made by management in applying the Group’s accounting policies involve the following areas:
(a) Accounting for share-based payments
When determining the grant date fair value of share-based payment awards, assumptions must be made regarding the key
parameters of the calculation (see Note ‘C.10.(b). Measurement of fair values of share options granted’). In 2024, the Company’s
share price volatility for the purposes of the calculation was determined on the basis of the 5-year annualized average share price
(since October 2024 5.5-year annualized share price), which management believes will be indicative of the share price
development of the Company in future periods. This led to a range of applied volatility rates in 2024 of 143% to 147% for the
different options granted during the year of this report.
Additionally, the Company must estimate the number of equity instruments which will vest in future periods as awards may
be forfeited prior to vesting due to an awardee’s failure to satisfy a performance condition, including due to employment
termination. An assumption of the forfeiture rate is regularly made on the basis of historical information and adjusted to reflect
future expectations. Revisions to the forfeiture rate could result in a cumulative effect of the change in estimate for current and
prior periods to be recognized in the period of change.
(b) Measurement of third-party R&D clinical trial and contracted manufacturing expense
In measuring R&D expenses for the reporting period, the Company estimates the amount of expense to recognize and liability
to accrue to the extent that invoices of the Company’s contract research organizations (“CROs”) and contract manufacturing
organizations (“CDMOs”) are not yet received and exceed any prepayments made. The timing of the invoicing of project services
by CROs follow contractual billing schedules and can occur several months prior to or following a reporting period. This
estimation involves determining a percentage-of-completion whereby the degree to which services have been rendered for the
individual project activities contracted from the CRO and CDMOs is assessed and estimated by in-house R&D project managers
and reviewed by the controlling department. This percentage-of-completion is used to measure the amount of the unbilled project
activities which have already been rendered by the reporting date and the associated R&D expense and liability to recognize as a
result.
The percentage-of-completion estimates are based on the best information available at the time. However, additional
information may become available in the future and management may adjust the estimate in such future periods. In this event, the
Company may be required to record adjustments to research and development expenses in future periods when the actual level of
activity becomes more certain. The Company recognizes the resulting increases or decreases in expenses as changes in estimates
and reflects such changes in research and development expenses in the period identified.
The Company accrued €6.6 million as of December 31, 2024 and €4.4 million as of December 31, 2023 (see Note D.11.
Trade and other payables) in third-party accruals in relation to its ongoing clinical trials and manufacturing activities. As of these
dates, prepayments were recorded for payments made to CROs and CDMOs against which no services had yet been rendered
(2024: €4.6 million, 2023: €3.7 million, see Note D.6. Other assets).
(c) Realizability of inventories
For determining the net realizable value, at each reporting date, the Company estimates excess and obsolete inventory
primarily using a model of expected future sales and using assumptions with significant estimation uncertainty such as expected
medical need and expected market penetration.
Additionally, these estimates rely, in part, on management’s assumptions about future events outside of the Company’s
control, such as continuation of the emergency use authorization in the United States and marketing authorization in the European
Union. In making these assumptions, management assesses the probability of these authorizations remaining in place or, by
considering correspondence with the relevant regulatory authorities and the Company’s actions to achieve any required conditions
for the authorizations.
Furthermore, the possible alternative uses for raw materials, unfinished and finished products is taken into consideration.
Management regularly assesses market and sales trends, market conditions, disease prevalence, competitive landscape, and
regulatory environment to refine estimates for excess and obsolete inventory. To the extent that inventories on-hand at the
reporting date exceed the amount recoverable from expected future sales prior to expiry of their shelf-life, inventories are written-
down to their net realizable value with the corresponding expense recognized in cost of sales.
F-18
Inventory write-downs for the year ended December 31, 2024 amounted to €3.3 million, were due mainly to quantities of
unfinished goods on-hand exceeding quantities expected to be sold prior to expiry and were determined by a multiple scenario
analysis (prior year: €0.5 million and mainly due to the expiration of shelf life of finished goods).
Assumptions included in the model of expected future demand may require revision in future periods which could result in
changes to the estimate of excess and obsolete inventory and in inventory write-downs.
C. Consolidated statements of operations and comprehensive loss
1. Revenues
2024
2023
2022
(in €)
Revenues
165,789
63,089
—
Total
165,789
63,089
—
For the twelve months ended December 31, 2024 and 2023, the Company realized revenues from product sales of GOHIBIC
(vilobelimab) in the amount of €0.2 million and €0.1 million respectively.
Revenues reported are sales to end customers (hospitals). Sales to distributors do not constitute revenue for the Company
under IFRS 15. All revenues are attributed to sales made in the United States.
2. Cost of sales
2024
2023
2022
(in €)
Cost of sales
3,317,039
532,262
—
Total
3,317,039
532,262
—
Cost of sales expenses increased by €2.8 million for the year ended December 31, 2024 compared to the corresponding costs
for the year ended December 31, 2023 due primarily to higher inventory write-downs of €2.8 million (Note B.5 for additional
information).
3. Marketing and sales expenses
Marketing and sales expenses in 2024 compared to 2023 increased by €2.8 million. The table below shows the composition
of sales and marketing expenses.
2024
2023
2022
(in €)
Third-party expenses
2,010,120
1,021,082
—
Marketing expenses
1,573,628
830,076
—
Employee benefits expenses
1,806,151
1,040,587
—
of which equity-settled share-based payment expense
191,111
67,462
Legal and consulting fees
910,146
1,054,971
—
Other expenses
456,550
54,583
—
Total sales and marketing expenses
6,756,595
4,001,299
—
During the twelve months ended December 31, 2024 the Group incurred €6.8 million of marketing and sales expenses in the
United States. These expenses are mainly composed of €1.8 million in personnel costs and €2.0 million in external services for
distribution and €1.6 million in marketing expenses of GOHIBIC (vilobelimab).
During the twelve months ended December 31, 2023 the Group incurred €4.0 million of sales and marketing expenses in the
United States of America . These expenses are mainly composed of €1.0 million in personnel costs and €1.0 million in external
services for distribution of GOHIBIC (vilobelimab).
The Group started with its commercialization activities when the EUA was granted in 2023. Prior to that, no sales and
marketing expenses had been incurred.
F-19
4. Research and development expenses
Research and development expenses in 2024 compared to 2023 decreased by €5.7 million. The table below shows the
composition of research and development expenses.
2024
2023
2022
(in €)
Third-party services
23,113,874 31,802,983 28,543,503
of which clinical material and related manufacturing services
4,619,437 18,109,345 16,194,152
of which clinical, pre-clinical studies
18,494,437 13,693,638 12,349,351
Employee benefits expenses
8,390,010
6,776,853
6,957,866
of which equity-settled share-based payment expense
1,873,958
1,500,670
2,456,571
Legal and consulting fees
1,362,029
1,758,283
1,690,448
Other expenses
2,497,983
686,012
334,273
Total
35,363,897 41,024,131 37,526,090
5. General and administrative expenses
General and administrative expenses in 2024 compared to 2023 increased by €0.4 million. The table below shows the
composition of general and administrative expenses.
2024
2023
2022
(in €)
Employee benefits expenses
6,339,421
5,392,905
7,125,798
of which equity-settled share-based payment expense
2,000,739
1,846,356
3,587,785
Legal and consulting fees
2,851,390
3,239,809
3,104,624
Insurance expenses
1,570,343
1,934,880
2,330,624
Depreciation & amortization expense
455,497
507,905
526,325
Compensation expense for non-executive directors
321,500
305,984
248,724
Other expenses
1,486,290
1,247,273
1,533,469
Total
13,024,441 12,628,756 14,869,564
6. Other income
Other income decreased in 2024 compared to the prior year due to the end, in June 2023, of the German federal government
grant for the development of vilobelimab in severe COVID-19 patients under which the Group recognized income in 2023 and
2022.
In 2024, the Group qualified for an allowance under the Forschungszulagengesetz (Research Allowance Act) in Germany, a
law designed to promote research and development. Under this allowance, the Group became eligible for reimbursement in cash,
by the German federal government, of a portion of certain eligible R&D expenses incurred in 2020 through 2027. Under IFRS, the
allowance is recognized as a government grant. Upon qualifying for the allowance, the Group recognized €5.1 million in income
relating to eligible expenses which were incurred in the years 2020 to 2024. The Group remains eligible for reimbursement of
expenses to be incurred from 2025 to 2027.
F-20
2024
2023
2022
(in €)
Other income from government grants and research allowances
5,081,772 13,155,250 20,097,496
Further other income
205,844
64,453
61,672
Total
5,287,616 13,219,704 20,159,169
7. Employee benefits expenses
The following table shows the items of employee benefits expenses:
2024
2023
2022
(in €)
Wages and salaries
10,416,490
8,192,143
6,863,423
Social security contributions (employer’s share)
1,282,973
944,712
672,534
Equity-settled share-based payment expenses (see Note C.10. Share-based
payments)
4,065,807
3,414,488
6,044,356
Other
770,311
659,002
503,351
Total
16,535,582 13,210,345 14,083,664
8. Net financial result
2024
2023
2022
(in €)
Interest income
3,196,813
3,804,827
608,679
Interest expenses
(885)
(16,538)
(23,303)
Interest on lease liabilities
(19,770)
(19,090)
(21,947)
Financial result
3,176,159
3,769,199
563,429
Foreign exchange income
6,876,161
5,529,389
6,924,697
Foreign exchange expense
(3,205,926) (7,371,261) (4,482,399)
Foreign exchange result
3,670,235 (1,841,872)
2,442,298
Other financial result
103,285
313,240
(252,471)
Net financial result
6,949,680
2,240,566
2,753,256
Net financial result increased by €4.7 million from 2023 to 2024. This overall increase was comprised of lower interest
income of €0.6 million from marketable securities and short-term deposits in U.S. dollars held by the Company and its
subsidiaries (from €3.8 million in 2023 to €3.2 million in 2024), and an increase in foreign exchange result by €5.5 million (from
€-1.8 million in 2023 to €3.7 million in 2024).
Foreign currency income and expenses arise from the translation of cash and cash equivalents, marketable securities and other
financial assets and liabilities denominated in foreign currencies at the exchange rates prevailing at the balance sheet date. All
resulting translation differences are recognized in the income statement. These gains and losses are caused by a change in
exchange rates at the reporting dates and may not ultimately be realized.
9. Loss per share
Loss per ordinary share is calculated by dividing the loss of the period by the weighted average number of ordinary shares
outstanding during the period. The weighted number of ordinary shares outstanding for the financial year 2024 was 58,919,958,
for 2023 it amounted to 54,940,137 and for 2022 it was 44,207,873. Loss per share was €0.78, €0.78 and €0.67 in 2024, 2023 and
2022, respectively.
As the Company is in a loss-making situation, the diluted loss per share is the same as basic loss per share, because the
weighted average number of shares to be issued upon the exercise of the stock options, the only dilutive instruments issued, would
produce an anti-dilutive effect. Refer to Note C.10. for the balances of outstanding share options.
F-21
10. Share-based payments
a) Equity-settled share-based payment arrangements
In the course of its historical financing rounds prior to 2016, InflaRx GmbH established equity-settled share-based payment
programs. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. in November 2017:
2024
Options
2024
WAEP*
2023
Options
2023
WAEP*
Outstanding at January 1
148,433 €
0.01
148,433 €
0.01
Exercised during the year
—
—
—
—
Outstanding at December 31
148,433 €
0.01
148,433 €
0.01
Exercisable at December 31
148,433 €
0.01
148,433 €
0.01
*
Weighted average share price (WAEP)
The exercise price for all options granted prior to 2016 outstanding at the end of the year was €0.01 per share or less (2023:
€0.01 or less).
Under the terms and conditions of the share option plan of 2016 (the “2016 Plan”), InflaRx GmbH granted rights to subscribe
for InflaRx GmbH’s common shares to directors, senior management, and key employees. Those InflaRx GmbH options were
converted into options for ordinary shares of the Company in November 2017:
2024
Options
2024
WAEP*
2023
Options
2023
WAEP*
Outstanding at January 1
888,632 $ 1.86/€1.68
888,632 $ 1.86/€1.74
Exercised during the year
—
—
Outstanding at December 31
888,632 $ 1.86/€1.79
888,632 $ 1.86/€1.68
Exercisable at December 31
888,632 $ 1.86/€1.79
888,632 $ 1.86/€1.68
*
Conversion rates used for one €: December 31,2024 $0.9626, average rate 2024 $0.9242, December 31,2023 $0.9050,
average rate 2023 $0.9246
The weighted average remaining contractual life for the share options outstanding under the 2016 Plan as of December 31,
2024 was 6.93 years (2023: 7.94 years).
In conjunction with the closing of its initial public offering, InflaRx N.V. established a new incentive plan (the “2017 Plan”).
The initial maximum number of ordinary shares available for issuance under equity incentive awards granted pursuant to the 2017
Plan equals 2,341,097 ordinary shares. On January 1, 2021 and on January 1 of each calendar year thereafter, an additional
number of shares equal to 4% of the total outstanding ordinary shares on December 31 of the immediately preceding year (or any
lower number of shares as determined by the Board of Directors) will become available for issuance under equity incentive
awards granted pursuant to the 2017 Plan:
2024
Options
2024
WAEP*
2023
Options
2023
WAEP*
Outstanding at January 1
6,584,946 $ 2.12/€1.92
4,985,523 $ 1.97 /€1.84
Granted during the year
2,332,500 $ 1.78/€1.65
1,735,750 $ 2.58/€2.39
Forfeited during the year
(12,000) $ 3.02/€2.79
(31,000) $ 2.70/€2.50
Exercised during the year
—
0
(105,327) $ 2.16/€2.00
Outstanding at December 31
8,905,446 $ 2.03/€1.95
6,584,946 $ 2.12/€1.92
Exercisable at December 31
8,129,196 $ 2.03/€1.96
5,577,384 $ 2.01/€1.82
*
Conversion rates used for one €: December 31,2024 $0.9626, average rate 2024 $0.9242, December 31,2023 $0.9050,
average rate 2023 $0.9246
The weighted average remaining contractual life for the share options outstanding under the 2017 Plan as of December 31,
2024 was 6.5 years (2023: 6.61 years).
All Options granted in 2024 vest over one year. Options granted before 2024 vest over a period of one, two or three years,
depending on the grant, with 1/2 or 1/3, respectively, of the options vesting after the end of the 1st year from vesting start and the
remaining options vesting quarterly in equal portions thereafter. Vesting of these unvested share options is subject to a service
condition at the time of vesting, and no market or performance conditions are applicable.
F-22
The weighted average fair value of options granted during 2024 was $1.78/€1.65 (2023: $2.58/€2.39). The range of exercise
prices for options outstanding at the end of the year was $1.51/€1.45 to $5.14/€4.95 (2023: $1.86/€1.74 to $5.14/€4.82).
b) Measurement of fair values of share options granted under the 2017 Plan
The fair value of options granted under the 2017 Plan was determined using the Black-Scholes valuation model. As the
Company’s ordinary shares are listed on the Nasdaq Global Select Market, the closing price of the ordinary shares at grant date
was used.
Other significant inputs into the model are as follows (weighted average):
Share options granted
Options
Fair
value
per share
option
FX rate
as
of grant
date
Fair
value
per share
option
Share
price
at grant
date/
Exercise
price
Expected
volatility
Expected
life
(midpoint
based)
Risk-free
rate
(interpolated,
U.S.
sovereign
strips
curve)
2022
January 12
1,516,666 $
3.66
0.8795 €
3.22 $
4.13
1.35
5.31
1.57%
January 12
45,000 $
3.68
0.8795 €
3.24 $
4.13
1.35
5.50
1.59%
Repricing, April 13
— $
1.20-
$1.63
0.9237 €
1.11-
€1.50 $
1.86
1.35
1.83-
4.94
2.6%
November 21
405,000 $
2.04
0.9760 €
1.99 $
2.44
1.35
4.0
4.15%
1,966,666
Of the 1,966,666 options granted in 2022, 1,223,500 were granted to members of the executive management or the Board of
Directors. In 2022, 136,259 options were forfeited, 14,930 were exercised.
Share options granted
Options
Fair
value
per share
option
FX rate
as
of grant
date
Fair
value
per share
option
Share
price
at grant
date/
Exercise
price
Expected
volatility
Expected
life
(midpoint
based)
Risk-free
rate
(interpolated,
U.S.
sovereign
strips
curve)
2023
January 24
1,454,250 $
2.11 0.9008 €
1.90 $
2.37
1.35
5.30
3.571%
January 24
52,500 $
2.13 0.9008 €
1.92 $
2.37
1.35
5.50
3.565%
May 31
60,500 $
3.61 0.9361 €
3.38 $
4.19
1.35
4.50
3.820%
July 7
57,000 $
3.59 0.9184 €
3.30 $
3.89
1.46
5.50
4.320%
July 7
100,000 $
3.64 0.9184 €
3.34 $
3.89
1.46
6.10
4.286%
July 19
4,000 $
3.55 0.8911 €
3.16 $
3.99
1.46
5.50
4.320%
September 18
7,500 $
3.15 0.9378 €
2.95 $
3.54
1.46
5.50
4.320%
1,735,750
Of the 1,735,750 options granted in 2023, 1,136,000 were granted to members of the executive management or the Board of
Directors. In 2023, 31,000 options were forfeited, 105,327 were exercised.
Share options granted
Number
Fair
value
per share
option
FX rate
as
of grant
date
Fair
value
per share
option
Share
price
at grant
date/
Exercise
price
Expected
volatility
Expected
life
(midpoint
based)
Risk-free
rate
(interpolated,
U.S.
sovereign
strips
curve)
2024
January 05
2,245,000 $
1.65
0.9160 €
1.51 $
1.79
1.47
5.30-
5.50
4.023-
4.025%
February 21
30,000 $
1.40
0.9250 €
1.30 $
1.51
1.47
5.50
4.308%
October 30
57,500 $
1.44
0.9246 €
1.33 $
1.57
1.43
5.50
4.155%
2,332,500
F-23
Of the 2,332,500 options granted in 2024, 1,300,000 were granted to members of the executive management or the Board of
Directors. In 2024, 12,000 options were forfeited, no options were exercised.
Expected dividends are nil for all share options listed above.
Share price volatility is calculated on the basis of annualized monthly volatility rate of the Company’s share price over the
last five years preceding the valuation date. From October 2024 on we calculated the annualized daily volatility rate of the
Company’s share price over the last five and a half years preceding the valuation date due to the change of a service provider.
The range of outcomes for the expected life of the instruments has been based on expectations on option holder behavior in
the scenarios considered.
The dividend yield has no impact due to the anti-dilution clause as defined in the 2017 Plan.
D. Notes to the consolidated statements of financial position
1. Property and equipment
Property and
equipment
Cost
At January 1, 2023
1,453,339
Additions
55,123
Disposals
(2,595)
Exchange differences
(14,342)
At December 31, 2023
1,491,525
Additions
22,723
Disposals
—
Exchange differences
25,822
At December 31, 2024
1,540,070
Accumulated depreciation
At January 1, 2023
(1,124,419)
Depreciation charge for the year
(93,791)
Disposals
2,594
Exchange differences
13,668
At December 31, 2023
(1,201,948)
Depreciation charge for the year
(56,077)
Disposals
—
Exchange differences
(25,765)
At December 31, 2024
(1,283,790)
Net book value
At December 31, 2023
289,577
At December 31, 2024
256,280
F-24
2. Right-of-use assets
Buildings
Cars
Total
Cost
(in €)
At January 1, 2023
2,579,342
125,130
2,704,472
Additions
91,125
49,004
140,129
Disposals
—
—
—
Exchange differences
(9,349)
—
(9,349)
At December 31, 2023
2,661,118
174,134
2,835,252
Additions
—
68,604
68,604
Disposals
—
—
—
Exchange differences
20,101
—
20,101
At December 31, 2024
2,681,219
242,738
2,923,957
Accumulated depreciation
At January 1, 2023
(1,286,625)
(106,039) (1,392,664)
Depreciation charge for the year*
(353,398)
(24,527)
(377,925)
Disposals
—
—
—
Exchange differences
7,003
—
7,003
At December 31, 2023
(1,633,020)
(130,566) (1,763,586)
Depreciation charge for the year
(353,426)
(33,427)
(386,852)
Disposals
—
—
—
Exchange differences
(15,151)
0
(15,151)
At December 31, 2024
(2,001,597)
(163,993) (2,165,590)
Net book value
At December 31, 2023
1,028,098
43,568
1,071,666
At December 31, 2024
679,622
78,745
758,367
F-25
3. Intangible assets
Purchased
IT-software
Advances
paid for
software
Total
Cost
(in €)
At January 1, 2023
723,250
—
723,250
Additions
—
25,977
25,977
Disposals
(7,009)
—
(7,009)
Exchange differences
(111)
—
(111)
At December 31, 2023
716,130
25,977
742,107
Additions
6,607
17,541
24,148
Disposals
—
—
—
Exchange differences
439
—
439
At December 31, 2024
723,176
43,518
766,694
Accumulated amortization
At January 1, 2023
(584,345)
—
(584,345)
Amortization charge for the year*
(96,063)
—
(96,063)
Disposals
7,009
—
7,009
Exchange differences
111
—
111
At December 31, 2023
(673,289)
—
(673,289)
Amortization charge for the year
(42,185)
—
(42,185)
Disposals
—
—
—
Exchange differences
(439)
—
(439)
At December 31, 2024
(715,913)
—
(715,913)
Net book value
At December 31, 2023
42,841
25,977
68,818
At December 31, 2024
7,263
43,518
50,781
Amortization of intangible assets is included in the line items ‘research and development expenses’ (2024: €785, 2023: €858,
2022: €858) and ‘general and administrative expenses’ (2024: €41,400, 2023: €95,205, 2022: €97,413) in the consolidated
statements of operations and comprehensive loss.
4. Leases
Lease obligations consist of payments pursuant to non-cancellable lease agreements mainly relating to the Company’s leases
of office space. The lease terms of the Company’s premises expire as follows: Jena, Germany in December 2025, Martinsried,
Germany in May 2027 and Ann Arbor, Michigan, United States in April 2026.
Set out below, are the carrying amounts and the movements of the Group’s lease liabilities:
Lease liabilities
2024
2023
(in €)
As of January 1
1,120,048
1,356,684
Additions
68,604
140,128
Derecognition
—
(20,555)
Payments
(388,114)
(353,422)
Short-term liability for accrued interest expense
(409)
(396)
Foreign exchange difference
4,959
(2,391)
As of December 31
805,086
1,120,048
F-26
The following are the amounts recognized in profit or loss:
2024
2023
2022
(in €)
Depreciation expense of right-of-use assets (see Note E.2.)
386,853
377,925
384,432
Interest expense on lease liabilities
19,770
19,090
21,947
Rental expense from leases
10,429
6,261
6,261
Thereof short-term leases (included in administrative expenses)
4,168
—
—
Thereof leases of low-value assets (included in administrative expenses)
6,261
6,261
6,261
Total amounts recognized in profit or loss
417,052
403,276
412,640
The Group had total cash outflows for leases of €0.4 million in 2024 (€0.4 million in 2023, €0.4 million in 2022).
5. Inventory
2024
2023
2022
(in €)
Raw material and supplies
82,087
423,560
—
Unfinished goods
6,758,952 10,614,159
—
Finished goods
56,627
330,087
—
Total
6,897,666 11,367,807
—
As of December 31, 2024, inventory amounted to €6.9 million compared to €11.4 million as of December 31, 2023. In 2024,
€1.2 million in unfinished inventory was recognized as research and development expense due to use in clinical studies.
In 2024 the Group recorded in cost of sales write downs of raw materials and supplies of €0.3 million (€0 million in 2023 and
2022), write downs of unfinished goods of €2.7 million (€0 million in 2023 and 2022) and write downs of finished goods of €0.3
million (€0.5 million in 2023, €0 million in 2022) due primarily to quantities on-hand exceeding quantities expected to be sold
prior to expiry.
6. Other assets
December
31,
2024
December
31,
2023
(in €)
Non-current other assets
Prepaid expenses
204,233
257,267
Total
204,233
257,267
Current other assets
Prepayments on research & development projects
4,628,878
3,670,167
Prepaid expenses
354,948
272,999
Others
119,576
93,482
Total
5,103,402
4,036,648
Total other assets
5,307,635
4,293,915
Other assets and other assets from government grants and research allowances
Current other assets from government grants and research allowances
5,081,772
—
Other assets and other assets from government grants and research allowances
5,081,772
—
Prepayments on research & development projects consists of prepayments on CRO and CDMO contracts. Prepaid expenses
mainly consist of prepaid insurance expenses. At December 31, 2024, other assets from government grants and research
allowances contains €5.1 million in research allowances are reimbursements we qualify for under the German Research
Allowance Act.
F-27
7. Income tax
The table below shows a reconciliation between the product of loss before tax multiplied by the Company’s applicable tax
rate and current income taxes recognized in profit or loss.
InflaRx Group
2024
2023
2022
(in €)
Loss for the period (accounting profit before income tax)
(46,059,185) (42,667,529) (29,484,611)
Tax rate
28.6%
28.6%
29.2%
Tax benefits at tax rate
13,159,368 12,160,545
8,610,381
Temporary differences and tax losses for which no deferred tax asset was
recognized
(14,577,752) (12,127,977) (7,480,169)
Non-recognition of tax effect on share-based payments
—
(32,182) (1,251,830)
Non-deductible expenses for tax purposes
(56,721)
(46,907)
(22,067)
Tax free income
1,475,105
—
—
Taxes prior years
(5,217)
—
—
Other differences due to tax rate
—
46,521
143,686
Income tax
(5,217)
—
—
The tax rate applied above represents the weighted average of the statutory tax rates in Germany and the United States. In
Germany, InflaRx N.V. and its subsidiary InflaRx GmbH are subject to corporate income tax (2024/2023/2022: 15%), a solidarity
surcharge (2024/2023/2022: 0.8%) and trade taxes (2024: 13.202%; 2023: 13.065%; 2022: 13.7%). This equals an average total
tax rate of 29.03 % in 2024 (2023: 28.99%; 2022: 29.5%). In 2023, the InflaRx GmbH established a managing director’s
permanent establishment (PE) in the UK. The taxable remuneration is subject to a tax rate of 25% less a deduction (small profits
relief). The taxes prior year result from the established PE. InflaRx Pharmaceuticals, Inc., Ann Arbor, Michigan, United States is
subject to an average total tax rate of 25.74% in 2024 (2023 25.74%; 2022: 25.74%), which is made up of U.S. federal tax (2024,
2023, 2022: 21%) and state tax of 4.74% in 2024 (2023 and 2022: 4.74%).
a) Tax losses carried forward
The Group has total tax loss carryforwards of €288.95 million (2023: €243.8 million) from three areas that cannot be utilized
outside these areas:
As of December 31, 2024 the Group had €238.4 million (2023: €196.2 million) for corporate income purposes and €206.7
million (2023: €164.4 million) for trade tax purposes of unrecognized and unused tax losses carried forward attributable to the tax
group formed by InflaRx N.V. since 2018; these tax losses do not expire and may not be used to offset taxable income elsewhere
in the Group. Since January 1, 2018, InflaRx GmbH has distributed its losses to the parent Company InflaRx N.V. under a profit
and loss transfer agreement. This tax group was formed in Germany and is subject to German tax legislation.
Tax losses of InflaRx GmbH until December 31, 2017 (€34.8 million) are frozen from 2018 onwards due to the creation
of a tax group with InflaRx N.V. Those losses of InflaRx GmbH do not expire and may be used to offset future taxable
●
income of InflaRx GmbH only.
●
In addition, the Group still has tax loss carryforwards of $16.36 million or €15.75 million (2023: $14.3 million or €12.97
million) from the operations of InflaRx Pharmaceuticals, Inc. which can also only be utilized there, generally do not
expire, but are generally limited to offset tax obligation for 80% of taxable income.
As of December 31, 2024, 2023 and 2022, no deferred tax assets were recognized for the carryforward of unused tax losses.
b) Current income tax receivable
Current income tax receivable includes tax claims because of income tax withheld on interest income earned by the Group on
the financial assets (2024: €1,281,649, 2023: €1,390,280). The Company is reimbursed for the payments after filing a tax return.
F-28
8. Financial assets and financial liabilities
Set out below is an overview of financial assets and liabilities, other than cash and short-term deposits included in cash
equivalents, held by the Group as at December 31, 2024 and December 31, 2023:
December
31,
2024
December
31,
2023
(in €)
Financial assets at amortized cost
Non-current financial assets
3,092,290
9,052,741
Thereof marketable securities
2,854,405
8,815,120
Current financial assets
34,462,352 77,504,518
Thereof marketable securities
33,969,390 76,803,111
Financial liabilities at amortized cost
Trade and other payables
11,549,150 14,716,441
The fair value of current and non-current financial assets amounted to €42.6 million (level 1; 2023: €85.5 million). The
Group’s financial assets at amortized cost consist mainly of quoted debt securities with fixed interest rates with high credit rating
(investment grade securities) by international rating agencies such as S&P Global and, therefore, are considered low credit risk
investments.
The maturities of all securities held as of December 31, 2024 are between one and thirteen months (2023: between one and
seventeen months); they bear nominal fixed interest in the range of 0.3% to 6.250% (2023: 0.4% to 4.125%).
9. Cash and cash equivalents
December
31,
2024
December
31,
2023
(in €)
Short-term deposits
Deposits held in U.S. dollars
13,408,478
4,120,951
Deposits held in Euro
700,000
1,020,000
Total
14,108,478
5,140,951
Cash at banks
Cash held in U.S. dollars
2,805,655
5,041,802
Cash held in Euro
1,461,847
2,585,190
Total
4,267,501
7,626,991
Total cash and cash equivalents
18,375,979 12,767,942
F-29
10. Equity
a) Issued capital
As of December 31, 2024, the issued capital of the Company is divided into 59,351,710 ordinary shares (2023: 58,883,272).
The nominal value per share is €0.12. All shares issued are fully paid and have the same rights on the distribution of dividends and
the repayment of capital.
On June 30, 2023, the Company filed a Form F-3 (2023Registration Statement) with the U.S. Securities and Exchange
Commission (the “SEC”) with respect to the offer and sale of securities of the Company, which became effective on July 11,
2023. The aggregate initial offering price of the securities that the Company may offer and sell under this prospectus will not
exceed $250 million. The Company also filed with the SEC a prospectus supplement relating to an at-the-market program
providing for the sale of up to $75.0 million of its ordinary shares over time pursuant the Sales Agreement with Leerink Partners
LLC (the “Sales Agreement”). No ordinary shares were issued by the Company under the 2023-Registration Statement within the
fiscal year 2023. As of December 31, 2024, the Company had issued 468,438 ordinary shares resulting in €0.8 million in net
proceeds to the Company with a remaining value authorized for sale under the Sales Agreement of $73.8 million.
During 2024, the Company issued no ordinary shares for the exercise of stock option rights granted under the 2017 Long-
Term Incentive Plan. We also refer to G. Significant events after the reporting date.
On July 8, 2020, the Company filed a Form F-3 (2020-Registration Statement) with the U.S. Securities and Exchange
Commission (the “SEC”) with respect to the offer and sale of securities of the Company. The Company also filed with the SEC a
prospectus supplement relating to an at-the-market program (2020) providing for the sale of up to $50.0 million of its ordinary
shares over time pursuant a sales agreement with SVB Leerink LLC (the “Leerink Sales Agreement”). As of December 31, 2022,
the Company had issued 2,568,208 ordinary shares resulting in €11.8 million in net proceeds to the Company with a remaining
value authorized for sale under the Leerink Sales Agreement of $35.2 million.
During the fiscal year 2023, the Company issued 3,235,723 ordinary shares under its at-the-market program (2020) resulting
in €14.4 million or $15.7 million in net proceeds. Following these and previous issuances under this at-the-market program
(2020), the remaining value authorized for sale under the Leerink Sales Agreement amounted to $19.0 million as of July 8, 2023;
the term of the at-the-market program (2020) expired on July 8, 2023.
Through an underwritten public offering in April 2023, the Company sold and issued an aggregate of 10,823,529 ordinary
shares, of which 1,411,764 were sold pursuant to the exercise of an overallotment option by the underwriters. The ordinary shares
were sold at a price of $4.25 per share and have a nominal value of €0.12 per share. Proceeds of this offering after deducting €2.5
million ($2.8 million) in underwriting discounts amounted to €39.1 million ($43.2 million). Other offering expenses amounted to
€0.4 million, resulting in a total of €38.7 million in net proceeds from this offering.
In connection with amending the Co-Development Agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.
(“Staidson”) on December 21, 2022, the Company entered into a share purchase agreement with Staidson pursuant to which
Staidson purchased ordinary shares of the Company for an aggregate amount of $2.5 million (€2.3 million) at a price of $5.00 per
share, resulting in the sale of 500,000 additional shares. Under the terms of the share purchase agreement, at the Company’s
option, Staidson may purchase additional shares for an aggregate purchase price of $7.5 million, which is subject to certain
conditions. The accounting impact of this put option is not material.
During 2023, the Company issued a total of 120,257 ordinary shares after former employees exercised stock option rights
granted under the 2017 Long-Term Incentive Plan. The ordinary shares have a nominal value of €0.12 per share. Therefrom,
98,754 ordinary shares were sold at a price of $1.85 per share, and 21,503 ordinary shares were sold at a price of $3.35. The
ordinary shares were registered in 2023, except 14,930 stock options which were exercised in December 2022 with resulting
ordinary shares having been registered in January 2023.
F-30
b) Authorized capital
According to the articles of association of the Company, up to 147,200,000 ordinary shares and up to 147,200,000 preferred
shares with a nominal value of €0.12 per share are authorized to be issued. All shares are registered shares. No share certificates
shall be issued.
In order to deter acquisition bids, the Company’s general meeting of shareholders approved the right of an independent
foundation under Dutch law, or protective foundation, to exercise a call option pursuant to the call option agreement, upon which
preferred shares will be issued by the Company to the protective foundation of up to 100% of the Company’s issued capital held
by others than the protective foundation, minus one share. The protective foundation is expected to enter into a finance
arrangement with a bank or, subject to applicable restrictions under Dutch law, the protective foundation may request the
Company to provide, or cause the Company’s subsidiaries to provide, sufficient funding to the protective foundation to enable it
to satisfy its payment obligation under the call option agreement.
These preferred shares will have both a liquidation and dividend preference over the Company’s ordinary shares and will
accrue cash dividends at a pre-determined rate. The protective foundation would be expected to require the Company to cancel its
preferred shares once the perceived threat to the Company and its stakeholders has been removed or sufficiently mitigated or
neutralized. The Company believes that the call option does not represent a significant fair value based on a level 3 valuation since
the preferred shares are restricted in use and can be cancelled by the Company.
For the year ended December 31, 2024, the Company expensed €50,000 of ongoing costs to reimburse expenses incurred by
the protective foundation.
c) Nature and purpose of equity reserves
In addition to the issued capital, the Company discloses the following other reserves:
●
Share premium records the amounts paid in upon issuance of ordinary shares in excess of nominal value of €0.12 per
share, net of related transaction costs.
●
The other capital reserves include the expense resulting from the issue of share options.
●
Accumulated deficit includes the losses of previous reporting periods.
Other components of equity exclusively include currency reserves from the conversion of financial statements in foreign
currencies.
11. Trade and other payables
December
31,
2024
December
31,
2023
(in €)
Accrued liabilities from R&D projects
6,609,925
4,414,142
Accrued liabilities from commercial activities
69,250
1,400,382
Accounts payable
3,413,064
5,102,700
Other accrued liabilities and payables
1,603,538
3,942,909
Total trade and other payables
11,695,777 14,860,134
Accrued liabilities from R&D projects include third party services from the Company’s ongoing R&D projects that have not
yet been invoiced to the Company as of the reporting date.
Accrued liabilities from commercial activities include services provided by commercial manufacturing partners that have not
yet been invoiced to the Company as of the reporting date.
F-31
12. Financial risk management
a) Financial risk management objectives and policies
The Group’s financial risks are predominantly controlled by central treasury activities under an investment policy approved
by the Board of Directors on October, 27, 2023 as revised on July 31, 2024. Those treasury activities identify, evaluate and
manage financial risks consistent with the Group’s operating needs. The Board of Directors provides policies for overall risk
management, covering specific areas, such as foreign exchange risk and credit risk. The Company does not intend to use
derivative financial instruments because the Group’s future risk exposures cannot be reliably forecasted (volume of business
activity, liquidity needs, foreign exchange exposure).
Hedging is not applied as most of the business activity is intended to be executed in U.S. dollars and paid with the U.S.
dollars funds raised in public offerings. The foreign exchange exposure from costs incurred in currencies other than Euro is
deemed immaterial.
The Group’s principal financial assets comprise quoted debt securities with high credit ratings. Besides these financial assets,
the Group has significant cash and cash equivalents. The Group’s principal financial liabilities comprise trade and other payables.
The main purpose of these financial assets, cash/cash equivalents and liabilities are to finance the Group’s development activities.
The Group is exposed to market risk, credit risk and liquidity risk. The Board of Directors reviews and adopts policies for
managing each of these risks, which are summarized below. The Group’s senior management oversees the management of these
risks.
Exposure
Measurement
Risk Management
Market risk
Future development costs;
Recognized financial assets and
liabilities not denominated in
Euro
Forecasted cash flows
Sensitivity analysis
Achievement of a natural hedge
in the future
Credit risk
Cash and cash equivalents,
current and non-current
financial assets
Credit rating
Diversification of bank deposits,
Investment guidelines for debt
investments
Liquidity
R&D and G&A cost, equity,
trade and other payables
Rolling cash flow forecast
Availability of funds through
financing rounds or public
offerings
b) Market risk
Market risk is the risk that changes in market prices (e.g., due to foreign exchange rates) will affect the Group’s income,
expenses or the value of its holdings of financial instruments. The objective of market risk management is to identify, manage and
control market risk exposures within acceptable parameters.
Foreign exchange risk arises when commercial transactions or recognized assets or liabilities are denominated in a currency
that is not an entity’s functional currency. The Group is exposed to transactional foreign currency risk to the extent that there is a
mismatch between the currencies in which costs and purchases are denominated and the respective functional currencies of Group
companies. The functional currencies of Group companies are primarily the Euro and U.S. dollars. The currencies in which these
transactions and financial assets are primarily denominated are Euro and U.S. dollars. The Group is exposed to the exchange rate
between the Euro and the U.S. dollars. Due to the Company’s various registered offerings of ordinary shares in U.S. dollars, the
Group has significant cash and cash equivalents in U.S. dollars. Currently the Group does not hedge U.S. dollars but intends to
achieve a natural hedge by contracting suppliers in U.S. dollars in the future. In 2024, the Group recognized significant foreign
exchange gains and losses as the natural hedge is not yet achieved and the functional currency for InflaRx N.V. and InflaRx
GmbH is Euro.
F-32
The Group is primarily exposed to changes in U.S. dollar to Euro exchange rates. The sensitivity of profit or loss to changes
in the exchange rates arises mainly from U.S. dollar denominated financial instruments at InflaRx N.V. and InflaRx GmbH.
In 2024, if the Euro had weakened/strengthened by 10% against the U.S. dollar with all other variables held constant, the
Group’s loss would have been €5.8 million higher/€4.7 million lower, mainly as a result of foreign exchange on translation of
U.S. dollar-denominated assets of InflaRx N.V. and InflaRx GmbH.
Cash, cash equivalents and financial assets denominated in U.S. dollars, InflaRx N.V. and InflaRx
GmbH
December
31,
2024
December
31,
2023
(in €)
Current and non current financial assets (securities and accrued interest)
37,316,756 80,935,197
Cash and cash equivalents
14,983,597
8,051,366
Total assets exposed to the risk
52,300,353 88,986,563
Conversion rate Euro to U.S. dollars at reporting date 1/1.0389
Sensitivity analysis:
Conversion
rate
Profit/(loss)
Carrying
amount
(in €)
Euro strengths against U.S. dollars
1.1428 (4,754,578) 47,545,775
Euro weakens against U.S. dollars
0.9350
5,811,150 58,111,503
Based on the exchange rate fluctuations from the last three years, the Company expects that exchange rate fluctuations of the
Euro to the U.S. dollar between 0.9350 and 1.1428 could be reasonably possible. Compared to the exchange rate on the statement
of financial position date (Euro to U.S. dollar at reporting date is 1/1.0389), these rates could have a material impact on the
Company’s total loss of the period.
c) Credit risk
Credit risk is the risk that a counterparty will not meet its obligations leading to a financial loss for the Company. The
Company is exposed to credit risk mainly from its financing activities, including deposits with banks and financial institutions,
foreign exchange transactions and other financial instruments.
Credit risk from balances with banks and financial institutions is managed by the Company in accordance with the
Company’s investment policy. Investment of financial resources which are currently not used to fund R&D or G&A activities, are
made only with counterparties within the credit limits approved by the investment policy. For investments in Euro or U.S. dollar
debt securities, a BBB+ to AAA credit rating (Standard & Poor’s and Fitch ratings; or equivalent ratings by Moody’s and DBRS)
is required. Complex financial products as well as other investments denominated in currencies other than Euros or U.S. dollars
are not permitted by the investment policy. Counterparty credit limits and the investment policy are discussed with the Company’s
Audit Committee on an annual basis and may be updated throughout the year subject to approval of the Company’s Audit
Committee. The limits are set to minimize the concentration of risks and therefore mitigate financial loss through a counterparty’s
potential failure to make payments.
The maximum exposure to counterparty credit risk is €61.0 million at December 31, 2024 (December 31, 2023: €99.3
million). This amount equals the carrying amount at year end of cash and cash equivalents (2024:€18.4 million; 2023: €12.8
million) and financial assets (2024:€42.6 million; 2023: €86.6 million).
d) Liquidity risk
The Company monitors its risk of a shortage of funds in every quarterly forecast as well as on an ongoing basis. The
Company disclosed the maturities of its principal liabilities under Note E ‘Commitments’. Prudent liquidity risk management
involves maintaining sufficient cash and marketable securities and the availability of funding to meet obligations when due. The
Group continually monitors its risk of a shortage of funds using short and mid-term liquidity planning. This takes into account of
the expected cash flows from all activities. The management team performs regular reviews of the budget.
F-33
The Company has a history of significant operating losses. Management expects that the Company incurs significant and
increasing losses for the foreseeable future; as the Company may not achieve or maintain profitability in the near future, it is
dependent on capital contributions or other funding.
The Group raised significant funding from various registered offerings, most recently from an underwritten public offering in
February 2025, that it estimates will enable the Group to fund operating expenses and capital expenditure requirements for at least
18 months from December 31, 2024. The Group expects to require additional funding to continue to advance the development of
product candidates. In the event regulatory approval is received and the Company implements a strategy to commercialize the
products itself, the Group would require additional capital.
At the end of the reporting period, the Group held the following deposits that are expected to readily generate cash inflows to
meet the outstanding financial commitments.
Liquidity
December
31,
2024
December
31,
2023
(in €)
Short-term deposits
14,108,478
5,140,951
Cash at banks
4,267,501
7,626,992
Marketable Securities (current and non-current)
36,829,741 85,727,461
Other (non-current portion)
237,886
237,621
Other (current)
5,574,734
701,407
Total funds available
61,018,339 99,434,432
13. Capital management
The Group’s policy for capital management is to ensure that it maintains its liquidity in order to finance its operating
activities, future business development and meet its liabilities when due. The Group manages its capital structure primarily
through equity. The Group does not have any financial liabilities, other than trade and other payables or leasing liabilities.
No changes were made in the objectives, policies or processes for managing capital during the year.
A. Commitments
1. Operating contracts or services
The Group enters into contracts in the normal course of business with CROs and clinical sites for the conduct of clinical trials,
professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts
can usually be terminated with 30 to 180 days’ notice. In addition to this minimum duration, these contracts require full payment
for services already rendered.
During 2024, the Group did not have any commitments to purchase property, plant and equipment or patents and trademarks
(respectively nil in 2023).
2. Lease obligations
The maturity analysis of lease liabilities is disclosed in the following table:
Maturity analysis for capitalized leases in 2024
Contractual
minimum
lease
obligations
Effect of
discounting
Lease
liabilities
(in €)
Within one year
416,347
10,327
406,020
After one year but not more than five years
405,722
6,656
399,066
More than five years
—
—
—
Total
822,069
16,983
805,086
Maturity analysis for capitalized leases in 2023
Contractual
minimum
lease
obligations
Effect of
discounting
Lease
liabilities
(in €)
Within one year
391,158
16,829
374,329
After one year but not more than five years
760,275
14,559
745,716
More than five years
—
—
—
Total
1,151,434
31,389
1,120,045
F-34
Maturity analysis for all lease obligations in 2024
Total
Low value
leases
Short-term
leases
Capitalized
leases
Within one year
424,328
6,592
1,389
416,347
After one year but not more than five years
413,811
8,089
—
405,722
More than five years
—
—
—
—
Total
838,139
14,681
1,389
822,069
Maturity analysis for all lease obligations in 2023
Total
Low value
leases
Short-term
leases
Capitalized
leases
(in €)
Within one year
397,942
4,816
1,968
391,158
After one year but not more than five years
760,421
146
—
760,275
More than five years
—
—
—
—
Total
1,158,363
4,962
1,968
1,151,434
Anticipated future lease expenses were converted with the exchange rate as of December 31, 2024, 1 Euro 1.0389 U.S. dollar.
The Group applies the ‘lease of low-value assets’ recognition exemptions. The Group also applied the ’short-term lease’
exemption for leases with a maturity of less than 12 months.
B. Other information
1. Segment reporting
The Group predominantly operates as a R&D focused biopharmaceutical company developing novel therapeutic products
targeting diseases of high unmet medical need. Since the EUA of the Company’s lead product vilobelimab for the treatment of
severe COVID-19 patients in April 2023, it also has commercial activities around the marketing and sales of GOHIBIC
(vilobelimab) in the U.S. However, the Group is not steered by segments. The Board of Directors is the chief operating decision
maker. Management of resources and reporting to the decision maker is based on the Group as a whole.
All operational activities are conducted in Germany and the United States. Revenues in the amount of $0.2 million (€0.2
million) were generated in 2024 ($0.1 million in 2023 and Nil in 2022). All revenues were generated in the United States. The
geographic location of the Group’s non-current assets are as follows:
●
December 31, 2024: €4.3 million in Germany and €0.1 million in the United States; and
●
December 31, 2023: €10.6 million in Germany and €0.1 million in the United States.
None of the non-current assets are in the country where the Company is incorporated (the Netherlands).
2. Related party transactions
Compensation of the Group’s executive management for the 12 months ending December 31:
Executive and Board compensation
2024
2023
2022
(in €)
Executive management
Short-term employee benefits
3,193,141
2,783,675
2,774,485
Share-based payments
2,570,489
2,507,453
4,808,094
Sub-total
5,763,630
5,291,128
7,582,579
Non-executive Board of Directors members
Short-term employee benefits
321,500
305,983
248,725
Share-based payments
280,379
285,177
529,859
Sub-total
601,879
591,160
778,584
Total compensation
6,365,509
5,882,288
8,361,163
F-35
Executive management comprises executive Directors of the Board of Directors and members of the senior management of
the Company.
The table above discloses short-term employee benefits that were contractually agreed for the Board of Directors and
executive management. As of December 31, 2024, €0.8 million were not paid but accrued (2023: €0.8 million) for executive
management and €0.1 million (2023: €0.1 million) for non-executive members of the Board of Directors.
Remuneration of the Group’s executive management comprises fixed and variable components and share-based payment
awards. In addition, executive management receive supplementary benefits and allowances.
The Company entered into indemnification agreements with its directors and senior management. The indemnification
agreements and the Company’s Articles of Association require the Company to indemnify its directors to the fullest extent
permitted by law.
The Company’s current and future directors (and such other officer or employee as designated by the Board of Directors)
have the benefit of indemnification provisions in the Articles of Association of InflaRx N.V. These provisions give the
indemnified persons the right to recover from the Company amounts, including, but not limited to, litigation expenses, and any
damages they are ordered to pay, in relation to acts or omissions in the performance of their duties. However, there is no
entitlement to indemnification for acts or omissions which are considered to constitute malice, gross negligence, intentional
recklessness and/or serious culpability attributable to such indemnified person. These agreements also provide, subject to certain
exceptions, for indemnification for related expenses including, among others, attorneys’ fees, judgements, penalties, fines and
settlement amounts incurred by any of these individuals in any action or proceeding. In addition to such indemnification, the
Company provides its directors with directors’ and officers’ liability insurance.
C. Significant events after the reporting date
On January 15, 2025, InflaRx received European Commission approval for GOHIBIC (vilobelimab) for the treatment of
SARS-CoV-2-Induced ARDS. The “marketing authorization under exceptional circumstances” for GOHIBIC is valid in all 27 EU
member states as well as Iceland, Liechtenstein, and Norway.
In January and February 2025, the Company issued 145,420 ordinary shares under its ATM program, resulting in $353
thousand in net proceeds. The remaining value available under the ATM program is $73.48 million.
In February 2025, the company completed an underwritten public offering of an aggregate of 8,250,000 ordinary shares and
pre-funded warrants to purchase 6,750,000 Ordinary Shares. The ordinary shares were sold at a price of $2.00 per share with a
nominal value of €0.12 per share. The public offering price for each pre-funded warrant was equal to the price per share at which
the ordinary shares were sold to the public, minus $0.001, which is the exercise price of each pre-funded warrant. The warrants
are only exercisable by cashless exercise; the amount of ordinary shares to be received upon cashless exercise of such warrants is
dependent on the Company’s market share price at the time of exercise. The gross proceeds from the offering were approximately
$30 million before underwriting discounts and offering expenses.
F-36
EX-8.1 2 ea023450401ex8-1_inflarxnv.htm LIST OF SUBSIDIARIES
Exhibit 8.1
Subsidiaries of the Registrant
Entity name
Jurisdiction of organization
InflaRx GmbH
Germany
InflaRx Pharmaceuticals, Inc.
Delaware
EX-11.1 3 ea023450401ex11-1_inflarxnv.htm INSIDER TRADING POLICY
Exhibit 11.1
InflaRx N.V.
Statement of Policy Concerning Trading in Company Securities
V5 revised and adopted December 11, 2024
I.
SUMMARY OF POLICY CONCERNING TRADING IN COMPANY SECURITIES
This Insider Trading Policy (the “Policy”) provides InflaRx N.V.’s and its subsidiaries’ (collectively, the “Company”) guidelines
that it will, without exception, comply with all applicable laws and regulations in conducting its business. Each employee, officer
and each director is expected to abide by this Policy. When carrying out Company business, employees and directors must avoid
any activity that violates applicable laws or regulations. In order to avoid even an appearance of impropriety, the Company’s
directors, officers and certain other employees are subject to pre-approval requirements and other limitations on their ability to
enter into transactions involving the Company’s securities. Although these limitations do not apply to transactions pursuant to
written plans for trading securities that comply with Rule 10b5-1 under the Securities Exchange Act of 1934 (the “Exchange
Act”), the entry into, amendment or termination of any such written trading plan is subject to pre-approval requirements and other
limitations.
II.
THE USE OF INSIDE INFORMATION IN CONNECTION WITH TRADING IN SECURITIES
A.
General Rule
U.S. and securities laws concerning insider trading apply to trading in securities of the Company. Securities laws regulate the sale
and purchase of securities in the interest of protecting the investing public. Securities laws give the Company, its officers,
directors, and other employees (collectively, “Insiders”) the responsibility to ensure that information about the Company is not
used unlawfully in the purchase and sale of securities.
All employees, officers and directors should pay particularly close attention to the laws against trading on “inside” information.
These laws are based upon the belief that all persons trading in a company’s securities should have equal access to all “material”
information about that company. For example, if an employee, officer or a director of a company knows material non-public
financial information, that employee, officer or director is prohibited from buying or selling shares in the company until the
information has been disclosed to the public. This is because the employee, officer or director knows information that will
possibly cause the share price to change, and it would be unfair for such employee, officer or director to have an advantage
(knowledge that the share price will change) that the rest of the investing public does not have. In fact, it is more than unfair; it is
considered to be fraudulent and illegal. Civil and criminal penalties for this kind of activity are severe.
The general rule can be stated as follows: It is a violation of applicable securities laws for any person, including Insiders, to buy or
sell securities if he or she is in possession of material inside information. This includes orders for purchases and sales of shares
and convertible securities, either directly or indirectly, and for one’s own account or the account of another person, including the
exercise of options and the exercise of similar rights to securities under any employee equity or share plan. Information is material
if there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision. It is
inside information if it has not been publicly disclosed in a manner making it available to investors generally on a broad-based
non-exclusionary basis.
Furthermore, it is illegal for any person in possession of material inside information, including Insiders, to provide other people
with such information or to recommend that they buy or sell the securities (this is called “tipping”). In that case, they may both be
held liable. The prohibition not to provide other people with material inside information does not apply if such information is
disclosed in the normal course of employment, profession or duties and the recipient of the material inside information has an
obligation of confidentiality. Furthermore, every Insider who has material inside information is prohibited from recommending or
inducing another person to trade in the Company’s securities.
2
The U.S. Securities and Exchange Commission (the “SEC”), the stock exchanges and plaintiffs’ lawyers focus on uncovering
insider trading. A breach of the insider trading laws could expose the Insider to criminal fines up to three times the profits earned
and imprisonment up to ten years, in addition to civil penalties (up to three times of the profits earned), and injunctive actions. In
addition, punitive damages may be imposed under applicable state laws. Securities laws also subject ‘controlling persons’ to civil
penalties for illegal insider trading by employees, including employees located outside the United States. Controlling persons
include directors, officers, and supervisors. These persons may be subject to fines up to the greater of $1,000,000 or three times
profit (or loss avoided) by the trading Insider.
Inside information does not belong to the individual directors, officers or other employees who may handle it or otherwise become
knowledgeable about it. It is an asset of the Company. For any person to use such information for personal benefit or to disclose it
to others outside the Company violates the Company’s interests. More particularly, in connection with trading in the Company’s
securities, it is a fraud against members of the investing public and against the Company.
B.
Definition of Material Nonpublic Information
Material Information: Information is considered “material” if a reasonable investor would consider that information important in
making a decision to buy, hold or sell securities. Any information that could be expected to affect a company’s stock/share price,
whether it is positive or negative, should be considered material. There is no bright-line standard for assessing materiality; rather,
materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by enforcement authorities with
the benefit of hindsight. While it is not possible to define all categories of material information, some examples of information
that ordinarily would be regarded as material are:
●
Projections of future earnings or losses, or other earnings guidance;
●
Changes to previously announced earnings guidance, or the decision to suspend earnings guidance;
●
A pending or proposed merger, acquisition or tender offer;
●
A pending or proposed acquisition or disposition of a significant asset;
●
A pending or proposed joint venture;
●
A Company restructuring;
●
Significant related party transactions;
●
A change in dividend policy, the declaration of a stock split, or an offering of additional securities;
●
Bank borrowings or other financing transactions out of the ordinary course;
●
The establishment of a repurchase program for Company securities;
●
A change in the Company’s pricing or cost structure;
●
Major marketing changes;
●
A change in management;
●
A change in auditors or notification that the auditor’s reports may no longer be relied upon;
●
Development of a significant new product, process, or service;
●
Pending or threatened significant litigation, or the resolution of such litigation;
●
Impending bankruptcy or the existence of severe liquidity problems;
●
The gain or loss of a significant customer or supplier;
●
Significant cybersecurity incidents; and
●
The imposition of a ban on trading in the Company’s securities.
3
If you are unsure whether information is material, you should either consult the Chief Executive Officer or the Chief Financial
Officer of the Company or his or her designee before making any decision to disclose such information (other than to persons who
need to know it) or to trade in or recommend trading in securities to which that information relates or assume that the information
is material.
When Information is Considered Public: Information that has not been disclosed to the public is generally considered to be
nonpublic information. In order to establish that the information has been disclosed to the public, it may be necessary to
demonstrate that the information has been widely disseminated. Information generally would be considered widely disseminated if
it has been disclosed through the Dow Jones “broad tape,” newswire services, a broadcast on widely- available radio or television
programs, publication in a widely-available newspaper, magazine or news website, or public disclosure documents filed with the
SEC that are available on the SEC’s website. By contrast, information would likely not be considered widely disseminated if it is
available only to the Company’s employees, or if it is only available to a select group of analysts, brokers and institutional
investors.
Once information is widely disseminated, it is still necessary to afford the investing public with sufficient time to absorb the
information. As a general rule, information should not be considered fully absorbed by the marketplace until after the second day
in which financial markets are open for trading (a “Business Day”) after the day on which the information is released. If, for
example, the Company were to make an announcement on a Monday, you should not trade in Company securities until Thursday.
Depending on the particular circumstances, the Company may determine that a longer or shorter period should apply to the release
of specific material nonpublic information.
C.
Who Does the Policy Apply To?
The prohibition against trading on inside information applies to directors, officers, all other employees, and to other people who
gain access to that inside information. The prohibition applies to both domestic and international employees of the Company and
its subsidiaries. Because of their access to confidential information on a regular basis, this Policy subjects its directors, officers
and certain employees (the “Window Group”) to additional restrictions on trading in Company securities. The restrictions for the
Window Group are discussed in Section G below. In addition, directors, officers and certain employees with inside knowledge of
material information may be subject to ad hoc restrictions on trading from time to time.
D.
Other Companies’ Stock.
It is the policy of the Company that no director, officer or other employee of the Company (or any other person designated as
subject to this Policy) who, in the course of working for the Company, learns of material nonpublic information about a company
with which the Company does business, including a customer or supplier of the Company, or that is involved in a potential
transaction or business relationship with the Company, may trade in that company’s securities until the information becomes
public or is no longer material.
4
E.
Hedging and Derivatives.
Insiders are prohibited from engaging in any hedging transactions (including transactions involving options, puts, calls, prepaid
variable forward contracts, equity swaps, collars and exchange funds or other derivatives) that are designed to hedge or speculate
on any change in the market value of the Company’s equity securities.
Trading in options or other derivatives is generally highly speculative and very risky. People who buy options are betting that the
share price will move rapidly. For that reason, when a person trades in options in his or her employer’s shares, it will arouse
suspicion in the eyes of the SEC that the person was trading on the basis of inside information, particularly where the trading
occurs before a company announcement or major event. It is difficult for an Insider to prove that he or she did not know about the
announcement or event.
If the SEC or the stock exchanges were to notice active options trading by an Insider prior to an announcement, they would
investigate. Such an investigation could be embarrassing to the Company (as well as expensive) and could result in severe
penalties and expense for the persons involved. For all of these reasons, the Company prohibits Insiders from trading in options or
other securities involving the Company’s shares. This Policy does not pertain to employee share options granted by the Company.
Employee share options cannot be traded.
F.
Pledging of Securities, Margin Accounts.
Pledged securities may be sold by the pledgee without the pledgor’s consent under certain conditions. For example, securities held
in a margin account may be sold by a broker without the customer’s consent if the customer fails to meet a margin call. Because
such a sale may occur at a time when an Insider has material inside information or is otherwise not permitted to trade in Company
securities, the Company prohibits Insiders from pledging Company securities in any circumstance, including by purchasing
Company securities on margin or holding Company securities in a margin account.
G.
General Guidelines.
The following guidelines should be followed in order to ensure compliance with applicable securities laws and this Policy:
1. Nondisclosure. Material inside information must not be disclosed to anyone, except to persons within the Company whose
positions require them to know it.
2. Trading in Company Securities. No Insider who is aware of material nonpublic information relating to the Company may,
directly, or indirectly through family members or other persons or entities place or recommend a purchase or sale of any Company
securities, disclosure such material nonpublic information to persons within the Company whose jobs do not require them to have
that information, or outside of the Company to other persons, including, but not limited to, family, friends, business associates,
investors and expert consulting firms, unless any such disclosure is made in accordance with the Company’s policies regarding the
protection or authorized external disclosure of information regarding the Company, or assist anyone engaged in the above
mentioned activities. This includes orders for purchases and sales of ordinary shares, and convertible securities, including the
exercise of stock options as well as derivative securities that are not issued by the Company such as exchange-traded put or call
options or swaps. Any Insider who possesses material inside information should wait until the start of the third Business Day after
the information has been publicly released before trading.
5
3. Avoid Speculation. Investing in the Company’s ordinary shares provides an opportunity to share in the future growth of the
Company. But investment in the Company and sharing in the growth of the Company does not mean short range speculation
based on fluctuations in the market. Such activities put the personal gain of the Insider in conflict with the best interests of the
Company and its shareholders. Although this Policy does not mean that Insiders may never sell shares, the Company encourages
Insiders to avoid frequent trading in Company shares. Speculating in Company shares is not part of the Company culture.
4. Trading in Other Securities. No Insider or other employee of the Company (or any other person designated as subjected to this
Policy) who, in the course of working for the Company, learns of material non-public information about a company with which
the Company does business, including a customer or supplier of the Company, or that is involved in a potential transaction or
business relationship of the Company, may trade in that company’s securities until the information becomes public or is no longer
material. For example, it would be a violation of the securities laws if an Insider learned through Company sources that the
Company intended to purchase assets from a company, and then engages in trading of that company’s securities while that
information is not public and is material.
5. Trading Window.
a. Trading is permitted from the start of the third Business Day following an earnings release with respect to the preceding fiscal
period until 2 days before the end of the fiscal quarter (the “Window”), subject to the restrictions below;
b. all trades are subject to prior review;
c. no trading is permitted outside the Window except for reasons of exceptional personal hardship and subject to prior review by
the Chief Executive Officer or Chief Financial Officer; provided that, if one of these individuals wishes to trade outside the
Window, it shall be subject to prior review by the other; and
d. individuals in the Window Group are also subject to the general restrictions on all employees.
Note that at times the Company may determine that no trades may occur even during the Window when clearance is requested. No
reasons may be provided and the closing of the Window itself may constitute material inside information that should not be
communicated. The restrictions in this subsection 5 shall not apply to trading conducted pursuant to a pre-arranged plan under
Section I below.
In this context “trade” means any sale, purchase or other act consisting of or aimed at acquiring or disposing of securities (either
directly or indirectly and for one’s own account or the account of another person), including the exercise of options and the
exercise of similar rights to (including depositary receipts for) securities under any employee equity or share plan. A reference to
“trading” is to be construed in the same way.
This prohibition does not apply to:
e. trade in discharge of an enforceable obligation that already existed at the time the Insider became acquainted with the material
inside information;
f. the acceptance of securities under a Company employee equity or share plan;
6
g. the exercise of options or the exercise of similar rights to (or depositary receipts for) securities under a Company employee
equity or share plan, provided there is no sale of the Company’s securities to cover the exercise price or taxes or for any other
reason.
H. Pre-Clearance Procedures
All transactions in the Company’s securities (including without limitation, acquisitions and dispositions of Company shares, the
exercise of share options and the sale of Company shares issued upon exercise of share options, and the creation or modification
of a pre-arranged trading plan) by Insiders must be pre-cleared by the Chief Executive Officer or the Chief Financial Officer of the
Company or his or her designee at least two days in advance of the proposed transaction.
Clearance for trading may be delayed or denied in the discretion of these two individuals without providing any reason for such
decision. Pre-cleared transactions not completed within three (3) Business Days shall again require pre-clearance under the
provisions of this Policy.
Notwithstanding the pre-clearance process, it is each Insider’s responsibility to determine for himself or herself whether he or she
is in possession of material inside information, and an open trading window or a pre-clearance of the trade does not absolve the
Insider from criminal liability for trading on material inside information.
I. Pre-Arranged Trading Plan
Trading under a pre-arranged trading plan is not deemed a violation of this Policy, even if the Insider is in possession of material
inside information at the time a trade is executed under such plan, provided that such plan meets the following conditions:
1
The Insider must enter into a binding contract or written plan with a licensed brokerage firm or other fiduciary that holds
discretionary authority over the plan;
2
The plan specifies the amount, price and date on which securities are to be purchased or sold (or some formula for making
such determinations);
3
The plan is established (or modified) at a time when the Insider does not possess material inside information and the Window
is open;
4
The plan prohibits the Insider from later asserting any influence over any person who exercises discretion as to how, when or
whether to effect the trades;
5
The plan allows for the cancellation of a transaction and/or suspension of the plan upon notice and request by the Company to
the Insider if the proposed transaction fails to comply with applicable laws or would create material adverse consequences for
the Company;
6
The plan may be terminated by the Insider upon prior notice to the Chief Executive Officer and Chief Financial Officer at any
time;
7
The plan and any modifications thereof are approved by the Chief Executive Officer or Chief Financial Officer; and
Transactions pursuant to an approved plan will not require further pre-clearance at the time of the transaction. Notwithstanding
any pre-clearance of a trading plan, the Company, its directors and its officers assume no liability for the consequences of any
transaction made pursuant to such plan. The Chief Executive Officer or Chief Financial Officer may reject an Insider’s plan or a
modification thereof if, in his or her sole discretion, he/she feels it will create an undue financial or administrative burden on the
Company.
7
J. Consequences of Violations
The purchase or sale of securities while aware of material nonpublic information, or the disclosure of material nonpublic
information to others who then trade in possession of such information, is prohibited by federal and state laws. Insider trading
violations are pursued vigorously by the SEC, U.S. Attorneys and state enforcement authorities as well as the laws of foreign
jurisdictions.
Punishment for insider trading violations is severe and could include significant fines and imprisonment. While the regulatory
authorities concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the federal
securities laws also impose potential liability on companies and other “controlling persons” if they fail to take reasonable steps to
prevent insider trading by company personnel. Regulators have also prosecuted insider trading violations where an employee or
insider has traded in the stock of another related company based on material nonpublic information learned in connection with
their employment or role as an insider.
In addition, an individual’s failure to comply with this Policy may subject the individual to Company-imposed sanctions,
including dismissal for cause, whether or not the employee’s failure to comply results in a violation of law. Needless to say, a
violation of law, or even an SEC investigation that does not result in prosecution, can tarnish a person’s reputation and irreparably
damage a career.
8
Prepared by:
Approved by:
Name
Christian Schmid, Corporate Counsel
The Board of Directors
Date
December 11, 2024
December 11, 2024
Signature
Christian Schmid, Corporate Counsel
Nicolas Fulpius, Chair
Change history of InflaRx’s Insider Trading Policy:
Version
Valid from
until
Reason for modification
V1
07 November 2017
07 August 2018
First implementation
V2
08 August 2018
03 November 2021
Revised
V3
04 November 2021
07 November 2022
Clarification of general rule
V4
08 November 2022
10 December 2024
(re-)insertion of numeration; no changes
content-wise
V5
11 December 2024
Section B: definition of material nonpublic
information (new); Section C & G.4:
addressed shadow trading; Section J:
consequences of violation (new)
9
EX-12.1 4 ea023450401ex12-1_inflarxnv.htm CERTIFICATION
Exhibit 12.1
CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Niels Riedemann, certify that:
1.
I have reviewed this Annual Report on Form 20-F of InflaRx N.V.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods
presented in this report;
4.
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the company, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
d.
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the
period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the
company’s internal control over financial reporting.
5.
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons
performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial
information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the
company’s internal control over financial reporting.
Date: March 20, 2025
/s/ Niels Riedemann
Chief Executive Officer
(Principal Executive Officer)
EX-12.2 5 ea023450401ex12-2_inflarxnv.htm CERTIFICATION
Exhibit 12.2
CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Thomas Taapken, certify that:
1.
I have reviewed this Annual Report on Form 20-F of InflaRx N.V.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods
presented in this report;
4.
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the company, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
d.
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the
period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the
company’s internal control over financial reporting.
5.
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons
performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial
information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the
company’s internal control over financial reporting.
Date: March 20, 2025
/s/ Thomas Taapken
Chief Financial Officer
(Principal Financial and Accounting Officer)
EX-13.1 6 ea023450401ex13-1_inflarxnv.htm CERTIFICATION
Exhibit 13.1
CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of InflaRx N.V. (the
“Company”) for the fiscal year ended December 31, 2024 (the “Report”), I, Niels Riedemann, certify pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
1.
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
Date: March 20, 2025
/s/ Niels Riedemann
Chief Executive Officer
(Principal Executive Officer)
EX-13.2 7 ea023450401ex13-2_inflarxnv.htm CERTIFICATION
Exhibit 13.2
CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The certification set forth below is being submitted in connection with the Annual Report of InflaRx N.V. (the “Company”) for
the fiscal year ended December 31, 2024 (the “Report”), I, Thomas Taapken, certify pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
1.
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
Date: March 20, 2025
/s/ Thomas Taapken
Chief Financial Officer
(Principal Financial and Accounting Officer)
EX-15.1 8 ea023450401ex15-1_inflarxnv.htm CONSENT OF EY GMBH & CO. KG
WIRTSCHAFTSPRUFUNGSGESELLSCHAFT
Exhibit 15.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form F-3 No. 333-273058) of InflaRx N.V.
(2) Registration Statement (Form S-8 No. 333-221656) pertaining to the InflaRx N.V. Long-Term Incentive Plan, InflaRx Stock
Option Plan 2016, InflaRx Options Issued Pursuant To The Series B Financing Arrangement
(3) Registration Statement (Form S-8 No. 333-240185) pertaining to the InflaRx N.V. Long-Term Incentive Plan
of our reports dated March 20, 2025, with respect to the consolidated financial statements of InflaRx N.V. and the effectiveness of
internal control over financial reporting of InflaRx N.V. included in this Annual Report (Form 20-F) of InflaRx N.V. for the year
ended December 31, 2024.
/s/ EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft
Munich, Germany
March 20, 2025
EX-97.1 9 ea023450401ex97-1_inflarxnv.htm CLAWBACK POLICY
Exhibit 97.1
31 October 2023
CLAWBACK POLICY
INFLARX N.V.
PURPOSE
InflaRx N.V. (the “Company”), believes that it is in the best interests of the Company and its shareholders and other
stakeholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-
for-performance compensation philosophy. The Company’s Board of Directors (the “Board” and each member a “Director”) has
therefore adopted this policy, which provides for the recoupment of certain executive compensation in the event that the Company
is required to prepare an accounting restatement of its financial statements due to material noncompliance with any financial
reporting requirement under the federal securities laws (this “Policy”). This Policy is designed to comply with Section 10D of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), the rules promulgated thereunder, and the listing standards of
the national securities exchange on which the Company’s securities are listed. This Policy also reflects certain rules of Dutch law
relating to the recoupment and/or adjustment of a Bonus (as defined below) from Directors under certain circumstances defined by
Dutch law (the “Dutch Clawback Rules”).
ADMINISTRATION
This Policy shall be administered by the Compensation Committee of the Board (the “Compensation Committee”). Any
determinations made by the Compensation Committee shall be final and binding on all affected individuals.
COVERED EXECUTIVES
This Policy applies to the Company’s current and former executive officers (as determined by the Compensation
Committee in accordance with Section 10D of the Exchange Act, the rules promulgated thereunder, and the listing standards of
the national securities exchange on which the Company’s securities are listed) and such other senior executives or employees who
may from time to time be deemed subject to this Policy by the Compensation Committee (collectively, the “Covered Executives”).
This Policy shall be binding and enforceable against all Covered Executives. Notwithstanding the previous sentences of this
paragraph, the Dutch Clawback Rules reflected in this Policy also apply to any Bonus (as defined below) received by Directors as
a matter of Dutch law.
RECOUPMENT; ACCOUNTING RESTATEMENT
In the event that the Company is required to prepare an accounting restatement of its financial statements due to the
Company’s material noncompliance with any financial reporting requirement under the securities laws, including (i) any required
accounting restatement to correct an error in previously issued financial statements that is material to the previously issued
financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period or left
uncorrected in the current period (each an “Accounting Restatement”), the Compensation Committee will reasonably promptly
require reimbursement or forfeiture of the Overpayment (as defined below) received by any Covered Executive (x) after beginning
service as a Covered Executive, (y) who served as a Covered Executive at any time during the performance period for such
Incentive-Based Compensation, and (z) during the three (3) completed fiscal years immediately preceding the date on which the
Company is required to prepare an Accounting Restatement and any transition period (that results from a change in the
Company’s fiscal year) within or immediately following those three (3) completed fiscal years.
INCENTIVE-BASED COMPENSATION
For purposes of this Policy, “Incentive-Based Compensation” means any compensation that is granted, earned, or vested
based wholly or in part upon the attainment of a financial reporting measures, including, but not limited to: (i) non-equity
incentive plan awards that are earned solely or in part by satisfying a financial reporting measure performance goal; (ii) bonuses
paid from a bonus pool, where the size of the pool is determined solely or in part by satisfying a financial reporting measure
performance goal; (iii) other cash awards based on satisfaction of a financial reporting measure performance goal; (iv) restricted
stock, restricted stock units, stock options, stock appreciation rights, and performance share units that are granted or vest solely or
in part based on satisfaction of a financial reporting measure performance goal; and (v) proceeds from the sale of shares acquired
through an incentive plan that were granted or vested solely or in part based on satisfaction of a financial reporting measure
performance goal.
Compensation that would not be considered Incentive-Based Compensation includes, but is not limited to: (a) salaries;
(b) bonuses paid solely based on satisfaction of subjective standards, such as demonstrating leadership, and/or completion of a
specified employment period; (c) non-equity incentive plan awards earned solely based on satisfaction of strategic or operational
measures; (d) wholly time-based equity awards; and (e) discretionary bonuses or other compensation that is not paid from a bonus
pool that is determined by satisfying a financial reporting measure performance goal.
A financial reporting measure is: (i) any measure that is determined and presented in accordance with the accounting
principles used in preparing financial statements, or any measure derived wholly or in part from such measure, such as revenues,
EBITDA, or net income and (ii) stock price and total shareholder return. Financial reporting measures include, but are not limited
to: revenues; net income; operating income; profitability of one or more reportable segments; financial ratios (e.g., accounts
receivable turnover and inventory turnover rates); net assets or net asset value per share; earnings before interest, taxes,
depreciation and amortization; funds from operations and adjusted funds from operations; liquidity measures (e.g., working
capital, operating cash flow); return measures (e.g., return on invested capital, return on assets); earnings measures (e.g., earnings
per share); sales per square foot or same store sales, where sales is subject to an accounting restatement; revenue per user, or
average revenue per user, where revenue is subject to an accounting restatement; cost per employee, where cost is subject to an
accounting restatement; any of such financial reporting measures relative to a peer group, where the Company’s financial
reporting measure is subject to an accounting restatement; and tax basis income.
2
OVERPAYMENT: AMOUNT SUBJECT TO RECOVERY
The amount to be recovered will be the amount of Incentive-Based Compensation received that exceeds the amount of
Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts,
and must be computed without regard to any taxes paid (the “Overpayment”). Incentive-Based Compensation is deemed received
in the Company’s fiscal period during which the financial reporting measure specified in the incentive-based compensation award
is attained, even if the vesting, payment or grant of the incentive-based compensation occurs after the end of that period.
For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously
awarded compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement,
the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total
shareholder return upon which the Incentive-Based Compensation was received, and the Company must maintain documentation
of the determination of that reasonable estimate and provide such documentation to the exchange on which the Company’s
securities are listed.
METHOD OF RECOUPMENT
The Compensation Committee will determine, in its sole discretion, the method or methods for recouping any
Overpayment hereunder which may include, without limitation:
●
requiring reimbursement of cash Incentive-Based Compensation previously paid;
●
seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any
equity-based awards granted as Incentive-Based Compensation;
●
offsetting any or all of the Overpayment from any compensation otherwise owed by the Company to the Covered
Executive;
●
cancelling outstanding vested or unvested equity awards; and/or
●
taking any other remedial and recovery action permitted by law, as determined by the Compensation Committee.
LIMITATION ON RECOVERY; NO ADDITIONAL PAYMENTS
The right to recovery will be limited to Overpayments received during the three (3) completed fiscal years prior to the
date on which the Company is required to prepare an Accounting Restatement and any transition period (that results from a
change in the Company’s fiscal year) within or immediately following those three (3) completed fiscal years. In no event shall the
Company be required to award Covered Executives an additional payment if the restated or accurate financial results would have
resulted in a higher Incentive-Based Compensation payment.
3
RECOUPMENT AND ADJUSTMENT OF A BONUS UNDER DUTCH LAW
For purposes of the Dutch Clawback Rules, a “Bonus” means any variable Director compensation that is partly or
entirely conditional on the achievement of certain targets or the occurrence of certain events (e.g., signing bonuses, severance pay,
cash bonuses, performance awards and contributions to pension funds).
Under Dutch law, the Company may and, if so directed by the Board shall, recoup all or part of a Bonus that has already
been paid to a Director, to the extent payment of such Bonus was based on inaccurate information as to the achievement of targets
or the occurrence of events on which the Bonus was based (as determined by the Board acting in good faith). The claim for
recoupment of a Bonus will expire after a period of five years has elapsed after the Company became aware that the Bonus was
based on inaccurate information.
In addition, under Dutch law, the Board may (but is not required to) adjust a Director’s entitlement to a Bonus that has
not yet been paid to an appropriate amount, if payment of the (unadjusted) Bonus would be unacceptable according to standards of
reasonableness and fairness (as determined by the Board acting in good faith).
NO INDEMNIFICATION
The Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive-Based
Compensation.
INTERPRETATION
The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations
necessary, appropriate, or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner
that is consistent with the requirements of Section 10D of the Exchange Act and the applicable rules or standards adopted by the
Securities and Exchange Commission or any national securities exchange on which the Company’s securities are listed.
EFFECTIVE DATE
Without prejudice to the application of the Dutch Clawback Rules in accordance with Dutch law, this Policy shall be
effective as of the date it is adopted by the Board (the “Effective Date”) and shall apply to Incentive-Based Compensation
(including Incentive-Based Compensation granted pursuant to arrangements existing prior to the Effective Date). Notwithstanding
the foregoing, this Policy shall only apply to Incentive-Based Compensation received (as determined pursuant to this Policy) on or
after the effective date of NASDAQ Listing Rule 5608.
4
AMENDMENT; TERMINATION
The Board may amend this Policy from time to time in its discretion. The Board may terminate this Policy at any time.
OTHER RECOUPMENT RIGHTS
The Board intends that this Policy will be applied to the fullest extent of the law. The Compensation Committee may
require that any employment or service agreement, cash-based bonus plan or program, equity award agreement, or similar
agreement entered into on or after the adoption of this Policy shall, as a condition to the grant of any benefit thereunder, require a
Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and
not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any
similar policy in any employment agreement, equity award agreement, cash-based bonus plan or program, or similar agreement
and any other legal remedies available to the Company.
IMPRACTICABILITY
The Compensation Committee shall recover any Overpayment in accordance with this Policy except to the extent that the
Compensation Committee determines such recovery would be impracticable because:
(A) The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered;
(B) Recovery would violate home country law of the Company where that law was adopted prior to November 28, 2022;
or
(C) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to
employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations
thereunder.
SUCCESSORS
This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors,
administrators or other legal representatives.
5